



Selected species

LS ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:1082026 CAPLUS Full-text
DN 142:38288
TI Preparation of dibenzo[b,e][1,4]diazepin-11-ones as kinase inhibitors for
treatment of cancer
IN Hasvold, Lisa A.; Hexamer, Laura; Li, Gaoquan; Lin, Nan-horng; Sham, Hing;
Sullivan, Gerard M.; Wang, Le; Xia, Ping
PA USA
SO U.S. Pat. Appl. Publ., 137 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004254159	A1	20041216	US 2004-785120	20040225
	WO 2004076424	A1	20040910	WO 2004-US5728	20040226
	W:				
	AE, AE, AG, AL, AL, AM, AM, AM, AT, AT, AU, AZ, AZ, BA, BB, BG,				
	BG, BR, BR, BW, BY, BY, BZ, BZ, CA, CH, CN, CN, CO, CO, CR, CR,				
	CU, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EC, EE, EE, EG, ES,				
	ES, FI, FI, GB, GD, GE, GE, GH, GM, HR, HR, HU, HU, ID, IL, IN,				
	IS, JP, JP, KE, KE, KG, KG, KP, KP, KP, KR, KR, KZ, KZ, KZ, LC,				
	LK, LR, LS, LS, LT, LU, LV, MA, MD, MD, MG, MK, MN, MW, MX, MX,				
	MZ, MZ, NA, NI				
	RW:				
	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE,				
	BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU,				
	MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN,				
	GQ, GW, ML, MR, NE, SN, TD, TG, BF, BJ, CF, CG, CI, CM, GA, GN,				
	GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI	US 2003-450476P	P	20030227		
	US 2003-375412	A	20030227		
	US 2004-785120	A	20040225		
OS	MARPAT 142:38288				
GI					



AB Title heterocycles and analogs I [wherein A1 = CR1, N; A2 = CR8, N; R1, R8 = independently H, alkoxy, (hydroxy)alkyl, amino(alkyl), CN, halo, OH, NO2; R2-R5 = independently H, alkenyl, (alkoxy)alkoxy(alkoxy), (alkoxy)alkyl, alkoxycarbonyl(alkyl), alkylcarbonyl(alkyl), amino(alkoxy), aminoalkyl, aminocarbonyl(alkyl), aminosulfonyl, aryl(alkoxy), aryl(oxy)alkyl, carboxy(alkyl), cyano(alkyl), cycloalkyl(alkyl), halo(alkoxy), haloalkyl, heterocyclyl(alkoxy), heterocyclyl(carbonyl)alkyl, heterocyclyloxyalkyl, hydroxy(alkoxy), hydroxyalkyl, nitro(alkyl), carbamoyl(alkyl); one of R6 and R7 = H and the other = H, aryl, cycloalkyl, halo, heterocyclyl, XR13; R13 = aryl, cycloalkyl, heterocyclyl; X = O, NR14, CO, S, SO2, (CH2)n, CONR14, NR14CO, SO2NR14, NR14SO2, O(CH2)m, (CH2)mO, CH=CH, C.tplbond.C; R14 = H,


alkenyl, (amino)alkyl, hydroxyalkyl; Y = NR₁₅, O; R₁₅ = H, alkoxycarbonyl, (cyclo)alkyl, alkylcarbonyl, arylalkyl, cycloalkylalkyl; m = 0-3; n = 1-3; and therapeutically acceptable salts thereof] were prepared as protein kinase inhibitors. For example, N-alkylation of Me 3,4-diaminobenzoate with Me 4-chloro-2-iodobenzoate using Cu and K₂CO₃ in PhCl gave Me 2-[[2-amino-4-(methoxycarbonyl)phenyl]amino]-4-chlorobenzoate (68%), which was cyclized with 37% HCl in MeOH to provide II (87%). In enzymic assays using recombinant Chk1 kinase domain protein and human cdc25c peptide substrate, compds. of the invention inhibited Chk1 at IC₅₀ values between about 0.2 nM and about 280 μM. Thus, I and their pharmaceutical compns. are useful for treatment of cancer (no data).

IT 755027-56-6P 755027-57-7P 755029-61-9P
 755030-80-9P 755031-15-3P 755031-24-4P
 755031-79-9P 755031-98-2P 755031-99-3P
 755032-00-9P 755032-01-0P 755032-28-1P
 755033-14-8P 755033-15-9P 755033-16-0P
 755035-46-2P 755035-47-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (kinase inhibitor; preparation of dibenzo[b,e][1,4]diazepin-11-ones as kinase inhibitors for treatment of cancer)


RN 755027-56-6 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-6-quinolinyl- (9CI) (CA INDEX NAME)




RN 755027-57-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-N-[4-(4-morpholinyl)phenyl]-11-oxo- (9CI) (CA INDEX NAME)




RN 755029-61-9 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-propanamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-N-[4-(4-morpholinyl)phenyl]-11-oxo- (9CI) (CA INDEX NAME)




RN 755030-80-9 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-α,α-dimethyl-N-[4-(4-morpholinyl)phenyl]-11-oxo- (9CI) (CA INDEX NAME)




RN 755031-15-3 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-(4-fluorophenyl)-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- α,α -dimethyl-11-oxo- (9CI)
(CA INDEX NAME)




RN 755031-24-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- α,α -dimethyl-N-[4-(4-morpholinyl)phenyl]-11-oxo- (9CI) (CA INDEX NAME)




RN 755031-79-9 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-2-methyl-N-[4-(4-morpholinyl)phenyl]-11-oxo- (9CI) (CA INDEX NAME)




RN 755031-98-2 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-(3-fluorophenyl)-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- α,α -dimethyl-11-oxo- (9CI)
(CA INDEX NAME)




RN 755031-99-3 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- α,α -dimethyl-11-oxo-N-[4-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 755032-00-9 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- α,α -dimethyl-11-oxo-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 755032-01-0 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-α,α-dimethyl-11-oxo-N-[3-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 755032-28-1 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, N-(4-fluorophenyl)-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-α,α-dimethyl-11-oxo- (9CI) (CA INDEX NAME)




RN 755033-14-8 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, N-[3-(aminocarbonyl)phenyl]-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 755033-15-9 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-N-[4-(4-morpholinyl)phenyl]-11-oxo- (9CI) (CA INDEX NAME)




RN 755033-16-0 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-6-quinolinyl- (9CI) (CA INDEX NAME)




RN 755035-46-2 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-propanamide, N-(4-fluorophenyl)-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)





RN 755035-47-3 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-propanamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



L5 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 2004:740305 CAPLUS Full-text
 DN 141:260782
 TI Preparation of dibenzo[b,e][1,4]diazepin-11-ones as kinase inhibitors for treatment of cancer
 IN Hasvold, Lisa A.; Hexamer, Laura; Li, Gaoquan; Lin, Nan-horng; Sham, Hing; Sowin, Tom; Sullivan, Gerard M.; Wang, Le; Xia, Ping Xia
 PA Abbott Laboratories, USA
 SO PCT Int. Appl., 382 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004076424	A1	20040910	WO 2004-US5728	20040226
	W: AE, AE, AG, AL, AL, AM, AM, AM, AT, AT, AU, AZ, AZ, BA, BB, BG, BG, BR, BR, BW, BY, BY, BZ, BZ, CA, CH, CN, CN, CO, CO, CR, CR, CU, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EC, EE, EE, EG, ES, ES, FI, FI, GB, GD, GE, GE, GH, GM, HR, HR, HU, HU, ID, IL, IN, IS, JP, JP, KE, KE, KG, KG, KP, KP, KP, KR, KR, KZ, KZ, KZ, LC, LK, LR, LS, LS, LT, LU, LV, MA, MD, MD, MG, MK, MN, MW, MX, MX, MZ, MZ, NA, NI				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2004254159	A1	20041216	US 2004-785120	20040225
PRAI	US 2003-375412	A	20030227		
	US 2004-785120	A	20040225		
	US 2003-450476P	P	20030227		
OS	MARPAT 141:260782				
GI					



AB Title heterocycles and analogs I [wherein A1 = CR1, N; A2 = CR8, N; R1, R8 = independently H, alkoxy, (hydroxy)alkyl, amino(alkyl), CN, halo, OH, NO2; R2-R5 = independently H, alkenyl, (alkoxy)alkoxy(alkoxy), (alkoxy)alkyl, alkoxycarbonyl(alkyl), alkylcarbonyl(alkyl), amino(alkoxy), aminoalkyl, aminocarbonyl(alkyl), aminosulfonyl, aryl(alkoxy), aryl(oxy)alkyl, carboxy(alkyl), cyano(alkyl), cycloalkyl(alkyl), halo(alkoxy), haloalkyl, heterocyclyl(alkoxy), heterocyclyl(carbonyl)alkyl, heterocyclyloxyalkyl, hydroxy(alkoxy), hydroxyalkyl, nitro(alkyl), carbamoyl(alkyl); one of R6 and R7 = H and the other = H, aryl, cycloalkyl, halo, heterocyclyl, XR13; R13 = aryl, cycloalkyl, heterocyclyl; X = O, NR14, CO, S, SO2, (CH2)n, CONR14, NR14CO, SO2NR14, NR14SO2, O(CH2)m, (CH2)mO, CH=CH, C.tplbond.C; R14 = H, alkenyl, (amino)alkyl, hydroxyalkyl; Y = NR15, O; R15 = H, alkoxycarbonyl,


(cyclo)alkyl, alkylcarbonyl, arylalkyl, cycloalkylalkyl; m = 0-3; n = 1-3; and therapeutically acceptable salts thereof] were prepared as protein kinase inhibitors. For example, N-alkylation of Me 3,4-diaminobenzoate with Me 4-chloro-2-iodobenzoate using Cu and K₂CO₃ in PhCl gave Me 2-[[2-amino-4-(methoxycarbonyl)phenyl]amino]-4-chlorobenzoate (68%), which was cyclized with 37% HCl in MeOH to provide II (87%). In enzymic assays using recombinant Chk1 kinase domain protein and human cdc25c peptide substrate, compds. of the invention inhibited Chk1 at IC₅₀ values between about 0.2 nM and about 280µM. Thus, I and their pharmaceutical compns. are useful for treatment of cancer (no data).

IT 755027-56-6P 755027-57-7P 755029-61-9P
 755030-80-9P 755031-15-3P 755031-24-4P
 755031-79-9P 755031-98-2P 755031-99-3P
 755032-00-9P 755032-01-0P 755032-28-1P
 755033-14-8P 755033-15-9P 755033-16-0P
 755035-46-2P 755035-47-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (kinase inhibitor; preparation of dibenzo[b,e][1,4]diazepin-11-ones as kinase inhibitors for treatment of cancer)


RN 755027-56-6 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-6-quinolinyl- (9CI) (CA INDEX NAME)




RN 755027-57-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-N-[4-(4-morpholinyl)phenyl]-11-oxo- (9CI) (CA INDEX NAME)




RN 755029-61-9 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-propanamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-N-[4-(4-morpholinyl)phenyl]-11-oxo- (9CI) (CA INDEX NAME)




RN 755030-80-9 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-α,α-dimethyl-N-[4-(4-morpholinyl)phenyl]-11-oxo- (9CI) (CA INDEX NAME)




RN 755031-15-3 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-(4-fluorophenyl)-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- α,α -dimethyl-11-oxo- (9CI)
(CA INDEX NAME)




RN 755031-24-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- α,α -dimethyl-N-[4-(4-morpholinyl)phenyl]-11-oxo- (9CI) (CA INDEX NAME)




RN 755031-79-9 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-2-methyl-N-[4-(4-morpholinyl)phenyl]-11-oxo- (9CI) (CA INDEX NAME)




RN 755031-98-2 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-(3-fluorophenyl)-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- α,α -dimethyl-11-oxo- (9CI)
(CA INDEX NAME)




RN 755031-99-3 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- α,α -dimethyl-11-oxo-N-[4-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 755032-00-9 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- α,α -dimethyl-11-oxo-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 755032-01-0 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-α,α-dimethyl-11-oxo-N-[3-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 755032-28-1 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, N-(4-fluorophenyl)-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-α,α-dimethyl-11-oxo- (9CI) (CA INDEX NAME)




RN 755033-14-8 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, N-[3-(aminocarbonyl)phenyl]-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 755033-15-9 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-N-[4-(4-morpholinyl)phenyl]-11-oxo- (9CI) (CA INDEX NAME)




RN 755033-16-0 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-6-quinolinyl- (9CI) (CA INDEX NAME)




RN 755035-46-2 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-propanamide, N-(4-fluorophenyl)-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 755035-47-3 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-propanamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d l2; d his; log y
 L2 HAS NO ANSWERS
 L1 STR



Structure attributes must be viewed using STN Express query preparation.
 L2 QUE ABB=ON PLU=ON L1

(FILE 'HOME' ENTERED AT 16:20:51 ON 12 AUG 2005)

FILE 'REGISTRY' ENTERED AT 16:20:57 ON 12 AUG 2005

L1 STRUCTURE UPLOADED
 L2 QUE L1
 L3 1 S L2
 L4 17 S L2 FUL

FILE 'CAPLUS' ENTERED AT 16:21:26 ON 12 AUG 2005


L5 2 S L4

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	10.33	171.87
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-1.46	-1.46


STN INTERNATIONAL LOGOFF AT 16:21:56 ON 12 AUG 2005

L25 ANSWER 1 OF 104 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 2005:633268 CAPLUS Full-text
 DN 143:133408
 TI Preparation of tricyclic compounds with NOS activity
 IN Rakhit, Suman; Ramnauth, Jailall; Bratovanov, Svetoslav; Maddaford, Shawn
 PA Neuraxon Inc., Can.
 SO U.S., 17 pp.
 CODEN: USXXAM
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6919328	B1	20050719	US 2002-265624	20021008
PRAI	US 2001-327317P	P	20011009		
GI					



I



II

AB The title compds. I [R1 = CO(alkenyl), CONHR2, CONHCOR2, CSNH2, etc.; R2 = (un)substituted (hetero)aryl; X = O, NH, N(alkyl), S] and their pharmaceutically acceptable salts, useful as neuroprotectants, in particular, for treating stroke, were prepared E.g., a 3-step synthesis of II, starting from Me 2-chloro-4-nitrobenzoate and 1,2-diaminobenzene, was given. The compound II showed IC50 of 400 µM and of 500 µM against nNOS and iNOS, resp. The pharmaceutical composition comprising the compound I is disclosed.


IT **359644-13-6P**

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of dibenzo[b,e][1,4]diazepin-11-one and dibenzo[b,f][1,4]oxazepin-11-one derivs. with NOS activity for treating stroke)

RN 359644-13-6 CAPLUS

CN Thiourea, N-(10,11-dihydro-11-oxodibenz[b,f][1,4]oxazepin-2-yl)-N'-phenyl- (9CI) (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 2 OF 104 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 2005:395446 CAPLUS Full-text
 DN 142:406543
 TI TAO kinase inhibitors for pharmaceutical use and for screening for kinase modulators
 IN Xu, Wei; Zheng, Wentao; Baly, Deborah Lynn; Galan, Adam Antoni; Ibrahim, Mohamed Abdulkader; Jaeger, Christopher; Kearney, Patrick; Leahy, James William; Lewis, Gary Lee; McMillan, Kirk; Noguchi, Robin Tammie; Nuss, John M.; Parks, Jason Jevious; Schnepp, Kevin Luke; Shi, Xian; Williams, Matthew Alan
 PA Exelixis, Inc., USA
 SO PCT Int. Appl., 109 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005040355	A2	20050506	WO 2004-US35469	20041022
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW:				
	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRAI US 2003-514377P P 20031024

OS MARPAT 142:406543


AB The invention provides compds. and methods for inhibition of kinases, such as those of the TAO family, more specifically KIAA1361, TAO, and JIK kinases. The invention provides compds. for modulating protein kinase enzymic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration, and chemoinvasion. Compds. of the invention inhibit, regulate and/or modulate kinase receptor signal transduction pathways related to the changes in cellular activities as mentioned above, and the invention includes compns. which contain these compds., and methods of using them to treat kinase-dependent diseases and conditions. Thus, N-(2,3-dihydro-1,4-benzodioxin-2-ylmethyl)-11-oxo-10,11-dihydro-5H-dibenzo[b,d][1,4]diazepine-3-carboxamide was synthesized. This compound exhibited an IC50 with JIK kinase of <50 nM and an IC50 with TAO kinase of between 50 and 500 nM.

IT **440120-49-0P**

RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (TAO kinase inhibitors for pharmaceutical use and for screening for kinase modulators)

RN 440120-49-0 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, N-[(2,3-dihydro-1,4-benzodioxin-2-yl)methyl]-10,11-dihydro-11-oxo- (9CI) (CA INDEX NAME)



L25 ANSWER 3 OF 104 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 2005:76302 CAPLUS Full-text
 DN 142:170068
 TI Small molecule toll-like receptor (TLR) antagonists
 IN Lipford, Grayson B.; Forsbach, Alexandra; Zepp, Charles M.
 PA Coley Pharmaceutical G.m.b.H., Germany; Coley Pharmaceutical Group, Inc.
 SO PCT Int. Appl., 193 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005007672	A2	20050127	WO 2004-US19714	20040618
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2005119273	A1	20050602	US 2004-872196	20040618
PRAI	US 2003-480588P	P	20030620		
	US 2004-556007P	P	20040323		

OS MARPAT 142:170068

AB The invention provides methods and compns. useful for modulating signaling through Toll-like receptors (TLR). The methods involve contacting a TLR-expressing cell with a small mol. having a core structure including at least two rings. Certain of the compds. are 4-primary amino quinolines. Many of the compds. and methods are useful specifically for inhibiting immune stimulation involving at least one of TLR9, TLR8, TLR7, and TLR3. The methods may have use in the treatment of autoimmunity, inflammation, allergy, asthma, graft rejection, graft vs. host disease, infection, sepsis, cancer, and immunodeficiency.


IT 499975-63-2

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(small mol. toll-like receptor antagonists such as 4-primary amino quinolines to inhibit immunostimulatory signaling in response to antigens such as nucleic acids for treatment of autoimmune disorders)

RN 499975-63-2 CAPLUS

CN Benzamide, N-[2-(8-chloro-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-5-yl)-2-oxoethyl]-N-[3-(diethylamino)propyl]-(9CI) (CA INDEX NAME)



L25 ANSWER 4 OF 104 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2004:1082026 CAPLUS Full-text

DN 142:38288

TI Preparation of dibenzo[b,e][1,4]diazepin-11-ones as kinase inhibitors for treatment of cancer

IN Hasvold, Lisa A.; Hexamer, Laura; Li, Gaoquan; Lin, Nan-horng; Sham, Hing; Sullivan, Gerard M.; Wang, Le; Xia, Ping

PA USA

SO U.S. Pat. Appl. Publ., 137 pp.


CODEN: USXXCO

DT Patent


LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004254159	A1	20041216	US 2004-785120	20040225
	WO 2004076424	A1	20040910	WO 2004-US5728	20040226
	W:	AE, AE, AG, AL, AL, AM, AM, AM, AT, AT, AU, AZ, AZ, BA, BB, BG, BG, BR, BR, BW, BY, BY, BZ, BZ, CA, CH, CN, CN, CO, CO, CR, CR, CU, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EC, EE, EE, EG, ES, ES, FI, FI, GB, GD, GE, GE, GH, GM, HR, HR, HU, HU, ID, IL, IN, IS, JP, JP, KE, KE, KG, KG, KP, KP, KR, KR, KZ, KZ, KZ, LC, LK, LR, LS, LS, LT, LU, LV, MA, MD, MD, MG, MK, MN, MW, MX, MX, MZ, MZ, NA, NI			
	RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
PRAI	US 2003-450476P	P	20030227		
	US 2003-375412	A	20030227		
	US 2004-785120	A	20040225		
OS	MARPAT 142:38288				
GI					



I




II

AB Title heterocycles and analogs I [wherein A1 = CR1, N; A2 = CR8, N; R1, R8 = independently H, alkoxy, (hydroxy)alkyl, amino(alkyl), CN, halo, OH, NO2; R2-R5 = independently H, alkenyl, (alkoxy)alkoxy(alkoxy), (alkoxy)alkyl, alkoxycarbonyl(alkyl), alkylcarbonyl(alkyl), amino(alkoxy), aminoalkyl, aminocarbonyl(alkyl), aminosulfonyl, aryl(alkoxy), aryl(oxy)alkyl, carboxy(alkyl), cyano(alkyl), cycloalkyl(alkyl), halo(alkoxy), haloalkyl, heterocyclyl(alkoxy), heterocyclyl(carbonyl)alkyl, heterocycliloxyalkyl, hydroxy(alkoxy), hydroxyalkyl, nitro(alkyl), carbamoyl(alkyl); one of R6 and R7 = H and the other = H, aryl, cycloalkyl, halo, heterocyclyl, XR13; R13 = aryl, cycloalkyl, heterocyclyl; X = O, NR14, CO, S, SO2, (CH2)n, CONR14, NR14CO, SO2NR14, NR14SO2, O(CH2)m, (CH2)mO, CH=CH, C.tplbond.C; R14 = H, alkenyl, (amino)alkyl, hydroxyalkyl; Y = NR15, O; R15 = H, alkoxycarbonyl,

(cyclo)alkyl, alkylcarbonyl, arylalkyl, cycloalkylalkyl; m = 0-3; n = 1-3; and therapeutically acceptable salts thereof] were prepared as protein kinase inhibitors. For example, N-alkylation of Me 3,4-diaminobenzoate with Me 4-chloro-2-iodobenzoate using Cu and K₂CO₃ in PhCl gave Me 2-[[2-amino-4-(methoxycarbonyl)phenyl]amino]-4-chlorobenzoate (68%), which was cyclized with 37% HCl in MeOH to provide II (87%). In enzymic assays using recombinant Chk1 kinase domain protein and human cdc25c peptide substrate, compds. of the invention inhibited Chk1 at IC₅₀ values between about 0.2 nM and about 280 μM. Thus, I and their pharmaceutical compns. are useful for treatment of cancer (no data).

- IT **755035-60-0P**, 7-Methoxy-3-(3-methoxy-4-nitrophenyl)-11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carboxylic acid
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (intermediate, kinase inhibitor; preparation of dibenzo[b,e][1,4]diazepin-11-ones as kinase inhibitors for treatment of cancer)
- RN **755035-60-0** CAPLUS
- CN **5H-Dibenzo[b,e][1,4]diazepine-8-carboxylic acid, 10,11-dihydro-7-methoxy-3-(3-methoxy-4-nitrophenyl)-11-oxo-** (9CI) (CA INDEX NAME)



- IT **755027-01-1P**, 8-(3-Aminophenyl)-3-chloro-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755027-03-3P**, 3-Chloro-8-(3-hydroxyphenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755027-05-5P**, 3-Chloro-8-(pyridin-3-yl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755027-07-7P**, 3-Chloro-8-(1H-pyrrol-2-yl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755027-13-5P** **755027-16-8P**, 3-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755027-33-9P**, 3-(2-Fluoropyridin-4-yl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755027-35-1P**, Methyl 3-(2-fluoro-4-pyridinyl)-11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carboxylate **755027-36-2P**, 3-(2-Fluoro-4-pyridinyl)-11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carboxylic acid **755027-38-4P** **755028-00-3P** **755028-37-6P**, 8-Amino-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755028-45-6P**, 3-Chloro-8-(2-oxopyrrolidin-1-yl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755028-48-9P**, 3-Chloro-8-(2-oxopiperidin-1-yl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755028-50-3P** **755028-97-8P** **755029-02-8P** **755029-21-1P**, 3-Chloro-8-[2-(pyridin-2-yloxy)ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755029-73-3P** **755029-76-6P** **755029-81-3P** **755030-51-4P**, 3-Chloro-8-[(E)-2-(pyridin-4-yl)ethenyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755030-52-5P**, 3-Chloro-8-[2-(pyridin-4-yl)ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755030-55-8P**, 3-Chloro-8-[(E)-2-(pyridin-2-yl)ethenyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755030-57-0P**, 3-Chloro-8-[2-(pyridin-2-yl)ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755030-88-7P**

755030-90-1P 755030-96-7P 755031-23-3P

755031-30-2P 755031-59-5P, 3-Chloro-8-[2-[[4-(morpholin-4-yl)phenyl]oxy]ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755031-63-1P 755031-64-2P, 3-Chloro-8-[2-[[4-(morpholin-4-yl)phenyl]amino]ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755031-72-2P, 3-Chloro-8-[1,1-dimethyl-2-(pyridin-2-yloxy)ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755031-74-4P,
3-Chloro-8-[1,1-dimethyl-2-(4-nitrophenoxy)ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755031-75-5P,
8-[2-(4-Aminophenoxy)-1,1-dimethylethyl]-3-chloro-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755031-76-6P,
3-Chloro-8-[1,1-dimethyl-2-[[4-(morpholin-4-yl)phenyl]oxy]ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755032-16-7P

755032-64-5P 755032-66-7P 755032-68-9P,

3-(2-Fluoropyridin-4-yl)-8-[2-(morpholin-4-yl)-2-oxoethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755032-70-3P

755033-42-2P, 3-Chloro-7-(piperidin-1-yl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755033-45-5P,

(S)-3-Chloro-7-[2-(hydroxymethyl)pyrrolidin-1-yl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755033-47-7P,

3-Chloro-7-(morpholin-4-yl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755033-51-3P, 3-Chloro-7-(4-hydroxypiperidin-1-yl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755033-72-8P

755033-95-5P 755034-28-7P, 8-Methoxy-3-(3-methoxy-4-nitrophenyl)-7-[[2-(trimethylsilyl)ethoxy]methoxy]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755034-37-8P,

7-Methoxy-3-(3-methoxy-4-nitrophenyl)-8-[[2-(trimethylsilyl)ethoxy]methoxy]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755034-68-5P

755034-96-9P, 3-Chloro-7-[[[2-(tetrahydro-2H-pyran-4-yl)ethyl]amino]methyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one

755035-15-5P, 3-Chloro-7-methoxy-8-[3-[(2-methylpyridin-3-yl)oxy]propyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one

755035-18-8P, 3-Chloro-7-methoxy-8-[3-[[4-(morpholin-4-yl)phenyl]oxy]propyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one

755035-41-7P 755035-81-5P, 3-Chloro-8-[[4-methylpiperazin-1-yl)methyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one

755035-83-7P, 8-[[4-Methylpiperazin-1-yl)methyl]-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755035-97-3P,


3-Chloro-8-(morpholin-4-ylmethyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of dibenzo[b,e][1,4]diazepin-11-ones as kinase inhibitors for treatment of cancer)


RN 755027-01-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-(3-aminophenyl)-3-chloro-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 755027-03-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-(3-hydroxyphenyl)- (9CI) (CA INDEX NAME)




RN 755027-05-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-(3-pyridinyl)- (9CI) (CA INDEX NAME)




RN 755027-07-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-(1H-pyrrol-2-yl)- (9CI) (CA INDEX NAME)




RN 755027-13-5 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 10,11-dihydro-11-oxo-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-, methyl ester (9CI) (CA INDEX NAME)




RN 755027-16-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)- (9CI) (CA INDEX NAME)




RN 755027-33-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-(2-fluoro-4-pyridinyl)-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 755027-35-1 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxylic acid, 3-(2-fluoro-4-pyridinyl)-10,11-dihydro-11-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 755027-36-2 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxylic acid, 3-(2-fluoro-4-pyridinyl)-10,11-dihydro-11-oxo- (9CI) (CA INDEX NAME)




RN 755027-38-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, 3-(2-fluoro-4-pyridinyl)-10,11-dihydro-11-oxo-N-[3-(1-pyrrolidinyl)propyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 755027-37-3


CMF C26 H26 F N5 O2



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 755028-00-3 CAPLUS


CN Carbamic acid, [(1S)-1-[[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]amino]carbonyl]-3-methylbutyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 755028-37-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-amino-5,10-dihydro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)- (9CI) (CA INDEX NAME)




RN 755028-45-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-(2-oxo-1-pyrrolidinyl)- (9CI) (CA INDEX NAME)




RN 755028-48-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-(2-oxo-1-piperidiny)- (9CI) (CA INDEX NAME)




RN 755028-50-3 CAPLUS

CN Butanamide, 4-chloro-N-[3-(4-chloro-3-methoxyphenyl)-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)




RN 755028-97-8 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 3-chloro-10,11-dihydro-α,α-dimethyl-N-[4-(4-morpholinyl)phenyl]-11-oxo- (9CI) (CA INDEX NAME)




RN 755029-02-8 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 3-[(2,6-difluoro-4-pyridinyl)amino]-10,11-dihydro-α,α-dimethyl-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755029-21-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-[2-(2-pyridinyloxy)ethyl]- (9CI) (CA INDEX NAME)



RN 755029-73-3 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-propanoic acid, 10,11-dihydro-11-oxo-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-, methyl ester (9CI) (CA INDEX NAME)



RN 755029-76-6 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-propanoic acid, 3-(4-chloro-3-

methoxyphenyl)-10,11-dihydro-11-oxo- (9CI) (CA INDEX NAME)



RN 755029-81-3 CAPLUS


CN Ethanimidamide, N-[3-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-1-oxopropoxy]- (9CI) (CA INDEX NAME)



RN 755030-51-4 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-[(1E)-2-(4-pyridinyl)ethenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 755030-52-5 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-[2-(4-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 755030-55-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-[(1E)-2-(2-


Double bond geometry as shown.




CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- α,α -dimethyl-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- α,α -dimethyl-11-oxo- (9CI) (CA INDEX NAME)




RN 755030-96-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 3-(4-cyano-3-methoxyphenyl)-10,11-dihydro- α,α -dimethyl-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755031-23-3 CAPLUS

CN Cyclopropanecarboxylic acid, 1-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)




RN 755031-30-2 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetic acid, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- α,α -dimethyl-11-oxo- (9CI) (CA INDEX NAME)




RN 755031-59-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-[2-[4-(4-morpholinyl)phenoxy]ethyl]- (9CI) (CA INDEX NAME)




RN 755031-63-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-[2-[[4-methylphenyl)sulfonyl]oxy]ethyl]- (9CI) (CA INDEX NAME)




RN 755031-64-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-[2-[[4-(4-morpholinyl)phenyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 755031-72-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-8-[1,1-dimethyl-2-(2-pyridinyloxy)ethyl]-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 755031-74-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-8-[1,1-dimethyl-2-(4-nitrophenoxy)ethyl]-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 755031-75-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-[2-(4-aminophenoxy)-1,1-dimethylethyl]-3-chloro-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 755031-76-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-8-[1,1-dimethyl-2-[4-(4-morpholinyl)phenoxy]ethyl]-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 755032-16-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 10,11-dihydro- α,α -dimethyl-11-oxo-3-(4-pyrimidinylamino)- (9CI) (CA INDEX NAME)




RN 755032-64-5 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 3-(2-fluoro-4-pyridinyl)-10,11-dihydro-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755032-66-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 3-(2-fluoro-4-pyridinyl)-10,11-dihydro-N,N-dimethyl-11-oxo- (9CI) (CA INDEX NAME)




RN 755032-68-9 CAPLUS

CN Morpholine, 4-[[3-(2-fluoro-4-pyridinyl)-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]acetyl]- (9CI) (CA INDEX NAME)




RN 755032-70-3 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 3-(2-fluoro-4-pyridinyl)-10,11-dihydro-N-[4-(4-morpholinyl)phenyl]-11-oxo- (9CI) (CA INDEX NAME)



RN 755033-42-2 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-7-(1-piperidinyl)- (9CI) (CA INDEX NAME)



RN 755033-45-5 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-7-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 755033-47-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-7-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 755033-51-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-7-(4-hydroxy-1-piperidiny)- (9CI) (CA INDEX NAME)




RN 755033-72-8 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 10,11-dihydro-11-oxo-3-(4-pyridinylamino)- (9CI) (CA INDEX NAME)




RN 755033-95-5 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 10,11-dihydro-α,α-dimethyl-3-[(2-methyl-4-pyridinyl)amino]-11-oxo- (9CI) (CA INDEX NAME)




RN 755034-28-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-7-[[2-(trimethylsilyl)ethoxy]methoxy]- (9CI) (CA INDEX NAME)




RN 755034-37-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-methoxy-3-(3-methoxy-4-nitrophenyl)-8-[[2-(trimethylsilyl)ethoxy]methoxy]- (9CI) (CA INDEX NAME)




RN 755034-68-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 7-[4-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]butoxy]-5,10-dihydro-3-(4-hydroxy-3-methoxyphenyl)-8-methoxy]- (9CI) (CA INDEX NAME)




RN 755034-96-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-7-[[2-(tetrahydro-2H-pyran-4-yl)ethyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 755035-15-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-7-methoxy-8-[3-[(2-methyl-3-pyridinyl)oxy]propyl]- (9CI) (CA INDEX NAME)




RN 755035-18-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-7-methoxy-8-[4-(4-morpholinyl)phenoxy]propyl]- (9CI) (CA INDEX NAME)




RN 755035-41-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-propanoic acid, 10,11-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 755035-81-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-[(4-methyl-1-piperazinyl)methyl]- (9CI) (CA INDEX NAME)




RN 755035-83-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-[(4-methyl-1-piperazinyl)methyl]-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)- (9CI)
(CA INDEX NAME)



RN 755035-97-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-(4-morpholinylmethyl)- (9CI) (CA INDEX NAME)



IT **755026-56-3P**, Methyl 3-(4-hydroxy-3-methoxyphenyl)-11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carboxylate **755026-57-4P**, 3-(4-Hydroxy-3-methoxyphenyl)-11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carboxylic acid **755026-72-3P**
755026-73-4P **755026-74-5P** **755027-09-9P**
755027-12-4P **755027-23-7P** **755027-24-8P**
755027-25-9P **755027-41-9P** **755027-43-1P**
755027-44-2P **755027-96-4P**, 8-Amino-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one trifluoroacetate **755028-36-5P** **755028-41-2P**, 8-Amino-3-(4-chloro-3-methoxyphenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755028-51-4P**
755028-57-0P **755028-65-0P**, 7-Amino-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755028-69-4P** **755029-08-4P** **755029-13-1P**
755029-56-2P **755029-58-4P** **755029-69-7P**, 8-(2-Hydroxyethyl)-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755029-70-0P**, 8-(3-Hydroxypropyl)-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755030-02-5P**,

7-(2-Hydroxyethyl)-8-methoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755031-18-6P

755032-40-7P 755032-41-8P 755032-44-1P

755032-47-4P 755032-56-5P 755032-58-7P

755033-90-0P 755034-22-1P, 7-Hydroxy-8-methoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one


755034-60-7P, 7-(2-Chloroethoxy)-8-methoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(kinase inhibitor; preparation of dibenzo[b,e][1,4]diazepin-11-ones as kinase inhibitors for treatment of cancer)


RN 755026-56-3 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxylic acid, 10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755026-57-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxylic acid, 10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo- (9CI) (CA INDEX NAME)



RN 755026-72-3 CAPLUS


CN 2-Piperidinecarboxylic acid, 1-[[10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 755026-73-4 CAPLUS


CN 3-Piperidinecarboxylic acid, 1-[[10,11-dihydro-3-(4-hydroxy-3-

methoxyphenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 755026-74-5 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[[10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 755027-09-9 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755027-12-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 3-(4-chloro-3-methoxyphenyl)-10,11-dihydro-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755027-23-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 3-(4-cyano-3-methoxyphenyl)-10,11-dihydro-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755027-24-8 CAPLUS

CN Benzoic acid, 4-(10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-3-yl)-2-methoxy-, methyl ester (9CI) (CA INDEX NAME)




RN 755027-25-9 CAPLUS

CN Benzoic acid, 4-(10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-3-yl)-2-methoxy- (9CI) (CA INDEX NAME)



RN 755027-41-9 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 3-(2-fluoro-5-methyl-4-pyridinyl)-10,11-dihydro-11-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 755027-43-1 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 10,11-dihydro-3-(2-methoxy-5-

methyl-4-pyridinyl)-11-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 755027-44-2 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 755027-96-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-amino-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 755027-95-3


CMF C20 H16 N4 O4



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 755028-36-5 CAPLUS

CN Benzonitrile, 4-(8-amino-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-3-yl)-2-methoxy- (9CI) (CA INDEX NAME)




RN 755028-41-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-amino-3-(4-chloro-3-methoxyphenyl)-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 755028-51-4 CAPLUS

CN 1-Propanesulfonamide, 3-chloro-N-[3-(4-chloro-3-methoxyphenyl)-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)




RN 755028-57-0 CAPLUS

CN 1-Propanesulfonamide, 3-chloro-N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)




RN 755028-65-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 7-amino-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755028-69-4 CAPLUS

CN 1-Propanesulfonamide, 3-chloro-N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]- (9CI) (CA INDEX NAME)




RN 755029-08-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 3-[(2-chloro-4-pyridinyl)amino]-10,11-dihydro-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755029-13-1 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 3-[(2-chloro-4-pyridinyl)amino]-10,11-dihydro-11-oxo- (9CI) (CA INDEX NAME)




RN 755029-56-2 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-propanoic acid, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755029-58-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-propanoic acid, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 755029-69-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-(2-hydroxyethyl)-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755029-70-0 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-(3-hydroxypropyl)-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755030-02-5 CAPLUS
 CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(2-hydroxyethyl)-8-methoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755031-18-6 CAPLUS
 CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 10,11-dihydro- α,α -dimethyl-11-oxo-3-(4-pyrimidinylamino)-, methyl ester (9CI) (CA INDEX NAME)



RN 755032-40-7 CAPLUS
 CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 3-(4-chloro-3-methoxyphenyl)-10,11-dihydro-11-oxo- (9CI) (CA INDEX NAME)




RN 755032-41-8 CAPLUS
 CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 3-(4-acetyl-3-methoxyphenyl)-10,11-dihydro-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755032-44-1 CAPLUS

CN Carbamic acid, [1-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]acetyl]-3-pyrrolidiny]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 755032-47-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 10,11-dihydro-3-(2-methoxy-5-methyl-4-pyridinyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 755032-56-5 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]acetyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 755032-58-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 3-(4-cyano-3-methoxyphenyl)-10,11-dihydro-11-oxo- (9CI) (CA INDEX NAME)




RN 755033-90-0 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 10,11-dihydro- α,α -dimethyl-3-[(2-methyl-4-pyridinyl)amino]-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755034-22-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-hydroxy-8-methoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 755034-60-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 7-(2-chloroethoxy)-5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)



IT **755026-54-1P**, 3-(4-Hydroxy-3-methoxyphenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755026-55-2P**
755026-58-5P, 3-(4-Hydroxy-3-methoxyphenyl)-11-oxo-N-[3-(1-pyrrolidinyl)propyl]-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carboxamide **755026-59-6P** **755026-60-9P**,
N-[3-(Dimethylamino)propyl]-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carboxamide **755026-61-0P**
755026-62-1P, 3-(4-Hydroxy-3-methoxyphenyl)-N-[3-(4-morpholinyl)propyl]-11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carboxamide **755026-63-2P** **755026-64-3P**,
3-(4-Hydroxy-3-methoxyphenyl)-11-oxo-N-[3-(2-oxo-1-pyrrolidinyl)propyl]-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carboxamide
755026-65-4P **755026-66-5P**, N-(2-Hydroxyethyl)-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-10,11-dihydro-5H-

dibenzo[b,e][1,4]diazepine-8-carboxamide **755026-67-6P**,
 N-(2,3-Dihydroxypropyl)-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-10,11-dihydro-
 5H-dibenzo[b,e][1,4]diazepine-8-carboxamide **755026-68-7P**,
 N-[2-(Acetylamino)ethyl]-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-10,11-
 dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carboxamide **755026-69-8P**
 , 3-(4-Hydroxy-3-methoxyphenyl)-8-[(3-hydroxy-1-pyrrolidinyl)carbonyl]-
 5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755026-70-1P**,
 (S)-3-(4-Hydroxy-3-methoxyphenyl)-8-[[2-(hydroxymethyl)-1-
 pyrrolidinyl]carbonyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755026-71-2P, 3-(4-Hydroxy-3-methoxyphenyl)-8-[[2-(hydroxymethyl)-
 1-piperidinyl]carbonyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755026-75-6P, 3-(4-Hydroxy-3-methoxyphenyl)-8-[(3-hydroxy-1-
 piperidinyl)carbonyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755026-76-7P, 3-(4-Hydroxy-3-methoxyphenyl)-11-oxo-N-[(3-
 pyridinyl)methyl]-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-
 carboxamide **755026-77-8P 755026-78-9P**,
 3-(4-Hydroxy-3-methoxyphenyl)-N-[4-(methylsulfonyl)benzyl]-11-oxo-10,11-
 dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carboxamide **755026-79-0P**
 , N-(2-Fluorobenzyl)-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-10,11-dihydro-5H-
 dibenzo[b,e][1,4]diazepine-8-carboxamide **755026-80-3P**,
 3-(4-Hydroxy-3-methoxyphenyl)-N-(2-methoxybenzyl)-11-oxo-10,11-dihydro-5H-
 dibenzo[b,e][1,4]diazepine-8-carboxamide **755026-81-4P**,
 3-(4-Hydroxy-3-methoxyphenyl)-11-oxo-N-[(2-pyridinyl)methyl]-10,11-dihydro-
 5H-dibenzo[b,e][1,4]diazepine-8-carboxamide **755026-82-5P**
755026-83-6P, 3-(4-Hydroxy-3-methoxyphenyl)-11-oxo-N-[(4-
 pyridinyl)methyl]-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-
 carboxamide **755026-84-7P 755026-85-8P**,
 3-(4-Hydroxy-3-methoxyphenyl)-N-[2-(4-methoxyphenyl)ethyl]-11-oxo-10,11-
 dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carboxamide **755026-86-9P**
755026-87-0P 755026-88-1P 755026-89-2P
755026-90-5P, 3-(4-Hydroxy-3-methoxyphenyl)-11-oxo-10,11-dihydro-
 5H-dibenzo[b,e][1,4]diazepine-8-carbonitrile **755026-91-6P**,
 3-(4-Hydroxy-3-methoxyphenyl)-8-nitro-5,10-dihydro-11H-
 dibenzo[b,e][1,4]diazepin-11-one **755026-92-7P**,
 8-Amino-3-(4-hydroxy-3-methoxyphenyl)-5,10-dihydro-11H-
 dibenzo[b,e][1,4]diazepin-11-one hydrochloride **755026-93-8P**
755026-95-0P 755026-97-2P 755026-99-4P
755027-00-0P, 8-(3-Aminophenyl)-3-(4-hydroxy-3-methoxyphenyl)-5,10-
 dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755027-02-2P**,
 3-(4-Hydroxy-3-methoxyphenyl)-8-(3-hydroxyphenyl)-5,10-dihydro-11H-
 dibenzo[b,e][1,4]diazepin-11-one **755027-04-4P**,
 3-(4-Hydroxy-3-methoxyphenyl)-8-(pyridin-3-yl)-5,10-dihydro-11H-
 dibenzo[b,e][1,4]diazepin-11-one **755027-06-6P**,
 3-(4-Hydroxy-3-methoxyphenyl)-8-(1H-pyrrol-2-yl)-5,10-dihydro-11H-
 dibenzo[b,e][1,4]diazepin-11-one **755027-08-8P**,
 3-(3-Methoxy-4-nitrophenyl)-8-(1H-pyrrol-2-yl)-5,10-dihydro-11H-
 dibenzo[b,e][1,4]diazepin-11-one **755027-10-2P**
755027-11-3P 755027-14-6P, 3-(3-Methoxy-4-nitrophenyl)-
 5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755027-15-7P**,
 3-(4-Chloro-3-methoxyphenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-
 one **755027-17-9P**, 3-(4-Bromo-3-methoxyphenyl)-5,10-dihydro-11H-
 dibenzo[b,e][1,4]diazepin-11-one **755027-19-1P**
755027-20-4P, 3-(4-Acetyl-3-methoxyphenyl)-5,10-dihydro-11H-
 dibenzo[b,e][1,4]diazepin-11-one **755027-22-6P**
755027-26-0P 755027-27-1P 755027-28-2P
755027-29-3P 755027-32-8P, 3-(2-Methoxypyridin-4-yl)-
 5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755027-34-0P**,
 3-(2-Methoxy-4-pyridinyl)-11-oxo-N-[3-(1-pyrrolidinyl)propyl]-10,11-
 dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carboxamide **755027-39-5P**
 , 11-Oxo-3-(2-oxo-1,2-dihydro-4-pyridinyl)-N-[3-(1-pyrrolidinyl)propyl]-

10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carboxamide
 755027-40-8P 755027-45-3P 755027-46-4P
 755027-47-5P, 8-[2-(3-Hydroxy-1-piperidiny1)-2-oxoethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
 755027-48-6P, 3-(3-Methoxy-4-nitrophenyl)-8-[2-(4-methyl-1,4-diazepan-1-yl)-2-oxoethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755027-50-0P 755027-51-1P, 8-[2-(4-Hydroxy-1-piperidiny1)-2-oxoethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755027-52-2P
 755027-53-3P 755027-54-4P 755027-55-5P
 755027-56-6P 755027-57-7P 755027-58-8P
 755027-59-9P 755027-60-2P 755027-61-3P
 755027-62-4P 755027-63-5P 755027-66-8P
 755027-67-9P 755027-68-0P 755027-69-1P
 755027-71-5P 755027-72-6P 755027-73-7P
 755027-74-8P 755027-75-9P 755027-76-0P
 755027-77-1P 755027-78-2P, 8-[2-(4-Ethyl-1-piperaziny1)-2-oxoethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755027-79-3P,
 8-[2-[4-(2-Hydroxyethyl)-1-piperaziny1]-2-oxoethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
 755027-80-6P 755027-81-7P, 3-(3-Methoxy-4-nitrophenyl)-8-[2-oxo-2-(4-phenyl-1-piperaziny1)ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755027-82-8P,
 3-(3-Methoxy-4-nitrophenyl)-8-[2-oxo-2-[4-(pyridin-2-yl)-1-piperaziny1]ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
 755027-83-9P 755027-84-0P 755027-85-1P
 755027-86-2P 755027-87-3P 755027-88-4P
 755027-89-5P 755027-90-8P 755027-91-9P
 755027-92-0P 755027-93-1P 755027-94-2P,
 (S)-8-[2-[2-(Hydroxymethyl)-1-pyrrolidinyl]-2-oxoethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
 755027-95-3P, 8-Amino-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755027-97-5P
 755027-98-6P 755027-99-7P 755028-01-4P
 755028-02-5P 755028-03-6P 755028-04-7P
 755028-05-8P 755028-06-9P 755028-07-0P
 755028-08-1P 755028-09-2P 755028-10-5P
 755028-11-6P 755028-12-7P 755028-13-8P
 755028-14-9P 755028-15-0P 755028-16-1P
 755028-19-4P 755028-21-8P 755028-22-9P
 755028-24-1P 755028-25-2P 755028-26-3P
 755028-27-4P 755028-28-5P 755028-29-6P
 755028-30-9P 755028-31-0P 755028-32-1P
 755028-33-2P 755028-34-3P 755028-35-4P
 755028-38-7P 755028-39-8P 755028-40-1P
 755028-42-3P 755028-43-4P, 3-(3-Methoxy-4-nitrophenyl)-8-(2-oxopyrrolidin-1-yl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
 755028-46-7P, 3-(3-Methoxy-4-nitrophenyl)-8-(2-oxopiperidin-1-yl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755028-49-0P,
 3-(4-Chloro-3-methoxyphenyl)-8-(2-oxopyrrolidin-1-yl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755028-52-5P
 755028-53-6P, 3-(4-Chloro-3-methoxyphenyl)-8-(1,1-dioxidoisothiazolidin-2-yl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755028-54-7P 755028-55-8P 755028-56-9P
 755028-58-1P, 8-(1,1-Dioxidoisothiazolidin-2-yl)-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
 755028-59-2P 755028-60-5P 755028-61-6P
 755028-62-7P 755028-63-8P 755028-64-9P
 755028-70-7P 755028-71-8P 755028-72-9P

755028-73-0P 755028-74-1P 755028-75-2P
755028-76-3P 755028-77-4P 755028-78-5P
755028-79-6P, 8-(1-Hydroxy-1-methylethyl)-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755028-81-0P, 8-(1-Ethyl-1-hydroxypropyl)-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755028-83-2P, 8-(1-Hydroxy-1-methylethyl)-3-[(pyridin-4-yl)amino]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755028-84-3P**,
3-[(2-Chloropyridin-4-yl)amino]-8-(1-hydroxy-1-methylethyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755028-86-5P**
755028-87-6P, 8-(1-Hydroxy-1-methylethyl)-3-[(pyrimidin-4-yl)amino]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755028-88-7P**,
8-(1-Hydroxy-1-methylethyl)-3-[(2,3,5,6-tetrafluoropyridin-4-yl)amino]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755028-89-8P, 8-(1-Ethyl-1-hydroxypropyl)-3-[(pyridin-4-yl)amino]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755028-90-1P**,
3-[(2-Aminopyrimidin-4-yl)amino]-8-(1-hydroxy-1-methylethyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755028-91-2P**,
3-[(2-Chloropyridin-4-yl)amino]-8-(1-ethyl-1-hydroxypropyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755028-92-3P**,
8-(1-Hydroxy-1-methylethyl)-3-[(2,3,6-trifluoropyridin-4-yl)amino]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755028-93-4P**,
3-[[2-[(2-Chloropyridin-4-yl)amino]pyridin-4-yl]amino]-8-(1-hydroxy-1-methylethyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755028-94-5P 755028-95-6P 755028-98-9P
755028-99-0P, 3-[(2,6-Difluoropyridin-4-yl)amino]-8-(2-hydroxyethyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755029-01-7P 755029-03-9P, 3-[(2,6-Difluoropyridin-4-yl)amino]-7-(morpholin-4-yl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755029-04-0P, 7-(Morpholin-4-yl)-3-[(2,3,6-trifluoropyridin-4-yl)amino]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755029-05-1P, 3-[(2,6-Difluoropyridin-4-yl)amino]-8-(2-hydroxy-2-methylpropyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755029-07-3P 755029-09-5P 755029-10-8P,
3-[(2-Chloropyridin-4-yl)amino]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755029-11-9P**, 8-Acetyl-3-[(2-chloropyridin-4-yl)amino]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755029-14-2P**,
3-[(2-Chloropyridin-4-yl)amino]-8-isopropenyl-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755029-15-3P**
755029-16-4P, 3-[(2-Chloropyridin-4-yl)amino]-8-(2-hydroxy-2-methylpropyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755029-17-5P 755029-18-6P, 3-[(2-Chloropyridin-4-yl)amino]-8-(2-oxopyrrolidin-1-yl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755029-19-7P**
755029-20-0P, 8-[2-(Pyridin-2-yloxy)ethyl]-3-[(2,3,6-trifluoropyridin-4-yl)amino]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755029-22-2P, 8-(2-Hydroxy-2-methylpropyl)-3-[(2,3,5-trifluorophenyl)amino]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755029-23-3P, 3-[(3,5-Difluorophenyl)amino]-7-(3-hydroxy-3-methylbutyl)-8-methoxy-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755029-39-1P, 7-(3-Hydroxy-3-methylbutyl)-8-methoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755029-41-5P, 3-[(2,6-Difluoropyridin-4-yl)amino]-7-(3-hydroxypropyl)-8-methoxy-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755029-44-8P, 7-(3-Hydroxypropyl)-8-methoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755029-46-0P, 3-[(2,6-Difluoropyridin-4-yl)amino]-8-(3-hydroxy-3-methylbutyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755029-54-0P, 8-(3-Hydroxy-3-methylbutyl)-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one


755029-60-8P 755029-61-9P 755029-63-1P,
 8-[3-(Azetidin-1-yl)-3-oxopropyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755029-64-2P,**
 3-(3-Methoxy-4-nitrophenyl)-8-[3-oxo-3-(pyrrolidin-1-yl)propyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755029-65-3P,**
 3-(3-Methoxy-4-nitrophenyl)-8-[3-(morpholin-4-yl)-3-oxopropyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755029-66-4P**
755029-67-5P, 8-[3-(4-Hydroxypiperidin-1-yl)-3-oxopropyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755029-68-6P 755029-72-2P 755029-74-4P
755029-78-8P, 3-(4-Chloro-3-methoxyphenyl)-8-(3-hydroxy-3-methylbutyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755029-80-2P, 3-(3-Methoxy-4-nitrophenyl)-8-[2-(3-methyl-1,2,4-oxadiazol-5-yl)ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755029-83-5P 755029-85-7P, 7-(2-Hydroxy-2-methylpropyl)-8-methoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755030-04-7P,**
 8-Methoxy-3-(3-methoxy-4-nitrophenyl)-7-(2-oxopropyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755030-06-9P,**
 7-(2-Hydroxy-1,1-dimethylethyl)-8-methoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755030-15-0P,**
 7-(3-Hydroxypropyl)-3-(3-methoxy-4-nitrophenyl)-8-(trifluoromethoxy)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755030-28-5P,**
 7-(3-Hydroxy-3-methylbutyl)-3-(3-methoxy-4-nitrophenyl)-8-(trifluoromethoxy)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755030-31-0P, 7-(3-Hydroxy-3-methylbutyl)-3-(3-methoxy-4-nitrophenyl)-8-methyl-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755030-48-9P, 3-(3-Methoxy-4-nitrophenyl)-8-[2-(pyridin-4-yl)ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755030-53-6P, 3-(3-Methoxy-4-nitrophenyl)-8-[2-(pyridin-2-yl)ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755030-60-5P 755030-62-7P 755030-63-8P
755030-65-0P, 3-(3-Methoxy-4-nitrophenyl)-8-[2-[(pyridin-2-yl)oxy]ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755030-66-1P, 8-[2-[(5-Chloropyridin-3-yl)oxy]ethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755030-67-2P, 8-Methoxy-3-(3-methoxy-4-nitrophenyl)-7-[2-[(pyridin-3-yl)oxy]ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755030-69-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(kinase inhibitor; preparation of dibenzo[b,e][1,4]diazepin-11-ones as kinase inhibitors for treatment of cancer)

RN 755026-54-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(4-hydroxy-3-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 755026-55-2 CAPLUS

CN Benzonitrile, 3-(10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-3-yl)-


N#Cc1ccc(cc1)-c2cc3c(cc2)c(=O)[nH]c4ccccc34

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, 10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-N-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)




CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, 10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-N-[3-(1-pyrrolidinyl)propyl]-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)


CRN 755026-58-5
CMF C28 H30 N4 O4



CRN 76-05-1
CMF C2 H F3 O2




RN 755026-60-9 CAPLUS
 CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, N-[3-(dimethylamino)propyl]-
 10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo- (9CI) (CA INDEX NAME)



RN 755026-61-0 CAPLUS
 CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, N-[3-(dimethylamino)propyl]-
 10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-,
 mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 755026-60-9
 CMF C26 H28 N4 O4




CM 2

CRN 76-05-1
 CMF C2 H F3 O2



RN 755026-62-1 CAPLUS
 CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, 10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-N-[3-(4-morpholinyl)propyl]-11-oxo- (9CI) (CA INDEX NAME)




RN 755026-63-2 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, 10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-N-[3-(4-morpholinyl)propyl]-11-oxo-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 755026-62-1


CMF C28 H30 N4 O5



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 755026-64-3 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, 10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-N-[3-(2-oxo-1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)




RN 755026-65-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, 10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-N-[3-(2-oxo-1-pyrrolidiny)propyl]-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 755026-64-3


CMF C28 H28 N4 O5



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 755026-66-5 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, 10,11-dihydro-N-(2-hydroxyethyl)-3-(4-hydroxy-3-methoxyphenyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 755026-67-6 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, N-(2,3-dihydroxypropyl)-10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 755026-68-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, N-[2-(acetylamino)ethyl]-10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo- (9CI) (CA INDEX NAME)



RN 755026-69-8 CAPLUS


CN 3-Pyrrolidinol, 1-[[10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]carbonyl]- (9CI) (CA INDEX NAME)



RN 755026-70-1 CAPLUS


CN 2-Pyrrolidinemethanol, 1-[[10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]carbonyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 755026-71-2 CAPLUS

CN 2-Piperidinemethanol, 1-[[[10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 755026-75-6 CAPLUS

CN 3-Piperidinol, 1-[[[10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]carbonyl]- (9CI) (CA INDEX NAME)



RN 755026-76-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, 10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 755026-77-8 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, 10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-N-(3-pyridinylmethyl)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 755026-76-7


CMF C27 H22 N4 O4



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 755026-78-9 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, 10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-N-[[4-(methylsulfonyl)phenyl]methyl]-11-oxo- (9CI) (CA INDEX NAME)



RN 755026-79-0 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, N-[(2-fluorophenyl)methyl]-10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo- (9CI) (CA INDEX NAME)



RN 755026-80-3 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, 10,11-dihydro-3-(4-hydroxy-3-

methoxyphenyl)-N-[(2-methoxyphenyl)methyl]-11-oxo- (9CI) (CA INDEX NAME)



RN 755026-81-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, 10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-N-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 755026-82-5 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, 10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-N-(2-pyridinylmethyl)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 755026-81-4


CMF C27 H22 N4 O4



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 755026-83-6 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, 10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 755026-84-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, 10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-N-(4-pyridinylmethyl)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 755026-83-6


CMF C27 H22 N4 O4



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 755026-85-8 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, 10,11-dihydro-3-(4-hydroxy-3-

methoxyphenyl)-N-[2-(4-methoxyphenyl)ethyl]-11-oxo- (9CI) (CA INDEX NAME)




RN 755026-86-9 CAPLUS

CN 2-Piperidinecarboxylic acid, 1-[[10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]carbonyl]- (9CI)
(CA INDEX NAME)




RN 755026-87-0 CAPLUS

CN 3-Piperidinecarboxylic acid, 1-[[10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]carbonyl]- (9CI)
(CA INDEX NAME)




RN 755026-88-1 CAPLUS


CN 4-Piperidinecarboxylic acid, 1-[[10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]carbonyl]- (9CI)
(CA INDEX NAME)




RN 755026-89-2 CAPLUS
 CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxylic acid, 10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-, 2-[(1,1-dimethylethoxy)carbonyl]hydrazide (9CI) (CA INDEX NAME)




RN 755026-90-5 CAPLUS
 CN 5H-Dibenzo[b,e][1,4]diazepine-8-carbonitrile, 10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo- (9CI) (CA INDEX NAME)



RN 755026-91-6 CAPLUS
 CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(4-hydroxy-3-methoxyphenyl)-8-nitro- (9CI) (CA INDEX NAME)




RN 755026-92-7 CAPLUS
 CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-amino-5,10-dihydro-3-(4-hydroxy-3-methoxyphenyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 755026-93-8 CAPLUS

CN Methanesulfonamide, N-[10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)




RN 755026-95-0 CAPLUS

CN Methanesulfonamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)




RN 755026-97-2 CAPLUS

CN Acetamide, N-[10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)




RN 755026-99-4 CAPLUS

CN Acetamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)




RN 755027-00-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-(3-aminophenyl)-5,10-dihydro-3-(4-hydroxy-3-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 755027-02-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(4-hydroxy-3-methoxyphenyl)-8-(3-hydroxyphenyl)- (9CI) (CA INDEX NAME)




RN 755027-04-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(4-hydroxy-3-methoxyphenyl)-8-(3-pyridinyl)- (9CI) (CA INDEX NAME)




RN 755027-06-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(4-hydroxy-3-methoxyphenyl)-8-(1H-pyrrol-2-yl)- (9CI) (CA INDEX NAME)




RN 755027-08-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-(1H-pyrrol-2-yl)- (9CI) (CA INDEX NAME)




RN 755027-10-2 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755027-11-3 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 10,11-dihydro-3-(3-methoxyphenyl)-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755027-14-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755027-15-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-(4-chloro-3-methoxyphenyl)-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 755027-17-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-(4-bromo-3-methoxyphenyl)-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 755027-19-1 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 3-(4-bromo-3-methoxyphenyl)-10,11-dihydro-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755027-20-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-(4-acetyl-3-methoxyphenyl)-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 755027-22-6 CAPLUS

CN Benzonitrile, 4-(10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-3-yl)-2-methoxy- (9CI) (CA INDEX NAME)




RN 755027-26-0 CAPLUS

CN Benzamide, 4-(10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-3-yl)-N-[(3,4-dihydroxyphenyl)methyl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 755027-27-1 CAPLUS

CN Benzamide, 4-(10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-3-yl)-2-methoxy- (9CI) (CA INDEX NAME)




RN 755027-28-2 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 10,11-dihydro-3-(5-methoxy-2-methyl-4-nitrophenyl)-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755027-29-3 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 3-(4-cyano-5-methoxy-2-methylphenyl)-10,11-dihydro-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755027-32-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(2-methoxy-4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 755027-34-0 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, 10,11-dihydro-3-(2-methoxy-4-pyridinyl)-11-oxo-N-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)



RN 755027-39-5 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, 3-(1,2-dihydro-2-oxo-4-pyridinyl)-10,11-dihydro-11-oxo-N-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)



RN 755027-40-8 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, 3-(1,2-dihydro-2-oxo-4-pyridinyl)-10,11-dihydro-11-oxo-N-[3-(1-pyrrolidinyl)propyl]-,

mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 755027-39-5


CMF C26 H27 N5 O3



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 755027-45-3 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)




RN 755027-46-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-[2-(dimethylamino)ethyl]-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-N-methyl-11-oxo- (9CI) (CA INDEX NAME)




RN 755027-47-5 CAPLUS

CN 3-Piperidinol, 1-[[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]acetyl]- (9CI) (CA INDEX NAME)




RN 755027-48-6 CAPLUS

CN 1H-1,4-Diazepine, 1-[[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]acetyl]hexahydro-4-methyl- (9CI) (CA INDEX NAME)




RN 755027-50-0 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-N,N-dimethyl-11-oxo- (9CI) (CA INDEX NAME)




RN 755027-51-1 CAPLUS

CN 4-Piperidinol, 1-[[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]acetyl]- (9CI) (CA INDEX NAME)




RN 755027-52-2 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 755027-53-3 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-[2-(3-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 755027-54-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-[2-(4-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 755027-55-5 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-3-quinolinyl- (9CI) (CA INDEX NAME)




RN 755027-56-6 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-6-quinolinyl- (9CI) (CA INDEX NAME)



RN 755027-57-7 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-N-[4-(4-morpholinyl)phenyl]-11-oxo- (9CI) (CA INDEX NAME)



RN 755027-58-8 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-N-[(1S)-1-(hydroxymethyl)-2-methylpropyl]-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 755027-59-9 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-N-[(1R)-1-(hydroxymethyl)-2-methylpropyl]-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 755027-60-2 CAPLUS
CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-(3-ethoxypropyl)-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 755027-61-3 CAPLUS
CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-[2-(diethylamino)ethyl]-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)



RN 755027-62-4 CAPLUS
CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-N-[(1R)-1-(hydroxymethyl)-3-methylbutyl]-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 755027-63-5 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-N-[(1S)-1-(hydroxymethyl)-3-methylbutyl]-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 755027-66-8 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-N-[3-(1H-imidazol-1-yl)propyl]-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 755027-67-9 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-N-(3-hydroxypropyl)-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 755027-68-0 CAPLUS
 CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-[3-(diethylamino)propyl]-
 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 755027-69-1 CAPLUS
 CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-N-[(1S)-2-hydroxy-1-phenylethyl]-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 755027-71-5 CAPLUS
 CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-N-[(1R)-2-hydroxy-1-phenylethyl]-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 755027-72-6 CAPLUS
 CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-[(3,4-difluorophenyl)methyl]-
 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 755027-73-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-N-(4-hydroxybutyl)-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 755027-74-8 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-[1-(phenylmethyl)-4-piperidiny]- (9CI) (CA INDEX NAME)



RN 755027-75-9 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-[4-(dimethylamino)butyl]-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)



RN 755027-76-0 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-[2-[4-(aminosulfonyl)phenyl]ethyl]-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-

oxo- (9CI) (CA INDEX NAME)




RN 755027-77-1 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-N-(2-hydroxyethyl)-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-propyl- (9CI) (CA INDEX NAME)




RN 755027-78-2 CAPLUS

CN Piperazine, 1-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]acetyl]-4-ethyl- (9CI) (CA INDEX NAME)




RN 755027-79-3 CAPLUS

CN 1-Piperazineethanol, 4-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]acetyl]- (9CI) (CA INDEX NAME)




RN 755027-80-6 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-N-methyl-11-oxo-N-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 755027-81-7 CAPLUS

CN Piperazine, 1-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]acetyl]-4-phenyl- (9CI) (CA INDEX NAME)




RN 755027-82-8 CAPLUS

CN Piperazine, 1-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]acetyl]-4-(2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 755027-83-9 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 755027-84-0 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 755027-85-1 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 755027-86-2 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-[2-(dimethylamino)ethyl]-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 755027-87-3 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-[3-(dimethylamino)propyl]-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 755027-88-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 755027-89-5 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-[2-(1-piperidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 755027-90-8 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-[3-(1-piperidinyl)propyl]- (9CI) (CA INDEX NAME)




RN 755027-91-9 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-N-[2-(4-morpholinyl)ethyl]-11-oxo- (9CI) (CA INDEX NAME)




RN 755027-92-0 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-N-[3-(4-morpholinyl)propyl]-11-oxo- (9CI) (CA INDEX NAME)



RN 755027-93-1 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-N-[2-(4-methyl-1-piperazinyl)ethyl]-11-oxo- (9CI) (CA INDEX NAME)




RN 755027-94-2 CAPLUS

CN 2-Pyrrolidinemethanol, 1-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]acetyl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 755027-95-3 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-amino-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 755027-97-5 CAPLUS
CN Urea, [10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)




RN 755027-98-6 CAPLUS
CN Acetamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-2-(dimethylamino)- (9CI) (CA INDEX NAME)




RN 755027-99-7 CAPLUS
CN Pentanamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-2-(dimethylamino)-4-methyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 755028-01-4 CAPLUS

CN Butanamide, 4-amino-N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)




RN 755028-02-5 CAPLUS

CN Propanamide, 3-amino-N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)




RN 755028-03-6 CAPLUS

CN 1H-Imidazole-5-acetamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-1-methyl- (9CI) (CA INDEX NAME)




RN 755028-04-7 CAPLUS

CN 1H-Imidazole-4-acetamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-1-methyl- (9CI) (CA INDEX NAME)




RN 755028-05-8 CAPLUS

CN 3-Thiophenecarboxamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)




RN 755028-06-9 CAPLUS

CN 1H-Pyrrole-2-carboxamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)




RN 755028-07-0 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 755028-08-1 CAPLUS

CN 4-Thiazolecarboxamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)




RN 755028-09-2 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)




RN 755028-10-5 CAPLUS

CN 1H-Pyrazole-4-carboxamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)




RN 755028-11-6 CAPLUS

CN 4-Pyridinecarboxamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)




RN 755028-12-7 CAPLUS

CN 1-Pyrrolidinepropanamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)




RN 755028-13-8 CAPLUS

CN 1-Piperidinepropanamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)



RN 755028-14-9 CAPLUS


CN 4-Morpholinepropanamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)



RN 755028-15-0 CAPLUS


CN Benzenebutanamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- α -hydroxy-, (α R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 755028-16-1 CAPLUS

CN Propanamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-3-(phenylsulfonyl)- (9CI) (CA INDEX NAME)




RN 755028-19-4 CAPLUS

CN Acetamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-2-[[(4-methylphenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 755028-21-8 CAPLUS

CN 2-Pyridinecarboxamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)




RN 755028-22-9 CAPLUS


CN 3-Pyridinecarboxamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)




RN 755028-24-1 CAPLUS
 CN 3-Pyridineacetamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)



RN 755028-25-2 CAPLUS
 CN 1-Piperazineacetamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-4-methyl- (9CI) (CA INDEX NAME)




RN 755028-26-3 CAPLUS
 CN Propanamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-3-ethoxy- (9CI) (CA INDEX NAME)




RN 755028-27-4 CAPLUS
 CN 2-Pyrrolidinecarboxamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-5-oxo-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 755028-28-5 CAPLUS


CN Cyclohexanecarboxamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-4-methoxy- (9CI) (CA INDEX NAME)



RN 755028-29-6 CAPLUS

CN Benzeneacetamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-α-methoxy-, (αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 755028-30-9 CAPLUS


CN Benzeneacetamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-α-methoxy-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 755028-31-0 CAPLUS

CN 2-Furancarboxamide, N-[2-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)




RN 755028-32-1 CAPLUS

CN 4-Piperidinecarboxamide, 1-acetyl-N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)




RN 755028-33-2 CAPLUS

CN Pentanediamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-N'-phenyl- (9CI) (CA INDEX NAME)



RN 755028-34-3 CAPLUS


CN Benzeneacetamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-4-(methylsulfonyl)- (9CI) (CA INDEX NAME)



RN 755028-35-4 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-5-oxo-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 755028-38-7 CAPLUS


CN Benzeneacetamide, N-[3-(4-cyano-3-methoxyphenyl)-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-α-methoxy-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 755028-39-8 CAPLUS

CN 1-Piperidinepropanamide, N-[3-(4-cyano-3-methoxyphenyl)-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)




RN 755028-40-1 CAPLUS

CN Methanesulfonamide, N-[3-(4-cyano-3-methoxyphenyl)-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)




RN 755028-42-3 CAPLUS

CN 1-Piperidinepropanamide, N-[3-(4-chloro-3-methoxyphenyl)-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)




RN 755028-43-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-(2-oxo-1-pyrrolidinyl)- (9CI) (CA INDEX NAME)




RN 755028-46-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-(2-oxo-1-piperidinyl)- (9CI) (CA INDEX NAME)




RN 755028-49-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-(4-chloro-3-methoxyphenyl)-5,10-dihydro-8-(2-oxo-1-pyrrolidinyl)- (9CI) (CA INDEX NAME)




RN 755028-52-5 CAPLUS

CN Benzenemesanesulfonamide, N-[3-(4-chloro-3-methoxyphenyl)-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)




RN 755028-53-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-(4-chloro-3-methoxyphenyl)-8-(1,1-dioxido-2-isothiazolidinyl)-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 755028-54-7 CAPLUS

CN Ethanesulfonamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-2,2,2-trifluoro- (9CI) (CA INDEX NAME)




RN 755028-55-8 CAPLUS

CN 1H-Imidazole-4-sulfonamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-1-methyl- (9CI) (CA INDEX NAME)




RN 755028-56-9 CAPLUS

CN Benzenemethanesulfonamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)




RN 755028-58-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-(1,1-dioxido-2-isothiazolidinyl)-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755028-59-2 CAPLUS

CN 4-Morpholinepropanesulfonamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)




RN 755028-60-5 CAPLUS

CN 1-Piperidinepropanesulfonamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)




RN 755028-61-6 CAPLUS

CN 1-Propanesulfonamide, 3-(diethylamino)-N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)




RN 755028-62-7 CAPLUS

CN 1-Propanesulfonamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-3-(dimethylamino)- (9CI) (CA INDEX NAME)




RN 755028-63-8 CAPLUS

CN Methanesulfonamide, 1-chloro-N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)




RN 755028-64-9 CAPLUS

CN Benzenesulfonamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-4-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 755028-70-7 CAPLUS

CN Benzenesulfonamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]- (9CI) (CA INDEX NAME)




RN 755028-71-8 CAPLUS

CN Benzenesulfonamide, 4-chloro-N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]- (9CI) (CA INDEX NAME)




RN 755028-72-9 CAPLUS

CN 1H-Imidazole-4-sulfonamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]-1-methyl- (9CI) (CA INDEX NAME)




RN 755028-73-0 CAPLUS

CN Methanesulfonamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]- (9CI) (CA INDEX NAME)




RN 755028-74-1 CAPLUS

CN 4-Morpholinepropanesulfonamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]- (9CI) (CA INDEX NAME)




RN 755028-75-2 CAPLUS

CN 1-Piperidinepropanesulfonamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]- (9CI) (CA INDEX NAME)




RN 755028-76-3 CAPLUS

CN 1-Propanesulfonamide, 3-(diethylamino)-N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]- (9CI) (CA INDEX NAME)




RN 755028-77-4 CAPLUS

CN 1-Propanesulfonamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]-3-(dimethylamino)- (9CI) (CA INDEX NAME)




RN 755028-78-5 CAPLUS

CN 2H-Pyran-4-carboxamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]tetrahydro- (9CI) (CA INDEX NAME)




RN 755028-79-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-(1-hydroxy-1-methylethyl)-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755028-81-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-(1-ethyl-1-hydroxypropyl)-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755028-83-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-(1-hydroxy-1-methylethyl)-3-(4-pyridinylamino)- (9CI) (CA INDEX NAME)




RN 755028-84-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-[(2-chloro-4-pyridinyl)amino]-5,10-dihydro-8-(1-hydroxy-1-methylethyl)- (9CI) (CA INDEX NAME)




RN 755028-86-5 CAPLUS

CN 2-Pyridinecarbonitrile, 4-[[10,11-dihydro-8-(1-hydroxy-1-methylethyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-3-yl]amino]- (9CI) (CA INDEX NAME)




RN 755028-87-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-(1-hydroxy-1-methylethyl)-3-(4-pyrimidinylamino)- (9CI) (CA INDEX NAME)




RN 755028-88-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-(1-hydroxy-1-methylethyl)-3-[(2,3,5,6-tetrafluoro-4-pyridinyl)amino]- (9CI) (CA INDEX NAME)




RN 755028-89-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-(1-ethyl-1-hydroxypropyl)-5,10-dihydro-3-(4-pyridinylamino)- (9CI) (CA INDEX NAME)




RN 755028-90-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-[(2-amino-4-pyrimidinyl)amino]-5,10-dihydro-8-(1-hydroxy-1-methylethyl)- (9CI) (CA INDEX NAME)




RN 755028-91-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-[(2-chloro-4-pyridinyl)amino]-8-(1-ethyl-1-hydroxypropyl)-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 755028-92-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-(1-hydroxy-1-methylethyl)-3-[(2,3,6-trifluoro-4-pyridinyl)amino]- (9CI) (CA INDEX NAME)




RN 755028-93-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-[[2-[(2-chloro-4-pyridinyl)amino]-4-pyridinyl]amino]-5,10-dihydro-8-(1-hydroxy-1-methylethyl)- (9CI) (CA INDEX NAME)




RN 755028-94-5 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 10,11-dihydro- α,α -dimethyl-11-oxo-3-[(2,3,6-trifluoro-4-pyridinyl)amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 755028-95-6 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro- α,α -dimethyl-N-[4-(4-morpholinyl)phenyl]-11-oxo-3-[(2,3,6-trifluoro-4-pyridinyl)amino]- (9CI) (CA INDEX NAME)




RN 755028-98-9 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 3-[(2,6-difluoro-4-pyridinyl)amino]-10,11-dihydro- α,α -dimethyl-N-[4-(4-morpholinyl)phenyl]-11-oxo- (9CI) (CA INDEX NAME)




RN 755028-99-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-[(2,6-difluoro-4-pyridinyl)amino]-5,10-dihydro-8-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)




RN 755029-01-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 3-[(2,6-difluoro-4-pyridinyl)amino]-10,11-dihydro- α,α -dimethyl-11-oxo- (9CI) (CA INDEX NAME)




RN 755029-03-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-[(2,6-difluoro-4-pyridinyl)amino]-5,10-dihydro-7-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 755029-04-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(4-morpholinyl)-3-[(2,3,6-trifluoro-4-pyridinyl)amino]- (9CI) (CA INDEX NAME)




RN 755029-05-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-[(2,6-difluoro-4-pyridinyl)amino]-5,10-dihydro-8-(2-hydroxy-2-methylpropyl)- (9CI) (CA INDEX NAME)




RN 755029-07-3 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 10,11-dihydro-11-oxo-3-(4-pyridinylamino)-, methyl ester (9CI) (CA INDEX NAME)




RN 755029-09-5 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 10,11-dihydro-3-[(2-methyl-4-pyridinyl)amino]-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755029-10-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-[(2-chloro-4-pyridinyl)amino]-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 755029-11-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-acetyl-3-[(2-chloro-4-pyridinyl)amino]-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 755029-14-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-[(2-chloro-4-pyridinyl)amino]-5,10-dihydro-8-(1-methylethenyl)- (9CI) (CA INDEX NAME)




RN 755029-15-3 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 3-[(2-chloro-4-pyridinyl)amino]-10,11-dihydro-N-[4-(4-morpholinyl)phenyl]-11-oxo- (9CI) (CA INDEX NAME)




RN 755029-16-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-[(2-chloro-4-pyridinyl)amino]-5,10-dihydro-8-(2-hydroxy-2-methylpropyl)- (9CI) (CA INDEX NAME)




RN 755029-17-5 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 3-[(2-chloro-4-pyridinyl)amino]-10,11-dihydro-α,α-dimethyl-N-[4-(4-morpholinyl)phenyl]-11-oxo- (9CI) (CA INDEX NAME)




RN 755029-18-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-[(2-chloro-4-pyridinyl)amino]-5,10-dihydro-8-(2-oxo-1-pyrrolidinyl)- (9CI) (CA INDEX NAME)




RN 755029-19-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetic acid, 3-[(2-chloro-4-pyridinyl)amino]-10,11-dihydro-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755029-20-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-[2-(2-pyridinyloxy)ethyl]-3-[(2,3,6-trifluoro-4-pyridinyl)amino]- (9CI) (CA INDEX NAME)




RN 755029-22-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-(2-hydroxy-2-methylpropyl)-3-[(2,3,5-trifluorophenyl)amino]- (9CI) (CA INDEX NAME)




RN 755029-23-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-[(3,5-difluorophenyl)amino]-5,10-dihydro-7-(3-hydroxy-3-methylbutyl)-8-methoxy- (9CI) (CA INDEX NAME)




RN 755029-39-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(3-hydroxy-3-methylbutyl)-8-methoxy-3-[(3-methoxy-4-nitrophenyl)amino]- (9CI) (CA INDEX NAME)




RN 755029-41-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-[(2,6-difluoro-4-pyridinyl)amino]-5,10-dihydro-7-(3-hydroxypropyl)-8-methoxy- (9CI) (CA INDEX NAME)




RN 755029-44-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(3-hydroxypropyl)-8-methoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755029-46-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-[(2,6-difluoro-4-pyridinyl)amino]-5,10-dihydro-8-(3-hydroxy-3-methylbutyl)- (9CI) (CA INDEX NAME)




RN 755029-54-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-(3-hydroxy-3-methylbutyl)-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755029-60-8 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-propanamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-N,N-dimethyl-11-oxo- (9CI) (CA INDEX NAME)




RN 755029-61-9 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-propanamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-N-[4-(4-morpholinyl)phenyl]-11-oxo- (9CI) (CA INDEX NAME)




RN 755029-63-1 CAPLUS

CN Azetidine, 1-[3-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-1-oxopropyl]- (9CI) (CA INDEX NAME)




RN 755029-64-2 CAPLUS

CN Pyrrolidine, 1-[3-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-1-oxopropyl]- (9CI) (CA INDEX NAME)




RN 755029-65-3 CAPLUS

CN Morpholine, 4-[3-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-1-oxopropyl]- (9CI) (CA INDEX NAME)




RN 755029-66-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-propanamide, N,N-diethyl-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 755029-67-5 CAPLUS

CN 4-Piperidinol, 1-[3-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-1-oxopropyl]- (9CI) (CA INDEX NAME)




RN 755029-68-6 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-propanamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-2-thiazolyl- (9CI) (CA INDEX NAME)




RN 755029-72-2 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-propanoic acid, 3-(4-chloro-3-methoxyphenyl)-10,11-dihydro-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755029-74-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-propanamide, 3-(4-chloro-3-methoxyphenyl)-10,11-dihydro-N,N-dimethyl-11-oxo- (9CI) (CA INDEX NAME)




RN 755029-78-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-(4-chloro-3-methoxyphenyl)-5,10-dihydro-8-(3-hydroxy-3-methylbutyl)- (9CI) (CA INDEX NAME)




RN 755029-80-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-(3-methyl-1,2,4-oxadiazol-5-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 755029-83-5 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-propanoic acid, 10,11-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755029-85-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(2-hydroxy-2-methylpropyl)-8-methoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755030-04-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-7-(2-oxopropyl)- (9CI) (CA INDEX NAME)




RN 755030-06-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(2-hydroxy-1,1-dimethylethyl)-8-methoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755030-15-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(3-hydroxypropyl)-3-(3-methoxy-4-nitrophenyl)-8-(trifluoromethoxy)- (9CI) (CA INDEX NAME)




RN 755030-28-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(3-hydroxy-3-methylbutyl)-3-(3-methoxy-4-nitrophenyl)-8-(trifluoromethoxy)- (9CI) (CA INDEX NAME)



RN 755030-31-0 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(3-hydroxy-3-methylbutyl)-3-(3-methoxy-4-nitrophenyl)-8-methyl- (9CI) (CA INDEX NAME)



RN 755030-48-9 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-

nitrophenyl)-8-[2-(4-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 755030-53-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 755030-60-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-(2-oxo-1(2H)-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 755030-62-7 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-[2-(5-fluoro-2-oxo-1(2H)-pyridinyl)ethyl]-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 755030-63-8 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-

nitrophenyl)-8-[2-(6-oxo-1(6H)-pyridazinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 755030-65-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-(2-pyridinyloxy)ethyl]- (9CI) (CA INDEX NAME)




RN 755030-66-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-[2-[(5-chloro-3-pyridinyl)oxy]ethyl]-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 755030-67-2 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-7-[2-(3-pyridinyloxy)ethyl]- (9CI) (CA INDEX NAME)



RN 755030-69-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 10,11-dihydro-3-(5-

isoquinolinyl)-11-oxo-, methyl ester (9CI) (CA INDEX NAME)



IT 755030-71-8P 755030-73-0P 755030-75-2P
755030-77-4P 755030-80-9P 755030-91-2P
755030-97-8P 755030-99-0P 755031-01-7P
755031-03-9P 755031-05-1P 755031-07-3P
755031-10-8P 755031-12-0P 755031-15-3P
755031-16-4P 755031-17-5P 755031-19-7P
755031-20-0P 755031-24-4P 755031-31-3P
755031-33-5P 755031-35-7P 755031-36-8P,
7-(3-Hydroxypropyl)-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755031-43-7P,
7-(3-Hydroxy-3-methylbutyl)-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755031-45-9P,
8-(2-Hydroxy-1,1-dimethylethyl)-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755031-47-1P,
8-(2-Hydroxy-1,1,2-trimethylpropyl)-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755031-49-3P,
8-(1,1-Dimethyl-2-oxopropyl)-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755031-51-7P,
7-(2-Hydroxy-1,1-dimethylethyl)-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755031-52-8P,
8-[1-(Hydroxymethyl)cyclopropyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755031-53-9P,
3-[(2-Chloropyridin-4-yl)amino]-8-(2-hydroxy-1,1-dimethylethyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755031-54-0P,
3-[(2,6-Difluoropyridin-4-yl)amino]-8-(2-hydroxy-1,1-dimethylethyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755031-55-1P,
3-[(2,6-Difluoropyridin-4-yl)amino]-8-(2-hydroxy-1,1,2-trimethylpropyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755031-57-3P,
3-(4-Chloro-3-methoxyphenyl)-8-(2-hydroxy-1,1-dimethylethyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755031-58-4P,
3-(3-Methoxy-4-nitrophenyl)-8-[2-[[4-(morpholin-4-yl)phenyl]oxy]ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755031-60-8P,
3-(4-Chloro-3-methoxyphenyl)-8-[2-[[4-(morpholin-4-yl)phenyl]oxy]ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755031-61-9P
755031-62-0P, 3-(3-Methoxy-4-nitrophenyl)-8-[2-[[4-(morpholin-4-yl)phenyl]amino]ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755031-65-3P 755031-67-5P, 3-(3-Methoxy-4-nitrophenyl)-8-[2-[[5-methylpyridin-2-yl]oxy]ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755031-68-6P
755031-69-7P, 8-[2-(Isoquinolin-3-yloxy)ethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755031-70-0P 755031-71-1P, 8-[1,1-Dimethyl-2-(pyridin-2-yloxy)ethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755031-73-3P,
8-[1,1-Dimethyl-2-[[4-(morpholin-4-yl)phenyl]oxy]ethyl]-3-(3-methoxy-4-

nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755031-77-7P 755031-78-8P, 8-(2-Hydroxy-1,1-dimethylethyl)-3-(3-methoxy-4-nitrophenyl)-7-methyl-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755031-79-9P**
755031-87-9P 755031-89-1P 755031-91-5P,
 8-(2-Hydroxy-1,1-dimethylethyl)-3-[(2-methylpyridin-4-yl)amino]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755031-92-6P**,
 8-(2-Hydroxy-1,1,2-trimethylpropyl)-3-[(pyrimidin-4-yl)amino]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755031-93-7P**
755031-94-8P 755031-95-9P 755031-96-0P
755031-97-1P 755031-98-2P 755031-99-3P
755032-00-9P 755032-01-0P 755032-02-1P
755032-03-2P 755032-04-3P 755032-05-4P
755032-06-5P 755032-07-6P 755032-08-7P
755032-09-8P 755032-10-1P 755032-11-2P
755032-12-3P 755032-13-4P 755032-14-5P
755032-15-6P 755032-17-8P 755032-18-9P,
 8-[1,1-Dimethyl-2-oxo-2-(4-phenylpiperazin-1-yl)ethyl]-3-[(pyrimidin-4-yl)amino]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755032-19-0P 755032-20-3P, 8-[1,1-Dimethyl-2-(morpholin-4-yl)-2-oxoethyl]-3-[(pyrimidin-4-yl)amino]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755032-21-4P**
755032-22-5P 755032-23-6P 755032-24-7P
755032-25-8P 755032-26-9P 755032-27-0P
755032-28-1P 755032-29-2P, 3-(3-Methoxy-4-nitrophenyl)-8-[2-[(quinolin-2-yl)oxy]ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755032-30-5P 755032-31-6P 755032-32-7P**
755032-33-8P 755032-34-9P 755032-35-0P,
 3-(3-Methoxy-4-nitrophenyl)-8-[2-[(4-methylpyridin-2-yl)oxy]ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755032-36-1P**,
 3-(3-Methoxy-4-nitrophenyl)-8-[2-[(3-methoxypyridin-2-yl)oxy]ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755032-37-2P**
755032-38-3P, 8-[2-[(6-Chloropyridin-2-yl)oxy]ethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755032-39-4P**, 8-[2-[(5-Chloropyridin-2-yl)oxy]ethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755032-42-9P 755032-43-0P 755032-45-2P**,
 8-[2-(3-Aminopyrrolidin-1-yl)-2-oxoethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755032-46-3P**,
 8-[2-(3-Aminopyrrolidin-1-yl)-2-oxoethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one trifluoroacetate
755032-48-5P 755032-49-6P, (S)-8-[2-[2-(Hydroxymethyl)pyrrolidin-1-yl]-2-oxoethyl]-3-(2-methoxy-5-methylpyridin-4-yl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755032-50-9P**
755032-51-0P 755032-52-1P 755032-53-2P,
 3-(4-Chloro-3-methoxyphenyl)-8-[2-(3-hydroxypiperidin-1-yl)-2-oxoethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755032-54-3P**,
 (S)-3-(4-Chloro-3-methoxyphenyl)-8-[2-[2-(hydroxymethyl)pyrrolidin-1-yl]-2-oxoethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755032-55-4P 755032-57-6P, 3-(3-Methoxy-4-nitrophenyl)-8-[2-oxo-2-(piperazin-1-yl)ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755032-59-8P 755032-60-1P 755032-61-2P**
 , 3-(3-Methoxy-4-nitrophenyl)-8-[2-(morpholin-4-yl)-2-oxoethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755032-62-3P**,
 3-(2-Methoxy-5-methylpyridin-4-yl)-8-[2-(morpholin-4-yl)-2-oxoethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755032-63-4P**
755032-65-6P 755032-67-8P, 8-[2-(Morpholin-4-yl)-2-oxoethyl]-3-(2-oxo-1,2-dihydropyridin-4-yl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755032-69-0P**
755032-71-4P 755032-75-8P, 3-(3-Methoxy-4-nitrophenyl)-7-

[2-(morpholin-4-yl)-2-oxoethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755032-76-9P 755032-77-0P 755032-78-1P**
755032-79-2P, 7-[2-(4-Hydroxypiperidin-1-yl)-2-oxoethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755032-80-5P**, 7-[2-(3-Hydroxypiperidin-1-yl)-2-oxoethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755032-81-6P 755032-82-7P 755032-83-8P**
755032-84-9P, 7-[2-(Azetidin-1-yl)-2-oxoethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755032-85-0P 755032-86-1P 755032-87-2P**,
 (R)-7-[2-[2-(Hydroxymethyl)pyrrolidin-1-yl]-2-oxoethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755032-88-3P 755032-89-4P 755032-90-7P**
755032-91-8P 755032-92-9P, (S)-7-[2-[2-(Hydroxymethyl)pyrrolidin-1-yl]-2-oxoethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755032-93-0P**,
 7-[2-(3-Aminopyrrolidin-1-yl)-2-oxoethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755032-94-1P**,
 3-(3-Methoxy-4-nitrophenyl)-7-[2-oxo-2-(piperazin-1-yl)ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755032-95-2P**
755032-96-3P 755032-97-4P 755032-99-6P
755033-01-3P, 3-(3-Methoxy-4-nitrophenyl)-7-[2-oxo-2-(4-thiomorpholinyl)ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755033-03-5P 755033-04-6P 755033-05-7P**
755033-06-8P 755033-07-9P 755033-08-0P
755033-09-1P 755033-10-4P, 7-[2-(1,4-Dioxo-8-azaspiro[4.5]decan-8-yl)-2-oxoethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755033-11-5P**,
 7-[2-(2,6-Dimethylmorpholin-4-yl)-2-oxoethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755033-12-6P**,
 7-[2-(4-Acetylpiperazin-1-yl)-2-oxoethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755033-13-7P**,
 3-(3-Methoxy-4-nitrophenyl)-7-[2-oxo-2-[4-(pyridin-2-yl)piperazin-1-yl]ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755033-14-8P 755033-15-9P 755033-16-0P**
755033-17-1P 755033-18-2P 755033-19-3P
755033-20-6P 755033-21-7P 755033-22-8P
755033-23-9P 755033-24-0P 755033-25-1P
755033-26-2P 755033-27-3P 755033-28-4P
755033-29-5P, 8-Hydroxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755033-30-8P**,
 8-Methoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755033-34-2P**,
 8-Ethoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755033-35-3P**,
 3-(3-Methoxy-4-nitrophenyl)-8-[2-(4-methyl-1,3-thiazol-5-yl)ethoxy]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755033-37-5P**,
 8-[3-(Dimethylamino)propoxy]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755033-38-6P**,
 3-(3-Methoxy-4-nitrophenyl)-8-[2-(morpholin-4-yl)ethoxy]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755033-39-7P**,
 3-(3-Methoxy-4-nitrophenyl)-8-[2-[4-(morpholin-4-yl)phenyl]ethoxy]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755033-41-1P**,
 3-(3-Methoxy-4-nitrophenyl)-7-(piperidin-1-yl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755033-43-3P**,
 (S)-7-[2-(Hydroxymethyl)pyrrolidin-1-yl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755033-46-6P**,
 3-(3-Methoxy-4-nitrophenyl)-7-(morpholin-4-yl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755033-48-8P**,
 7-(4-Hydroxypiperidin-1-yl)-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-


dibenzo[b,e][1,4]diazepin-11-one 755033-54-6P
755033-59-1P, 8-(2-Ethyl-2-hydroxybutyl)-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755033-65-9P, 3-[(2-Chloropyridin-4-yl)amino]-8-(2-ethyl-2-hydroxybutyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755033-68-2P 755033-75-1P 755033-79-5P,
8-(2-Hydroxy-2-methylpropyl)-3-[(pyrimidin-4-yl)amino]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755033-81-9P,
8-(2-Hydroxy-2-methylpropyl)-3-[(2-methylpyridin-4-yl)amino]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755033-83-1P,
3-(3-Methoxy-4-nitrophenyl)-8-(2-oxopropyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755033-87-5P,
3-[(2-Chloropyridin-4-yl)amino]-8-(2-oxopropyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755033-89-7P,
3-[[2-[(2-Chloropyridin-4-yl)amino]pyridin-4-yl]amino]-8-(2-oxopropyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755033-92-2P
755033-93-3P 755033-96-6P, 3-[[3-(2-Hydroxyethyl)pyridin-4-yl]amino]-8-(1-hydroxy-1-methylethyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755034-00-5P,
8-(2-Hydroxy-2-methylpropyl)-3-[(2-methoxypyridin-4-yl)amino]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755034-02-7P, Methyl
11-oxo-3-(pyrimidin-4-ylamino)-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-7-carboxylate 755034-08-3P, 7-(1-Hydroxy-1-methylethyl)-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755034-11-8P, 7-(1-Hydroxy-1-methylethyl)-3-[(pyrimidin-4-yl)amino]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755034-12-9P 755034-14-1P, 3-(3-Methoxy-4-nitrophenyl)-8-[2-[[6-(morpholin-4-yl)pyridin-3-yl]oxy]ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755034-18-5P,
3-(4-Hydroxy-3-methoxyphenyl)-8-[2-[[4-(morpholin-4-yl)phenyl]oxy]ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755034-20-9P,
3-[[2-(6-Difluoropyridin-4-yl)amino]-8-[2-[[4-(morpholin-4-yl)phenyl]oxy]ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755034-29-8P, 8-Hydroxy-7-methoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755034-38-9P,
8-Methoxy-3-(3-methoxy-4-nitrophenyl)-7-[(tetrahydro-2H-pyran-2-yl)methoxy]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755034-39-0P, 8-Methoxy-3-(3-methoxy-4-nitrophenyl)-7-[(1-methylpiperidin-3-yl)methoxy]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755034-40-3P, 8-Methoxy-3-(3-methoxy-4-nitrophenyl)-7-[(pyridin-2-yl)methoxy]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755034-41-4P, 8-Methoxy-3-(3-methoxy-4-nitrophenyl)-7-[(pyridin-3-yl)methoxy]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755034-42-5P, 8-Methoxy-3-(3-methoxy-4-nitrophenyl)-7-[(pyridin-4-yl)methoxy]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755034-43-6P 755034-44-7P 755034-45-8P,
8-Methoxy-3-(3-methoxy-4-nitrophenyl)-7-[(2-methyl-1,3-thiazol-4-yl)methoxy]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755034-46-9P, 8-Methoxy-3-(3-methoxy-4-nitrophenyl)-7-[(2-oxo-1,3-oxazolidin-5-yl)methoxy]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755034-48-1P, 8-Methoxy-3-(3-methoxy-4-nitrophenyl)-7-[(tetrahydrofuran-2-yl)methoxy]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755034-49-2P, 7-[(2,2-Dimethyl-1,3-dioxolan-4-yl)methoxy]-8-methoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755034-50-5P,
(R)-8-Methoxy-3-(3-methoxy-4-nitrophenyl)-7-[(pyrrolidin-2-yl)methoxy]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755034-51-6P
755034-52-7P, 7,8-Dimethoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755034-53-8P,
8-Methoxy-7-[2-(2-methoxyethoxy)ethoxy]-3-(3-methoxy-4-nitrophenyl)-5,10-

dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755034-54-9P**,
 7-(2,3-Dihydroxypropoxy)-8-methoxy-3-(3-methoxy-4-nitrophenyl)-5,10-
 dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755034-55-0P**,
 7-[3-Hydroxy-2,2-bis(hydroxymethyl)propoxy]-8-methoxy-3-(3-methoxy-4-
 nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755034-56-1P 755034-57-2P, 7-(3-Aminopropoxy)-8-methoxy-
 3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-
 one **755034-58-3P**, 7-(3-Aminopropoxy)-8-methoxy-3-(3-methoxy-4-
 nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
 trifluoroacetate **755034-59-4P**, 7-[2-(Dimethylamino)ethoxy]-8-
 methoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-
 dibenzo[b,e][1,4]diazepin-11-one **755034-61-8P**,
 8-Methoxy-3-(3-methoxy-4-nitrophenyl)-7-[2-(pyrrolidin-1-yl)ethoxy]-5,10-
 dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755034-63-0P**,
 8-Methoxy-3-(3-methoxy-4-nitrophenyl)-7-[2-(morpholin-4-yl)ethoxy]-5,10-
 dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755034-64-1P**,
 7-(4-Hydroxybutoxy)-8-methoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-
 dibenzo[b,e][1,4]diazepin-11-one **755034-65-2P**,
 7-(4-Hydroxybutoxy)-3-(4-hydroxy-3-methoxyphenyl)-8-methoxy-5,10-dihydro-
 11H-dibenzo[b,e][1,4]diazepin-11-one **755034-69-6P**,
 7-(4-Hydroxybutoxy)-8-methoxy-3-[(pyrimidin-4-yl)amino]-5,10-dihydro-11H-
 dibenzo[b,e][1,4]diazepin-11-one **755034-70-9P**
755034-71-0P, 3-[(2,6-Difluoropyridin-4-yl)amino]-7-(4-
 hydroxybutoxy)-8-methoxy-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755034-72-1P, 7-(4-Hydroxybutoxy)-8-methoxy-3-[(2,3,6-
 trifluoropyridin-4-yl)amino]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-
 one **755034-73-2P**, 7-Ethoxy-3-(3-methoxy-4-nitrophenyl)-5,10-
 dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(kinase inhibitor; preparation of dibenzo[b,e][1,4]diazepin-11-ones as
 kinase inhibitors for treatment of cancer)


RN 755030-71-8 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 10,11-dihydro-3-(8-nitro-5-
 isoquinolinyl)-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755030-73-0 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-propanoic acid, 3-(4-formyl-3-
 methoxyphenyl)-10,11-dihydro-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755030-75-2 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-propanoic acid, 10,11-dihydro-3-[4-(hydroxymethyl)-3-methoxyphenyl]-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755030-77-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-propanoic acid, 10,11-dihydro-3-[3-methoxy-4-(1-oxopropyl)phenyl]-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755030-80-9 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- α,α -dimethyl-N-[4-(4-morpholinyl)phenyl]-11-oxo- (9CI) (CA INDEX NAME)




RN 755030-91-2 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 3-(4-cyano-3-methoxyphenyl)-10,11-dihydro- α,α -dimethyl-N-[4-(4-morpholinyl)phenyl]-11-oxo- (9CI) (CA INDEX NAME)




RN 755030-97-8 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 3-(4-chloro-3-methoxyphenyl)-10,11-dihydro-α,α-dimethyl-N-[4-(4-morpholinyl)phenyl]-11-oxo- (9CI) (CA INDEX NAME)




RN 755030-99-0 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-α,α-dimethyl-11-oxo-N-2-pyridinyl- (9CI) (CA INDEX NAME)




RN 755031-01-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-α,α-dimethyl-11-oxo-N-3-pyridinyl- (9CI) (CA INDEX NAME)




RN 755031-03-9 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- α,α -dimethyl-11-oxo-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 755031-05-1 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- α,α -dimethyl-11-oxo-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 755031-07-3 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- α,α -dimethyl-11-oxo-N-[(tetrahydro-3-furanyl)methyl]- (9CI) (CA INDEX NAME)




RN 755031-10-8 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- α,α -dimethyl-11-oxo-N-2-thiazolyl- (9CI) (CA INDEX NAME)




RN 755031-12-0 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- α,α -dimethyl-11-oxo-N-[[6-(trifluoromethyl)-3-pyridinyl]methyl]- (9CI) (CA INDEX NAME)




RN 755031-15-3 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-(4-fluorophenyl)-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- α,α -dimethyl-11-oxo- (9CI) (CA INDEX NAME)




RN 755031-16-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-[(2,5-difluorophenyl)methyl]-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- α,α -dimethyl-11-oxo- (9CI) (CA INDEX NAME)




RN 755031-17-5 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro- α,α -dimethyl-11-oxo-3-(4-pyrimidinylamino)-N-[[3-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 755031-19-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro- α,α -dimethyl-11-oxo-3-(4-pyrimidinylamino)-N-[[3-(trifluoromethoxy)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 755031-20-0 CAPLUS

CN Cyclopropanecarboxamide, 1-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-N-[4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 755031-24-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- α,α -dimethyl-N-[4-(4-morpholinyl)phenyl]-11-oxo- (9CI) (CA INDEX NAME)




RN 755031-31-3 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-α,α-dimethyl-11-oxo-N-(2-pyridinylmethyl)- (9CI)
(CA INDEX NAME)




RN 755031-33-5 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-α,α-dimethyl-11-oxo-N-(2-thienylmethyl)- (9CI)
(CA INDEX NAME)



RN 755031-35-7 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, N-(cyclopropylmethyl)-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-α,α-dimethyl-11-oxo- (9CI)
(CA INDEX NAME)



RN 755031-36-8 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(3-hydroxypropyl)-3-

(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755031-43-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(3-hydroxy-3-methylbutyl)-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755031-45-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-(2-hydroxy-1,1-dimethylethyl)-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755031-47-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-(2-hydroxy-1,1,2-trimethylpropyl)-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755031-49-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-(1,1-dimethyl-2-oxopropyl)-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755031-51-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(2-hydroxy-1,1-dimethylethyl)-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755031-52-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-[1-(hydroxymethyl)cyclopropyl]-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755031-53-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-[(2-chloro-4-pyridinyl)amino]-5,10-dihydro-8-(2-hydroxy-1,1-dimethylethyl)- (9CI) (CA INDEX NAME)




RN 755031-54-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-[(2,6-difluoro-4-pyridinyl)amino]-5,10-dihydro-8-(2-hydroxy-1,1-dimethylethyl)- (9CI) (CA INDEX NAME)




RN 755031-55-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-[(2,6-difluoro-4-pyridinyl)amino]-5,10-dihydro-8-(2-hydroxy-1,1,2-trimethylpropyl)- (9CI) (CA INDEX NAME)




RN 755031-57-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-(4-chloro-3-methoxyphenyl)-5,10-dihydro-8-(2-hydroxy-1,1-dimethylethyl)- (9CI) (CA INDEX NAME)




RN 755031-58-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-[4-(4-morpholinyl)phenoxy]ethyl]- (9CI) (CA INDEX NAME)




RN 755031-60-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-(4-chloro-3-methoxyphenyl)-5,10-dihydro-8-[2-[4-(4-morpholinyl)phenoxy]ethyl]- (9CI) (CA INDEX NAME)




RN 755031-61-9 CAPLUS

CN Benzonitrile, 4-[10,11-dihydro-8-[2-[4-(4-morpholinyl)phenoxy]ethyl]-11-oxo-5H-dibenzo[b,e][1,4]diazepin-3-yl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 755031-62-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-[[4-(4-morpholinyl)phenyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 755031-65-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-(3-methyl-2-oxo-1(2H)-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 755031-67-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-[(5-methyl-2-pyridinyl)oxy]ethyl]- (9CI) (CA INDEX NAME)




RN 755031-68-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-(4-methyl-2-oxo-1(2H)-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 755031-69-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-[2-(3-isoquinolinyl)oxy]ethyl]-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755031-70-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-[2-(5-chloro-2-oxo-1(2H)-pyridinyl)ethyl]-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755031-71-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-[1,1-dimethyl-2-(2-pyridinyloxy)ethyl]-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755031-73-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-[1,1-dimethyl-2-[4-(4-morpholinyl)phenoxy]ethyl]-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755031-77-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- α,α -dimethyl-11-oxo-N-[(tetrahydro-2-furanyl)methyl]- (9CI) (CA INDEX NAME)




RN 755031-78-8 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-(2-hydroxy-1,1-dimethylethyl)-3-(3-methoxy-4-nitrophenyl)-7-methyl- (9CI) (CA INDEX NAME)




RN 755031-79-9 CAPLUS
 CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-2-methyl-N-[4-(4-morpholinyl)phenyl]-11-oxo- (9CI) (CA INDEX NAME)



RN 755031-87-9 CAPLUS
 CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 3-[4-(aminomethyl)-3-methoxyphenyl]-10,11-dihydro-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755031-89-1 CAPLUS
 CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(2-methoxy-5-methyl-4-pyridinyl)- α,α -dimethyl-N-[4-(4-morpholinyl)phenyl]-11-oxo-, dihydrochloride (9CI) (CA INDEX NAME)




●2 HCl

RN 755031-91-5 CAPLUS
 CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-(2-hydroxy-1,1-dimethylethyl)-3-[(2-methyl-4-pyridinyl)amino]- (9CI) (CA INDEX NAME)




RN 755031-92-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-(2-hydroxy-1,1,2-trimethylpropyl)-3-(4-pyrimidinylamino)- (9CI) (CA INDEX NAME)




RN 755031-93-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-N-methyl-11-oxo-N-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)




RN 755031-94-8 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-alpha,alpha-dimethyl-11-oxo-N-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)




RN 755031-95-9 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-alpha,alpha-dimethyl-11-oxo-N-4-pyrimidinyl- (9CI) (CA INDEX NAME)




RN 755031-96-0 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-α,α-dimethyl-N-(4-methyl-2-thiazolyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 755031-97-1 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-α,α-dimethyl-11-oxo-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)



RN 755031-98-2 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-(3-fluorophenyl)-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-α,α-dimethyl-11-oxo- (9CI) (CA INDEX NAME)



RN 755031-99-3 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-α,α-dimethyl-11-oxo-N-[4-(4-methyl-2-thiazolyl)]- (9CI) (CA INDEX NAME)

(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 755032-00-9 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-α,α-dimethyl-11-oxo-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 755032-01-0 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-α,α-dimethyl-11-oxo-N-[3-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 755032-02-1 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-α,α-dimethyl-11-oxo- (9CI) (CA INDEX NAME)




RN 755032-03-2 CAPLUS
 CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-[(2-fluorophenyl)methyl]-
 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- α,α -dimethyl-11-oxo-
 (9CI) (CA INDEX NAME)




RN 755032-04-3 CAPLUS
 CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-[(3-fluorophenyl)methyl]-
 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- α,α -dimethyl-11-oxo-
 (9CI) (CA INDEX NAME)



RN 755032-05-4 CAPLUS
 CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-[(4-fluorophenyl)methyl]-
 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- α,α -dimethyl-11-oxo-
 (9CI) (CA INDEX NAME)




RN 755032-06-5 CAPLUS
 CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-
 nitrophenyl)- α,α -dimethyl-11-oxo-N-[[4-
 (trifluoromethoxy)phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 755032-07-6 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- α,α -dimethyl-11-oxo-N-[[3-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 755032-08-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- α,α -dimethyl-11-oxo-N-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 755032-09-8 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- α,α -dimethyl-11-oxo-N-[[3-(trifluoromethoxy)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 755032-10-1 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-[2-(2-fluorophenyl)ethyl]-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- α,α -dimethyl-11-oxo- (9CI) (CA INDEX NAME)




RN 755032-11-2 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-[2-(3-fluorophenyl)ethyl]-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-α,α-dimethyl-11-oxo- (9CI) (CA INDEX NAME)




RN 755032-12-3 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-[(2,4-difluorophenyl)methyl]-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-α,α-dimethyl-11-oxo- (9CI) (CA INDEX NAME)



RN 755032-13-4 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-[(2,6-difluorophenyl)methyl]-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-α,α-dimethyl-11-oxo- (9CI) (CA INDEX NAME)



RN 755032-14-5 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-(cyclopropylmethyl)-10,11-

dihydro-3-(3-methoxy-4-nitrophenyl)- α,α -dimethyl-11-oxo- (9CI)
(CA INDEX NAME)




RN 755032-15-6 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-(3-ethoxypropyl)-10,11-dihydro- α,α -dimethyl-11-oxo-3-(4-pyrimidinylamino)- (9CI) (CA INDEX NAME)




RN 755032-17-8 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-[(3,4-difluorophenyl)methyl]-10,11-dihydro- α,α -dimethyl-11-oxo-3-(4-pyrimidinylamino)- (9CI) (CA INDEX NAME)




RN 755032-18-9 CAPLUS

CN Piperazine, 1-[2-[10,11-dihydro-11-oxo-3-(4-pyrimidinylamino)-5H-dibenzo[b,e][1,4]diazepin-8-yl]-2-methyl-1-oxopropyl]-4-phenyl- (9CI) (CA INDEX NAME)




RN 755032-19-0 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-cyclopentyl-10,11-dihydro- α,α -dimethyl-11-oxo-3-(4-pyrimidinylamino)- (9CI) (CA INDEX NAME)




RN 755032-20-3 CAPLUS

CN Morpholine, 4-[2-[10,11-dihydro-11-oxo-3-(4-pyrimidinylamino)-5H-dibenzo[b,e][1,4]diazepin-8-yl]-2-methyl-1-oxopropyl]- (9CI) (CA INDEX NAME)




RN 755032-21-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro- α,α -dimethyl-11-oxo-3-(4-pyrimidinylamino)-N-[(tetrahydro-3-furanyl)methyl]- (9CI) (CA INDEX NAME)




RN 755032-22-5 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-(cyclopentylmethyl)-10,11-dihydro- α,α -dimethyl-11-oxo-3-(4-pyrimidinylamino)- (9CI) (CA INDEX NAME)




RN 755032-23-6 CAPLUS
 CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-(cyclopropylmethyl)-10,11-dihydro- α,α -dimethyl-11-oxo-3-(4-pyrimidinylamino)- (9CI) (CA INDEX NAME)




RN 755032-24-7 CAPLUS
 CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro- α,α -dimethyl-11-oxo-3-(4-pyrimidinylamino)-N-[(tetrahydro-2-furanyl)methyl]- (9CI) (CA INDEX NAME)



RN 755032-25-8 CAPLUS
 CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro- α,α -dimethyl-11-oxo-3-(4-pyrimidinylamino)-N-2-thiazolyl- (9CI) (CA INDEX NAME)




RN 755032-26-9 CAPLUS
 CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, N-[(2,5-difluorophenyl)methyl]-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- α,α -dimethyl-11-oxo- (9CI) (CA INDEX NAME)




RN 755032-27-0 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, N-(2-ethoxyethyl)-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-α,α-dimethyl-11-oxo- (9CI) (CA INDEX NAME)




RN 755032-28-1 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, N-(4-fluorophenyl)-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-α,α-dimethyl-11-oxo- (9CI) (CA INDEX NAME)




RN 755032-29-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-(2-quinolinylloxy)ethyl]- (9CI) (CA INDEX NAME)




RN 755032-30-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-(5-methyl-2-oxo-1(2H)-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 755032-31-6 CAPLUS

CN 3-Pyridinecarbonitrile, 2-[2-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]ethoxy]-6-methyl- (9CI) (CA INDEX NAME)




RN 755032-32-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-(1-oxo-2(1H)-isoquinolinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 755032-33-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-[2-oxo-5-(trifluoromethyl)-1(2H)-pyridinyl]ethyl]- (9CI) (CA INDEX NAME)




RN 755032-34-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-(3-methoxy-2-oxo-1(2H)-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 755032-35-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-[(4-methyl-2-pyridinyl)oxy]ethyl]- (9CI) (CA INDEX NAME)



RN 755032-36-1 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-[(3-methoxy-2-pyridinyl)oxy]ethyl]- (9CI) (CA INDEX NAME)



RN 755032-37-2 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-

nitrophenyl)-8-[2-(3-oxo-2(3H)-isoquinolinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 755032-38-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-[2-[(6-chloro-2-pyridinyl)oxy]ethyl]-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755032-39-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-[2-[(5-chloro-2-pyridinyl)oxy]ethyl]-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755032-42-9 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 3-(4-acetyl-3-methoxyphenyl)-10,11-dihydro-11-oxo- (9CI) (CA INDEX NAME)




RN 755032-43-0 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 3-(4-chloro-3-methoxyphenyl)-
10,11-dihydro-N,N-dimethyl-11-oxo- (9CI) (CA INDEX NAME)



RN 755032-45-2 CAPLUS

CN 3-Pyrrolidinamine, 1-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]acetyl]- (9CI) (CA INDEX NAME)




RN 755032-46-3 CAPLUS

CN 3-Pyrrolidinamine, 1-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]acetyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 755032-45-2


CMF C26 H25 N5 O5



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 755032-48-5 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(2-methoxy-5-methyl-4-pyridinyl)-N,N-dimethyl-11-oxo- (9CI) (CA INDEX NAME)



RN 755032-49-6 CAPLUS


CN 2-Pyrrolidinemethanol, 1-[[10,11-dihydro-3-(2-methoxy-5-methyl-4-pyridinyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]acetyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 755032-50-9 CAPLUS

CN Carbamic acid, [1-[[10,11-dihydro-3-(2-methoxy-5-methyl-4-pyridinyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]acetyl]-3-pyrrolidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 755032-51-0 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-[2-[4-(aminosulfonyl)phenyl]ethyl]-3-(4-chloro-3-methoxyphenyl)-10,11-dihydro-11-oxo- (9CI) (CA INDEX NAME)




RN 755032-52-1 CAPLUS

CN Carbamic acid, [1-[[3-(4-chloro-3-methoxyphenyl)-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]acetyl]-3-pyrrolidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 755032-53-2 CAPLUS


CN 3-Piperidinol, 1-[[3-(4-chloro-3-methoxyphenyl)-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]acetyl]- (9CI) (CA INDEX NAME)



RN 755032-54-3 CAPLUS


CN 2-Pyrrolidinemethanol, 1-[[3-(4-chloro-3-methoxyphenyl)-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]acetyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 755032-55-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 3-(4-chloro-3-methoxyphenyl)-10,11-dihydro-N-[4-(4-morpholinyl)phenyl]-11-oxo- (9CI) (CA INDEX NAME)




RN 755032-57-6 CAPLUS

CN Piperazine, 1-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]acetyl]- (9CI) (CA INDEX NAME)




RN 755032-59-8 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 3-(4-cyano-3-methoxyphenyl)-10,11-dihydro-N-[4-(4-morpholinyl)phenyl]-11-oxo- (9CI) (CA INDEX NAME)




RN 755032-60-1 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-N-methyl-11-oxo- (9CI) (CA INDEX NAME)




RN 755032-61-2 CAPLUS

CN Morpholine, 4-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]acetyl]- (9CI) (CA INDEX NAME)




RN 755032-62-3 CAPLUS

CN Morpholine, 4-[[10,11-dihydro-3-(2-methoxy-5-methyl-4-pyridinyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]acetyl]- (9CI) (CA INDEX NAME)




RN 755032-63-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 3-(2-fluoro-4-pyridinyl)-10,11-dihydro-11-oxo- (9CI) (CA INDEX NAME)




RN 755032-65-6 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 3-(1,2-dihydro-2-oxo-4-pyridinyl)-10,11-dihydro-N,N-dimethyl-11-oxo- (9CI) (CA INDEX NAME)




RN 755032-67-8 CAPLUS

CN Morpholine, 4-[[3-(1,2-dihydro-2-oxo-4-pyridinyl)-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]acetyl]- (9CI) (CA INDEX NAME)




RN 755032-69-0 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 3-(1,2-dihydro-2-oxo-4-pyridinyl)-10,11-dihydro-N-[4-(4-morpholinyl)phenyl]-11-oxo- (9CI) (CA INDEX NAME)




RN 755032-71-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 3-(1,2-dihydro-2-oxo-4-pyridinyl)-10,11-dihydro-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755032-75-8 CAPLUS

CN Morpholine, 4-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]acetyl]- (9CI) (CA INDEX NAME)




RN 755032-76-9 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-2-pyridinyl- (9CI) (CA INDEX NAME)




RN 755032-77-0 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-3-pyridinyl- (9CI) (CA INDEX NAME)



RN 755032-78-1 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-4-pyridinyl- (9CI) (CA INDEX NAME)



RN 755032-79-2 CAPLUS


CN 4-Piperidinol, 1-[(10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-

dibenzo[b,e][1,4]diazepin-7-yl]acetyl]- (9CI) (CA INDEX NAME)




RN 755032-80-5 CAPLUS

CN 3-Piperidinol, 1-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]acetyl]- (9CI) (CA INDEX NAME)




RN 755032-81-6 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 755032-82-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 755032-83-8 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 755032-84-9 CAPLUS

CN Azetidine, 1-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]acetyl]- (9CI) (CA INDEX NAME)




RN 755032-85-0 CAPLUS

CN 3-Piperidinecarboxamide, 1-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]acetyl]- (9CI) (CA INDEX NAME)



RN 755032-86-1 CAPLUS


CN 4-Piperidinecarboxamide, 1-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]acetyl]- (9CI) (CA INDEX NAME)



RN 755032-87-2 CAPLUS


CN 2-Pyrrolidinemethanol, 1-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]acetyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 755032-88-3 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-N,N-dimethyl-11-oxo- (9CI) (CA INDEX NAME)



RN 755032-89-4 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-N,N-bis(2-methoxyethyl)-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)



RN 755032-90-7 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-[[(2S)-tetrahydro-2-furanyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 755032-91-8 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-(2-propoxyethyl)- (9CI) (CA INDEX NAME)



RN 755032-92-9 CAPLUS


CN 2-Pyrrolidinemethanol, 1-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]acetyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 755032-93-0 CAPLUS

CN 3-Pyrrolidinamine, 1-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]acetyl]- (9CI) (CA INDEX NAME)




RN 755032-94-1 CAPLUS

CN Piperazine, 1-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]acetyl]- (9CI) (CA INDEX NAME)




RN 755032-95-2 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-N-(3-methoxypropyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 755032-96-3 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, N-(cyanomethyl)-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 755032-97-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, N-(cyclopropylmethyl)-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 755032-99-6 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, N-(1,3-dioxolan-2-ylmethyl)-
10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-N-methyl-11-oxo- (9CI) (CA
INDEX NAME)




RN 755033-01-3 CAPLUS

CN Thiomorpholine, 4-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-
dibenzo[b,e][1,4]diazepin-7-yl]acetyl]- (9CI) (CA INDEX NAME)




RN 755033-03-5 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-3-(3-methoxy-4-
nitrophenyl)-11-oxo-N-[2-(3-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 755033-04-6 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-3-(3-methoxy-4-
nitrophenyl)-11-oxo-N-[2-(4-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 755033-05-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, N-[2-(2,3-dimethoxyphenyl)ethyl]-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-(9CI) (CA INDEX NAME)




RN 755033-06-8 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, N-[2-(1,3-benzodioxol-5-yl)ethyl]-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 755033-07-9 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-(2-thienylmethyl)- (9CI) (CA INDEX NAME)




RN 755033-08-0 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-(5-thiazolylmethyl)- (9CI) (CA INDEX NAME)




RN 755033-09-1 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-N-[2-(1H-imidazol-4-yl)ethyl]-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 755033-10-4 CAPLUS

CN 1,4-Dioxa-8-azaspiro[4.5]decane, 8-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]acetyl]- (9CI) (CA INDEX NAME)




RN 755033-11-5 CAPLUS

CN Morpholine, 4-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]acetyl]-2,6-dimethyl- (9CI) (CA INDEX NAME)




RN 755033-12-6 CAPLUS

CN Piperazine, 1-acetyl-4-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]acetyl]- (9CI) (CA INDEX NAME)




RN 755033-13-7 CAPLUS

CN Piperazine, 1-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]acetyl]-4-(2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 755033-14-8 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, N-[3-(aminocarbonyl)phenyl]-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 755033-15-9 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-N-[4-(4-morpholinyl)phenyl]-11-oxo- (9CI) (CA INDEX NAME)



RN 755033-16-0 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-6-quinolinyl- (9CI) (CA INDEX NAME)



RN 755033-17-1 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-N-[(1S)-1-(hydroxymethyl)-2-methylpropyl]-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 755033-18-2 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, N-[(1S)-1-(aminocarbonyl)-3-methylbutyl]-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 755033-19-3 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-N-[(1S)-2-hydroxy-1-phenylethyl]-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 755033-20-6 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, N-(2,3-dihydroxypropyl)-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 755033-21-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-N-[3-(1H-imidazol-1-yl)propyl]-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 755033-22-8 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-[3-(2-oxo-1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)




RN 755033-23-9 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, N-[(2,6-difluorophenyl)methyl]-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)



RN 755033-24-0 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, N-[2-[4-(aminosulfonyl)phenyl]ethyl]-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)



RN 755033-25-1 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-N-[(1R)-1-(hydroxymethyl)-2-methylpropyl]-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 755033-26-2 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-N-[(1R)-2-hydroxy-1-phenylethyl]-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 755033-27-3 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-(3-thienylmethyl)- (9CI) (CA INDEX NAME)




RN 755033-28-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 3-[4-(aminocarbonyl)-3-methoxyphenyl]-10,11-dihydro-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755033-29-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-hydroxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755033-30-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755033-34-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-ethoxy-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755033-35-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-(4-methyl-5-thiazolyl)ethoxy]- (9CI) (CA INDEX NAME)




RN 755033-37-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-[3-(dimethylamino)propoxy]-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755033-38-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-(4-morpholinyl)ethoxy]- (9CI) (CA INDEX NAME)




RN 755033-39-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-[4-(4-morpholinyl)phenyl]ethoxy]- (9CI) (CA INDEX NAME)



RN 755033-41-1 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-7-(1-piperidinyl)- (9CI) (CA INDEX NAME)



RN 755033-43-3 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 755033-46-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-7-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 755033-48-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(4-hydroxy-1-piperidinyl)-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755033-54-6 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 10,11-dihydro-3-[3-methoxy-4-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755033-59-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-(2-ethyl-2-hydroxybutyl)-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755033-65-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-[(2-chloro-4-pyridinyl)amino]-8-(2-ethyl-2-hydroxybutyl)-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 755033-68-2 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-N,N-dimethyl-11-oxo-3-(4-pyridinylamino)- (9CI) (CA INDEX NAME)




RN 755033-75-1 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-N-[4-(4-morpholinyl)phenyl]-11-oxo-3-(4-pyridinylamino)- (9CI) (CA INDEX NAME)




RN 755033-79-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-(2-hydroxy-2-methylpropyl)-3-(4-pyrimidinylamino)- (9CI) (CA INDEX NAME)




RN 755033-81-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-(2-hydroxy-2-methylpropyl)-3-[(2-methyl-4-pyridinyl)amino]- (9CI) (CA INDEX NAME)




RN 755033-83-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-(2-oxopropyl)- (9CI) (CA INDEX NAME)




RN 755033-87-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-[(2-chloro-4-pyridinyl)amino]-5,10-dihydro-8-(2-oxopropyl)- (9CI) (CA INDEX NAME)




RN 755033-89-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-[[2-[(2-chloro-4-pyridinyl)amino]-4-pyridinyl]amino]-5,10-dihydro-8-(2-oxopropyl)- (9CI) (CA INDEX NAME)




RN 755033-92-2 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-α,α-dimethyl-N-[4-(4-morpholinyl)phenyl]-11-oxo-3-(4-pyrimidinylamino)- (9CI) (CA INDEX NAME)




RN 755033-93-3 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro- α,α -dimethyl-3-[(2-methyl-4-pyridinyl)amino]-N-[4-(4-morpholinyl)phenyl]-11-oxo- (9CI) (CA INDEX NAME)




RN 755033-96-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-[[3-(2-hydroxyethyl)-4-pyridinyl]amino]-8-(1-hydroxy-1-methylethyl)- (9CI) (CA INDEX NAME)




RN 755034-00-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-(2-hydroxy-2-methylpropyl)-3-[(2-methoxy-4-pyridinyl)amino]- (9CI) (CA INDEX NAME)




RN 755034-02-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-carboxylic acid, 10,11-dihydro-11-oxo-3-(4-pyrimidinylamino)-, methyl ester (9CI) (CA INDEX NAME)




RN 755034-08-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(1-hydroxy-1-methylethyl)-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755034-11-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(1-hydroxy-1-methylethyl)-3-(4-pyrimidinylamino)- (9CI) (CA INDEX NAME)



RN 755034-12-9 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-[(6-methoxy-4-pyrimidinyl)amino]-α,α-dimethyl-N-[4-(4-morpholinyl)phenyl]-11-oxo- (9CI) (CA INDEX NAME)



RN 755034-14-1 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-

nitrophenyl)-8-[2-[[6-(4-morpholinyl)-3-pyridinyl]oxy]ethyl]- (9CI) (CA INDEX NAME)




RN 755034-18-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(4-hydroxy-3-methoxyphenyl)-8-[2-[4-(4-morpholinyl)phenoxy]ethyl]- (9CI) (CA INDEX NAME)




RN 755034-20-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-[(2,6-difluoro-4-pyridinyl)amino]-5,10-dihydro-8-[2-[4-(4-morpholinyl)phenoxy]ethyl]- (9CI) (CA INDEX NAME)




RN 755034-29-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-hydroxy-7-methoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755034-38-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-7-[(tetrahydro-2H-pyran-2-yl)methoxy]- (9CI) (CA INDEX NAME)




RN 755034-39-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-7-[(1-methyl-3-piperidiny)methoxy]- (9CI) (CA INDEX NAME)




RN 755034-40-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-7-(2-pyridinylmethoxy)- (9CI) (CA INDEX NAME)




RN 755034-41-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-7-(3-pyridinylmethoxy)- (9CI) (CA INDEX NAME)




RN 755034-42-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-7-(4-pyridinylmethoxy)- (9CI) (CA INDEX NAME)




RN 755034-43-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-7-[(5-methyl-3-isoxazolyl)methoxy]- (9CI) (CA INDEX NAME)




RN 755034-44-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-7-[(1-methyl-1H-imidazol-5-yl)methoxy]- (9CI) (CA INDEX NAME)




RN 755034-45-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-7-[(2-methyl-4-thiazolyl)methoxy]- (9CI) (CA INDEX NAME)




RN 755034-46-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-7-[(2-oxo-5-oxazolidinyl)methoxy]- (9CI) (CA INDEX NAME)




RN 755034-48-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-7-[(tetrahydro-2-furanyl)methoxy]- (9CI) (CA INDEX NAME)



RN 755034-49-2 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 7-[(2,2-dimethyl-1,3-dioxolan-4-yl)methoxy]-5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 755034-50-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-7-[(2R)-2-pyrrolidinylmethoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 755034-51-6 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-7-[(2R)-2-pyrrolidinylmethoxy]-, mono(trifluoroacetate)
(9CI) (CA INDEX NAME)

CM 1


CRN 755034-50-5
CMF C26 H26 N4 O6

Absolute stereochemistry.




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 755034-52-7 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7,8-dimethoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755034-53-8 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-methoxy-7-[2-(2-

methoxyethoxy)ethoxy]-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755034-54-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 7-(2,3-dihydroxypropoxy)-5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755034-55-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-[3-hydroxy-2,2-bis(hydroxymethyl)propoxy]-8-methoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755034-56-1 CAPLUS

CN 1-Propanesulfonic acid, 3-[[10,11-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]oxy]-2-hydroxy- (9CI) (CA INDEX NAME)



RN 755034-57-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 7-(3-aminopropoxy)-5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755034-58-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 7-(3-aminopropoxy)-5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 755034-57-2


CMF C24 H24 N4 O6



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 755034-59-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 7-[2-(dimethylamino)ethoxy]-5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755034-61-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-7-[2-(1-pyrrolidinyl)ethoxy]- (9CI) (CA INDEX NAME)




RN 755034-63-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-7-[2-(4-morpholinyl)ethoxy]- (9CI) (CA INDEX NAME)




RN 755034-64-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(4-hydroxybutoxy)-8-methoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755034-65-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(4-hydroxybutoxy)-3-(4-hydroxy-3-methoxyphenyl)-8-methoxy- (9CI) (CA INDEX NAME)




RN 755034-69-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(4-hydroxybutoxy)-8-methoxy-3-(4-pyrimidinylamino)- (9CI) (CA INDEX NAME)




RN 755034-70-9 CAPLUS

CN 2-Pyridinecarbonitrile, 4-[[10,11-dihydro-7-(4-hydroxybutoxy)-8-methoxy-11-oxo-5H-dibenzo[b,e][1,4]diazepin-3-yl]amino]- (9CI) (CA INDEX NAME)




RN 755034-71-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-[(2,6-difluoro-4-pyridinyl)amino]-5,10-dihydro-7-(4-hydroxybutoxy)-8-methoxy- (9CI) (CA INDEX NAME)




RN 755034-72-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(4-hydroxybutoxy)-8-methoxy-3-[(2,3,6-trifluoro-4-pyridinyl)amino]- (9CI) (CA INDEX NAME)



RN 755034-73-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 7-ethoxy-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)



IT 755034-76-5P, 7-(4-Hydroxybutoxy)-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755034-80-1P, 7-(2-Hydroxyethoxy)-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755034-82-3P, 7-(2,3-Dihydroxypropoxy)-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755034-83-4P, 7-[2-(2-Methoxyethoxy)ethoxy]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755034-84-5P, 7-(Methoxymethyl)-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755034-91-4P, 7-(3-Methoxy-4-nitrobenzyl)-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755034-93-6P, 7-[[[2-(Dimethylamino)ethyl](methyl)amino]methyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755034-95-8P, 3-(3-Methoxy-4-nitrophenyl)-7-[[[2-(tetrahydro-2H-pyran-4-yl)ethyl]amino]methyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755034-97-0P, 8-Ethyl-7-methoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755035-04-2P, 8-Methoxy-3-(3-methoxy-4-nitrophenyl)-7-vinyl-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755035-07-5P, 8-(3-Hydroxypropyl)-7-methoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755035-14-4P, 7-Methoxy-3-(3-methoxy-4-nitrophenyl)-8-[3-[(2-methylpyridin-3-yl)oxy]propyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755035-16-6P, 8-[3-[(2-Chloropyridin-3-yl)oxy]propyl]-7-methoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755035-17-7P, 7-Methoxy-3-(3-methoxy-4-nitrophenyl)-8-[3-[[4-(morpholin-4-yl)phenyl]oxy]propyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755035-19-9P, 8-[3-(Isoquinolin-3-yloxy)propyl]-7-methoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755035-20-2P 755035-22-4P, Methyl 7-methoxy-3-(3-methoxy-4-nitrophenyl)-11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carboxylate 755035-25-7P, Methyl 7-methoxy-11-oxo-3-(pyrimidin-4-ylamino)-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carboxylate 755035-26-8P, 3-[(2,6-Difluoropyridin-4-yl)amino]-8-[1,1-dimethyl-2-(morpholin-4-yl)-2-oxoethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755035-27-9P 755035-28-0P 755035-30-4P 755035-31-5P 755035-33-7P, 3-[(2,6-Difluoropyridin-4-yl)amino]-8-[2-(4-hydroxypiperidin-1-yl)-1,1-dimethyl-2-oxoethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755035-34-8P, (S)-3-[(2,6-Difluoropyridin-4-yl)amino]-8-[2-[2-(hydroxymethyl)pyrrolidin-1-yl]-1,1-dimethyl-2-oxoethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755035-35-9P, 3-[(2,6-Difluoropyridin-4-yl)amino]-8-[1,1-dimethyl-2-oxo-2-(pyrrolidin-1-yl)ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755035-36-0P 755035-37-1P 755035-38-2P 755035-39-3P,

(R)-3-[(2,6-Difluoropyridin-4-yl)amino]-8-[2-[2-(hydroxymethyl)pyrrolidin-1-yl]-1,1-dimethyl-2-oxoethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755035-40-6P**, 8-Methoxy-3-(3-methoxy-4-nitrophenyl)-7-[3-(morpholin-4-yl)-3-oxopropyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755035-42-8P 755035-44-0P 755035-45-1P**, 8-[3-(3-Hydroxypiperidin-1-yl)-3-oxopropyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755035-46-2P 755035-47-3P 755035-48-4P 755035-49-5P 755035-50-8P**, 8-[2-[(6-Chloropyridin-3-yl)oxy]ethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755035-51-9P**, 8-[2-[(2-Chloropyridin-3-yl)oxy]ethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755035-52-0P**, 3-(3-Methoxy-4-nitrophenyl)-8-[2-[(6-methylpyridin-3-yl)oxy]ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755035-53-1P**, 3-(3-Methoxy-4-nitrophenyl)-8-[2-[(2-methylpyridin-3-yl)oxy]ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755035-54-2P**, 3-(3-Methoxy-4-nitrophenyl)-8-[2-[(pyridin-3-yl)oxy]ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755035-56-4P**, 8-[2-[(2,6-Dimethylpyridin-3-yl)oxy]ethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755035-57-5P**, 8-[2-[[2-[(Dimethylamino)methyl]pyridin-3-yl]oxy]ethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755035-58-6P**, 8-[2-(Isoquinolin-7-yloxy)ethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755035-59-7P**, 7-Methoxy-3-(3-methoxy-4-nitrophenyl)-N,N-dimethyl-11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carboxamide **755035-61-1P**, 7-[2-[(2-Chloropyridin-3-yl)oxy]ethyl]-8-methoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755035-63-3P**, 8-[2-(Isoquinolin-5-yloxy)ethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755035-64-4P**, 3-(3-Methoxy-4-nitrophenyl)-8-[2-[(quinolin-5-yl)oxy]ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755035-65-5P**, 3-(3-Methoxy-4-nitrophenyl)-8-[2-(4-methoxyphenoxy)ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755035-67-7P**, 3-(3-Methoxy-4-nitrophenyl)-8-[2-(3-methoxyphenoxy)ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755035-68-8P 755035-69-9P**, 3-(3-Methoxy-4-nitrophenyl)-8-[3-[[4-(morpholin-4-yl)phenyl]oxy]propyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755035-70-2P**, 3-(3-Methoxy-4-nitrophenyl)-8-[3-[(pyridin-3-yl)oxy]propyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755035-71-3P**, 8-[2-(3-Aminophenoxy)ethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755035-72-4P**, 3-(3-Methoxy-4-nitrophenyl)-8-[2-[(2-methyl-1,3-benzothiazol-7-yl)oxy]ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755035-73-5P 755035-74-6P**, 8-(2-Hydroxy-2-methylpropyl)-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755035-75-7P**, 3-(3-Methoxy-4-nitrophenyl)-8-[(4-methylpiperazin-1-yl)methyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755035-82-6P**, 3-(4-Chloro-3-methoxyphenyl)-8-[(4-methylpiperazin-1-yl)methyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755035-84-8P 755035-86-0P**, 3-(4-Hydroxy-3-methoxyphenyl)-8-(hydroxymethyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755035-91-7P**, 3-(3-Methoxy-4-nitrophenyl)-8-[(morpholin-4-yl)methyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755035-99-5P**, (R)-8-[[2-(Hydroxymethyl)pyrrolidin-1-yl]methyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755036-00-1P**, 7-(2-Hydroxyethoxy)-8-methoxy-3-(3-methoxy-4-


nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755036-01-2P, 8-[3-[2-(Hydroxymethyl)pyrrolidin-1-yl]-3-oxopropyl]-
 3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-
 one **755036-02-3P 755036-04-5P**, 8-Amino-3-(4-hydroxy-3-
 methoxyphenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755036-06-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(kinase inhibitor; preparation of dibenzo[b,e][1,4]diazepin-11-ones as
 kinase inhibitors for treatment of cancer)


RN 755034-76-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(4-hydroxybutoxy)-3-
 (3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755034-80-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(2-hydroxyethoxy)-3-
 (3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755034-82-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 7-(2,3-dihydroxypropoxy)-5,10-
 dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755034-83-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-[2-(2-
 methoxyethoxy)ethoxy]-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755034-84-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(methoxymethyl)-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755034-91-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-7-[(3-methoxy-4-nitrophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 755034-93-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 7-[[[2-(dimethylamino)ethyl]methylamino]methyl]-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755034-95-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-7-[[[2-(tetrahydro-2H-pyran-4-yl)ethyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 755034-97-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-ethyl-5,10-dihydro-7-methoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755035-04-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 7-ethenyl-5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755035-07-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-(3-hydroxypropyl)-7-methoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755035-14-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-methoxy-3-(3-methoxy-4-nitrophenyl)-8-[3-[(2-methyl-3-pyridinyl)oxy]propyl]- (9CI) (CA INDEX NAME)




RN 755035-16-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-[3-[(2-chloro-3-pyridinyl)oxy]propyl]-5,10-dihydro-7-methoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755035-17-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-methoxy-3-(3-methoxy-4-nitrophenyl)-8-[3-[4-(4-morpholinyl)phenoxy]propyl]- (9CI) (CA INDEX NAME)




RN 755035-19-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-[3-(3-isoquinolinyl)oxy]propyl]-7-methoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755035-20-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-methoxy-3-(3-methoxy-4-nitrophenyl)-8-[3-(3-oxo-2(3H)-isoquinolinyl)propyl]- (9CI) (CA INDEX NAME)




RN 755035-22-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxylic acid, 10,11-dihydro-7-methoxy-3-(3-methoxy-4-nitrophenyl)-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755035-25-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxylic acid, 10,11-dihydro-7-methoxy-11-oxo-3-(4-pyrimidinylamino)-, methyl ester (9CI) (CA INDEX NAME)



RN 755035-26-8 CAPLUS


CN Morpholine, 4-[2-[3-[(2,6-difluoro-4-pyridinyl)amino]-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-2-methyl-1-oxopropyl]- (9CI) (CA INDEX NAME)



RN 755035-27-9 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 3-[(2,6-difluoro-4-

pyridinyl) amino]-10,11-dihydro-N,N, α,α -tetramethyl-11-oxo-
(9CI) (CA INDEX NAME)




RN 755035-28-0 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 3-[(2,6-difluoro-4-pyridinyl) amino]-10,11-dihydro- α,α -dimethyl-11-oxo-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 755035-30-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 3-[(2,6-difluoro-4-pyridinyl) amino]-10,11-dihydro- α,α -dimethyl-11-oxo-N-2-thiazolyl- (9CI) (CA INDEX NAME)




RN 755035-31-5 CAPLUS

CN 3-Piperidinol, 1-[2-[3-[(2,6-difluoro-4-pyridinyl) amino]-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-2-methyl-1-oxopropyl]- (9CI) (CA INDEX NAME)



RN 755035-33-7 CAPLUS


CN 4-Piperidinol, 1-[2-[3-[(2,6-difluoro-4-pyridinyl)amino]-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-2-methyl-1-oxopropyl]- (9CI) (CA INDEX NAME)



RN 755035-34-8 CAPLUS


CN 2-Pyrrolidinemethanol, 1-[2-[3-[(2,6-difluoro-4-pyridinyl)amino]-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-2-methyl-1-oxopropyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 755035-35-9 CAPLUS

CN Pyrrolidine, 1-[2-[3-[(2,6-difluoro-4-pyridinyl)amino]-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-2-methyl-1-oxopropyl]- (9CI) (CA INDEX NAME)




RN 755035-36-0 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 3-[(2,6-difluoro-4-pyridinyl)amino]-10,11-dihydro- α,α -dimethyl-11-oxo-N-2-pyridinyl- (9CI) (CA INDEX NAME)




RN 755035-37-1 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 3-[(2,6-difluoro-4-pyridinyl)amino]-10,11-dihydro-α,α-dimethyl-11-oxo-N-3-pyridinyl- (9CI) (CA INDEX NAME)



RN 755035-38-2 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 3-[(2,6-difluoro-4-pyridinyl)amino]-N-(4-fluorophenyl)-10,11-dihydro-α,α-dimethyl-11-oxo- (9CI) (CA INDEX NAME)



RN 755035-39-3 CAPLUS


CN 2-Pyrrolidinemethanol, 1-[2-[3-[(2,6-difluoro-4-pyridinyl)amino]-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-2-methyl-1-oxopropyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 755035-40-6 CAPLUS

CN Morpholine, 4-[3-[10,11-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]-1-oxopropyl]- (9CI) (CA INDEX NAME)




RN 755035-42-8 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-propanamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-3-pyridinyl- (9CI) (CA INDEX NAME)




RN 755035-44-0 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-propanamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 755035-45-1 CAPLUS

CN 3-Piperidinol, 1-[3-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-1-oxopropyl]- (9CI) (CA INDEX NAME)




RN 755035-46-2 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-propanamide, N-(4-fluorophenyl)-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 755035-47-3 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-propanamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 755035-48-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-propanamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-N-methyl-11-oxo- (9CI) (CA INDEX NAME)




RN 755035-49-5 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-propanamide, 10,11-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-N,N-dimethyl-11-oxo- (9CI) (CA INDEX NAME)




RN 755035-50-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-[2-[(6-chloro-3-pyridinyl)oxy]ethyl]-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755035-51-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-[2-[(2-chloro-3-pyridinyl)oxy]ethyl]-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 755035-52-0 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-[(6-methyl-3-pyridinyl)oxy]ethyl]- (9CI) (CA INDEX NAME)



RN 755035-53-1 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-

nitrophenyl)-8-[2-[(2-methyl-3-pyridinyl)oxy]ethyl]- (9CI) (CA INDEX NAME)




RN 755035-54-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-(3-pyridinyloxy)ethyl]- (9CI) (CA INDEX NAME)




RN 755035-56-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-[2-[(2,6-dimethyl-3-pyridinyl)oxy]ethyl]-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755035-57-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-[2-[[2-[(dimethylamino)methyl]-3-pyridinyl]oxy]ethyl]-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755035-58-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-[2-(7-isoquinolinyloxy)ethyl]-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755035-59-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, 10,11-dihydro-7-methoxy-3-(3-methoxy-4-nitrophenyl)-N,N-dimethyl-11-oxo- (9CI) (CA INDEX NAME)




RN 755035-61-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 7-[2-[(2-chloro-3-pyridinyl)oxy]ethyl]-5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755035-63-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-[2-(5-isoquinolinyloxy)ethyl]-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755035-64-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-(5-quinolinyl)oxy]ethyl- (9CI) (CA INDEX NAME)




RN 755035-65-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-(4-methoxyphenoxy)ethyl]- (9CI) (CA INDEX NAME)




RN 755035-67-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-(3-methoxyphenoxy)ethyl]- (9CI) (CA INDEX NAME)




RN 755035-68-8 CAPLUS

CN 2-Pyridinecarboxamide, 3-[2-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]ethoxy]- (9CI) (CA INDEX NAME)




RN 755035-69-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[3-[4-(4-morpholinyl)phenoxy]propyl]- (9CI) (CA INDEX NAME)




RN 755035-70-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[3-(3-pyridinyloxy)propyl]- (9CI) (CA INDEX NAME)




RN 755035-71-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-[2-(3-aminophenoxy)ethyl]-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755035-72-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-[(2-methyl-7-benzothiazolyl)oxy]ethyl]- (9CI) (CA INDEX NAME)




RN 755035-73-5 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- α,α -dimethyl-11-oxo-N-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 755035-74-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-(2-hydroxy-2-methylpropyl)-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755035-75-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[(4-methyl-1-piperazinyl)methyl]- (9CI) (CA INDEX NAME)




RN 755035-82-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-(4-chloro-3-methoxyphenyl)-5,10-dihydro-8-[(4-methyl-1-piperazinyl)methyl]- (9CI) (CA INDEX NAME)




RN 755035-84-8 CAPLUS

CN Benzonitrile, 4-[10,11-dihydro-8-[(4-methyl-1-piperazinyl)methyl]-11-oxo-5H-dibenzo[b,e][1,4]diazepin-3-yl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 755035-86-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(4-hydroxy-3-methoxyphenyl)-8-(hydroxymethyl)- (9CI) (CA INDEX NAME)



RN 755035-91-7 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-(4-morpholinylmethyl)- (9CI) (CA INDEX NAME)



RN 755035-99-5 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-[[(2R)-2-(hydroxymethyl)-1-pyrrolidinyl]methyl]-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 755036-00-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(2-hydroxyethoxy)-8-methoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755036-01-2 CAPLUS

CN 2-Pyrrolidinemethanol, 1-[3-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-1-oxopropyl]- (9CI) (CA INDEX NAME)




RN 755036-02-3 CAPLUS

CN Cyclohexanecarboxamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]-4-hydroxy-, cis- (9CI) (CA INDEX NAME)




RN 755036-04-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-amino-5,10-dihydro-3-(4-hydroxy-3-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 755036-06-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(2-methoxy-5-methyl-4-pyridinyl)-α,α-dimethyl-N-[4-(4-morpholinyl)phenyl]-11-oxo- (9CI) (CA INDEX NAME)




IT 755031-66-4P

RL: BYP (Byproduct); PREP (Preparation)

(preparation of dibenzo[b,e][1,4]diazepin-11-ones as kinase inhibitors for treatment of cancer)


RN 755031-66-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-[(3-methyl-2-pyridinyl)oxy]ethyl]- (9CI) (CA INDEX NAME)




L25 ANSWER 5 OF 104 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 2004:740305 CAPLUS Full-text
 DN 141:260782
 TI Preparation of dibenzo[b,e][1,4]diazepin-11-ones as kinase inhibitors for treatment of cancer
 IN Hasvold, Lisa A.; Hexamer, Laura; Li, Gaoquan; Lin, Nan-horng; Sham, Hing; Sowin, Tom; Sullivan, Gerard M.; Wang, Le; Xia, Ping Xia
 PA Abbott Laboratories, USA
 SO PCT Int. Appl., 382 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004076424	A1	20040910	WO 2004-US5728	20040226
	W: AE, AE, AG, AL, AL, AM, AM, AM, AT, AT, AU, AZ, AZ, BA, BB, BG, BG, BR, BR, BW, BY, BY, BZ, BZ, CA, CH, CN, CN, CO, CO, CR, CR, CU, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EC, EE, EE, EG, ES, ES, FI, FI, GB, GD, GE, GE, GH, GM, HR, HR, HU, HU, ID, IL, IN, IS, JP, JP, KE, KE, KG, KG, KP, KP, KR, KR, KZ, KZ, KZ, LC, LK, LR, LS, LS, LT, LU, LV, MA, MD, MD, MG, MK, MN, MW, MX, MX, MZ, MZ, NA, NI RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2004254159	A1	20041216	US 2004-785120	20040225
PRAI	US 2003-375412	A	20030227		
	US 2004-785120	A	20040225		
	US 2003-450476P	P	20030227		
OS	MARPAT 141:260782				
GI					



I




II

AB Title heterocycles and analogs I [wherein A1 = CR1, N; A2 = CR8, N; R1, R8 = independently H, alkoxy, (hydroxy)alkyl, amino(alkyl), CN, halo, OH, NO2; R2-R5 = independently H, alkenyl, (alkoxy)alkoxy(alkoxy), (alkoxy)alkyl, alkoxycarbonyl(alkyl), alkylcarbonyl(alkyl), amino(alkoxy), aminoalkyl,

aminocarbonyl(alkyl), aminosulfonyl, aryl(alkoxy), aryl(oxy)alkyl, carboxy(alkyl), cyano(alkyl), cycloalkyl(alkyl), halo(alkoxy), haloalkyl, heterocyclyl(alkoxy), heterocyclyl(carbonyl)alkyl, heterocyclyloxyalkyl, hydroxy(alkoxy), hydroxyalkyl, nitro(alkyl), carbamoyl(alkyl); one of R6 and R7 = H and the other = H, aryl, cycloalkyl, halo, heterocyclyl, XR13; R13 = aryl, cycloalkyl, heterocyclyl; X = O, NR14, CO, S, SO2, (CH2)n, CONR14, NR14CO, SO2NR14, NR14SO2, O(CH2)m, (CH2)mO, CH=CH, C.tplbond.C; R14 = H, alkenyl, (amino)alkyl, hydroxyalkyl; Y = NR15, O; R15 = H, alkoxycarbonyl, (cyclo)alkyl, alkylcarbonyl, arylalkyl, cycloalkylalkyl; m = 0-3; n = 1-3; and therapeutically acceptable salts thereof] were prepared as protein kinase inhibitors. For example, N-alkylation of Me 3,4-diaminobenzoate with Me 4-chloro-2-iodobenzoate using Cu and K2CO3 in PhCl gave Me 2-[[2-amino-4-(methoxycarbonyl)phenyl]amino]-4-chlorobenzoate (68%), which was cyclized with 37% HCl in MeOH to provide II (87%). In enzymic assays using recombinant Chk1 kinase domain protein and human cdc25c peptide substrate, compds. of the invention inhibited Chk1 at IC50 values between about 0.2 nM and about 280µM. Thus, I and their pharmaceutical compns. are useful for treatment of cancer (no data).

- IT **755035-60-0P**, 7-Methoxy-3-(3-methoxy-4-nitrophenyl)-11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carboxylic acid
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (intermediate, kinase inhibitor; preparation of dibenzo[b,e][1,4]diazepin-11-ones as kinase inhibitors for treatment of cancer)
 RN **755035-60-0** CAPLUS
 CN **5H-Dibenzo[b,e][1,4]diazepine-8-carboxylic acid, 10,11-dihydro-7-methoxy-3-(3-methoxy-4-nitrophenyl)-11-oxo-** (9CI) (CA INDEX NAME)




- IT **755027-01-1P**, 8-(3-Aminophenyl)-3-chloro-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755027-03-3P**, 3-Chloro-8-(3-hydroxyphenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755027-05-5P**, 3-Chloro-8-(pyridin-3-yl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755027-07-7P**, 3-Chloro-8-(1H-pyrrol-2-yl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755027-13-5P** **755027-16-8P**, 3-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755027-33-9P**, 3-(2-Fluoropyridin-4-yl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755027-35-1P**, Methyl 3-(2-fluoro-4-pyridinyl)-11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carboxylate **755027-36-2P**, 3-(2-Fluoro-4-pyridinyl)-11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carboxylic acid **755027-38-4P** **755028-00-3P** **755028-37-6P**, 8-Amino-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755028-45-6P**, 3-Chloro-8-(2-oxopyrrolidin-1-yl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755028-48-9P**,

3-Chloro-8-(2-oxopiperidin-1-yl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755028-50-3P**
755028-97-8P 755029-02-8P 755029-21-1P,
 3-Chloro-8-[2-(pyridin-2-yloxy)ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755029-73-3P**
755029-76-6P 755029-81-3P 755030-51-4P,
 3-Chloro-8-[(E)-2-(pyridin-4-yl)ethenyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755030-52-5P,**
 3-Chloro-8-[2-(pyridin-4-yl)ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755030-55-8P,**
 3-Chloro-8-[(E)-2-(pyridin-2-yl)ethenyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755030-57-0P,**
 3-Chloro-8-[2-(pyridin-2-yl)ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755030-88-7P**
755030-90-1P 755030-96-7P 755031-23-3P
755031-30-2P 755031-59-5P, 3-Chloro-8-[2-[[4-(morpholin-4-yl)phenyl]oxy]ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755031-63-1P 755031-64-2P,** 3-Chloro-8-[2-[[4-(morpholin-4-yl)phenyl]amino]ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755031-72-2P,** 3-Chloro-8-[1,1-dimethyl-2-(pyridin-2-yloxy)ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755031-74-4P,** 3-Chloro-8-[1,1-dimethyl-2-(4-nitrophenoxy)ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755031-75-5P,** 8-[2-(4-Aminophenoxy)-1,1-dimethylethyl]-3-chloro-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755031-76-6P,** 3-Chloro-8-[1,1-dimethyl-2-[[4-(morpholin-4-yl)phenyl]oxy]ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755032-16-7P**
755032-64-5P 755032-66-7P 755032-68-9P,
 3-(2-Fluoropyridin-4-yl)-8-[2-(morpholin-4-yl)-2-oxoethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755032-70-3P**
755033-42-2P, 3-Chloro-7-(piperidin-1-yl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755033-45-5P,**
 (S)-3-Chloro-7-[2-(hydroxymethyl)pyrrolidin-1-yl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755033-47-7P,**
 3-Chloro-7-(morpholin-4-yl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755033-51-3P,** 3-Chloro-7-(4-hydroxypiperidin-1-yl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755033-72-8P**
755033-95-5P 755034-28-7P, 8-Methoxy-3-(3-methoxy-4-nitrophenyl)-7-[[2-(trimethylsilyl)ethoxy]methoxy]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755034-37-8P,**
 7-Methoxy-3-(3-methoxy-4-nitrophenyl)-8-[[2-(trimethylsilyl)ethoxy]methoxy]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755034-68-5P**
755034-96-9P, 3-Chloro-7-[[2-(tetrahydro-2H-pyran-4-yl)ethyl]amino]methyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755035-15-5P,** 3-Chloro-7-methoxy-8-[3-[(2-methylpyridin-3-yl)oxy]propyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755035-18-8P,** 3-Chloro-7-methoxy-8-[3-[[4-(morpholin-4-yl)phenyl]oxy]propyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755035-41-7P 755035-81-5P,** 3-Chloro-8-[(4-methylpiperazin-1-yl)methyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755035-83-7P,** 8-[(4-Methylpiperazin-1-yl)methyl]-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755035-97-3P,** 3-Chloro-8-(morpholin-4-ylmethyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of dibenzo[b,e][1,4]diazepin-11-ones as kinase inhibitors for treatment of cancer)


RN 755027-01-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-(3-aminophenyl)-3-chloro-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 755027-03-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-(3-hydroxyphenyl)- (9CI) (CA INDEX NAME)




RN 755027-05-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-(3-pyridinyl)- (9CI) (CA INDEX NAME)



RN 755027-07-7 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-(1H-pyrrol-2-yl)- (9CI) (CA INDEX NAME)



RN 755027-13-5 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 10,11-dihydro-11-oxo-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-, methyl ester (9CI) (CA

INDEX NAME)




RN 755027-16-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)- (9CI) (CA INDEX NAME)




RN 755027-33-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-(2-fluoro-4-pyridinyl)-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 755027-35-1 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxylic acid, 3-(2-fluoro-4-pyridinyl)-10,11-dihydro-11-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 755027-36-2 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxylic acid, 3-(2-fluoro-4-pyridinyl)-
10,11-dihydro-11-oxo- (9CI) (CA INDEX NAME)




RN 755027-38-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, 3-(2-fluoro-4-pyridinyl)-
10,11-dihydro-11-oxo-N-[3-(1-pyrrolidinyl)propyl]-, mono(trifluoroacetate)
(9CI) (CA INDEX NAME)

CM 1

CRN 755027-37-3


CMF C26 H26 F N5 O2



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 755028-00-3 CAPLUS


CN Carbamic acid, [(1S)-1-[[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-
5H-dibenzo[b,e][1,4]diazepin-8-yl]amino]carbonyl]-3-methylbutyl]-,
1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 755028-37-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-amino-5,10-dihydro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)- (9CI) (CA INDEX NAME)




RN 755028-45-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-(2-oxo-1-pyrrolidinyl)- (9CI) (CA INDEX NAME)




RN 755028-48-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-(2-oxo-1-piperidinyl)- (9CI) (CA INDEX NAME)




RN 755028-50-3 CAPLUS

CN Butanamide, 4-chloro-N-[3-(4-chloro-3-methoxyphenyl)-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)




RN 755028-97-8 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 3-chloro-10,11-dihydro- α,α -dimethyl-N-[4-(4-morpholinyl)phenyl]-11-oxo- (9CI) (CA INDEX NAME)




RN 755029-02-8 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 3-[(2,6-difluoro-4-pyridinyl)amino]-10,11-dihydro- α,α -dimethyl-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755029-21-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-[2-(2-pyridinyloxy)ethyl]- (9CI) (CA INDEX NAME)




RN 755029-73-3 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-propanoic acid, 10,11-dihydro-11-oxo-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-, methyl ester (9CI) (CA INDEX NAME)




RN 755029-76-6 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-propanoic acid, 3-(4-chloro-3-methoxyphenyl)-10,11-dihydro-11-oxo- (9CI) (CA INDEX NAME)



RN 755029-81-3 CAPLUS


CN Ethanimidamide, N-[3-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-1-oxopropoxy]- (9CI) (CA INDEX NAME)



RN 755030-51-4 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-[(1E)-2-(4-pyridinyl)ethenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 755030-52-5 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-[2-(4-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 755030-55-8 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-[(1E)-2-(2-pyridinyl)ethenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 755030-57-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 755030-88-7 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- α,α -dimethyl-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755030-90-1 CAPLUS
 CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- α,α -dimethyl-11-oxo- (9CI) (CA INDEX NAME)




RN 755030-96-7 CAPLUS
 CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 3-(4-cyano-3-methoxyphenyl)-10,11-dihydro- α,α -dimethyl-11-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 755031-23-3 CAPLUS
 CN Cyclopropanecarboxylic acid, 1-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)




RN 755031-30-2 CAPLUS
 CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetic acid, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- α,α -dimethyl-11-oxo- (9CI) (CA INDEX NAME)




RN 755031-59-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-[2-[4-(4-morpholinyl)phenoxy]ethyl]- (9CI) (CA INDEX NAME)




RN 755031-63-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-[2-[[4-(methylphenyl)sulfonyl]oxy]ethyl]- (9CI) (CA INDEX NAME)




RN 755031-64-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-[2-[[4-(4-morpholinyl)phenyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 755031-72-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-8-[1,1-dimethyl-2-(2-pyridinyloxy)ethyl]-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 755031-74-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-8-[1,1-dimethyl-2-(4-nitrophenoxy)ethyl]-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 755031-75-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-[2-(4-aminophenoxy)-1,1-dimethylethyl]-3-chloro-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 755031-76-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-8-[1,1-dimethyl-2-[4-(4-morpholinyl)phenoxy]ethyl]-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 755032-16-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 10,11-dihydro- α,α -dimethyl-11-oxo-3-(4-pyrimidinylamino)- (9CI) (CA INDEX NAME)




RN 755032-64-5 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 3-(2-fluoro-4-pyridinyl)-10,11-dihydro-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755032-66-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 3-(2-fluoro-4-pyridinyl)-10,11-dihydro-N,N-dimethyl-11-oxo- (9CI) (CA INDEX NAME)




RN 755032-68-9 CAPLUS

CN Morpholine, 4-[[3-(2-fluoro-4-pyridinyl)-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]acetyl]- (9CI) (CA INDEX NAME)




RN 755032-70-3 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 3-(2-fluoro-4-pyridinyl)-10,11-dihydro-N-[4-(4-morpholinyl)phenyl]-11-oxo- (9CI) (CA INDEX NAME)



RN 755033-42-2 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-7-(1-piperidinyl)- (9CI) (CA INDEX NAME)



RN 755033-45-5 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-7-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 755033-47-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-7-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 755033-51-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-7-(4-hydroxy-1-piperidinyl)- (9CI) (CA INDEX NAME)




RN 755033-72-8 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 10,11-dihydro-11-oxo-3-(4-pyridinylamino)- (9CI) (CA INDEX NAME)




RN 755033-95-5 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 10,11-dihydro- α,α -dimethyl-3-[(2-methyl-4-pyridinyl)amino]-11-oxo- (9CI) (CA INDEX NAME)




RN 755034-28-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-7-[[2-(trimethylsilyl)ethoxy]methoxy]- (9CI) (CA INDEX NAME)



RN 755034-37-8 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-methoxy-3-(3-methoxy-4-nitrophenyl)-8-[[2-(trimethylsilyl)ethoxy]methoxy]- (9CI) (CA INDEX NAME)



RN 755034-68-5 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 7-[4-[[[1,1-dimethylethyl]dimethylsilyl]oxy]butoxy]-5,10-dihydro-3-(4-hydroxy-3-

methoxyphenyl)-8-methoxy- (9CI) (CA INDEX NAME)




RN 755034-96-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-7-[[[2-(tetrahydro-2H-pyran-4-yl)ethyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 755035-15-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-7-methoxy-8-[3-[(2-methyl-3-pyridinyl)oxy]propyl]- (9CI) (CA INDEX NAME)




RN 755035-18-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-7-methoxy-8-[3-[4-(4-morpholinyl)phenoxy]propyl]- (9CI) (CA INDEX NAME)




RN 755035-41-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-propanoic acid, 10,11-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 755035-81-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-[(4-methyl-1-piperazinyl)methyl]- (9CI) (CA INDEX NAME)




RN 755035-83-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-[(4-methyl-1-piperazinyl)methyl]-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)- (9CI) (CA INDEX NAME)



RN 755035-97-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-8-(4-morpholinylmethyl)- (9CI) (CA INDEX NAME)




IT 755026-56-3P, Methyl 3-(4-hydroxy-3-methoxyphenyl)-11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carboxylate 755026-57-4P, 3-(4-Hydroxy-3-methoxyphenyl)-11-oxo-10,11-dihydro-5H-

dibenzo[b,e][1,4]diazepine-8-carboxylic acid 755026-72-3P
 755026-73-4P 755026-74-5P 755027-09-9P
 755027-12-4P 755027-23-7P 755027-24-8P
 755027-25-9P 755027-41-9P 755027-43-1P
 755027-44-2P 755027-96-4P, 8-Amino-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one trifluoroacetate 755028-36-5P 755028-41-2P,
 8-Amino-3-(4-chloro-3-methoxyphenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755028-51-4P
 755028-57-0P 755028-65-0P, 7-Amino-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755028-69-4P 755029-08-4P 755029-13-1P
 755029-56-2P 755029-58-4P 755029-69-7P,
 8-(2-Hydroxyethyl)-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755029-70-0P,
 8-(3-Hydroxypropyl)-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755030-02-5P,
 7-(2-Hydroxyethyl)-8-methoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755031-18-6P
 755032-40-7P 755032-41-8P 755032-44-1P
 755032-47-4P 755032-56-5P 755032-58-7P
 755033-90-0P 755034-22-1P, 7-Hydroxy-8-methoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755034-60-7P, 7-(2-Chloroethoxy)-8-methoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (kinase inhibitor; preparation of dibenzo[b,e][1,4]diazepin-11-ones as kinase inhibitors for treatment of cancer)


RN 755026-56-3 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxylic acid, 10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755026-57-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxylic acid, 10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 755026-72-3 CAPLUS

CN 2-Piperidinecarboxylic acid, 1-[[10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 755026-73-4 CAPLUS

CN 3-Piperidinecarboxylic acid, 1-[[10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 755026-74-5 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[[10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 755027-09-9 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755027-12-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 3-(4-chloro-3-methoxyphenyl)-10,11-dihydro-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755027-23-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 3-(4-cyano-3-methoxyphenyl)-10,11-dihydro-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755027-24-8 CAPLUS

CN Benzoic acid, 4-(10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-3-yl)-2-methoxy-, methyl ester (9CI) (CA INDEX NAME)




RN 755027-25-9 CAPLUS

CN Benzoic acid, 4-(10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-3-yl)-2-methoxy- (9CI) (CA INDEX NAME)




RN 755027-41-9 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 3-(2-fluoro-5-methyl-4-pyridinyl)-10,11-dihydro-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755027-43-1 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 10,11-dihydro-3-(2-methoxy-5-methyl-4-pyridinyl)-11-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 755027-44-2 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 755027-96-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-amino-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 755027-95-3


CMF C20 H16 N4 O4



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 755028-36-5 CAPLUS

CN Benzonitrile, 4-(8-amino-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-3-yl)-2-methoxy- (9CI) (CA INDEX NAME)




RN 755028-41-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-amino-3-(4-chloro-3-methoxyphenyl)-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 755028-51-4 CAPLUS

CN 1-Propanesulfonamide, 3-chloro-N-[3-(4-chloro-3-methoxyphenyl)-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)




RN 755028-57-0 CAPLUS

CN 1-Propanesulfonamide, 3-chloro-N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)




RN 755028-65-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 7-amino-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755028-69-4 CAPLUS

CN 1-Propanesulfonamide, 3-chloro-N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]- (9CI) (CA INDEX NAME)




RN 755029-08-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 3-[(2-chloro-4-pyridinyl)amino]-10,11-dihydro-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755029-13-1 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 3-[(2-chloro-4-pyridinyl)amino]-10,11-dihydro-11-oxo- (9CI) (CA INDEX NAME)




RN 755029-56-2 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-propanoic acid, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755029-58-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-propanoic acid, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 755029-69-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-(2-hydroxyethyl)-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755029-70-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-(3-hydroxypropyl)-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755030-02-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(2-hydroxyethyl)-8-methoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755031-18-6 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 10,11-dihydro-α,α-dimethyl-11-oxo-3-(4-pyrimidinylamino)-, methyl ester (9CI) (CA INDEX NAME)




RN 755032-40-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 3-(4-chloro-3-methoxyphenyl)-10,11-dihydro-11-oxo- (9CI) (CA INDEX NAME)




RN 755032-41-8 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 3-(4-acetyl-3-methoxyphenyl)-10,11-dihydro-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755032-44-1 CAPLUS

CN Carbamic acid, [1-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]acetyl]-3-pyrrolidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 755032-47-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 10,11-dihydro-3-(2-methoxy-5-methyl-4-pyridinyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 755032-56-5 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]acetyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 755032-58-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 3-(4-cyano-3-methoxyphenyl)-10,11-dihydro-11-oxo- (9CI) (CA INDEX NAME)




RN 755033-90-0 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 10,11-dihydro-α,α-dimethyl-3-[(2-methyl-4-pyridinyl)amino]-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755034-22-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-hydroxy-8-methoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 755034-60-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 7-(2-chloroethoxy)-5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)



- IT 755026-54-1P, 3-(4-Hydroxy-3-methoxyphenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755026-55-2P
 755026-58-5P, 3-(4-Hydroxy-3-methoxyphenyl)-11-oxo-N-[3-(1-pyrrolidinyl)propyl]-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carboxamide 755026-59-6P 755026-60-9P,
 N-[3-(Dimethylamino)propyl]-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carboxamide 755026-61-0P
 755026-62-1P, 3-(4-Hydroxy-3-methoxyphenyl)-N-[3-(4-morpholinyl)propyl]-11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carboxamide 755026-63-2P 755026-64-3P,
 3-(4-Hydroxy-3-methoxyphenyl)-11-oxo-N-[3-(2-oxo-1-pyrrolidinyl)propyl]-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carboxamide
 755026-65-4P 755026-66-5P, N-(2-Hydroxyethyl)-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carboxamide 755026-67-6P,
 N-(2,3-Dihydroxypropyl)-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carboxamide 755026-68-7P,
 N-[2-(Acetylamino)ethyl]-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carboxamide 755026-69-8P
 , 3-(4-Hydroxy-3-methoxyphenyl)-8-[(3-hydroxy-1-pyrrolidinyl)carbonyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755026-70-1P,
 (S)-3-(4-Hydroxy-3-methoxyphenyl)-8-[[2-(hydroxymethyl)-1-pyrrolidinyl]carbonyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755026-71-2P, 3-(4-Hydroxy-3-methoxyphenyl)-8-[[2-(hydroxymethyl)-1-piperidinyl]carbonyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
 755026-75-6P, 3-(4-Hydroxy-3-methoxyphenyl)-8-[(3-hydroxy-1-piperidinyl)carbonyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
 755026-76-7P, 3-(4-Hydroxy-3-methoxyphenyl)-11-oxo-N-[(3-pyridinyl)methyl]-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carboxamide 755026-77-8P 755026-78-9P,
 3-(4-Hydroxy-3-methoxyphenyl)-N-[4-(methylsulfonyl)benzyl]-11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carboxamide 755026-79-0P
 , N-(2-Fluorobenzyl)-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carboxamide 755026-80-3P,
 3-(4-Hydroxy-3-methoxyphenyl)-N-(2-methoxybenzyl)-11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carboxamide 755026-81-4P,
 3-(4-Hydroxy-3-methoxyphenyl)-11-oxo-N-[(2-pyridinyl)methyl]-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carboxamide 755026-82-5P
 755026-83-6P, 3-(4-Hydroxy-3-methoxyphenyl)-11-oxo-N-[(4-pyridinyl)methyl]-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carboxamide 755026-84-7P 755026-85-8P,
 3-(4-Hydroxy-3-methoxyphenyl)-N-[2-(4-methoxyphenyl)ethyl]-11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carboxamide 755026-86-9P
 755026-87-0P 755026-88-1P 755026-89-2P
 755026-90-5P, 3-(4-Hydroxy-3-methoxyphenyl)-11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carbonitrile 755026-91-6P,
 3-(4-Hydroxy-3-methoxyphenyl)-8-nitro-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755026-92-7P,
 8-Amino-3-(4-hydroxy-3-methoxyphenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one hydrochloride 755026-93-8P

755026-95-0P 755026-97-2P 755026-99-4P
 755027-00-0P, 8-(3-Aminophenyl)-3-(4-hydroxy-3-methoxyphenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755027-02-2P,
 3-(4-Hydroxy-3-methoxyphenyl)-8-(3-hydroxyphenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755027-04-4P,
 3-(4-Hydroxy-3-methoxyphenyl)-8-(pyridin-3-yl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755027-06-6P,
 3-(4-Hydroxy-3-methoxyphenyl)-8-(1H-pyrrol-2-yl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755027-08-8P,
 3-(3-Methoxy-4-nitrophenyl)-8-(1H-pyrrol-2-yl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755027-10-2P
 755027-11-3P 755027-14-6P, 3-(3-Methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755027-15-7P,
 3-(4-Chloro-3-methoxyphenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755027-17-9P, 3-(4-Bromo-3-methoxyphenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755027-19-1P
 755027-20-4P, 3-(4-Acetyl-3-methoxyphenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755027-22-6P
 755027-26-0P 755027-27-1P 755027-28-2P
 755027-29-3P 755027-32-8P, 3-(2-Methoxypyridin-4-yl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755027-34-0P,
 3-(2-Methoxy-4-pyridinyl)-11-oxo-N-[3-(1-pyrrolidinyl)propyl]-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carboxamide 755027-39-5P
 , 11-Oxo-3-(2-oxo-1,2-dihydro-4-pyridinyl)-N-[3-(1-pyrrolidinyl)propyl]-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carboxamide
 755027-40-8P 755027-45-3P 755027-46-4P
 755027-47-5P, 8-[2-(3-Hydroxy-1-piperidinyl)-2-oxoethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
 755027-48-6P, 3-(3-Methoxy-4-nitrophenyl)-8-[2-(4-methyl-1,4-diazepan-1-yl)-2-oxoethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755027-50-0P 755027-51-1P, 8-[2-(4-Hydroxy-1-piperidinyl)-2-oxoethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755027-52-2P
 755027-53-3P 755027-54-4P 755027-55-5P
 755027-56-6P 755027-57-7P 755027-58-8P
 755027-59-9P 755027-60-2P 755027-61-3P
 755027-62-4P 755027-63-5P 755027-66-8P
 755027-67-9P 755027-68-0P 755027-69-1P
 755027-71-5P 755027-72-6P 755027-73-7P
 755027-74-8P 755027-75-9P 755027-76-0P
 755027-77-1P 755027-78-2P, 8-[2-(4-Ethyl-1-piperazinyl)-2-oxoethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755027-79-3P,
 8-[2-[4-(2-Hydroxyethyl)-1-piperazinyl]-2-oxoethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
 755027-80-6P 755027-81-7P, 3-(3-Methoxy-4-nitrophenyl)-8-[2-oxo-2-(4-phenyl-1-piperazinyl)ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755027-82-8P,
 3-(3-Methoxy-4-nitrophenyl)-8-[2-oxo-2-[4-(pyridin-2-yl)-1-piperazinyl]ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
 755027-83-9P 755027-84-0P 755027-85-1P
 755027-86-2P 755027-87-3P 755027-88-4P
 755027-89-5P 755027-90-8P 755027-91-9P
 755027-92-0P 755027-93-1P 755027-94-2P,
 (S)-8-[2-[2-(Hydroxymethyl)-1-pyrrolidinyl]-2-oxoethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
 755027-95-3P, 8-Amino-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755027-97-5P
 755027-98-6P 755027-99-7P 755028-01-4P
 755028-02-5P 755028-03-6P 755028-04-7P

755028-05-8P 755028-06-9P 755028-07-0P
 755028-08-1P 755028-09-2P 755028-10-5P
 755028-11-6P 755028-12-7P 755028-13-8P
 755028-14-9P 755028-15-0P 755028-16-1P
 755028-19-4P 755028-21-8P 755028-22-9P
 755028-24-1P 755028-25-2P 755028-26-3P
 755028-27-4P 755028-28-5P 755028-29-6P
 755028-30-9P 755028-31-0P 755028-32-1P
 755028-33-2P 755028-34-3P 755028-35-4P
 755028-38-7P 755028-39-8P 755028-40-1P
 755028-42-3P 755028-43-4P, 3-(3-Methoxy-4-nitrophenyl)-8-(2-oxopyrrolidin-1-yl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
 755028-46-7P, 3-(3-Methoxy-4-nitrophenyl)-8-(2-oxopiperidin-1-yl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755028-49-0P,
 3-(4-Chloro-3-methoxyphenyl)-8-(2-oxopyrrolidin-1-yl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755028-52-5P
 755028-53-6P, 3-(4-Chloro-3-methoxyphenyl)-8-(1,1-dioxidoisothiazolidin-2-yl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755028-54-7P 755028-55-8P 755028-56-9P
 755028-58-1P, 8-(1,1-Dioxidoisothiazolidin-2-yl)-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
 755028-59-2P 755028-60-5P 755028-61-6P
 755028-62-7P 755028-63-8P 755028-64-9P
 755028-70-7P 755028-71-8P 755028-72-9P
 755028-73-0P 755028-74-1P 755028-75-2P
 755028-76-3P 755028-77-4P 755028-78-5P
 755028-79-6P, 8-(1-Hydroxy-1-methylethyl)-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
 755028-81-0P, 8-(1-Ethyl-1-hydroxypropyl)-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
 755028-83-2P, 8-(1-Hydroxy-1-methylethyl)-3-[(pyridin-4-yl)amino]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755028-84-3P,
 3-[(2-Chloropyridin-4-yl)amino]-8-(1-hydroxy-1-methylethyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755028-86-5P
 755028-87-6P, 8-(1-Hydroxy-1-methylethyl)-3-[(pyrimidin-4-yl)amino]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755028-88-7P,
 8-(1-Hydroxy-1-methylethyl)-3-[(2,3,5,6-tetrafluoropyridin-4-yl)amino]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
 755028-89-8P, 8-(1-Ethyl-1-hydroxypropyl)-3-[(pyridin-4-yl)amino]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755028-90-1P,
 3-[(2-Aminopyrimidin-4-yl)amino]-8-(1-hydroxy-1-methylethyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755028-91-2P,
 3-[(2-Chloropyridin-4-yl)amino]-8-(1-ethyl-1-hydroxypropyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755028-92-3P,
 8-(1-Hydroxy-1-methylethyl)-3-[(2,3,6-trifluoropyridin-4-yl)amino]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755028-93-4P,
 3-[[2-[(2-Chloropyridin-4-yl)amino]pyridin-4-yl]amino]-8-(1-hydroxy-1-methylethyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
 755028-94-5P 755028-95-6P 755028-98-9P
 755028-99-0P, 3-[(2,6-Difluoropyridin-4-yl)amino]-8-(2-hydroxyethyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
 755029-01-7P 755029-03-9P, 3-[(2,6-Difluoropyridin-4-yl)amino]-7-(morpholin-4-yl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755029-04-0P,
 7-(Morpholin-4-yl)-3-[(2,3,6-trifluoropyridin-4-yl)amino]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
 755029-05-1P, 3-[(2,6-Difluoropyridin-4-yl)amino]-8-(2-hydroxy-2-methylpropyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
 755029-07-3P 755029-09-5P 755029-10-8P,
 3-[(2-Chloropyridin-4-yl)amino]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755029-11-9P, 8-Acetyl-3-[(2-chloropyridin-4-yl)amino]-

5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755029-14-2P**,
 3-[(2-Chloropyridin-4-yl)amino]-8-isopropenyl-5,10-dihydro-11H-
 dibenzo[b,e][1,4]diazepin-11-one **755029-15-3P**
755029-16-4P, 3-[(2-Chloropyridin-4-yl)amino]-8-(2-hydroxy-2-
 methylpropyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755029-17-5P 755029-18-6P, 3-[(2-Chloropyridin-4-
 yl)amino]-8-(2-oxopyrrolidin-1-yl)-5,10-dihydro-11H-
 dibenzo[b,e][1,4]diazepin-11-one **755029-19-7P**
755029-20-0P, 8-[2-(Pyridin-2-yloxy)ethyl]-3-[(2,3,6-
 trifluoropyridin-4-yl)amino]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-
 one **755029-22-2P**, 8-(2-Hydroxy-2-methylpropyl)-3-[(2,3,5-
 trifluorophenyl)amino]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755029-23-3P, 3-[(3,5-Difluorophenyl)amino]-7-(3-hydroxy-3-
 methylbutyl)-8-methoxy-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755029-39-1P, 7-(3-Hydroxy-3-methylbutyl)-8-methoxy-3-(3-methoxy-4-
 nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755029-41-5P, 3-[(2,6-Difluoropyridin-4-yl)amino]-7-(3-
 hydroxypropyl)-8-methoxy-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755029-44-8P, 7-(3-Hydroxypropyl)-8-methoxy-3-(3-methoxy-4-
 nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755029-46-0P, 3-[(2,6-Difluoropyridin-4-yl)amino]-8-(3-hydroxy-3-
 methylbutyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755029-54-0P, 8-(3-Hydroxy-3-methylbutyl)-3-(3-methoxy-4-
 nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755029-60-8P 755029-61-9P 755029-63-1P,
 8-[3-(Azetidin-1-yl)-3-oxopropyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-
 11H-dibenzo[b,e][1,4]diazepin-11-one **755029-64-2P**,
 3-(3-Methoxy-4-nitrophenyl)-8-[3-oxo-3-(pyrrolidin-1-yl)propyl]-5,10-
 dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755029-65-3P**,
 3-(3-Methoxy-4-nitrophenyl)-8-[3-(morpholin-4-yl)-3-oxopropyl]-5,10-
 dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755029-66-4P**
755029-67-5P, 8-[3-(4-Hydroxypiperidin-1-yl)-3-oxopropyl]-3-(3-
 methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755029-68-6P 755029-72-2P 755029-74-4P
755029-78-8P, 3-(4-Chloro-3-methoxyphenyl)-8-(3-hydroxy-3-
 methylbutyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755029-80-2P, 3-(3-Methoxy-4-nitrophenyl)-8-[2-(3-methyl-1,2,4-
 oxadiazol-5-yl)ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755029-83-5P 755029-85-7P, 7-(2-Hydroxy-2-methylpropyl)-
 8-methoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-
 dibenzo[b,e][1,4]diazepin-11-one **755030-04-7P**,
 8-Methoxy-3-(3-methoxy-4-nitrophenyl)-7-(2-oxopropyl)-5,10-dihydro-11H-
 dibenzo[b,e][1,4]diazepin-11-one **755030-06-9P**,
 7-(2-Hydroxy-1,1-dimethylethyl)-8-methoxy-3-(3-methoxy-4-nitrophenyl)-5,10-
 dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755030-15-0P**,
 7-(3-Hydroxypropyl)-3-(3-methoxy-4-nitrophenyl)-8-(trifluoromethoxy)-5,10-
 dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755030-28-5P**,
 7-(3-Hydroxy-3-methylbutyl)-3-(3-methoxy-4-nitrophenyl)-8-
 (trifluoromethoxy)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755030-31-0P, 7-(3-Hydroxy-3-methylbutyl)-3-(3-methoxy-4-
 nitrophenyl)-8-methyl-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755030-48-9P, 3-(3-Methoxy-4-nitrophenyl)-8-[2-(pyridin-4-
 yl)ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755030-53-6P, 3-(3-Methoxy-4-nitrophenyl)-8-[2-(pyridin-2-
 yl)ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755030-60-5P 755030-62-7P 755030-63-8P
755030-65-0P, 3-(3-Methoxy-4-nitrophenyl)-8-[2-[(pyridin-2-
 yl)oxy]ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755030-66-1P, 8-[2-[(5-Chloropyridin-3-yl)oxy]ethyl]-3-(3-methoxy-
 4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one

755030-67-2P, 8-Methoxy-3-(3-methoxy-4-nitrophenyl)-7-[2-[(pyridin-3-yl)oxy]ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one


755030-69-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(kinase inhibitor; preparation of dibenzo[b,e][1,4]diazepin-11-ones as kinase inhibitors for treatment of cancer)


RN 755026-54-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(4-hydroxy-3-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 755026-55-2 CAPLUS

CN Benzonitrile, 3-(10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-3-yl)- (9CI) (CA INDEX NAME)



RN 755026-58-5 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, 10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-N-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)




RN 755026-59-6 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, 10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-N-[3-(1-pyrrolidinyl)propyl]-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 755026-58-5


CMF C28 H30 N4 O4



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 755026-60-9 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, N-[3-(dimethylamino)propyl]-10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 755026-61-0 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, N-[3-(dimethylamino)propyl]-10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-, mono(trifluoroacetate) (salt) (9CI). (CA INDEX NAME)

CM 1

CRN 755026-60-9


CMF C26 H28 N4 O4



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 755026-62-1 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, 10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-N-[3-(4-morpholinyl)propyl]-11-oxo- (9CI) (CA INDEX NAME)




RN 755026-63-2 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, 10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-N-[3-(4-morpholinyl)propyl]-11-oxo-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 755026-62-1


CMF C28 H30 N4 O5



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 755026-64-3 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, 10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-N-[3-(2-oxo-1-pyrrolidiny)propyl]- (9CI) (CA INDEX NAME)




RN 755026-65-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, 10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-N-[3-(2-oxo-1-pyrrolidiny)propyl]-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 755026-64-3


CMF C28 H28 N4 O5



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 755026-66-5 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, 10,11-dihydro-N-(2-hydroxyethyl)-3-(4-hydroxy-3-methoxyphenyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 755026-67-6 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, N-(2,3-dihydroxypropyl)-10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 755026-68-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, N-[2-(acetylamino)ethyl]-10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo- (9CI) (CA INDEX NAME)



RN 755026-69-8 CAPLUS

CN 3-Pyrrolidinol, 1-[[10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 755026-70-1 CAPLUS

CN 2-Pyrrolidinemethanol, 1-[[10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]carbonyl]-, (2S)- (9CI) (CA INDEX NAME)


NAME)

Absolute stereochemistry.




RN 755026-71-2 CAPLUS

CN 2-Piperidinemethanol, 1-[[10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 755026-75-6 CAPLUS

CN 3-Piperidinol, 1-[[10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]carbonyl]- (9CI) (CA INDEX NAME)



RN 755026-76-7 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, 10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 755026-77-8 CAPLUS
 CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, 10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-N-(3-pyridinylmethyl)-, mono(trifluoroacetate)
 (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 755026-76-7
 CMF C27 H22 N4 O4




CM 2


CRN 76-05-1
 CMF C2 H F3 O2



RN 755026-78-9 CAPLUS
 CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, 10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-N-[[4-(methylsulfonyl)phenyl]methyl]-11-oxo- (9CI) (CA INDEX NAME)




RN 755026-79-0 CAPLUS
 CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, N-[(2-fluorophenyl)methyl]-10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 755026-80-3 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, 10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-N-[(2-methoxyphenyl)methyl]-11-oxo- (9CI) (CA INDEX NAME)



RN 755026-81-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, 10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-N-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 755026-82-5 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, 10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-N-(2-pyridinylmethyl)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 755026-81-4


CMF C27 H22 N4 O4



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 755026-83-6 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, 10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 755026-84-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, 10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-N-(4-pyridinylmethyl)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 755026-83-6


CMF C27 H22 N4 O4



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 755026-85-8 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, 10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-N-[2-(4-methoxyphenyl)ethyl]-11-oxo- (9CI) (CA INDEX NAME)




RN 755026-86-9 CAPLUS

CN 2-Piperidinecarboxylic acid, 1-[[10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 755026-87-0 CAPLUS

CN 3-Piperidinecarboxylic acid, 1-[[10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 755026-88-1 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[[10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]carbonyl]- (9CI)
(CA INDEX NAME)




RN 755026-89-2 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxylic acid, 10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-, 2-[(1,1-dimethylethoxy)carbonyl]hydrazide (9CI) (CA INDEX NAME)




RN 755026-90-5 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carbonitrile, 10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 755026-91-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(4-hydroxy-3-methoxyphenyl)-8-nitro- (9CI) (CA INDEX NAME)



RN 755026-92-7 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-amino-5,10-dihydro-3-(4-hydroxy-3-methoxyphenyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 755026-93-8 CAPLUS

CN Methanesulfonamide, N-[10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)




RN 755026-95-0 CAPLUS

CN Methanesulfonamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)




RN 755026-97-2 CAPLUS

CN Acetamide, N-[10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)




RN 755026-99-4 CAPLUS

CN Acetamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)




RN 755027-00-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-(3-aminophenyl)-5,10-dihydro-3-(4-hydroxy-3-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 755027-02-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(4-hydroxy-3-methoxyphenyl)-8-(3-hydroxyphenyl)- (9CI) (CA INDEX NAME)




RN 755027-04-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(4-hydroxy-3-methoxyphenyl)-8-(3-pyridinyl)- (9CI) (CA INDEX NAME)




RN 755027-06-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(4-hydroxy-3-methoxyphenyl)-8-(1H-pyrrol-2-yl)- (9CI) (CA INDEX NAME)




RN 755027-08-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-(1H-pyrrol-2-yl)- (9CI) (CA INDEX NAME)




RN 755027-10-2 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 10,11-dihydro-3-(4-hydroxy-3-methoxyphenyl)-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755027-11-3 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755027-14-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755027-15-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-(4-chloro-3-methoxyphenyl)-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 755027-17-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-(4-bromo-3-methoxyphenyl)-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 755027-19-1 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 3-(4-bromo-3-methoxyphenyl)-10,11-dihydro-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755027-20-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-(4-acetyl-3-methoxyphenyl)-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 755027-22-6 CAPLUS

CN Benzonitrile, 4-(10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-3-yl)-2-methoxy- (9CI) (CA INDEX NAME)




RN 755027-26-0 CAPLUS

CN Benzamide, 4-(10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-3-yl)-N-[(3,4-dihydroxyphenyl)methyl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 755027-27-1 CAPLUS

CN Benzamide, 4-(10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-3-yl)-2-methoxy- (9CI) (CA INDEX NAME)




RN 755027-28-2 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 10,11-dihydro-3-(5-methoxy-2-methyl-4-nitrophenyl)-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755027-29-3 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 3-(4-cyano-5-methoxy-2-methylphenyl)-10,11-dihydro-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755027-32-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(2-methoxy-4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 755027-34-0 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, 10,11-dihydro-3-(2-methoxy-4-pyridinyl)-11-oxo-N-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)



RN 755027-39-5 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, 3-(1,2-dihydro-2-oxo-4-pyridinyl)-10,11-dihydro-11-oxo-N-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)




RN 755027-40-8 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, 3-(1,2-dihydro-2-oxo-4-pyridinyl)-10,11-dihydro-11-oxo-N-[3-(1-pyrrolidinyl)propyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 755027-39-5


CMF C26 H27 N5 O3



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 755027-45-3 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)




RN 755027-46-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-[2-(dimethylamino)ethyl]-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-N-methyl-11-oxo- (9CI) (CA INDEX NAME)




RN 755027-47-5 CAPLUS

CN 3-Piperidinol, 1-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]acetyl]- (9CI) (CA INDEX NAME)




RN 755027-48-6 CAPLUS


CN 1H-1,4-Diazepine, 1-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]acetyl]hexahydro-4-methyl- (9CI) (CA INDEX NAME)




CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-N,N-dimethyl-11-oxo- (9CI) (CA INDEX NAME)




CN 4-Piperidinol, 1-[[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]acetyl]- (9CI) (CA INDEX NAME)



CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-[2-(3-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 755027-54-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-[2-(4-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 755027-55-5 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-3-quinolinyl- (9CI) (CA INDEX NAME)




RN 755027-56-6 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-6-quinolinyl- (9CI) (CA INDEX NAME)



RN 755027-57-7 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-N-[4-(4-morpholinyl)phenyl]-11-oxo- (9CI) (CA INDEX NAME)



RN 755027-58-8 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-N-[(1S)-1-(hydroxymethyl)-2-methylpropyl]-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 755027-59-9 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-N-[(1R)-1-(hydroxymethyl)-2-methylpropyl]-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 755027-60-2 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-(3-ethoxypropyl)-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)



RN 755027-61-3 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-[2-(diethylamino)ethyl]-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)



RN 755027-62-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-N-[(1R)-1-(hydroxymethyl)-3-methylbutyl]-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 755027-63-5 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-N-[(1S)-1-(hydroxymethyl)-3-methylbutyl]-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 755027-66-8 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-N-[3-(1H-imidazol-1-yl)propyl]-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 755027-67-9 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-N-(3-hydroxypropyl)-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)



RN 755027-68-0 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-[3-(diethylamino)propyl]-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)



RN 755027-69-1 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-N-[(1S)-2-hydroxy-1-phenylethyl]-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 755027-71-5 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-N-[(1R)-2-hydroxy-


1-phenylethyl]-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 755027-72-6 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-[(3,4-difluorophenyl)methyl]-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 755027-73-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-N-(4-hydroxybutyl)-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 755027-74-8 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-[1-(phenylmethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 755027-75-9 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-[4-(dimethylamino)butyl]-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 755027-76-0 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-[2-[4-(aminosulfonyl)phenyl]ethyl]-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 755027-77-1 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-N-(2-hydroxyethyl)-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-propyl- (9CI) (CA INDEX NAME)




RN 755027-78-2 CAPLUS

CN Piperazine, 1-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]acetyl]-4-ethyl- (9CI) (CA INDEX NAME)




RN 755027-79-3 CAPLUS

CN 1-Piperazineethanol, 4-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]acetyl]- (9CI) (CA INDEX NAME)




RN 755027-80-6 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-N-methyl-11-oxo-N-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 755027-81-7 CAPLUS


CN Piperazine, 1-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]acetyl]-4-phenyl- (9CI) (CA INDEX NAME)



RN 755027-82-8 CAPLUS


CN Piperazine, 1-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-

dibenzo[b,e][1,4]diazepin-8-yl]acetyl]-4-(2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 755027-83-9 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 755027-84-0 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 755027-85-1 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 755027-86-2 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-[2-(dimethylamino)ethyl]-
10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 755027-87-3 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-[3-(dimethylamino)propyl]-
10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 755027-88-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 755027-89-5 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-[2-(1-piperidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 755027-90-8 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-[3-(1-piperidinyl)propyl]- (9CI) (CA INDEX NAME)




RN 755027-91-9 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-N-[2-(4-morpholinyl)ethyl]-11-oxo- (9CI) (CA INDEX NAME)




RN 755027-92-0 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-N-[3-(4-morpholinyl)propyl]-11-oxo- (9CI) (CA INDEX NAME)



RN 755027-93-1 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-N-[2-(4-methyl-1-piperazinyl)ethyl]-11-oxo- (9CI) (CA INDEX NAME)



RN 755027-94-2 CAPLUS


CN 2-Pyrrolidinemethanol, 1-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]acetyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 755027-95-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-amino-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755027-97-5 CAPLUS

CN Urea, [10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)




RN 755027-98-6 CAPLUS

CN Acetamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-2-(dimethylamino)- (9CI) (CA INDEX NAME)




RN 755027-99-7 CAPLUS
 CN Pentanamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-2-(dimethylamino)-4-methyl-, (2S)- (9CI)
 (CA INDEX NAME)


Absolute stereochemistry.




RN 755028-01-4 CAPLUS
 CN Butanamide, 4-amino-N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)



RN 755028-02-5 CAPLUS
 CN Propanamide, 3-amino-N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)




RN 755028-03-6 CAPLUS
 CN 1H-Imidazole-5-acetamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-1-methyl- (9CI) (CA INDEX NAME)




RN 755028-04-7 CAPLUS

CN 1H-Imidazole-4-acetamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)




RN 755028-05-8 CAPLUS

CN 3-Thiophenecarboxamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)




RN 755028-06-9 CAPLUS

CN 1H-Pyrrole-2-carboxamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)




RN 755028-07-0 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 755028-08-1 CAPLUS

CN 4-Thiazolecarboxamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)




RN 755028-09-2 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)




RN 755028-10-5 CAPLUS

CN 1H-Pyrazole-4-carboxamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)




RN 755028-11-6 CAPLUS

CN 4-Pyridinecarboxamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)




RN 755028-12-7 CAPLUS

CN 1-Pyrrolidinepropanamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)




RN 755028-13-8 CAPLUS

CN 1-Piperidinepropanamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)



RN 755028-14-9 CAPLUS


CN 4-Morpholinepropanamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)



RN 755028-15-0 CAPLUS


CN Benzenebutamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-α-hydroxy-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 755028-16-1 CAPLUS

CN Propanamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-3-(phenylsulfonyl)- (9CI) (CA INDEX NAME)




RN 755028-19-4 CAPLUS

CN Acetamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-2-[[(4-methylphenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 755028-21-8 CAPLUS

CN 2-Pyridinecarboxamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)




RN 755028-22-9 CAPLUS

CN 3-Pyridinecarboxamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)




RN 755028-24-1 CAPLUS

CN 3-Pyridineacetamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)




RN 755028-25-2 CAPLUS

CN 1-Piperazineacetamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-4-methyl- (9CI) (CA INDEX NAME)



RN 755028-26-3 CAPLUS


CN Propanamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-3-ethoxy- (9CI) (CA INDEX NAME)



RN 755028-27-4 CAPLUS


CN 2-Pyrrolidinecarboxamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-5-oxo-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 755028-28-5 CAPLUS


CN Cyclohexanecarboxamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-4-methoxy- (9CI) (CA INDEX NAME)



RN 755028-29-6 CAPLUS

CN Benzeneacetamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-α-methoxy-, (αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 755028-30-9 CAPLUS


CN Benzeneacetamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-α-methoxy-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 755028-31-0 CAPLUS

CN 2-Furancarboxamide, N-[2-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)




RN 755028-32-1 CAPLUS

CN 4-Piperidinecarboxamide, 1-acetyl-N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)




RN 755028-33-2 CAPLUS

CN Pentanediamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-N'-phenyl- (9CI) (CA INDEX NAME)



RN 755028-34-3 CAPLUS


CN Benzeneacetamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-4-(methylsulfonyl)- (9CI) (CA INDEX NAME)



RN 755028-35-4 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-5-oxo-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 755028-38-7 CAPLUS


CN Benzeneacetamide, N-[3-(4-cyano-3-methoxyphenyl)-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- α -methoxy-, (α S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 755028-39-8 CAPLUS

CN 1-Piperidinepropanamide, N-[3-(4-cyano-3-methoxyphenyl)-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)




RN 755028-40-1 CAPLUS

CN Methanesulfonamide, N-[3-(4-cyano-3-methoxyphenyl)-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)




RN 755028-42-3 CAPLUS

CN 1-Piperidinepropanamide, N-[3-(4-chloro-3-methoxyphenyl)-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)




RN 755028-43-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-(2-oxo-1-pyrrolidinyl)- (9CI) (CA INDEX NAME)




RN 755028-46-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-(2-oxo-1-piperidiny)- (9CI) (CA INDEX NAME)




RN 755028-49-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-(4-chloro-3-methoxyphenyl)-5,10-dihydro-8-(2-oxo-1-pyrrolidinyl)- (9CI) (CA INDEX NAME)




RN 755028-52-5 CAPLUS

CN Benzenemethanesulfonamide, N-[3-(4-chloro-3-methoxyphenyl)-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)




RN 755028-53-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-(4-chloro-3-methoxyphenyl)-8-(1,1-dioxido-2-isothiazolidinyl)-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 755028-54-7 CAPLUS

CN Ethanesulfonamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-2,2,2-trifluoro- (9CI) (CA INDEX NAME)




RN 755028-55-8 CAPLUS

CN 1H-Imidazole-4-sulfonamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-1-methyl- (9CI) (CA INDEX NAME)




RN 755028-56-9 CAPLUS

CN Benzenemethanesulfonamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)




RN 755028-58-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-(1,1-dioxido-2-isothiazolidinyl)-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755028-59-2 CAPLUS

CN 4-Morpholinepropanesulfonamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)




RN 755028-60-5 CAPLUS

CN 1-Piperidinepropanesulfonamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)




RN 755028-61-6 CAPLUS

CN 1-Propanesulfonamide, 3-(diethylamino)-N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)




RN 755028-62-7 CAPLUS

CN 1-Propanesulfonamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-3-(dimethylamino)- (9CI) (CA INDEX NAME)




RN 755028-63-8 CAPLUS

CN Methanesulfonamide, 1-chloro-N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]- (9CI) (CA INDEX NAME)




RN 755028-64-9 CAPLUS

CN Benzamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-4-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 755028-70-7 CAPLUS

CN Benzenemethanesulfonamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]- (9CI) (CA INDEX NAME)




RN 755028-71-8 CAPLUS

CN Benzenemethanesulfonamide, 4-chloro-N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]- (9CI) (CA INDEX NAME)




RN 755028-72-9 CAPLUS

CN 1H-Imidazole-4-sulfonamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]-1-methyl- (9CI) (CA INDEX NAME)



RN 755028-73-0 CAPLUS


CN Methanesulfonamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]- (9CI) (CA INDEX NAME)



RN 755028-74-1 CAPLUS


CN 4-Morpholinepropanesulfonamide, N-[10,11-dihydro-3-(3-methoxy-4-

nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]- (9CI) (CA INDEX NAME)




RN 755028-75-2 CAPLUS

CN 1-Piperidinepropanesulfonamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]- (9CI) (CA INDEX NAME)




RN 755028-76-3 CAPLUS

CN 1-Propanesulfonamide, 3-(diethylamino)-N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]- (9CI) (CA INDEX NAME)




RN 755028-77-4 CAPLUS

CN 1-Propanesulfonamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]-3-(dimethylamino)- (9CI) (CA INDEX NAME)




RN 755028-78-5 CAPLUS

CN 2H-Pyran-4-carboxamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]tetrahydro- (9CI) (CA INDEX NAME)




RN 755028-79-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-(1-hydroxy-1-methylethyl)-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755028-81-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-(1-ethyl-1-hydroxypropyl)-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755028-83-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-(1-hydroxy-1-methylethyl)-3-(4-pyridinylamino)- (9CI) (CA INDEX NAME)




RN 755028-84-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-[(2-chloro-4-pyridinyl)amino]-5,10-dihydro-8-(1-hydroxy-1-methylethyl)- (9CI) (CA INDEX NAME)




RN 755028-86-5 CAPLUS

CN 2-Pyridinecarbonitrile, 4-[[10,11-dihydro-8-(1-hydroxy-1-methylethyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-3-yl]amino]- (9CI) (CA INDEX NAME)




RN 755028-87-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-(1-hydroxy-1-methylethyl)-3-(4-pyrimidinylamino)- (9CI) (CA INDEX NAME)




RN 755028-88-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-(1-hydroxy-1-methylethyl)-3-[(2,3,5,6-tetrafluoro-4-pyridinyl)amino]- (9CI) (CA INDEX NAME)




RN 755028-89-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-(1-ethyl-1-hydroxypropyl)-5,10-dihydro-3-(4-pyridinylamino)- (9CI) (CA INDEX NAME)




RN 755028-90-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-[(2-amino-4-pyrimidinyl)amino]-5,10-dihydro-8-(1-hydroxy-1-methylethyl)- (9CI) (CA INDEX NAME)




RN 755028-91-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-[(2-chloro-4-pyridinyl)amino]-8-(1-ethyl-1-hydroxypropyl)-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 755028-92-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-(1-hydroxy-1-methylethyl)-3-[(2,3,6-trifluoro-4-pyridinyl)amino]- (9CI) (CA INDEX NAME)




RN 755028-93-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-[[2-[(2-chloro-4-pyridinyl)amino]-4-pyridinyl]amino]-5,10-dihydro-8-(1-hydroxy-1-methylethyl)- (9CI) (CA INDEX NAME)




RN 755028-94-5 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 10,11-dihydro- α,α -dimethyl-11-oxo-3-[(2,3,6-trifluoro-4-pyridinyl)amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 755028-95-6 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro- α,α -dimethyl-N-[4-(4-morpholinyl)phenyl]-11-oxo-3-[(2,3,6-trifluoro-4-pyridinyl)amino]- (9CI) (CA INDEX NAME)




RN 755028-98-9 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 3-[(2,6-difluoro-4-pyridinyl)amino]-10,11-dihydro- α,α -dimethyl-N-[4-(4-morpholinyl)phenyl]-11-oxo- (9CI) (CA INDEX NAME)




RN 755028-99-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-[(2,6-difluoro-4-pyridinyl)amino]-5,10-dihydro-8-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)




RN 755029-01-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 3-[(2,6-difluoro-4-pyridinyl)amino]-10,11-dihydro- α,α -dimethyl-11-oxo- (9CI) (CA INDEX NAME)




RN 755029-03-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-[(2,6-difluoro-4-pyridinyl)amino]-5,10-dihydro-7-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 755029-04-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(4-morpholinyl)-3-[(2,3,6-trifluoro-4-pyridinyl)amino]- (9CI) (CA INDEX NAME)




RN 755029-05-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-[(2,6-difluoro-4-pyridinyl)amino]-5,10-dihydro-8-(2-hydroxy-2-methylpropyl)- (9CI) (CA INDEX NAME)




RN 755029-07-3 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 10,11-dihydro-11-oxo-3-(4-pyridinylamino)-, methyl ester (9CI) (CA INDEX NAME)




RN 755029-09-5 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 10,11-dihydro-3-[(2-methyl-4-pyridinyl)amino]-11-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 755029-10-8 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-[(2-chloro-4-pyridinyl)amino]-5,10-dihydro- (9CI) (CA INDEX NAME)



RN 755029-11-9 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-acetyl-3-[(2-chloro-4-

pyridinyl)amino]-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 755029-14-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-[(2-chloro-4-pyridinyl)amino]-5,10-dihydro-8-(1-methylethenyl)- (9CI) (CA INDEX NAME)




RN 755029-15-3 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 3-[(2-chloro-4-pyridinyl)amino]-10,11-dihydro-N-[4-(4-morpholinyl)phenyl]-11-oxo- (9CI) (CA INDEX NAME)




RN 755029-16-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-[(2-chloro-4-pyridinyl)amino]-5,10-dihydro-8-(2-hydroxy-2-methylpropyl)- (9CI) (CA INDEX NAME)




RN 755029-17-5 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 3-[(2-chloro-4-pyridinyl)amino]-10,11-dihydro-α,α-dimethyl-N-[4-(4-morpholinyl)phenyl]-11-oxo- (9CI) (CA INDEX NAME)




RN 755029-18-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-[(2-chloro-4-pyridinyl)amino]-5,10-dihydro-8-(2-oxo-1-pyrrolidinyl)- (9CI) (CA INDEX NAME)




RN 755029-19-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetic acid, 3-[(2-chloro-4-pyridinyl)amino]-10,11-dihydro-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755029-20-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-[2-(2-pyridinyloxy)ethyl]-3-[(2,3,6-trifluoro-4-pyridinyl)amino]- (9CI) (CA INDEX NAME)




RN 755029-22-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-(2-hydroxy-2-methylpropyl)-3-[(2,3,5-trifluorophenyl)amino]- (9CI) (CA INDEX NAME)




RN 755029-23-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-[(3,5-difluorophenyl)amino]-5,10-dihydro-7-(3-hydroxy-3-methylbutyl)-8-methoxy- (9CI) (CA INDEX NAME)




RN 755029-39-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(3-hydroxy-3-methylbutyl)-8-methoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755029-41-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-[(2,6-difluoro-4-pyridinyl)amino]-5,10-dihydro-7-(3-hydroxypropyl)-8-methoxy- (9CI) (CA INDEX NAME)




RN 755029-44-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(3-hydroxypropyl)-8-methoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755029-46-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-[(2,6-difluoro-4-pyridinyl)amino]-5,10-dihydro-8-(3-hydroxy-3-methylbutyl)- (9CI) (CA INDEX NAME)




RN 755029-54-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-(3-hydroxy-3-methylbutyl)-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755029-60-8 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-propanamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-N,N-dimethyl-11-oxo- (9CI) (CA INDEX NAME)




RN 755029-61-9 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-propanamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-N-[4-(4-morpholinyl)phenyl]-11-oxo- (9CI) (CA INDEX NAME)




RN 755029-63-1 CAPLUS

CN Azetidine, 1-[3-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-1-oxopropyl]- (9CI) (CA INDEX NAME)




RN 755029-64-2 CAPLUS

CN Pyrrolidine, 1-[3-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-1-oxopropyl]- (9CI) (CA INDEX NAME)




RN 755029-65-3 CAPLUS

CN Morpholine, 4-[3-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-1-oxopropyl]- (9CI) (CA INDEX NAME)




RN 755029-66-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-propanamide, N,N-diethyl-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755029-67-5 CAPLUS

CN 4-Piperidinol, 1-[3-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-1-oxopropyl]- (9CI) (CA INDEX NAME)




RN 755029-68-6 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-propanamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-2-thiazolyl- (9CI) (CA INDEX NAME)




RN 755029-72-2 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-propanoic acid, 3-(4-chloro-3-methoxyphenyl)-10,11-dihydro-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755029-74-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-propanamide, 3-(4-chloro-3-methoxyphenyl)-10,11-dihydro-N,N-dimethyl-11-oxo- (9CI) (CA INDEX NAME)




RN 755029-78-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-(4-chloro-3-methoxyphenyl)-5,10-dihydro-8-(3-hydroxy-3-methylbutyl)- (9CI) (CA INDEX NAME)




RN 755029-80-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-(3-methyl-1,2,4-oxadiazol-5-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 755029-83-5 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-propanoic acid, 10,11-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755029-85-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(2-hydroxy-2-methylpropyl)-8-methoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755030-04-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-7-(2-oxopropyl)- (9CI) (CA INDEX NAME)




RN 755030-06-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(2-hydroxy-1,1-dimethylethyl)-8-methoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755030-15-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(3-hydroxypropyl)-3-(3-methoxy-4-nitrophenyl)-8-(trifluoromethoxy)- (9CI) (CA INDEX NAME)




RN 755030-28-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(3-hydroxy-3-methylbutyl)-3-(3-methoxy-4-nitrophenyl)-8-(trifluoromethoxy)- (9CI) (CA INDEX NAME)




RN 755030-31-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(3-hydroxy-3-methylbutyl)-3-(3-methoxy-4-nitrophenyl)-8-methyl- (9CI) (CA INDEX NAME)




RN 755030-48-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-(4-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 755030-53-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 755030-60-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-(2-oxo-1(2H)-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 755030-62-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-[2-(5-fluoro-2-oxo-1(2H)-pyridinyl)ethyl]-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755030-63-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-(6-oxo-1(6H)-pyridazinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 755030-65-0 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-(2-pyridinyloxy)ethyl]- (9CI) (CA INDEX NAME)



RN 755030-66-1 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-[2-[(5-chloro-3-pyridinyl)oxy]ethyl]-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)

INDEX NAME)




RN 755030-67-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-7-[2-(3-pyridinyloxy)ethyl]- (9CI) (CA INDEX NAME)



RN 755030-69-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 10,11-dihydro-3-(5-isoquinolinyl)-11-oxo-, methyl ester (9CI) (CA INDEX NAME)



IT 755030-71-8P 755030-73-0P 755030-75-2P

755030-77-4P 755030-80-9P 755030-91-2P

755030-97-8P 755030-99-0P 755031-01-7P

755031-03-9P 755031-05-1P 755031-07-3P

755031-10-8P 755031-12-0P 755031-15-3P

755031-16-4P 755031-17-5P 755031-19-7P

755031-20-0P 755031-24-4P 755031-31-3P

755031-33-5P 755031-35-7P 755031-36-8P,

7-(3-Hydroxypropyl)-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755031-43-7P,

7-(3-Hydroxy-3-methylbutyl)-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755031-45-9P,

8-(2-Hydroxy-1,1-dimethylethyl)-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755031-47-1P,

8-(2-Hydroxy-1,1,2-trimethylpropyl)-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 755031-49-3P,

8-(1,1-Dimethyl-2-oxopropyl)-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755031-51-7P**,
 7-(2-Hydroxy-1,1-dimethylethyl)-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755031-52-8P**,
 8-[1-(Hydroxymethyl)cyclopropyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755031-53-9P**,
 3-[(2-Chloropyridin-4-yl)amino]-8-(2-hydroxy-1,1-dimethylethyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755031-54-0P**,
 3-[(2,6-Difluoropyridin-4-yl)amino]-8-(2-hydroxy-1,1-dimethylethyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755031-55-1P**,
 3-[(2,6-Difluoropyridin-4-yl)amino]-8-(2-hydroxy-1,1,2-trimethylpropyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755031-57-3P**,
 3-(4-Chloro-3-methoxyphenyl)-8-(2-hydroxy-1,1-dimethylethyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755031-58-4P**,
 3-(3-Methoxy-4-nitrophenyl)-8-[2-[[4-(morpholin-4-yl)phenyl]oxy]ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755031-60-8P**,
 3-(4-Chloro-3-methoxyphenyl)-8-[2-[[4-(morpholin-4-yl)phenyl]oxy]ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755031-61-9P**
755031-62-0P, 3-(3-Methoxy-4-nitrophenyl)-8-[2-[[4-(morpholin-4-yl)phenyl]amino]ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755031-65-3P** **755031-67-5P**, 3-(3-Methoxy-4-nitrophenyl)-8-[2-[[5-methylpyridin-2-yl]oxy]ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755031-68-6P**
755031-69-7P, 8-[2-(Isoquinolin-3-yloxy)ethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755031-70-0P** **755031-71-1P**, 8-[1,1-Dimethyl-2-(pyridin-2-yloxy)ethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755031-73-3P**,
 8-[1,1-Dimethyl-2-[[4-(morpholin-4-yl)phenyl]oxy]ethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755031-77-7P** **755031-78-8P**, 8-(2-Hydroxy-1,1-dimethylethyl)-3-(3-methoxy-4-nitrophenyl)-7-methyl-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755031-79-9P**
755031-87-9P **755031-89-1P** **755031-91-5P**,
 8-(2-Hydroxy-1,1-dimethylethyl)-3-[(2-methylpyridin-4-yl)amino]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755031-92-6P**,
 8-(2-Hydroxy-1,1,2-trimethylpropyl)-3-[(pyrimidin-4-yl)amino]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755031-93-7P**
755031-94-8P **755031-95-9P** **755031-96-0P**
755031-97-1P **755031-98-2P** **755031-99-3P**
755032-00-9P **755032-01-0P** **755032-02-1P**
755032-03-2P **755032-04-3P** **755032-05-4P**
755032-06-5P **755032-07-6P** **755032-08-7P**
755032-09-8P **755032-10-1P** **755032-11-2P**
755032-12-3P **755032-13-4P** **755032-14-5P**
755032-15-6P **755032-17-8P** **755032-18-9P**,
 8-[1,1-Dimethyl-2-oxo-2-(4-phenylpiperazin-1-yl)ethyl]-3-[(pyrimidin-4-yl)amino]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755032-19-0P** **755032-20-3P**, 8-[1,1-Dimethyl-2-(morpholin-4-yl)-2-oxoethyl]-3-[(pyrimidin-4-yl)amino]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755032-21-4P**
755032-22-5P **755032-23-6P** **755032-24-7P**
755032-25-8P **755032-26-9P** **755032-27-0P**
755032-28-1P **755032-29-2P**, 3-(3-Methoxy-4-nitrophenyl)-8-[2-[(quinolin-2-yl)oxy]ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755032-30-5P** **755032-31-6P** **755032-32-7P**
755032-33-8P **755032-34-9P** **755032-35-0P**,
 3-(3-Methoxy-4-nitrophenyl)-8-[2-[(4-methylpyridin-2-yl)oxy]ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755032-36-1P**,
 3-(3-Methoxy-4-nitrophenyl)-8-[2-[(3-methoxypyridin-2-yl)oxy]ethyl]-5,10-

dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755032-37-2P**
755032-38-3P, 8-[2-[(6-Chloropyridin-2-yl)oxy]ethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755032-39-4P, 8-[2-[(5-Chloropyridin-2-yl)oxy]ethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755032-42-9P 755032-43-0P 755032-45-2P,
 8-[2-(3-Aminopyrrolidin-1-yl)-2-oxoethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755032-46-3P**,
 8-[2-(3-Aminopyrrolidin-1-yl)-2-oxoethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one trifluoroacetate
755032-48-5P 755032-49-6P, (S)-8-[2-[2-(Hydroxymethyl)pyrrolidin-1-yl]-2-oxoethyl]-3-(2-methoxy-5-methylpyridin-4-yl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755032-50-9P**
755032-51-0P 755032-52-1P 755032-53-2P,
 3-(4-Chloro-3-methoxyphenyl)-8-[2-(3-hydroxypiperidin-1-yl)-2-oxoethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755032-54-3P**,
 (S)-3-(4-Chloro-3-methoxyphenyl)-8-[2-[2-(hydroxymethyl)pyrrolidin-1-yl]-2-oxoethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755032-55-4P 755032-57-6P, 3-(3-Methoxy-4-nitrophenyl)-8-[2-oxo-2-(piperazin-1-yl)ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755032-59-8P 755032-60-1P 755032-61-2P**
 , 3-(3-Methoxy-4-nitrophenyl)-8-[2-(morpholin-4-yl)-2-oxoethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755032-62-3P**,
 3-(2-Methoxy-5-methylpyridin-4-yl)-8-[2-(morpholin-4-yl)-2-oxoethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755032-63-4P**
755032-65-6P 755032-67-8P, 8-[2-(Morpholin-4-yl)-2-oxoethyl]-3-(2-oxo-1,2-dihydropyridin-4-yl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755032-69-0P**
755032-71-4P 755032-75-8P, 3-(3-Methoxy-4-nitrophenyl)-7-[2-(morpholin-4-yl)-2-oxoethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755032-76-9P 755032-77-0P 755032-78-1P**
755032-79-2P, 7-[2-(4-Hydroxypiperidin-1-yl)-2-oxoethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755032-80-5P, 7-[2-(3-Hydroxypiperidin-1-yl)-2-oxoethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755032-81-6P 755032-82-7P 755032-83-8P
755032-84-9P, 7-[2-(Azetidin-1-yl)-2-oxoethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755032-85-0P 755032-86-1P 755032-87-2P,
 (R)-7-[2-[2-(Hydroxymethyl)pyrrolidin-1-yl]-2-oxoethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755032-88-3P 755032-89-4P 755032-90-7P
755032-91-8P 755032-92-9P, (S)-7-[2-[2-(Hydroxymethyl)pyrrolidin-1-yl]-2-oxoethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755032-93-0P**,
 7-[2-(3-Aminopyrrolidin-1-yl)-2-oxoethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755032-94-1P**,
 3-(3-Methoxy-4-nitrophenyl)-7-[2-oxo-2-(piperazin-1-yl)ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755032-95-2P**
755032-96-3P 755032-97-4P 755032-99-6P
755033-01-3P, 3-(3-Methoxy-4-nitrophenyl)-7-[2-oxo-2-(4-thiomorpholinyl)ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755033-03-5P 755033-04-6P 755033-05-7P
755033-06-8P 755033-07-9P 755033-08-0P
755033-09-1P 755033-10-4P, 7-[2-(1,4-Dioxo-8-azaspiro[4.5]decan-8-yl)-2-oxoethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755033-11-5P**,
 7-[2-(2,6-Dimethylmorpholin-4-yl)-2-oxoethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755033-12-6P**,
 7-[2-(4-Acetylpiperazin-1-yl)-2-oxoethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-

dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755033-13-7P**,
 3-(3-Methoxy-4-nitrophenyl)-7-[2-oxo-2-[4-(pyridin-2-yl)piperazin-1-yl]ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755033-14-8P 755033-15-9P 755033-16-0P
755033-17-1P 755033-18-2P 755033-19-3P
755033-20-6P 755033-21-7P 755033-22-8P
755033-23-9P 755033-24-0P 755033-25-1P
755033-26-2P 755033-27-3P 755033-28-4P
755033-29-5P, 8-Hydroxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755033-30-8P**,
 8-Methoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755033-34-2P**,
 8-Ethoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755033-35-3P**,
 3-(3-Methoxy-4-nitrophenyl)-8-[2-(4-methyl-1,3-thiazol-5-yl)ethoxy]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755033-37-5P**,
 8-[3-(Dimethylamino)propoxy]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755033-38-6P**,
 3-(3-Methoxy-4-nitrophenyl)-8-[2-(morpholin-4-yl)ethoxy]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755033-39-7P**,
 3-(3-Methoxy-4-nitrophenyl)-8-[2-[4-(morpholin-4-yl)phenyl]ethoxy]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755033-41-1P**,
 3-(3-Methoxy-4-nitrophenyl)-7-(piperidin-1-yl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755033-43-3P**,
 (S)-7-[2-(Hydroxymethyl)pyrrolidin-1-yl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755033-46-6P**,
 3-(3-Methoxy-4-nitrophenyl)-7-(morpholin-4-yl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755033-48-8P**,
 7-(4-Hydroxypiperidin-1-yl)-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755033-54-6P**
755033-59-1P, 8-(2-Ethyl-2-hydroxybutyl)-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755033-65-9P, 3-[(2-Chloropyridin-4-yl)amino]-8-(2-ethyl-2-hydroxybutyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755033-68-2P 755033-75-1P 755033-79-5P,
 8-(2-Hydroxy-2-methylpropyl)-3-[(pyrimidin-4-yl)amino]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755033-81-9P**,
 8-(2-Hydroxy-2-methylpropyl)-3-[(2-methylpyridin-4-yl)amino]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755033-83-1P**,
 3-(3-Methoxy-4-nitrophenyl)-8-(2-oxopropyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755033-87-5P**,
 3-[(2-Chloropyridin-4-yl)amino]-8-(2-oxopropyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755033-89-7P**,
 3-[[2-[(2-Chloropyridin-4-yl)amino]pyridin-4-yl]amino]-8-(2-oxopropyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755033-92-2P**
755033-93-3P 755033-96-6P, 3-[[3-(2-Hydroxyethyl)pyridin-4-yl]amino]-8-(1-hydroxy-1-methylethyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755034-00-5P**,
 8-(2-Hydroxy-2-methylpropyl)-3-[(2-methoxypyridin-4-yl)amino]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755034-02-7P**, Methyl
 11-oxo-3-(pyrimidin-4-ylamino)-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-7-carboxylate **755034-08-3P**, 7-(1-Hydroxy-1-methylethyl)-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755034-11-8P, 7-(1-Hydroxy-1-methylethyl)-3-[(pyrimidin-4-yl)amino]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755034-12-9P 755034-14-1P, 3-(3-Methoxy-4-nitrophenyl)-8-[2-[[6-(morpholin-4-yl)pyridin-3-yl]oxy]ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755034-18-5P**,
 3-(4-Hydroxy-3-methoxyphenyl)-8-[2-[[4-(morpholin-4-yl)phenyl]oxy]ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755034-20-9P**,


3-[(2,6-Difluoropyridin-4-yl)amino]-8-[2-[[4-(morpholin-4-yl)phenyl]oxy]ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755034-29-8P, 8-Hydroxy-7-methoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755034-38-9P**,
 8-Methoxy-3-(3-methoxy-4-nitrophenyl)-7-[(tetrahydro-2H-pyran-2-yl)methoxy]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755034-39-0P, 8-Methoxy-3-(3-methoxy-4-nitrophenyl)-7-[(1-methylpiperidin-3-yl)methoxy]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755034-40-3P**,
 8-Methoxy-3-(3-methoxy-4-nitrophenyl)-7-[(pyridin-2-yl)methoxy]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755034-41-4P, 8-Methoxy-3-(3-methoxy-4-nitrophenyl)-7-[(pyridin-3-yl)methoxy]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755034-42-5P, 8-Methoxy-3-(3-methoxy-4-nitrophenyl)-7-[(pyridin-4-yl)methoxy]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755034-43-6P 755034-44-7P 755034-45-8P,
 8-Methoxy-3-(3-methoxy-4-nitrophenyl)-7-[(2-methyl-1,3-thiazol-4-yl)methoxy]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755034-46-9P, 8-Methoxy-3-(3-methoxy-4-nitrophenyl)-7-[(2-oxo-1,3-oxazolidin-5-yl)methoxy]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755034-48-1P, 8-Methoxy-3-(3-methoxy-4-nitrophenyl)-7-[(tetrahydrofuran-2-yl)methoxy]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755034-49-2P, 7-[(2,2-Dimethyl-1,3-dioxolan-4-yl)methoxy]-8-methoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755034-50-5P**,
 (R)-8-Methoxy-3-(3-methoxy-4-nitrophenyl)-7-[(pyrrolidin-2-yl)methoxy]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755034-51-6P**
755034-52-7P, 7,8-Dimethoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755034-53-8P**,
 8-Methoxy-7-[2-(2-methoxyethoxy)ethoxy]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755034-54-9P**,
 7-(2,3-Dihydroxypropoxy)-8-methoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755034-55-0P**,
 7-[3-Hydroxy-2,2-bis(hydroxymethyl)propoxy]-8-methoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755034-56-1P 755034-57-2P, 7-(3-Aminopropoxy)-8-methoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755034-58-3P, 7-(3-Aminopropoxy)-8-methoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
 trifluoroacetate **755034-59-4P**, 7-[2-(Dimethylamino)ethoxy]-8-methoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755034-61-8P**,
 8-Methoxy-3-(3-methoxy-4-nitrophenyl)-7-[2-(pyrrolidin-1-yl)ethoxy]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755034-63-0P**,
 8-Methoxy-3-(3-methoxy-4-nitrophenyl)-7-[2-(morpholin-4-yl)ethoxy]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755034-64-1P**,
 7-(4-Hydroxybutoxy)-8-methoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755034-65-2P**,
 7-(4-Hydroxybutoxy)-3-(4-hydroxy-3-methoxyphenyl)-8-methoxy-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755034-69-6P**,
 7-(4-Hydroxybutoxy)-8-methoxy-3-[(pyrimidin-4-yl)amino]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755034-70-9P**
755034-71-0P, 3-[(2,6-Difluoropyridin-4-yl)amino]-7-(4-hydroxybutoxy)-8-methoxy-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755034-72-1P, 7-(4-Hydroxybutoxy)-8-methoxy-3-[(2,3,6-trifluoropyridin-4-yl)amino]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755034-73-2P, 7-Ethoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(kinase inhibitor; preparation of dibenzo[b,e][1,4]diazepin-11-ones as kinase inhibitors for treatment of cancer)


RN 755030-71-8 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 10,11-dihydro-3-(8-nitro-5-isoquinolinyl)-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755030-73-0 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-propanoic acid, 3-(4-formyl-3-methoxyphenyl)-10,11-dihydro-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755030-75-2 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-propanoic acid, 10,11-dihydro-3-[4-(hydroxymethyl)-3-methoxyphenyl]-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755030-77-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-propanoic acid, 10,11-dihydro-3-[3-methoxy-4-(1-oxopropyl)phenyl]-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755030-80-9 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-α,α-dimethyl-N-[4-(4-morpholinyl)phenyl]-11-oxo- (9CI) (CA INDEX NAME)




RN 755030-91-2 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 3-(4-cyano-3-methoxyphenyl)-10,11-dihydro-α,α-dimethyl-N-[4-(4-morpholinyl)phenyl]-11-oxo- (9CI) (CA INDEX NAME)




RN 755030-97-8 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 3-(4-chloro-3-methoxyphenyl)-10,11-dihydro-α,α-dimethyl-N-[4-(4-morpholinyl)phenyl]-11-oxo- (9CI) (CA INDEX NAME)




RN 755030-99-0 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-α,α-dimethyl-11-oxo-N-2-pyridinyl- (9CI) (CA INDEX NAME)




RN 755031-01-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-α,α-dimethyl-11-oxo-N-3-pyridinyl- (9CI) (CA INDEX NAME)




RN 755031-03-9 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-α,α-dimethyl-11-oxo-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 755031-05-1 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-α,α-dimethyl-11-oxo-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 755031-07-3 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-α,α-dimethyl-11-oxo-N-[(tetrahydro-3-furanyl)methyl]- (9CI) (CA INDEX NAME)




RN 755031-10-8 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-α,α-dimethyl-11-oxo-N-2-thiazolyl- (9CI) (CA INDEX NAME)



RN 755031-12-0 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-α,α-dimethyl-11-oxo-N-[[6-(trifluoromethyl)-3-pyridinyl]methyl]- (9CI) (CA INDEX NAME)



RN 755031-15-3 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-(4-fluorophenyl)-10,11-

dihydro-3-(3-methoxy-4-nitrophenyl)- α,α -dimethyl-11-oxo- (9CI)
(CA INDEX NAME)




RN 755031-16-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-[(2,5-difluorophenyl)methyl]-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- α,α -dimethyl-11-oxo- (9CI) (CA INDEX NAME)




RN 755031-17-5 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro- α,α -dimethyl-11-oxo-3-(4-pyrimidinylamino)-N-[[3-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 755031-19-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro- α,α -dimethyl-11-oxo-3-(4-pyrimidinylamino)-N-[[3-(trifluoromethoxy)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 755031-20-0 CAPLUS

CN Cyclopropanecarboxamide, 1-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-N-[4-(4-morpholinyl)phenyl]- (9CI)
(CA INDEX NAME)




RN 755031-24-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- α,α -dimethyl-N-[4-(4-morpholinyl)phenyl]-11-oxo- (9CI) (CA INDEX NAME)




RN 755031-31-3 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- α,α -dimethyl-11-oxo-N-(2-pyridinylmethyl)- (9CI)
(CA INDEX NAME)




RN 755031-33-5 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- α,α -dimethyl-11-oxo-N-(2-thienylmethyl)- (9CI)
(CA INDEX NAME)




RN 755031-35-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, N-(cyclopropylmethyl)-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- α,α -dimethyl-11-oxo- (9CI)
(CA INDEX NAME)




RN 755031-36-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(3-hydroxypropyl)-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755031-43-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(3-hydroxy-3-methylbutyl)-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755031-45-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-(2-hydroxy-1,1-dimethylethyl)-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755031-47-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-(2-hydroxy-1,1,2-trimethylpropyl)-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755031-49-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-(1,1-dimethyl-2-oxopropyl)-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755031-51-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(2-hydroxy-1,1-dimethylethyl)-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755031-52-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-[1-(hydroxymethyl)cyclopropyl]-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755031-53-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-[(2-chloro-4-pyridinyl)amino]-5,10-dihydro-8-(2-hydroxy-1,1-dimethylethyl)- (9CI) (CA INDEX NAME)




RN 755031-54-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-[(2,6-difluoro-4-pyridinyl)amino]-5,10-dihydro-8-(2-hydroxy-1,1-dimethylethyl)- (9CI) (CA INDEX NAME)



RN 755031-55-1 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-[(2,6-difluoro-4-pyridinyl)amino]-5,10-dihydro-8-(2-hydroxy-1,1,2-trimethylpropyl)- (9CI) (CA INDEX NAME)



RN 755031-57-3 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-(4-chloro-3-methoxyphenyl)-5,10-

dihydro-8-(2-hydroxy-1,1-dimethylethyl)- (9CI) (CA INDEX NAME)




RN 755031-58-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-[4-(4-morpholinyl)phenoxy]ethyl]- (9CI) (CA INDEX NAME)




RN 755031-60-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-(4-chloro-3-methoxyphenyl)-5,10-dihydro-8-[2-[4-(4-morpholinyl)phenoxy]ethyl]- (9CI) (CA INDEX NAME)




RN 755031-61-9 CAPLUS

CN Benzonitrile, 4-[10,11-dihydro-8-[2-[4-(4-morpholinyl)phenoxy]ethyl]-11-oxo-5H-dibenzo[b,e][1,4]diazepin-3-yl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 755031-62-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-[[4-(4-morpholinyl)phenyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 755031-65-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-(3-methyl-2-oxo-1(2H)-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 755031-67-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-[(5-methyl-2-pyridinyl)oxy]ethyl]- (9CI) (CA INDEX NAME)




RN 755031-68-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-(4-methyl-2-oxo-1(2H)-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 755031-69-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-[2-(3-isoquinolinyloxy)ethyl]-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755031-70-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-[2-(5-chloro-2-oxo-1(2H)-pyridinyl)ethyl]-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755031-71-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-[1,1-dimethyl-2-(2-pyridinyloxy)ethyl]-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755031-73-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-[1,1-dimethyl-2-[4-(4-morpholinyl)phenoxy]ethyl]-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755031-77-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- α,α -dimethyl-11-oxo-N-[(tetrahydro-2-furanyl)methyl]- (9CI) (CA INDEX NAME)




RN 755031-78-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-(2-hydroxy-1,1-dimethylethyl)-3-(3-methoxy-4-nitrophenyl)-7-methyl- (9CI) (CA INDEX NAME)




RN 755031-79-9 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-2-methyl-N-[4-(4-morpholinyl)phenyl]-11-oxo- (9CI) (CA INDEX NAME)




RN 755031-87-9 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 3-[4-(aminomethyl)-3-methoxyphenyl]-10,11-dihydro-11-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 755031-89-1 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(2-methoxy-5-methyl-4-pyridinyl)-α,α-dimethyl-N-[4-(4-morpholinyl)phenyl]-11-oxo-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl


RN 755031-91-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-(2-hydroxy-1,1-dimethylethyl)-3-[(2-methyl-4-pyridinyl)amino]- (9CI) (CA INDEX NAME)




RN 755031-92-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-(2-hydroxy-1,1,2-trimethylpropyl)-3-(4-pyrimidinylamino)- (9CI) (CA INDEX NAME)




RN 755031-93-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-N-methyl-11-oxo-N-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)




RN 755031-94-8 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- α,α -dimethyl-11-oxo-N-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)




RN 755031-95-9 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- α,α -dimethyl-11-oxo-N-4-pyrimidinyl- (9CI) (CA INDEX NAME)




RN 755031-96-0 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- α,α -dimethyl-N-(4-methyl-2-thiazolyl)-11-oxo- (9CI) (CA INDEX NAME)




CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- α,α -dimethyl-11-oxo-N-(2,2,2-trifluoroethyl)-(9CI) (CA INDEX NAME)




CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-(3-fluorophenyl)-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- α,α -dimethyl-11-oxo- (9CI)
(CA INDEX NAME)



CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- α,α -dimethyl-11-oxo-N-[4-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)




CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- α,α -dimethyl-11-oxo-N-[3-(trifluoromethyl)phenyl]-
(9CI) (CA INDEX NAME)




RN 755032-01-0 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- α,α -dimethyl-11-oxo-N-[3-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 755032-02-1 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-[[3-fluoro-5-(trifluoromethyl)phenyl)methyl]-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- α,α -dimethyl-11-oxo- (9CI) (CA INDEX NAME)




RN 755032-03-2 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-[(2-fluorophenyl)methyl]-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- α,α -dimethyl-11-oxo- (9CI) (CA INDEX NAME)




RN 755032-04-3 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-[(3-fluorophenyl)methyl]-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- α,α -dimethyl-11-oxo- (9CI) (CA INDEX NAME)




RN 755032-05-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-[(4-fluorophenyl)methyl]-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-α,α-dimethyl-11-oxo- (9CI) (CA INDEX NAME)




RN 755032-06-5 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-α,α-dimethyl-11-oxo-N-[[4-(trifluoromethoxy)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 755032-07-6 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-α,α-dimethyl-11-oxo-N-[[3-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 755032-08-7 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-α,α-dimethyl-11-oxo-N-[[4-

(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 755032-09-8 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-α,α-dimethyl-11-oxo-N-[[3-(trifluoromethoxy)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 755032-10-1 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-[2-(2-fluorophenyl)ethyl]-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-α,α-dimethyl-11-oxo- (9CI) (CA INDEX NAME)




RN 755032-11-2 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-[2-(3-fluorophenyl)ethyl]-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-α,α-dimethyl-11-oxo- (9CI) (CA INDEX NAME)




RN 755032-12-3 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-[(2,4-difluorophenyl)methyl]-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- α,α -dimethyl-11-oxo- (9CI) (CA INDEX NAME)




RN 755032-13-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-[(2,6-difluorophenyl)methyl]-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- α,α -dimethyl-11-oxo- (9CI) (CA INDEX NAME)




RN 755032-14-5 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-(cyclopropylmethyl)-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- α,α -dimethyl-11-oxo- (9CI) (CA INDEX NAME)




RN 755032-15-6 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-(3-ethoxypropyl)-10,11-dihydro- α,α -dimethyl-11-oxo-3-(4-pyrimidinylamino)- (9CI) (CA INDEX NAME)




RN 755032-17-8 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-[(3,4-difluorophenyl)methyl]-10,11-dihydro-α,α-dimethyl-11-oxo-3-(4-pyrimidinylamino)- (9CI) (CA INDEX NAME)




RN 755032-18-9 CAPLUS

CN Piperazine, 1-[2-[10,11-dihydro-11-oxo-3-(4-pyrimidinylamino)-5H-dibenzo[b,e][1,4]diazepin-8-yl]-2-methyl-1-oxopropyl]-4-phenyl- (9CI) (CA INDEX NAME)



RN 755032-19-0 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-cyclopentyl-10,11-dihydro-α,α-dimethyl-11-oxo-3-(4-pyrimidinylamino)- (9CI) (CA INDEX NAME)



RN 755032-20-3 CAPLUS


CN Morpholine, 4-[2-[10,11-dihydro-11-oxo-3-(4-pyrimidinylamino)-5H-dibenzo[b,e][1,4]diazepin-8-yl]-2-methyl-1-oxopropyl]- (9CI) (CA INDEX NAME)

NAME)




RN 755032-21-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro- α,α -dimethyl-11-oxo-3-(4-pyrimidinylamino)-N-[(tetrahydro-3-furanyl)methyl]- (9CI) (CA INDEX NAME)




RN 755032-22-5 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-(cyclopentylmethyl)-10,11-dihydro- α,α -dimethyl-11-oxo-3-(4-pyrimidinylamino)- (9CI) (CA INDEX NAME)




RN 755032-23-6 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-(cyclopropylmethyl)-10,11-dihydro- α,α -dimethyl-11-oxo-3-(4-pyrimidinylamino)- (9CI) (CA INDEX NAME)




RN 755032-24-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro- α,α -dimethyl-11-oxo-3-(4-pyrimidinylamino)-N-[(tetrahydro-2-furanyl)methyl]-(9CI) (CA INDEX NAME)




RN 755032-25-8 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro- α,α -dimethyl-11-oxo-3-(4-pyrimidinylamino)-N-2-thiazolyl- (9CI) (CA INDEX NAME)




RN 755032-26-9 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, N-[(2,5-difluorophenyl)methyl]-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- α,α -dimethyl-11-oxo- (9CI) (CA INDEX NAME)




RN 755032-27-0 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, N-(2-ethoxyethyl)-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)- α,α -dimethyl-11-oxo- (9CI) (CA INDEX NAME)




RN 755032-28-1 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, N-(4-fluorophenyl)-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-α,α-dimethyl-11-oxo- (9CI)
(CA INDEX NAME)




RN 755032-29-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-(2-quinolinylloxy)ethyl]- (9CI) (CA INDEX NAME)



RN 755032-30-5 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-(5-methyl-2-oxo-1(2H)-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 755032-31-6 CAPLUS

CN 3-Pyridinecarbonitrile, 2-[2-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-


oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]ethoxy]-6-methyl- (9CI) (CA INDEX NAME)




RN 755032-32-7 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-(1-oxo-2(1H)-isoquinolinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 755032-33-8 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-[2-oxo-5-(trifluoromethyl)-1(2H)-pyridinyl]ethyl]- (9CI) (CA INDEX NAME)




RN 755032-34-9 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-(3-methoxy-2-oxo-1(2H)-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 755032-35-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-[(4-methyl-2-pyridinyl)oxy]ethyl]- (9CI) (CA INDEX NAME)




RN 755032-36-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-[(3-methoxy-2-pyridinyl)oxy]ethyl]- (9CI) (CA INDEX NAME)




RN 755032-37-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-(3-oxo-2(3H)-isoquinolinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 755032-38-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-[2-[(6-chloro-2-pyridinyl)oxy]ethyl]-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755032-39-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-[2-[(5-chloro-2-pyridinyl)oxy]ethyl]-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755032-42-9 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 3-(4-acetyl-3-methoxyphenyl)-10,11-dihydro-11-oxo- (9CI) (CA INDEX NAME)




RN 755032-43-0 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 3-(4-chloro-3-methoxyphenyl)-10,11-dihydro-N,N-dimethyl-11-oxo- (9CI) (CA INDEX NAME)



RN 755032-45-2 CAPLUS

CN 3-Pyrrolidinamine, 1-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]acetyl]- (9CI) (CA INDEX NAME)




RN 755032-46-3 CAPLUS

CN 3-Pyrrolidinamine, 1-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]acetyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 755032-45-2


CMF C26 H25 N5 O5



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 755032-48-5 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(2-methoxy-5-methyl-4-pyridinyl)-N,N-dimethyl-11-oxo- (9CI) (CA INDEX NAME)



RN 755032-49-6 CAPLUS


CN 2-Pyrrolidinemethanol, 1-[[[10,11-dihydro-3-(2-methoxy-5-methyl-4-pyridinyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]acetyl]-, (2S)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 755032-50-9 CAPLUS

CN Carbamic acid, [1-[[[10,11-dihydro-3-(2-methoxy-5-methyl-4-pyridinyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]acetyl]-3-pyrrolidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 755032-51-0 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, N-[2-[4-(aminosulfonyl)phenyl]ethyl]-3-(4-chloro-3-methoxyphenyl)-10,11-dihydro-11-oxo- (9CI) (CA INDEX NAME)




RN 755032-52-1 CAPLUS

CN Carbamic acid, [1-[[[3-(4-chloro-3-methoxyphenyl)-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]acetyl]-3-pyrrolidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 755032-53-2 CAPLUS


CN 3-Piperidinol, 1-[[[3-(4-chloro-3-methoxyphenyl)-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]acetyl]- (9CI) (CA INDEX NAME)



RN 755032-54-3 CAPLUS


CN 2-Pyrrolidinemethanol, 1-[[[3-(4-chloro-3-methoxyphenyl)-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]acetyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 755032-55-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 3-(4-chloro-3-methoxyphenyl)-10,11-dihydro-N-[4-(4-morpholinyl)phenyl]-11-oxo- (9CI) (CA INDEX NAME)




RN 755032-57-6 CAPLUS

CN Piperazine, 1-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]acetyl]- (9CI) (CA INDEX NAME)




RN 755032-59-8 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 3-(4-cyano-3-methoxyphenyl)-10,11-dihydro-N-[4-(4-morpholinyl)phenyl]-11-oxo- (9CI) (CA INDEX NAME)




RN 755032-60-1 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-N-methyl-11-oxo- (9CI) (CA INDEX NAME)



RN 755032-61-2 CAPLUS


CN Morpholine, 4-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]acetyl]- (9CI) (CA INDEX NAME)



RN 755032-62-3 CAPLUS


CN Morpholine, 4-[[10,11-dihydro-3-(2-methoxy-5-methyl-4-pyridinyl)-11-oxo-5H-

dibenzo[b,e][1,4]diazepin-8-yl]acetyl]- (9CI) (CA INDEX NAME)




RN 755032-63-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 3-(2-fluoro-4-pyridinyl)-10,11-dihydro-11-oxo- (9CI) (CA INDEX NAME)




RN 755032-65-6 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 3-(1,2-dihydro-2-oxo-4-pyridinyl)-10,11-dihydro-N,N-dimethyl-11-oxo- (9CI) (CA INDEX NAME)



RN 755032-67-8 CAPLUS


CN Morpholine, 4-[[3-(1,2-dihydro-2-oxo-4-pyridinyl)-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]acetyl]- (9CI) (CA INDEX NAME)



RN 755032-69-0 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 3-(1,2-dihydro-2-oxo-4-

pyridinyl)-10,11-dihydro-N-[4-(4-morpholinyl)phenyl]-11-oxo- (9CI) (CA INDEX NAME)




RN 755032-71-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 3-(1,2-dihydro-2-oxo-4-pyridinyl)-10,11-dihydro-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755032-75-8 CAPLUS

CN Morpholine, 4-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]acetyl]- (9CI) (CA INDEX NAME)




RN 755032-76-9 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-2-pyridinyl- (9CI) (CA INDEX NAME)




RN 755032-77-0 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-3-pyridinyl- (9CI) (CA INDEX NAME)




RN 755032-78-1 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 755032-79-2 CAPLUS

CN 4-Piperidinol, 1-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]acetyl]- (9CI) (CA INDEX NAME)




RN 755032-80-5 CAPLUS

CN 3-Piperidinol, 1-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]acetyl]- (9CI) (CA INDEX NAME)




RN 755032-81-6 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 755032-82-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 755032-83-8 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 755032-84-9 CAPLUS

CN Azetidine, 1-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]acetyl]- (9CI) (CA INDEX NAME)




RN 755032-85-0 CAPLUS

CN 3-Piperidinecarboxamide, 1-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]acetyl]- (9CI) (CA INDEX NAME)



RN 755032-86-1 CAPLUS


CN 4-Piperidinecarboxamide, 1-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]acetyl]- (9CI) (CA INDEX NAME)



RN 755032-87-2 CAPLUS


CN 2-Pyrrolidinemethanol, 1-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]acetyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 755032-88-3 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-N,N-dimethyl-11-oxo- (9CI) (CA INDEX NAME)



RN 755032-89-4 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-N,N-bis(2-methoxyethyl)-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)



RN 755032-90-7 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-[[(2S)-tetrahydro-2-furanyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 755032-91-8 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-(2-propoxyethyl)- (9CI) (CA INDEX NAME)



RN 755032-92-9 CAPLUS


CN 2-Pyrrolidinemethanol, 1-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]acetyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 755032-93-0 CAPLUS

CN 3-Pyrrolidinamine, 1-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]acetyl]- (9CI) (CA INDEX NAME)




RN 755032-94-1 CAPLUS

CN Piperazine, 1-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]acetyl]- (9CI) (CA INDEX NAME)




RN 755032-95-2 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-N-(3-methoxypropyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 755032-96-3 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, N-(cyanomethyl)-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 755032-97-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, N-(cyclopropylmethyl)-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 755032-99-6 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, N-(1,3-dioxolan-2-ylmethyl)-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-N-methyl-11-oxo- (9CI) (CA INDEX NAME)




RN 755033-01-3 CAPLUS

CN Thiomorpholine, 4-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]acetyl]- (9CI) (CA INDEX NAME)




RN 755033-03-5 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-[2-(3-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 755033-04-6 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-[2-(4-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 755033-05-7 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, N-[2-(2,3-dimethoxyphenyl)ethyl]-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)



RN 755033-06-8 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, N-[2-(1,3-benzodioxol-5-

yl)ethyl]-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 755033-07-9 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-(2-thienylmethyl)- (9CI) (CA INDEX NAME)




RN 755033-08-0 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-(5-thiazolylmethyl)- (9CI) (CA INDEX NAME)



RN 755033-09-1 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-N-[2-(1H-imidazol-4-yl)ethyl]-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)



RN 755033-10-4 CAPLUS


CN 1,4-Dioxo-8-azaspiro[4.5]decane, 8-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]acetyl]- (9CI) (CA INDEX NAME)

INDEX NAME)




RN 755033-11-5 CAPLUS

CN Morpholine, 4-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]acetyl]-2,6-dimethyl- (9CI) (CA INDEX NAME)




RN 755033-12-6 CAPLUS

CN Piperazine, 1-acetyl-4-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]acetyl]- (9CI) (CA INDEX NAME)




RN 755033-13-7 CAPLUS

CN Piperazine, 1-[[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]acetyl]-4-(2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 755033-14-8 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, N-[3-(aminocarbonyl)phenyl]-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 755033-15-9 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-N-[4-(4-morpholinyl)phenyl]-11-oxo- (9CI) (CA INDEX NAME)



RN 755033-16-0 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-6-quinolinyl- (9CI) (CA INDEX NAME)



RN 755033-17-1 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-N-[(1S)-1-(hydroxymethyl)-2-methylpropyl]-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 755033-18-2 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, N-[(1S)-1-(aminocarbonyl)-3-methylbutyl]-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 755033-19-3 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-N-[(1S)-2-hydroxy-1-phenylethyl]-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 755033-20-6 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, N-(2,3-dihydroxypropyl)-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 755033-21-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-N-[3-(1H-imidazol-1-yl)propyl]-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 755033-22-8 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-[3-(2-oxo-1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)




RN 755033-23-9 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, N-[(2,6-difluorophenyl)methyl]-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)



RN 755033-24-0 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, N-[2-[4-(aminosulfonyl)phenyl]ethyl]-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)



RN 755033-25-1 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-N-[(1R)-1-(hydroxymethyl)-2-methylpropyl]-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 755033-26-2 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-N-[(1R)-2-hydroxy-1-phenylethyl]-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 755033-27-3 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-(3-thienylmethyl)- (9CI) (CA INDEX NAME)




RN 755033-28-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 3-[4-(aminocarbonyl)-3-methoxyphenyl]-10,11-dihydro-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755033-29-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-hydroxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755033-30-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755033-34-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-ethoxy-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755033-35-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-(4-methyl-5-thiazolyl)ethoxy]- (9CI) (CA INDEX NAME)




RN 755033-37-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-[3-(dimethylamino)propoxy]-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755033-38-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-(4-morpholinyl)ethoxy]- (9CI) (CA INDEX NAME)




RN 755033-39-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-[4-(4-morpholinyl)phenyl]ethoxy]- (9CI) (CA INDEX NAME)



RN 755033-41-1 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-7-(1-piperidinyl)- (9CI) (CA INDEX NAME)



RN 755033-43-3 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 755033-46-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-7-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 755033-48-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(4-hydroxy-1-piperidinyl)-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755033-54-6 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetic acid, 10,11-dihydro-3-[3-methoxy-4-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755033-59-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-(2-ethyl-2-hydroxybutyl)-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755033-65-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-[(2-chloro-4-pyridinyl)amino]-8-(2-ethyl-2-hydroxybutyl)-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 755033-68-2 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-N,N-dimethyl-11-oxo-3-(4-pyridinylamino)- (9CI) (CA INDEX NAME)




RN 755033-75-1 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-N-[4-(4-morpholinyl)phenyl]-11-oxo-3-(4-pyridinylamino)- (9CI) (CA INDEX NAME)




RN 755033-79-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-(2-hydroxy-2-methylpropyl)-3-(4-pyrimidinylamino)- (9CI) (CA INDEX NAME)




RN 755033-81-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-(2-hydroxy-2-methylpropyl)-3-[(2-methyl-4-pyridinyl)amino]- (9CI) (CA INDEX NAME)




RN 755033-83-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-(2-oxopropyl)- (9CI) (CA INDEX NAME)




RN 755033-87-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-[(2-chloro-4-pyridinyl)amino]-5,10-dihydro-8-(2-oxopropyl)- (9CI) (CA INDEX NAME)




RN 755033-89-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-[[2-[(2-chloro-4-pyridinyl)amino]-4-pyridinyl]amino]-5,10-dihydro-8-(2-oxopropyl)- (9CI) (CA INDEX NAME)




RN 755033-92-2 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-α,α-dimethyl-N-[4-(4-morpholinyl)phenyl]-11-oxo-3-(4-pyrimidinylamino)- (9CI) (CA INDEX NAME)




RN 755033-93-3 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-α,α-dimethyl-3-[(2-methyl-4-pyridinyl)amino]-N-[4-(4-morpholinyl)phenyl]-11-oxo- (9CI) (CA INDEX NAME)




RN 755033-96-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-[[3-(2-hydroxyethyl)-4-pyridinyl]amino]-8-(1-hydroxy-1-methylethyl)- (9CI) (CA INDEX NAME)




RN 755034-00-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-(2-hydroxy-2-methylpropyl)-3-[(2-methoxy-4-pyridinyl)amino]- (9CI) (CA INDEX NAME)




RN 755034-02-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-carboxylic acid, 10,11-dihydro-11-oxo-3-(4-pyrimidinylamino)-, methyl ester (9CI) (CA INDEX NAME)




RN 755034-08-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(1-hydroxy-1-methylethyl)-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755034-11-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(1-hydroxy-1-methylethyl)-3-(4-pyrimidinylamino)- (9CI) (CA INDEX NAME)




RN 755034-12-9 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8'-acetamide, 10,11-dihydro-3-[(6-methoxy-4-pyrimidinyl)amino]- α,α -dimethyl-N-[4-(4-morpholinyl)phenyl]-11-oxo- (9CI) (CA INDEX NAME)




RN 755034-14-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-[[6-(4-morpholinyl)-3-pyridinyl]oxy]ethyl]- (9CI) (CA INDEX NAME)




RN 755034-18-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(4-hydroxy-3-methoxyphenyl)-8-[2-[4-(4-morpholinyl)phenoxy]ethyl]- (9CI) (CA INDEX NAME)




RN 755034-20-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-[(2,6-difluoro-4-pyridinyl)amino]-5,10-dihydro-8-[2-[4-(4-morpholinyl)phenoxy]ethyl]- (9CI) (CA INDEX NAME)




RN 755034-29-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-hydroxy-7-methoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755034-38-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-7-[(tetrahydro-2H-pyran-2-yl)methoxy]- (9CI) (CA INDEX NAME)




RN 755034-39-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-7-[(1-methyl-3-piperidinyl)methoxy]- (9CI) (CA INDEX NAME)




RN 755034-40-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-7-(2-pyridinylmethoxy)- (9CI) (CA INDEX NAME)




RN 755034-41-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-7-(3-pyridinylmethoxy)- (9CI) (CA INDEX NAME)




RN 755034-42-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-7-(4-pyridinylmethoxy)- (9CI) (CA INDEX NAME)




RN 755034-43-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-7-[(5-methyl-3-isoxazolyl)methoxy]- (9CI) (CA INDEX NAME)




RN 755034-44-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-7-[(1-methyl-1H-imidazol-5-yl)methoxy]- (9CI) (CA INDEX NAME)




RN 755034-45-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-7-[(2-methyl-4-thiazolyl)methoxy]- (9CI) (CA INDEX NAME)




RN 755034-46-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-7-[(2-oxo-5-oxazolidinyl)methoxy]- (9CI) (CA INDEX NAME)




RN 755034-48-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-7-[(tetrahydro-2-furanyl)methoxy]- (9CI) (CA INDEX NAME)



RN 755034-49-2 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 7-[(2,2-dimethyl-1,3-dioxolan-4-yl)methoxy]-5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 755034-50-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-7-[(2R)-2-pyrrolidinylmethoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 755034-51-6 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-7-[(2R)-2-pyrrolidinylmethoxy]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 755034-50-5

CMF C26 H26 N4 O6


Absolute stereochemistry.



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 755034-52-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7,8-dimethoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 755034-53-8 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-methoxy-7-[2-(2-methoxyethoxy)ethoxy]-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 755034-54-9 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 7-(2,3-dihydroxypropoxy)-5,10-

dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755034-55-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-[3-hydroxy-2,2-bis(hydroxymethyl)propoxy]-8-methoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755034-56-1 CAPLUS

CN 1-Propanesulfonic acid, 3-[[10,11-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]oxy]-2-hydroxy- (9CI) (CA INDEX NAME)



RN 755034-57-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 7-(3-aminopropoxy)-5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755034-58-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 7-(3-aminopropoxy)-5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 755034-57-2


CMF C24 H24 N4 O6



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 755034-59-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 7-[2-(dimethylamino)ethoxy]-5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755034-61-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-7-[2-(1-pyrrolidinyl)ethoxy]- (9CI) (CA INDEX NAME)




RN 755034-63-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-7-[2-(4-morpholinyl)ethoxy]- (9CI) (CA INDEX NAME)




RN 755034-64-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(4-hydroxybutoxy)-8-methoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755034-65-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(4-hydroxybutoxy)-3-(4-hydroxy-3-methoxyphenyl)-8-methoxy- (9CI) (CA INDEX NAME)




RN 755034-69-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(4-hydroxybutoxy)-8-methoxy-3-(4-pyrimidinylamino)- (9CI) (CA INDEX NAME)




RN 755034-70-9 CAPLUS

CN 2-Pyridinecarbonitrile, 4-[[10,11-dihydro-7-(4-hydroxybutoxy)-8-methoxy-11-oxo-5H-dibenzo[b,e][1,4]diazepin-3-yl]amino]- (9CI) (CA INDEX NAME)




RN 755034-71-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-[(2,6-difluoro-4-pyridinyl)amino]-5,10-dihydro-7-(4-hydroxybutoxy)-8-methoxy- (9CI) (CA INDEX NAME)




RN 755034-72-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(4-hydroxybutoxy)-8-methoxy-3-[(2,3,6-trifluoro-4-pyridinyl)amino]- (9CI) (CA INDEX NAME)



RN 755034-73-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 7-ethoxy-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)



IT 755034-76-5P, 7-(4-Hydroxybutoxy)-3-(3-methoxy-4-nitrophenyl)-5,10-

dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755034-80-1P**,
 7-(2-Hydroxyethoxy)-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-
 dibenzo[b,e][1,4]diazepin-11-one **755034-82-3P**,
 7-(2,3-Dihydroxypropoxy)-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-
 dibenzo[b,e][1,4]diazepin-11-one **755034-83-4P**,
 7-[2-(2-Methoxyethoxy)ethoxy]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-
 dibenzo[b,e][1,4]diazepin-11-one **755034-84-5P**,
 7-(Methoxymethyl)-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-
 dibenzo[b,e][1,4]diazepin-11-one **755034-91-4P**,
 7-(3-Methoxy-4-nitrobenzyl)-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-
 dibenzo[b,e][1,4]diazepin-11-one **755034-93-6P**,
 7-[[[2-(Dimethylamino)ethyl](methyl)amino]methyl]-3-(3-methoxy-4-
 nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755034-95-8P, 3-(3-Methoxy-4-nitrophenyl)-7-[[[2-(tetrahydro-2H-
 pyran-4-yl)ethyl]amino]methyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-
 11-one **755034-97-0P**, 8-Ethyl-7-methoxy-3-(3-methoxy-4-
 nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755035-04-2P, 8-Methoxy-3-(3-methoxy-4-nitrophenyl)-7-vinyl-5,10-
 dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755035-07-5P**,
 8-(3-Hydroxypropyl)-7-methoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-
 dibenzo[b,e][1,4]diazepin-11-one **755035-14-4P**,
 7-Methoxy-3-(3-methoxy-4-nitrophenyl)-8-[3-[(2-methylpyridin-3-
 yl)oxy]propyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755035-16-6P, 8-[3-[(2-Chloropyridin-3-yl)oxy]propyl]-7-methoxy-3-
 (3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-
 one **755035-17-7P**, 7-Methoxy-3-(3-methoxy-4-nitrophenyl)-8-[3-[[4-
 (morpholin-4-yl)phenyl]oxy]propyl]-5,10-dihydro-11H-
 dibenzo[b,e][1,4]diazepin-11-one **755035-19-9P**,
 8-[3-(Isoquinolin-3-yloxy)propyl]-7-methoxy-3-(3-methoxy-4-nitrophenyl)-
 5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755035-20-2P**
755035-22-4P, Methyl 7-methoxy-3-(3-methoxy-4-nitrophenyl)-11-oxo-
 10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carboxylate
755035-25-7P, Methyl 7-methoxy-11-oxo-3-(pyrimidin-4-ylamino)-
 10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carboxylate
755035-26-8P, 3-[(2,6-Difluoropyridin-4-yl)amino]-8-[1,1-dimethyl-
 2-(morpholin-4-yl)-2-oxoethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-
 11-one **755035-27-9P** **755035-28-0P** **755035-30-4P**
755035-31-5P **755035-33-7P**, 3-[(2,6-Difluoropyridin-4-
 yl)amino]-8-[2-(4-hydroxypiperidin-1-yl)-1,1-dimethyl-2-oxoethyl]-5,10-
 dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755035-34-8P**,
 (S)-3-[(2,6-Difluoropyridin-4-yl)amino]-8-[2-[2-(hydroxymethyl)pyrrolidin-
 1-yl]-1,1-dimethyl-2-oxoethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-
 11-one **755035-35-9P**, 3-[(2,6-Difluoropyridin-4-yl)amino]-8-[1,1-
 dimethyl-2-oxo-2-(pyrrolidin-1-yl)ethyl]-5,10-dihydro-11H-
 dibenzo[b,e][1,4]diazepin-11-one **755035-36-0P**
755035-37-1P **755035-38-2P** **755035-39-3P**,
 (R)-3-[(2,6-Difluoropyridin-4-yl)amino]-8-[2-[2-(hydroxymethyl)pyrrolidin-
 1-yl]-1,1-dimethyl-2-oxoethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-
 11-one **755035-40-6P**, 8-Methoxy-3-(3-methoxy-4-nitrophenyl)-7-[3-
 (morpholin-4-yl)-3-oxopropyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-
 11-one **755035-42-8P** **755035-44-0P** **755035-45-1P**
 , 8-[3-(3-Hydroxypiperidin-1-yl)-3-oxopropyl]-3-(3-methoxy-4-nitrophenyl)-
 5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755035-46-2P**
755035-47-3P **755035-48-4P** **755035-49-5P**
755035-50-8P, 8-[2-[(6-Chloropyridin-3-yl)oxy]ethyl]-3-(3-methoxy-
 4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755035-51-9P, 8-[2-[(2-Chloropyridin-3-yl)oxy]ethyl]-3-(3-methoxy-
 4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755035-52-0P, 3-(3-Methoxy-4-nitrophenyl)-8-[2-[(6-methylpyridin-3-
 yl)oxy]ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one


755035-53-1P, 3-(3-Methoxy-4-nitrophenyl)-8-[2-[(2-methylpyridin-3-yl)oxy]ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755035-54-2P, 3-(3-Methoxy-4-nitrophenyl)-8-[2-[(pyridin-3-yl)oxy]ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755035-56-4P, 8-[2-[(2,6-Dimethylpyridin-3-yl)oxy]ethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755035-57-5P, 8-[2-[[2-[(Dimethylamino)methyl]pyridin-3-yl]oxy]ethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755035-58-6P**,
8-[2-(Isoquinolin-7-yloxy)ethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755035-59-7P**,
7-Methoxy-3-(3-methoxy-4-nitrophenyl)-N,N-dimethyl-11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-8-carboxamide **755035-61-1P**,
7-[2-[(2-Chloropyridin-3-yl)oxy]ethyl]-8-methoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755035-63-3P, 8-[2-(Isoquinolin-5-yloxy)ethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755035-64-4P, 3-(3-Methoxy-4-nitrophenyl)-8-[2-[(quinolin-5-yl)oxy]ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755035-65-5P, 3-(3-Methoxy-4-nitrophenyl)-8-[2-(4-methoxyphenoxy)ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755035-67-7P, 3-(3-Methoxy-4-nitrophenyl)-8-[2-(3-methoxyphenoxy)ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755035-68-8P 755035-69-9P, 3-(3-Methoxy-4-nitrophenyl)-8-[3-[[4-(morpholin-4-yl)phenyl]oxy]propyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755035-70-2P**,
3-(3-Methoxy-4-nitrophenyl)-8-[3-[(pyridin-3-yl)oxy]propyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755035-71-3P**,
8-[2-(3-Aminophenoxy)ethyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755035-72-4P**,
3-(3-Methoxy-4-nitrophenyl)-8-[2-[(2-methyl-1,3-benzothiazol-7-yl)oxy]ethyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755035-73-5P 755035-74-6P, 8-(2-Hydroxy-2-methylpropyl)-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755035-75-7P, 3-(3-Methoxy-4-nitrophenyl)-8-[(4-methylpiperazin-1-yl)methyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755035-82-6P, 3-(4-Chloro-3-methoxyphenyl)-8-[(4-methylpiperazin-1-yl)methyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755035-84-8P 755035-86-0P, 3-(4-Hydroxy-3-methoxyphenyl)-8-(hydroxymethyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755035-91-7P**,
3-(3-Methoxy-4-nitrophenyl)-8-[(morpholin-4-yl)methyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one **755035-99-5P**,
(R)-8-[[2-(Hydroxymethyl)pyrrolidin-1-yl]methyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755036-00-1P, 7-(2-Hydroxyethoxy)-8-methoxy-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755036-01-2P, 8-[3-[2-(Hydroxymethyl)pyrrolidin-1-yl]-3-oxopropyl]-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755036-02-3P 755036-04-5P, 8-Amino-3-(4-hydroxy-3-methoxyphenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one
755036-06-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(kinase inhibitor; preparation of dibenzo[b,e][1,4]diazepin-11-ones as kinase inhibitors for treatment of cancer)


RN 755034-76-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(4-hydroxybutoxy)-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755034-80-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(2-hydroxyethoxy)-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755034-82-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 7-(2,3-dihydroxypropoxy)-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755034-83-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-[2-(2-methoxyethoxy)ethoxy]-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755034-84-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(methoxymethyl)-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755034-91-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-7-[(3-methoxy-4-nitrophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 755034-93-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 7-[[[2-(dimethylamino)ethyl]methylamino]methyl]-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755034-95-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-7-[[2-(tetrahydro-2H-pyran-4-yl)ethyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 755034-97-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-ethyl-5,10-dihydro-7-methoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755035-04-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 7-ethenyl-5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755035-07-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-(3-hydroxypropyl)-7-methoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755035-14-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-methoxy-3-(3-methoxy-4-nitrophenyl)-8-[3-[(2-methyl-3-pyridinyl)oxy]propyl]- (9CI) (CA INDEX NAME)




RN 755035-16-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-[3-[(2-chloro-3-pyridinyl)oxy]propyl]-5,10-dihydro-7-methoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755035-17-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-methoxy-3-(3-methoxy-4-nitrophenyl)-8-[3-[4-(4-morpholinyl)phenoxy]propyl]- (9CI) (CA INDEX NAME)




RN 755035-19-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-[3-(3-isoquinolinyl)propyl]-7-methoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755035-20-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-methoxy-3-(3-methoxy-4-nitrophenyl)-8-[3-(3-oxo-2(3H)-isoquinolinyl)propyl]- (9CI) (CA INDEX NAME)




RN 755035-22-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxylic acid, 10,11-dihydro-7-methoxy-3-(3-methoxy-4-nitrophenyl)-11-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 755035-25-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxylic acid, 10,11-dihydro-7-methoxy-11-oxo-3-(4-pyrimidinylamino)-, methyl ester (9CI) (CA INDEX NAME)




RN 755035-26-8 CAPLUS

CN Morpholine, 4-[2-[3-[(2,6-difluoro-4-pyridinyl)amino]-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-2-methyl-1-oxopropyl]- (9CI) (CA INDEX NAME)



RN 755035-27-9 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 3-[(2,6-difluoro-4-pyridinyl)amino]-10,11-dihydro-N,N,α,α-tetramethyl-11-oxo- (9CI) (CA INDEX NAME)



RN 755035-28-0 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 3-[(2,6-difluoro-4-

pyridinyl)amino]-10,11-dihydro- α,α -dimethyl-11-oxo-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 755035-30-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 3-[(2,6-difluoro-4-pyridinyl)amino]-10,11-dihydro- α,α -dimethyl-11-oxo-N-2-thiazolyl- (9CI) (CA INDEX NAME)




RN 755035-31-5 CAPLUS

CN 3-Piperidinol, 1-[2-[3-[(2,6-difluoro-4-pyridinyl)amino]-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-2-methyl-1-oxopropyl]- (9CI) (CA INDEX NAME)



RN 755035-33-7 CAPLUS


CN 4-Piperidinol, 1-[2-[3-[(2,6-difluoro-4-pyridinyl)amino]-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-2-methyl-1-oxopropyl]- (9CI) (CA INDEX NAME)



RN 755035-34-8 CAPLUS


CN 2-Pyrrolidinemethanol, 1-[2-[3-[(2,6-difluoro-4-pyridinyl)amino]-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-2-methyl-1-oxopropyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 755035-35-9 CAPLUS

CN Pyrrolidine, 1-[2-[3-[(2,6-difluoro-4-pyridinyl)amino]-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-2-methyl-1-oxopropyl]- (9CI) (CA INDEX NAME)




RN 755035-36-0 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 3-[(2,6-difluoro-4-pyridinyl)amino]-10,11-dihydro- α,α -dimethyl-11-oxo-N-2-pyridinyl- (9CI) (CA INDEX NAME)




RN 755035-37-1 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 3-[(2,6-difluoro-4-pyridinyl)amino]-10,11-dihydro- α,α -dimethyl-11-oxo-N-3-pyridinyl- (9CI) (CA INDEX NAME)



RN 755035-38-2 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 3-[(2,6-difluoro-4-pyridinyl)amino]-N-(4-fluorophenyl)-10,11-dihydro-α,α-dimethyl-11-oxo- (9CI) (CA INDEX NAME)



RN 755035-39-3 CAPLUS


CN 2-Pyrrolidinemethanol, 1-[2-[3-[(2,6-difluoro-4-pyridinyl)amino]-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-2-methyl-1-oxopropyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 755035-40-6 CAPLUS

CN Morpholine, 4-[3-[10,11-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]-1-oxopropyl]- (9CI) (CA INDEX NAME)




RN 755035-42-8 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-propanamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-3-pyridinyl- (9CI) (CA INDEX NAME)




RN 755035-44-0 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-propanamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 755035-45-1 CAPLUS

CN 3-Piperidinol, 1-[3-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-1-oxopropyl]- (9CI) (CA INDEX NAME)




RN 755035-46-2 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-propanamide, N-(4-fluorophenyl)-10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 755035-47-3 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-propanamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 755035-48-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-propanamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-N-methyl-11-oxo- (9CI) (CA INDEX NAME)




RN 755035-49-5 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-7-propanamide, 10,11-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)-N,N-dimethyl-11-oxo- (9CI) (CA INDEX NAME)




RN 755035-50-8 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-[2-[(6-chloro-3-pyridinyl)oxy]ethyl]-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755035-51-9 CAPLUS
 CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-[2-[(2-chloro-3-pyridinyl)oxy]ethyl]-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755035-52-0 CAPLUS
 CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-[(6-methyl-3-pyridinyl)oxy]ethyl]- (9CI) (CA INDEX NAME)



RN 755035-53-1 CAPLUS
 CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-[(2-methyl-3-pyridinyl)oxy]ethyl]- (9CI) (CA INDEX NAME)




RN 755035-54-2 CAPLUS
 CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-(3-pyridinyloxy)ethyl]- (9CI) (CA INDEX NAME)




RN 755035-56-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-[2-[(2,6-dimethyl-3-pyridinyl)oxy]ethyl]-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755035-57-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-[2-[[2-[(dimethylamino)methyl]-3-pyridinyl]oxy]ethyl]-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755035-58-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-[2-(7-isoquinolinyl)oxy]ethyl]-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755035-59-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, 10,11-dihydro-7-methoxy-3-(3-methoxy-4-nitrophenyl)-N,N-dimethyl-11-oxo- (9CI) (CA INDEX NAME)




RN 755035-61-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 7-[2-[(2-chloro-3-pyridinyl)oxy]ethyl]-5,10-dihydro-8-methoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755035-63-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-[2-(5-isoquinolinyl)oxy]ethyl]-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755035-64-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-(5-quinolinyl)oxy]ethyl]- (9CI) (CA INDEX NAME)




RN 755035-65-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-(4-methoxyphenoxy)ethyl]- (9CI) (CA INDEX NAME)




RN 755035-67-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-(3-methoxyphenoxy)ethyl]- (9CI) (CA INDEX NAME)




RN 755035-68-8 CAPLUS

CN 2-Pyridinecarboxamide, 3-[2-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]ethoxy]- (9CI) (CA INDEX NAME)




RN 755035-69-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[3-[4-(4-morpholinyl)phenoxy]propyl]- (9CI) (CA INDEX NAME)




RN 755035-70-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[3-(3-pyridinyloxy)propyl]- (9CI) (CA INDEX NAME)




RN 755035-71-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-[2-(3-aminophenoxy)ethyl]-5,10-dihydro-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755035-72-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-[(2-methyl-7-benzothiazolyl)oxy]ethyl]- (9CI) (CA INDEX NAME)




RN 755035-73-5 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-α,α-dimethyl-11-oxo-N-(2-pyridinylmethyl)- (9CI)
(CA INDEX NAME)




RN 755035-74-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-(2-hydroxy-2-methylpropyl)-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 755035-75-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[(4-methyl-1-piperazinyl)methyl]- (9CI) (CA INDEX NAME)




RN 755035-82-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-(4-chloro-3-methoxyphenyl)-5,10-dihydro-8-[(4-methyl-1-piperazinyl)methyl]- (9CI) (CA INDEX NAME)




RN 755035-84-8 CAPLUS

CN Benzonitrile, 4-[10,11-dihydro-8-[(4-methyl-1-piperazinyl)methyl]-11-oxo-5H-dibenzo[b,e][1,4]diazepin-3-yl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 755035-86-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(4-hydroxy-3-methoxyphenyl)-8-(hydroxymethyl)- (9CI) (CA INDEX NAME)



RN 755035-91-7 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-(4-morpholinylmethyl)- (9CI) (CA INDEX NAME)



RN 755035-99-5 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-[[(2R)-2-(hydroxymethyl)-1-pyrrolidinyl]methyl]-3-(3-methoxy-4-nitrophenyl)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 755036-00-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(2-hydroxyethoxy)-8-methoxy-3-(3-methoxy-4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 755036-01-2 CAPLUS


CN 2-Pyrrolidinemethanol, 1-[3-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl]-1-oxopropyl]- (9CI) (CA INDEX NAME)



RN 755036-02-3 CAPLUS


CN Cyclohexanecarboxamide, N-[10,11-dihydro-3-(3-methoxy-4-nitrophenyl)-11-oxo-5H-dibenzo[b,e][1,4]diazepin-7-yl]-4-hydroxy-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 755036-04-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-amino-5,10-dihydro-3-(4-hydroxy-3-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 755036-06-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-acetamide, 10,11-dihydro-3-(2-methoxy-5-methyl-4-pyridinyl)-α,α-dimethyl-N-[4-(4-morpholinyl)phenyl]-11-oxo- (9CI) (CA INDEX NAME)




IT 755031-66-4P

RL: BYP (Byproduct); PREP (Preparation)

(preparation of dibenzo[b,e][1,4]diazepin-11-ones as kinase inhibitors for treatment of cancer)

RN 755031-66-4 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-3-(3-methoxy-4-nitrophenyl)-8-[2-[(3-methyl-2-pyridinyl)oxy]ethyl]- (9CI) (CA INDEX NAME)




RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 6 OF 104 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 2004:566934 CAPLUS Full-text
 DN 141:325138
 TI Fluorescent Pirenzepine Derivatives as Potential Bitopic Ligands of the Human M1 Muscarinic Receptor
 AU Tahtaoui, Chouaib; Parrot, Isabelle; Klotz, Philippe; Guillier, Fabrice; Galzi, Jean-Luc; Hibert, Marcel; Ilien, Brigitte
 CS Laboratoire de Pharmacochimie de la Communication Cellulaire Faculte de Pharmacie, UMR CNRS/ULP 7081, Illkirch, 67412, Fr.
 SO Journal of Medicinal Chemistry (2004), 47(17), 4300-4315
 CODEN: JMCMAR; ISSN: 0022-2623
 PB American Chemical Society
 DT Journal
 LA English
 AB Following a recent description of fluorescence resonance energy transfer between enhanced green fluorescent protein (EGFP)-fused human muscarinic M1 receptors and Bodipy-labeled pirenzepine, the authors synthesized seven fluorescent derivs. of this antagonist in order to further characterize ligand-receptor interactions. These compds. carry Bodipy [558/568], Rhodamine Red-X [560/580], or Fluorolink Cy3 [550/570] fluorophores connected to pirenzepine through various linkers. All mols. reversibly bind with high affinity to M1 receptors (radioligand and energy transfer binding expts.) provided that the linker contains more than six atoms. The energy transfer efficiency exhibits modest variations among ligands, indicating that the distance separating EGFP from the fluorophores remains almost constant This also supports the notion that the fluorophores may bind to the receptor protein. Kinetic analyses reveal that the dissociation of two Bodipy derivs. (10 or 12 atom long linkers) is sensitive to the presence of the allosteric modulator brucine, while that of all other mols. (15-24 atom long linkers) is not. The data favor the idea that these analogs might interact with both the acetylcholine and the brucine binding domains.
 IT **850734-75-7P 850734-76-8P**
 RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (fluorescent pirenzepine derivs. as potential bitopic ligands of human M1 muscarinic receptor)
 RN 850734-75-7 CAPLUS
 CN Xanthylum, 3,6-bis(diethylamino)-9-[4-[[[6-[[2-[2-[2-[4-[2-(10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-5-yl)-2-oxoethyl]-1-piperazinyl]ethoxy]ethoxy]ethyl]amino]-6-oxohexyl]amino]sulfonyl]-2-sulphophenyl]-, inner salt (9CI) (CA INDEX NAME)


PAGE 1-A





PAGE 2-A



PAGE 3-A



RN 850734-76-8 CAPLUS
 CN 3H-Indolium, 2-[3-[1-[6-[[2-[2-[4-[2-(10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-5-yl)-2-oxoethyl]-1-piperazinyl]ethoxy]ethyl]amino]-6-oxohexyl]-1,3-dihydro-3,3-dimethyl-5-sulfo-2H-indol-2-ylidene]-1-propenyl]-1-ethyl-3,3-dimethyl-5-sulfo-, inner salt (9CI) (CA INDEX NAME)



RE.CNT 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 7 OF 104 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2004:2852 CAPLUS Full-text

DN 140:59520

TI Preparation of pyrrolidine and piperidinecarboxamides as inhibitors of phosphodiesterase IV (PDE 4)

IN Egerland, Ute; Rueger, Carla; Schindler, Rudolf; Rundfeldt, Chris; Kuss, Hildegard; Lichoscherstow, Arkadi M.; Seredenin, Sergey B.; Borissenko, Sergey A.

PA Elbion A.-G., Germany

SO PCT Int. Appl., 79 pp.


CODEN: PIXXD2

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004000806	A1	20031231	WO 2003-EP6590	20030623
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	DE 10228132	A1	20040122	DE 2002-10228132	20020624
PRAI	DE 2002-10228132	A	20020624		
OS	MARPAT 140:59520				
GI					



AB Title compds. [I; n = 1, 2; X = NH₂, N:CR₃R₄; NHCHR₃R₄; NR₃CHR₃R₄; NHCH₂R₄, NHCOR₄; R₁, R₄ = (substituted) 3-14 membered (saturated) (poly)cyclyl; 5-15 membered (saturated) (poly)heterocyclyl; R₂ = H, (substituted) (branched) alkyl, PhCH₂; NR₁R₂ = (substituted) heterocyclyl, R₃ = H, (substituted) (branched) alkyl], were prepared Thus, 1-amino-pyrrolidine-2-carboxylic acid, 2,6-dichlorophenylamide, and 3,4-dimethoxybenzaldehyde in 2-propanol were refluxed for 4 h to give 84% N-(2,6-dichlorophenyl)-(E)-1-([(3,4-dimethoxyphenyl)methylene]amino)pyrrolidine-2-carboxamide. Several I at 114-5,000 nmol/L inhibited PDE 4 with IC₅₀ = 32.4-79.6%.


IT 638207-45-1P 638207-46-2P 638207-47-3P
638207-48-4P 638207-49-5P 638207-50-8P
638207-51-9P 638207-52-0P 638207-53-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrrolidine and piperidinecarboxamides as inhibitors of phosphodiesterase IV (PDE 4))

RN 638207-45-1 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[(1-amino-2-piperidinyl)carbonyl]-8-chloro-5,10-dihydro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 638207-46-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-chloro-5-[[1-[[[3,4-dimethoxyphenyl)methylene]amino]-2-piperidinyl]carbonyl]-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 638207-47-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-chloro-5,10-dihydro-5-[[1-[[[4-methoxy-3-(2-methylpropoxy)phenyl)methylene]amino]-2-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 638207-48-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-chloro-5-[[1-[[[3-(difluoromethoxy)-4-methoxyphenyl)methylene]amino]-2-piperidinyl]carbonyl]-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 638207-49-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-chloro-5-[[1-[[[3-(cyclopropylmethoxy)-4-methoxyphenyl]methylene]amino]-2-piperidinyl]carbonyl]-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 638207-50-8 CAPLUS

CN Butanoic acid, 3-methyl-, 5-[[[2-[(8-chloro-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-5-yl)carbonyl]-1-piperidinyl]imino]methyl]-2-methoxyphenyl ester (9CI) (CA INDEX NAME)




RN 638207-51-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-chloro-5-[[1-[[[3-(cyclopentyloxy)-4-methoxyphenyl]methylene]amino]-2-piperidinyl]carbonyl]-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 638207-52-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-chloro-5,10-dihydro-5-[[1-[[[4-methoxy-3-(2-propenyloxy)phenyl]methylene]amino]-2-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 638207-53-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-chloro-5-[[1-[[[4-(difluoromethoxy)-3-methoxyphenyl]methylene]amino]-2-piperidinyl]carbonyl]-5,10-dihydro- (9CI) (CA INDEX NAME)



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 8 OF 104 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2003:967777 CAPLUS Full-text

DN 140:139900

TI Muscarinic receptor subtypes in the human colon: lack of evidence for atypical subtypes

AU Mansfield, Kylie J.; Mitchelson, Frederick J.; Moore, Kate H.; Burcher, Elizabeth

CS Department of Physiology and Pharmacology, University of New South Wales, Sydney, 2052, Australia

SO European Journal of Pharmacology (2003), 482(1-3), 101-109

CODEN: EJPHAZ; ISSN: 0014-2999

PB Elsevier Science B.V.

DT Journal

LA English

AB Characteristics of muscarinic receptors were investigated in circular muscle from normal human colon. In saturation studies (n=18), binding of [3H]quinuclidinyl benzylate (QNB) was of high affinity (Kd 87.3 pM) and capacity (Bmax 362±27 fmol/mg protein), with no differences between ascending and sigmoid colon. Kinetic studies gave a Kd of 55 pM. Methoctramine and darifenacin displayed biphasic binding profiles, the high affinity components being compatible with a population of approx. 80±5% M2 and 13±2% M3 muscarinic receptors, resp. Pirenzepine, mamba toxin 1 and mamba toxin 3 were very weak competitors, indicating negligible expression of muscarinic M1 and M4 receptors. Six other subtype-preferring antagonists exhibited Ki values typical of those reported at cloned human muscarinic M2 receptors. In the presence of methoctramine, pre-treatment with alkylating agent 4-diphenylacetoxy-N-(2-chloroethyl)-piperidine hydrochloride (4-DAMP mustard) inhibited [3H]quinuclidinyl benzylate binding to 26% of sites. Following alkylation of muscarinic M3 receptors, darifenacin bound to a single low affinity site, indicating binding to muscarinic M2 receptors.


IT 120382-14-1, UH-AH 37

RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)

(muscarinic receptor subtype characterization by various ligands in human colon in relation to lack of evidence for atypical subtypes)

RN 120382-14-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 6-chloro-5,10-dihydro-5-[(1-methyl-4-piperidinyl)acetyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RE.CNT 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 9 OF 104 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 2003:551518 CAPLUS Full-text
 DN 139:101151
 TI Preparation of dibenzodiazepine derivates and use as inhibitors of
 poly(ADP-ribose) polymerase
 IN Lubisch, Wilfried; Grandel, Roland; Braje, Wilfried; Subkowski, Thomas;
 Mueller, Reinhold; Wernet, Wolfgang; Drescher, Karla
 PA Abbott G.m.b.H. & Co. K.-G., Germany
 SO PCT Int. Appl., 40 pp.
 CODEN: PIXXD2


DT Patent
 LA English

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003057699	A1	20030717	WO 2003-EP192	20030110
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2003139394	A1	20030724	US 2002-41556	20020110
	CA 2472107	AA	20030717	CA 2003-2472107	20030110
	EP 1463731	A1	20041006	EP 2003-729243	20030110
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2005516031	T2	20050602	JP 2003-558014	20030110
PRAI	US 2002-41556	A	20020110		
	WO 2003-EP192	W	20030110		
OS	CASREACT 139:101151; MARPAT 139:101151				
GI					




I



III



IV



V

AB The invention relates to compds. I [A = (un)saturated or partially unsatd. C6-ring, unsatd. or partially unsatd. ring containing 3 - 5 C, 1 - 3 N, 1 O and/or 1 S; B = (un)saturated or partially unsatd. mono- bi- or tricyclic ring containing 3 - 15 C or 3 - 14 C, 0 - 5 N, 0 - 2 O and/or 0 - 2 S, etc.; R1 = H, Cl, Br, F, I, (un)branched C1-6-alkyl, OH, NO2, CF3, CN, NR11R12, NHCOR13, O-(C1-6-alkyl) R11, R12 = H, C1-4-alkyl; R13 = H, C1-4-alkyl, (C1-4-alkyl)phenyl, Ph ; X1 = S, O, NH] and their tautomeric forms, possible enantiomeric and diastereomeric forms and their prodrugs, and to their

preparation and use. Their preparation comprises: condensing aldehyde, BCHO (II) with benzodiazepine III; III is prepared by reaction nitrobenzoic esters IV [R2 = (un)branched, (un)saturated C1-6-alkyl, Z = leaving group] with diamines V in a polar solvent and in the presence of a base, and with subsequent hydrogenation. Thus, I (B = Ph) was prepared from IV (R1 = H, R2 = Me, Z = Cl) via cyclization with 1,2-C6H4(NH2)2 in DMF containing K2CO3, hydrogenation over Pd/C in DMF and cyclocondensation with PhCHO in MeOH containing AcOH. Inhibition of the enzyme, poly(ADP-ribose) polymerase (PARP) by I was tested (no data).

IT 561054-22-6P 561054-23-7P 561054-24-8P


561054-25-9P 561054-26-0P 561054-27-1P

RL: BSU (Biological study, unclassified); IMF (Industrial manufacture); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of dibenzodiazepine derivates and use as inhibitors of poly(ADP-ribose) polymerase)


RN 561054-22-6 CAPLUS

CN Benz[b]imidazo[4,5,1-jk][1,4]benzodiazepin-6(7H)-one, 1-phenyl- (9CI) (CA INDEX NAME)




RN 561054-23-7 CAPLUS

CN Benz[b]imidazo[4,5,1-jk][1,4]benzodiazepin-6(7H)-one, 1-[4-(4-methyl-1-piperazinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 561054-24-8 CAPLUS

CN Benz[b]imidazo[4,5,1-jk][1,4]benzodiazepin-6(7H)-one, 1-[4-[2-(diethylamino)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 561054-25-9 CAPLUS

CN Benz[b]imidazo[4,5,1-jk][1,4]benzodiazepin-6(7H)-one, 1-[4-(1H-imidazol-1-yl)phenyl]- (9CI) (CA INDEX NAME)




RN 561054-26-0 CAPLUS

CN Benz[b]imidazo[4,5,1-jk][1,4]benzodiazepin-6(7H)-one, 1-(1-propyl-4-piperidinyl)- (9CI) (CA INDEX NAME)



RN 561054-27-1 CAPLUS

CN Benz[b]imidazo[4,5,1-jk][1,4]benzodiazepin-6(7H)-one, 1-(1H-indol-3-yl)- (9CI) (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 10 OF 104 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2001:216424 CAPLUS Full-text

DN 135:40884

TI Analysis of the muscarinic receptor subtype mediating inhibition of the neurogenic contractions in rabbit isolated vas deferens by a series of polymethylene tetra-amines

AU Budriesi, R.; Cacciaguerra, S.; Di Toro, R.; Bolognesi, M. L.; Chiarini, A.; Minarini, A.; Rosini, M.; Spampinato, S.; Tumiatti, V.; Melchiorre, C.

CS Department of Pharmaceutical Sciences, University of Bologna, Bologna, 40126, Italy

SO British Journal of Pharmacology (2001), 132(5), 1009-1016

CODEN: BJPCBM; ISSN: 0007-1188

PB Nature Publishing Group

DT Journal

LA English

AB The pharmacol. characteristics of the presynaptic muscarinic receptor subtype, which mediates inhibition of the neurogenic contractions in the prostatic portion of rabbit vas deferens, have been investigated by using a series of polymethylene tetra-amines, which were selected for their ability to differentiate among muscarinic receptor subtypes. It was found that all tetra-amines antagonized McN-A-343-induced inhibition in elec. stimulated rabbit vas deferens in a competitive manner and with affinity values (pA_2) ranging between 6.27 ± 0.09 (spirotramine) and 8.51 ± 0.02 (AM170). Competition radioligand binding studies, using native muscarinic receptors from rat tissues (M1, cortex; M2, heart; M3, submaxillary gland) or from NG 108-15 cells (M4) and human cloned muscarinic M1-M4 receptors expressed in CHO-K1 cells, were undertaken with the same tetra-amines employed in functional assays. All antagonists indicated a one-site fit. The affinity ests. (pK_i) of tetra-amines calculated in binding assays using native receptors were similar to those obtained using cloned receptors. Among these compds. some displayed selectivity between muscarinic receptor subtypes, indicating that they may be valuable tools in receptor characterization. Spirotramine was selective for M1 receptors vs. all other subtypes (pK_i native: M1, 7.32 ± 0.10 ; M2, 6.50 ± 0.11 ; M3, 6.02 ± 0.13 ; M4, 6.28 ± 0.16 ; pK_i cloned: M1, 7.69 ± 0.08 ; M2, 6.22 ± 0.14 ; M3, 6.11 ± 0.16 ; 6.35 ± 0.11) whereas CC8 is highly selective for M2 receptors vs. the other subtypes (pK_i native: M1, 7.50 ± 0.04 ; M2, 9.01 ± 0.12 ; M3, 6.70 ± 0.08 ; M4, 7.56 ± 0.04 ; pK_i cloned: M1, 7.90 ± 0.20 ; M2, 9.04 ± 0.08 ; M3, 6.40 ± 0.07 ; M4, 7.40 ± 0.04). Furthermore, particularly relevant for this investigation were tetra-amines dipitramine and AM172 for their ability to significantly differentiate M1 and M4 receptors. Thlle apparent affinity values (pA_2) obtained for tetra-amines in functional studies using the prostatic portion of rabbit vas deferens correlated most closely with the values (pK_i) obtained at either native or human recombinant muscarinic M4 receptors. This supports the view that the muscarinic receptor mediating inhibition of neurogenic contractions of rabbit vas deferens may not belong to the M1 type but rather appears to be of the M4 subtype.


IT 214751-07-2 214751-09-4

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)

(anal. of muscarinic receptor subtype mediating inhibition of neurogenic contractions in rabbit isolated vas deferens by a series of polymethylene tetra-amines)

RN 214751-07-2 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,5'-(10,19-dimethyl-1,28-dioxo-3,10,19,26-tetraaaoctacosane-1,28-diyl)bis[5,10-dihydro- (9CI) (CA INDEX NAME)





RN 214751-09-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,5'-[[[6-[[8-[[6-[[2-(10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-5-yl)-2-oxoethyl]amino]hexyl]methylamino]octyl]methylamino]hexyl]imino]bis(1-oxo-2,1-ethanediyl)]bis[5,10-dihydro- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RE.CNT 33

THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 11 OF 104 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2000:893923 CAPLUS Full-text

DN 134:51341

TI Interactions of alcuronium, TMB-8, and other allosteric ligands with muscarinic acetylcholine receptors: studies with chimeric receptors

AU Ellis, John; Seidenberg, Margaret

CS Departments of Psychiatry and Pharmacology, The Pennsylvania State University College of Medicine, Hershey, PA, USA

SO Molecular Pharmacology (2000), 58(6), 1451-1460

CODEN: MOPMA3; ISSN: 0026-895X

PB American Society for Pharmacology and Experimental Therapeutics

DT Journal

LA English

AB A series of ligands that allosterically modulate the binding of classical ligands to muscarinic receptors was evaluated at wild-type and chimeric receptors. All of the ligands studied had highest affinity toward the M2 subtype and lowest affinity toward the M5 subtype. The chimeric receptors were mostly M5 sequence; the amount of M2 sequence ranged from about 6 to just under 30%. Alcuronium and TMB-8 had much higher affinity for the chimeric receptor that included the M2 second outer loop of the receptor plus flanking regions of TM4 and TM5 than for any of the other chimeric receptors (the affinities of which remained similar to that of the M5 subtype). However, this chimera retained the neg. cooperativity between alcuronium and the classical antagonist N-methylscopolamine that is characteristic of M5 (these ligands are pos. cooperative at M2). Verapamil, tetrahydroaminoacridine, and d-tubocurarine were also sensitive to that chimeric substitution, although verapamil and tetrahydroaminoacridine had even higher affinity for a chimera with M2 sequence in TM7. None of these ligands shared gallamine's sensitivity to a region of the third outer loop, but studies in which obidoxime reversed the allosteric effects of gallamine and other ligands suggested that they nevertheless compete for a common site. In summary, although the present data are consistent with previous studies that have suggested that allosteric ligands bind to the outermost regions of muscarinic receptors, it appears that different allosteric ligands may derive subtype selectivity from different regions of the receptor.


IT 120382-14-1, UH-AH-37

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(interactions of alcuronium, TMB-8, and other allosteric ligands with muscarinic acetylcholine receptors: studies with chimeric receptors)

RN 120382-14-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 6-chloro-5,10-dihydro-5-[(1-methyl-4-piperidinyl)acetyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L25 ANSWER 12 OF 104 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2000:642477 CAPLUS Full-text

DN 133:305541

TI Site-directed mutagenesis implicates a threonine residue in TM6 in the subtype selectivities of UH-AH 37 and pirenzepine at muscarinic receptors

AU Ellis, John; Seidenberg, Margaret

CS Department of Psychiatry and Pharmacology, The Pennsylvania State University College of Medicine, Hershey, PA, USA

SO Pharmacology (2000), 61(2), 62-69

CODEN: PHMGBN; ISSN: 0031-7012

PB S. Karger AG

DT Journal

LA English

AB The structural basis for the selectivity of the antagonist UH-AH 37 at human muscarinic acetylcholine receptors was investigated by expressing mutant receptors in COS-7 cells. Previous studies have demonstrated that the interaction between UH-AH 37 and [3H]N-methylsco-polamine in equilibrium assays is competitive and that the high affinity of UH-AH 37 for the M5 subtype, compared to M2, is due to an epitope in the sixth transmembrane domain (TM6) or the third outer loop of the receptor. By mutating each nonconserved residue in this region of M2 and M5 to its counterpart in the other receptor, we identified a threonine residue in the middle of TM6 uniquely responsible for the higher affinity of the M5 receptor (M1, M3, and M4 receptors also carry a threonine at that location and also have high affinity for UH-AH 37). The mutant receptor in which the corresponding alanine of the M2 receptor was replaced by threonine, M2401alathr, expressed enhanced affinity for pirenzepine as well as for UH-AH 37. The chick M2 receptor, which expresses anomalously high affinity for pirenzepine, differs from its mammalian counterparts by the presence of a threonine at this position. Affinities of AF-DX 116 and 4-DAMP, as well as the allosteric potency of UH-AH 37, were not sensitive to the M2401 ala-thr mutation.


IT 120382-14-1, UH-AH 37

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)

(site-directed mutagenesis implicates a threonine residue in TM6 in subtype selectivities of UH-AH 37 and pirenzepine at muscarinic receptors)

RN 120382-14-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 6-chloro-5,10-dihydro-5-[(1-methyl-4-piperidinyl)acetyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RE.CNT 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 13 OF 104 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2000:221253 CAPLUS Full-text

DN 133:38104

TI In vitro and in vivo m2 muscarinic subtype selectivity of some
'dibenzodiazepinones and pyridobenzodiazepinones

AU Cohen, V. I.; Jin, B.; McRee, R. C.; Boulay, S. F.; Cohen, E. I.; Sood, V.
K.; Zeeberg, B. R.; Reba, R. C.

CS N.W., 2300 Eye St., Walter G. Ross Hall, Section of Radiopharmaceutical
Chemistry, George Washington University Medical Center, Washington, DC,
USA

SO Brain Research (2000), 861(2), 305-315

CODEN: BRREAP; ISSN: 0006-8993

PB Elsevier Science B.V.

DT Journal

LA English

AB Alzheimer's disease (AD) involves selective loss of muscarinic m2, but not m1,
subtype receptors in cortical and hippocampal regions of the human brain.
Emission tomog. study of the loss of m2 receptors in AD has been limited by
the absence of available m2-selective radioligands, which can penetrate the
blood-brain barrier. We now report on the in vitro and in vivo m2 muscarinic
subtype selectivity of a series of dibenzodiazepinones and
pyridobenzodiazepinones determined by competition studies against (R)-3-
quinuclidinyl (S)-4-iodobenzilate ((R,S)-[125I]IQNB) or [3H]QNB. Of the
compsds. examined, three of the 5-[[4-[(4-dialkylamino)butyl]-1-
piperidinyl]acetyl]-10,11-dihydro-5-H-dibenzo[b,e][1,4]diazepin-11-ones
(including DIBA) and three of the 11-[[4-[4-(dialkylamino)butyl]-1-
phenyl]acetyl]-5,11-dihydro-6H-pyrido [2,3-b][1,4]benzodiazepin-6-ones
(including PBID) exhibited both high binding affinity for the m2 subtype (≤ 5
nM) and high m2/m1 selectivity (≥ 10). In vivo rat brain dissection studies of
the competition of PBID or DIBD against (R,S)[125I]IQNB or [3H]QNB exhibited a
dose-dependent preferential decrease in the binding of the radiotracer in
brain regions that are enriched in the m2 muscarinic subtype. In vivo rat
brain autoradiog. studies of the competition of PBID, BIBN 99, or DIBD against
(R,S)[125I]IQNB exhibited an insignificant effect of BIBN 99 and confirmed the
effect of PBID and DIBD in decreasing the binding of (R,S)[125I]IQNB in brain
regions that are enriched in the m2 muscarinic subtype. We conclude that PBID
and DIBD are potentially useful parent compds. from which in vivo m2 selective
derivs. may be prepared for potential use in positron emission tomog. (PET)
study of the loss of m2 receptors in AD.


IT 213208-20-9 213208-21-0 213208-22-1
213208-23-2 213208-24-3 213208-25-4
213208-32-3 213208-33-4 213208-34-5
213208-35-6 213208-36-7 213208-37-8
213208-38-9 213208-41-4 213208-42-5

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL
(Biological study); PROC (Process)

(In vitro and in vivo m2 muscarinic subtype selectivity of
dibenzodiazepinones and pyridobenzodiazepinones for potential use in
tomog. brain imaging)


RN 213208-20-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-[4-
(diethylamino)butyl]phenyl]acetyl]-1-fluoro-5,10-dihydro- (9CI) (CA INDEX
NAME)




RN 213208-21-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-[4-[bis(1-methylethyl)amino]butyl]phenyl]acetyl]-1-fluoro-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 213208-22-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-[4-(diethylamino)butyl]phenyl]acetyl]-3-fluoro-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 213208-23-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-[4-[bis(1-methylethyl)amino]butyl]phenyl]acetyl]-3-fluoro-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 213208-24-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-[4-[bis(2-methylpropyl)amino]butyl]phenyl]acetyl]-3-fluoro-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 213208-25-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 2-chloro-5-[[4-[3-(ethylamino)propyl]phenyl]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 213208-32-3 CAPLUS

CN Pentanamide, N-[3-[4-[2-(10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-5-yl)-2-oxoethyl]phenyl]propyl]-N-ethyl-2,2-dimethyl- (9CI) (CA INDEX NAME)




RN 213208-33-4 CAPLUS

CN Pentanamide, N-[3-[4-[2-(2-chloro-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-5-yl)-2-oxoethyl]phenyl]propyl]-N-ethyl-2,2-dimethyl- (9CI) (CA INDEX NAME)




RN 213208-34-5 CAPLUS

CN Pentanamide, N-[4-[4-[2-(10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-5-yl)-2-oxoethyl]phenyl]butyl]-N-ethyl-2,2-dimethyl- (9CI) (CA INDEX NAME)




RN 213208-35-6 CAPLUS

CN Pentanamide, N-[4-[4-[2-(2-chloro-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-5-yl)-2-oxoethyl]phenyl]butyl]-N-ethyl-2,2-dimethyl- (9CI) (CA INDEX NAME)




RN 213208-36-7 CAPLUS

CN Butanamide, N-[4-[4-[2-(10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-5-yl)-2-oxoethyl]phenyl]butyl]-N-(2-methylpropyl)- (9CI) (CA INDEX NAME)




RN 213208-37-8 CAPLUS

CN Propanamide, N-[4-[4-[2-(10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-5-yl)-2-oxoethyl]phenyl]butyl]-2-methyl-N-(2-methylpropyl)- (9CI) (CA INDEX NAME)




RN 213208-38-9 CAPLUS

CN Butanamide, N-[4-[4-[2-(10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-5-yl)-2-oxoethyl]phenyl]butyl]-3-methyl-N-(2-methylpropyl)- (9CI) (CA INDEX NAME)




RN 213208-41-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-[4-[bis(2-methylpropyl)amino]butyl]phenyl]acetyl]-5,10-dihydro-2-iodo- (9CI) (CA INDEX NAME)



RN 213208-42-5 CAPLUS
 CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-[4-[bis(2-methylpropyl)amino]butyl]phenyl]acetyl]-5,10-dihydro-4-iodo- (9CI) (CA INDEX NAME)



RE.CNT 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 14 OF 104 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1999:684270 CAPLUS Full-text

DN 131:286831

TI Preparation of piperazine-containing peptidomimetics for use as NPY antagonists

IN Rudolf, Klaus; Eberlein, Wolfgang; Engel, Wolfhard; Mihm, Gerhard; Doods, Henri; Willim, Klaus-Dieter; Krause, Juergen; Wieland, Heike-Andrea; Schnorrenberg, Gerd; Esser, Franz; Dollinger, Horst

PA Boehringer Ingelheim Pharma K.-G., Germany

SO Ger. Offen., 40 pp.



CODEN: GWXXBX

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 19816889	A1	19991021	DE 1998-19816889	19980416
PRAI	DE 1998-19816889		19980416		
OS	MARPAT 131:286831				
GI					



AB Title compds. (e.g. I) were prepared for use as NPY antagonists for pharmacol. use. Thus, 1,1-cyclopentane-diacetic acid anhydride was reacted with 4-amino-benzonitrile and then with 1-(diphenyl- methyl)piperazine to give a cyano-product which was hydrogenated to the amino-imine (II). In in vitro tests with NPY receptors prepared from rabbits, title compds. had IC50 ≤10,000 nM.


IT 122860-12-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and reaction of in the synthesis of piperazine-containing peptidomimetics for use as NPY antagonists)

RN 122860-12-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-(1-piperazinylcarbonyl)- (9CI) (CA INDEX NAME)




IT 246515-37-7P 246515-39-9P 246515-42-4P
246515-46-8P 246515-90-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of as peptidomimetics for use as NPY antagonists)


RN 246515-37-7 CAPLUS

CN Benzenepropanamide, 4-cyano- α -[[[1-[2-[4-[(10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-5-yl)carbonyl]-1-piperazinyl]-2-oxoethyl]cyclopentyl]acetyl]amino]-N-(3-phenylpropyl)- (9CI) (CA INDEX NAME)



RN 246515-39-9 CAPLUS


CN Benzenepropanamide, 4-(aminoiminomethyl)- α -[[[1-[2-[4-[(10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-5-yl)carbonyl]-1-piperazinyl]-2-oxoethyl]cyclopentyl]acetyl]amino]-N-(3-phenylpropyl)-, monohydrochloride (9CI) (CA INDEX NAME)



RN 246515-42-4 CAPLUS

CN Benzenepropanamide, α -[[[1-[2-[4-[(10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-5-yl) carbonyl]-1-piperazinyl]-2-oxoethyl]cyclopentyl]acetyl]amino]-N-(3-phenylpropyl)-, (α S)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 246515-46-8 CAPLUS

CN Benzeneacetamide, α -[[[1-[2-[4-[(10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-5-yl) carbonyl]-1-piperazinyl]-2-oxoethyl]cyclopentyl]acetyl]amino]-N-(3-phenylpropyl)-, (α S)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 246515-90-2 CAPLUS


CN Benzenepropanamide, 4-(aminoiminomethyl)-α-[[[1-[2-[4-[(10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-5-yl)carbonyl]-1-piperazinyl]-2-oxoethyl]cyclopentyl]acetyl]amino]-N-(3-phenylpropyl)-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




IT 246514-61-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(reaction of in the synthesis of piperazine-containing peptidomimetics for


use as NPY antagonists)
 RN 246514-61-4 CAPLUS
 CN Cyclopentaneacetic acid, 1-[2-[4-[(10,11-dihydro-11-oxo-5H-
 dibenzo[b,e][1,4]diazepin-5-yl)carbonyl]-1-piperazinyl]-2-oxoethyl]- (9CI)
 (CA INDEX NAME)



L25 ANSWER 15 OF 104 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1999:404950 CAPLUS Full-text
 DN 131:58843
 TI preparation of 3-piperidyl-4-oxoquinazoline derivatives as medicinal
 compositions
 IN Sato, Motohide; Katsushima, Takeo; Kinoshita, Hajime
 PA Japan Tobacco Inc., Japan
 SO PCT Int. Appl., 142 pp.
 CODEN: PIXXD2

DT Patent
 LA Japanese
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9931085	A1	19990624	WO 1998-JP5628	19981211
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	JP 11228569	A2	19990824	JP 1998-288979	19981012
	JP 2959765	B2	19991006		
	ZA 9811315	A	19990630	ZA 1998-11315	19981210
	CA 2280705	AA	19990624	CA 1998-2280705	19981211
	AU 9915068	A1	19990705	AU 1999-15068	19981211
	AU 717963	B2	20000406		
	EP 970954	A1	20000112	EP 1998-959187	19981211
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, RO				
	BR 9807339	A	20000321	BR 1998-7339	19981211
	TR 9901933	T1	20000321	TR 1999-9901933	19981211
	NZ 337118	A	20000327	NZ 1998-337118	19981211
	NO 9903868	A	19991012	NO 1999-3868	19990811
	US 6235730	B1	20010522	US 1999-367242	19991026
PRAI	JP 1997-362819	A	19971212		
	JP 1998-288979	A	19981012		
	WO 1998-JP5628	W	19981211		
OS	MARPAT 131:58843				
GI					



AB 3-Piperidyl-4-oxoquinazoline derivs. or pharmaceutically acceptable salts [I; R = amino substituted by optionally substituted aryl, heteroaryl, or cyclic amino such as dibenzazepine; n = integer from 1 to 4; R3, R4 = H, lower alkyl, etc.], having an excellent MTP-inhibitory activity, thus useful in inhibiting the formation of LDL causative of arteriosclerotic diseases and enabling the regulation of TG, cholesterol and lipoproteins such as LDL in the blood and cellular lipids via the regulation of the MTP activity, were prepared I are expected also as a novel type of remedies or preventives for hyperlipemia or arteriosclerotic diseases and, moreover, as remedies or preventives for


pancreatitis, obesity, hypercholesterolemia, hypertriglyceridemia, etc.
 Refluxing a mixture of BrCH₂CH₂NPh₂ and 3-(piperidin-4-yl)-3H-quinazolin-4-one containing K₂CO₃ in MeCN gave 55% I (R = Ph₂N, R₃ = R₄ = H, n = 2) (II).
 II.2HCl showed IC₅₀ of 0.1 μM against apolipoprotein B secretion and 0.6 μM against triglyceride transport in vitro.

IT **227806-49-7P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of 3-piperidyl-4-oxoquinazoline derivs. as medicinal compns.)

RN 227806-49-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[2-[4-(4-oxo-3(4H)-quinazolinyl)-1-piperidinyl]ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)




IT **5814-41-5P 227805-92-7P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of 3-piperidyl-4-oxoquinazoline derivs. as medicinal compns.)


RN 5814-41-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro- (7CI, 8CI, 9CI) (CA INDEX NAME)



RN 227805-92-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[2-[4-(4-oxo-3(4H)-quinazolinyl)-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)



RE.CNT 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 16 OF 104 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1999:176508 CAPLUS Full-text

DN 130:296672

TI Solid support synthesis of 2-substituted dibenz[b,f]oxazepin-11(10H)-ones via SNAr methodology on AMEBA resin

AU Ouyang, Xiaohu; Tamayo, Nuria; Kiselyov, Alexander S.

CS Small Molecule Drug Discovery, Amgen Inc., Thousand Oaks, CA, 91320, USA

SO Tetrahedron (1999), 55(10), 2827-2834

CODEN: TETRAB; ISSN: 0040-4020

PB Elsevier Science Ltd.

DT Journal

LA English

AB Efficient assembly of dibenz[b,f]oxazepin-11(10H)-ones utilizing the SNAr of fluorine in 2-fluoro-5-nitrobenzoic acid with the OH of various 2-aminophenols on solid support is reported. The flexibility of this synthesis, as well as the excellent purity (>90%) of the final products are the distinctive characteristics of the resulting library.

IT 223261-49-2P 223261-50-5P 223261-51-6P

223261-53-8P 223261-54-9P 223261-55-0P


223261-57-2P 223261-58-3P 223261-59-4P

223261-61-8P 223261-62-9P 223261-63-0P

RL: SPN (Synthetic preparation); PREP (Preparation)
(solid support synthesis of dibenzoxazepinones)


RN 223261-49-2 CAPLUS

CN Benzamide, N-(10,11-dihydro-11-oxodibenz[b,f][1,4]oxazepin-2-yl)-4-fluoro-
(9CI) (CA INDEX NAME)




RN 223261-50-5 CAPLUS

CN Benzamide, N-(10,11-dihydro-11-oxodibenz[b,f][1,4]oxazepin-2-yl)-4-methyl-
(9CI) (CA INDEX NAME)




RN 223261-51-6 CAPLUS

CN Benzamide, N-(10,11-dihydro-11-oxodibenz[b,f][1,4]oxazepin-2-yl)-4-methoxy-
(9CI) (CA INDEX NAME)




RN 223261-53-8 CAPLUS

CN Benzamide, N-(10,11-dihydro-7-methyl-11-oxodibenz[b,f][1,4]oxazepin-2-yl)-
4-fluoro- (9CI) (CA INDEX NAME)




RN 223261-54-9 CAPLUS

CN Benzamide, N-(10,11-dihydro-7-methyl-11-oxodibenz[b,f][1,4]oxazepin-2-yl)-
4-methyl- (9CI) (CA INDEX NAME)




RN 223261-55-0 CAPLUS

CN Benzamide, N-(10,11-dihydro-7-methyl-11-oxodibenz[b,f][1,4]oxazepin-2-yl)-4-methoxy- (9CI) (CA INDEX NAME)




RN 223261-57-2 CAPLUS

CN Benzamide, N-(10,11-dihydro-8-methyl-11-oxodibenz[b,f][1,4]oxazepin-2-yl)-4-fluoro- (9CI) (CA INDEX NAME)




RN 223261-58-3 CAPLUS

CN Benzamide, N-(10,11-dihydro-8-methyl-11-oxodibenz[b,f][1,4]oxazepin-2-yl)-4-methyl- (9CI) (CA INDEX NAME)




RN 223261-59-4 CAPLUS

CN Benzamide, N-(10,11-dihydro-9-methyl-11-oxodibenz[b,f][1,4]oxazepin-2-yl)-4-methoxy- (9CI) (CA INDEX NAME)




RN 223261-61-8 CAPLUS

CN Benzamide, N-(10,11-dihydro-9-methyl-11-oxodibenz[b,f][1,4]oxazepin-2-yl)-4-fluoro- (9CI) (CA INDEX NAME)




RN 223261-62-9 CAPLUS

CN Benzamide, N-(10,11-dihydro-9-methyl-11-oxodibenz[b,f][1,4]oxazepin-2-yl)-4-methyl- (9CI) (CA INDEX NAME)



RN 223261-63-0 CAPLUS

CN Benzamide, N-(10,11-dihydro-9-methyl-11-oxodibenz[b,f][1,4]oxazepin-2-yl)-4-methoxy- (9CI) (CA INDEX NAME)



RE.CNT 46 THERE ARE 46 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 17 OF 104 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1999:17046 CAPLUS Full-text

DN 130:204682

TI Competitive and allosteric interactions of 6-chloro-5,10-dihydro-5-[(1-methyl-4-piperidinyl) acetyl]-11H-dibenzo[b,e][1, 4]diazepine-11-one hydrochloride (UH-AH 37) at muscarinic receptors, via distinct epitopes

AU Ellis, John; Seidenberg, Margaret

CS Departments of Psychiatry and Pharmacology, The Pennsylvania State University College of Medicine, Hershey, PA, 17033, USA

SO Biochemical Pharmacology (1999), 57(2), 181-186

CODEN: BCPCA6; ISSN: 0006-2952

PB Elsevier Science Inc.

DT Journal

LA English

AB 6-Chloro-5,10-dihydro-5-[(1-methyl-4-piperidinyl)acetyl]-11H-dibenzo[b,e][1,4]diazepine-11-one hydrochloride (UH-AH 37) is an analog of pirenzepine that has previously been reported to interact with classical muscarinic antagonists in a competitive manner, yet its binding has also been found to be sensitive to the same epitope as is that of the allosteric ligand gallamine. The present study was carried out with wild-type and chimeric muscarinic receptors to determine whether UH-AH 37 might also have an allosteric mode of action. In assays that detect only allosteric interactions, UH-AH 37 slowed the rate of dissociation of [3H]N-methylscopolamine (NMS) from all five muscarinic receptor subtypes, with the highest apparent affinity at m2. By contrast, studies carried out under equilibrium conditions have found UH-AH 37 to have the lowest affinity for the m2 subtype. Studies with m2/m5 chimeric receptors found the allosteric potency of UH-AH 37 to be sensitive to an epitope in the seventh transmembrane domain (TM). Again, this contrasts with equilibrium studies, wherein an epitope in the sixth TM has been implicated. Simultaneous anal. of the interactions between UH-AH 37 and [3H]NMS at the m2 receptor under equilibrium and non-equilibrium conditions found that a simple allosteric model could not accommodate both sets of data. On the other hand, the model did accommodate such data for gallamine; gallamine also displays concordance in order-of-potency and epitope sensitivity between equilibrium and non-equilibrium assays. Based on these results, the authors conclude that UH-AH 37 interacts at the classical muscarinic binding site with high affinity and at a second (allosteric) site with lower affinity.


IT 120382-14-1, UH-AH 37

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(competitive and allosteric interactions of UH-AH 37 at muscarinic receptors, via distinct epitopes)

RN 120382-14-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 6-chloro-5,10-dihydro-5-[(1-methyl-4-piperidinyl)acetyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RE.CNT 19

THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 18 OF 104 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1998:713027 CAPLUS Full-text

DN 130:52395

TI Solid-phase synthesis of 1,5-benzodiazepin-2-ones

AU Schwarz, Matthias; Tumelty, David; Gallop, Mark A.

CS Affymax Res. Inst., Palo Alto, CA, 94304, USA

SO Tetrahedron Letters (1998), 39(46), 8397-8400

CODEN: TELEAY; ISSN: 0040-4039

PB Elsevier Science Ltd.

DT Journal

LA English


AB A solid-phase synthesis of polysubstituted 1,5-benzodiazepin-2-ones is described. Resin-bound 4-fluoro-3-nitrobenzoic acid was reacted with different β -amino acids, followed by nitro group reduction and formation of the seven-membered ring. Subsequent alkylations at N(5) and N(1) afforded the title compds. in high purities and yields.

IT **217300-48-6P**

RL: SPN (Synthetic preparation); PREP (Preparation)
(solid-phase synthesis of benzodiazepinones)

RN 217300-48-6 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-8-carboxamide, 10,11-dihydro-11-oxo-5-[[3-(oxophenylacetyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RE.CNT 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 19 OF 104 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1998:682355 CAPLUS Full-text
 DN 129:302376
 TI Preparation of arylalkylamine as calcilytic compounds
 IN Barmore, Robert M.; Bhatnagar, Pradip Kumar; Bryan, William M.; Burgess, Joelle Lorraine; Callahan, James Francis; Calvo, Raul Rolando; Del Mar, Eric G.; et al.
 PA Smithkline Beecham Corporation, USA; Nps Pharmaceuticals, Inc.
 SO PCT Int. Appl., 102 pp.
 CODEN: PIXXD2

DT Patent
 LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9845255	A1	19981015	WO 1998-US6928	19980408
	W: AL, AU, BA, BB, BG, BR, CA, CN, CZ, EE, GE, HU, ID, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	ZA 9802951	A	19990316	ZA 1998-2951	19980407
	CA 2286454	AA	19981015	CA 1998-2286454	19980408
	AU 9868900	A1	19981030	AU 1998-68900	19980408
	AU 721910	B2	20000720		
	EP 973730	A1	20000126	EP 1998-914581	19980408
	EP 973730	B1	20040616		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI				
	TR 9902516	T2	20000221	TR 1999-9902516	19980408
	BR 9808491	A	20000523	BR 1998-8491	19980408
	JP 2001523223	T2	20011120	JP 1998-543055	19980408
	AT 269300	E	20040715	AT 1998-914581	19980408
	ES 2223126	T3	20050216	ES 1998-914581	19980408
	TW 407144	B	20001001	TW 1998-87105217	19980722
	US 6294531	B1	20010925	US 1999-402310	19991001
	NO 9904877	A	19991007	NO 1999-4877	19991007
PRAI	US 1997-42724P	P	19970408		
	US 1997-61327P	P	19971008		
	US 1997-61329P	P	19971008		
	US 1997-61330P	P	19971008		
	US 1997-61331P	P	19971008		
	US 1997-61333P	P	19971008		
	WO 1998-US6928	W	19980408		

OS MARPAT 129:302376

AB Title compds. XZY1CR7R8Y2NHCR3R4GABR5 [Y1 = covalent bond, alkylene, alkenylene, alkyl; Y2 = methylene, alkyl, CF3; Z = O, S, NH, alkyl, etc.; R3 = CH3, CH3CH2; R4 = CH3, CH3CH2; R3-R4 = cyclopropyl; R5 = C6H5, naphthyl, OH, alkoxy, cycloalkyl, CN, NO2, etc.; G = electron pair, COH, CH, CO; R7 = H, OH, alkoxy; R8 = H, alky; R7-R8 = carbonyl moiety; AB = CH2CH2, CH:CH, CC, covalent bond; X = (un)substituted phenylaminosulfonyl, phenylaminocarbonylalkyl, phenylcarbonylamino, phenylsulfonylamino, etc.] exhibiting calcilytic properties are prepared of treating abnormal bone or mineral homeostasis (no data).

IT 214623-53-7P 214625-44-2P 214625-45-3P
 214625-46-4P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);

BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of arylalkylamine as calcilytic compds.)

RN 214623-53-7 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 3-[(2R)-3-[[1,1-dimethyl-2-(2-naphthalenyl)ethyl]amino]-2-hydroxypropoxy]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 214625-44-2 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 3-[(2R)-2-hydroxy-3-[[2-(4-methoxyphenyl)-1,1-dimethylethyl]amino]propoxy]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 214625-45-3 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 3-[(2R)-3-[[1,1-dimethyl-4-phenylbutyl]amino]-2-hydroxypropoxy]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 214625-46-4 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 3-[(2R)-3-[[1,1-dimethyl-2-(1-methyl-1-phenylethoxy)ethyl]amino]-2-hydroxypropoxy]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

IT 214624-36-9P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of arylalkylamine as calcilytic compds.)

RN 214624-36-9 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 7-[(2R)-oxiranylmethoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

AN 1998:591639 CAPLUS Full-text

DN 129:310389

TI Universal template approach to drug design: polyamines as selective muscarinic receptor antagonists

AU Bolognesi, Maria L.; Minarini, Anna; Budriesi, Roberta; Cacciaguerra, Silvia; Chiarini, Alberto; Spampinato, Santi; Tumiatti, Vincenzo; Melchiorre, Carlo

CS Department of Pharmaceutical Sciences, University of Bologna, Bologna, 40126, Italy

SO Journal of Medicinal Chemistry (1998), 41(21), 4150-4160

CODEN: JMCMAR; ISSN: 0022-2623

PB American Chemical Society

DT Journal

LA English

AB The concept that polyamines may represent a universal template in the receptor recognition process is embodied in the design of new selective muscarinic ligands. Tetraamines and diamine diamides analog to tripitramine were synthesized, and their pharmacol. profiles at muscarinic receptor subtypes were assessed by functional expts. in isolated guinea pig left atrium (M2) and ileum (M3) and by binding assays in rat cortex (M1), heart (M2), submaxillary gland (M3), and NG 108-15 cells (M4). It was confirmed that appropriate substituents on the terminal N atoms of a tetraamine template can tune both affinity and selectivity for muscarinic receptors. The novel tetraamine C-tripitramine (17) was able to discriminate significantly M1 and M2 receptors vs. the other subtypes, and in addition it was 100-fold more lipophilic than the lead compound tripitramine. Tripinamide, in which the tetraamine backbone was transformed into a diamine diamide one, retained high affinity for muscarinic subtypes, displaying a binding affinity profile (M2 > M1 > M4 > M3) qual. similar to that of tripitramine. Both these ligands, owing to their improved lipophilicity relative to tripitramine and methoctramine, could serve as tools in investigating cholinergic functions in the central nervous system. Furthermore, notwithstanding the fact that the highest affinity was always associated with muscarinic M2 receptors, for the 1st time polyamines were shown to display high pA2 values also toward muscarinic M3 receptors.


IT 214751-05-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of aromatic heterocyclic polyamines as selective muscarinic receptor antagonists)

RN 214751-05-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,5'-[10,19-dimethyl-1,28-dioxo-3,26-bis(phenylmethyl)-3,10,19,26-tetraazaoctacosane-1,28-diyl]bis[5,10-dihydro-(9CI) (CA INDEX NAME)



IT 214751-07-2P


RL: PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of aromatic heterocyclic polyamines as selective muscarinic receptor antagonists and their functional activity)

RN 214751-07-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,5'-(10,19-dimethyl-1,28-dioxo-

3,10,19,26-tetrazaoctacosane-1,28-diyl)bis[5,10-dihydro- (9CI) (CA INDEX NAME)




IT 214751-09-4P

RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(preparation of aromatic heterocyclic polyamines as selective muscarinic receptor antagonists and their functional activity)



RN 214751-09-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,5'-[[[6-[[8-[[6-[[2-(10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-5-yl)-2-oxoethyl]amino]hexyl]methylamino]octyl]methylamino]hexyl]imino]bis(1-oxo-2,1-ethanediyl)]bis[5,10-dihydro- (9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 2-A



L25 ANSWER 21 OF 104 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1998:517394 CAPLUS Full-text
 DN 129:245121
 TI Synthesis of some substituted dibenzodiazepinones and
 pyridobenzodiazepinones
 AU Cohen, Victor I.; Jin, Biyun; Cohen, Emil I.; Zeeberg, Barry R.; Reba,
 Richard C.
 CS Section Radiopharmaceutical Chem., George Washington Univ. Medical Center,
 Washington, DC, 20037, USA
 SO Journal of Heterocyclic Chemistry (1998), 35(3), 675-686
 CODEN: JHTCAD; ISSN: 0022-152X
 PB HeteroCorporation
 DT Journal
 LA English
 AB Fluoro- and iodo-derivs. of 5-[[4-[(4-diisobutylamino)butyl]-1-
 phenyl]acetyl]-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepin-11-one and 11-[[4-
 [(dialkylamino)butyl]-1-phenyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-
 b][1,4]benzodiazepin-6-ones and their analogs were synthesized. The synthesis
 of dibenzodiazepinones was based on the reaction between 1,4-phenylenediamine
 and substituted benzoic acids. The intermediate pyridobenzodiazepinones were
 prepared by condensation of 2-chloro-3-aminopyridine with Me anthranilate and
 its chlorine derivative. The condensation of 4-[(halo)alkyl]phenylacetyl
 chloride with dibenzodiazepinones and pyridobenzodiazepinones followed by the
 reaction of mono- or dialkyl- or dialkenylamine provided 11-[[4-
 [(dialkylamino)butyl]-1-phenyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-
 b][1,4]benzodiazepin-6-ones.
 IT 5814-41-5P 163400-03-1P 213208-08-3P
 213208-09-4P 213208-10-7P 213208-11-8P
 213208-12-9P 213208-13-0P 213208-14-1P
 213208-17-4P 213208-18-5P 213208-19-6P
 213208-20-9P 213208-21-0P 213208-22-1P
 213208-23-2P 213208-24-3P 213208-25-4P
 213208-26-5P 213208-33-4P 213208-39-0P
 213208-40-3P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of dibenzodiazepinone and pyridobenzodiazepinone derivs.)
 RN 5814-41-5 CAPLUS
 CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro- (7CI, 8CI, 9CI) (CA
 INDEX NAME)




RN 163400-03-1 CAPLUS
 CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-(4-bromobutyl)phenyl]acetyl]-
 5,10-dihydro- (9CI) (CA INDEX NAME)




RN 213208-08-3 CAPLUS

CN Carbamic acid, (10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-2-yl)-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 213208-09-4 CAPLUS

CN Carbamic acid, (10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-4-yl)-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 213208-10-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-(4-bromobutyl)phenyl]acetyl]-1-fluoro-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 213208-11-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-(4-bromobutyl)phenyl]acetyl]-3-fluoro-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 213208-12-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 2-chloro-5-[[4-(3-chloropropyl)phenyl]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)



RN 213208-13-0 CAPLUS


CN Carbamic acid, [5-[[4-(4-bromobutyl)phenyl]acetyl]-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-2-yl]-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 213208-14-1 CAPLUS


CN Carbamic acid, [5-[[4-(4-bromobutyl)phenyl]acetyl]-10,11-dihydro-11-oxo-5H-

dibenzo[b,e][1,4]diazepin-4-yl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 213208-17-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-[[4-[bis(2-methyl-2-propenyl)amino]butyl]phenyl]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)



RN 213208-18-5 CAPLUS


CN Carbamic acid, [5-[[4-[[4-[bis(2-methylpropyl)amino]butyl]phenyl]acetyl]-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-2-yl]-, phenylmethyl ester (9CI) (CA INDEX NAME)



(i-Bu)₂N-(CH₂)₄

RN 213208-19-6 CAPLUS


CN Carbamic acid, [5-[[4-[4-[bis(2-methylpropyl)amino]butyl]phenyl]acetyl]-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-4-yl]-, phenylmethyl ester (9CI) (CA INDEX NAME)



(i-Bu)₂N-(CH₂)₄

RN 213208-20-9 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-[4-(diethylamino)butyl]phenyl]acetyl]-1-fluoro-5,10-dihydro- (9CI) (CA INDEX NAME)



Et₂N-(CH₂)₄


RN 213208-21-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-[4-[bis(1-methylethyl)amino]butyl]phenyl]acetyl]-1-fluoro-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 213208-22-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-[4-(diethylamino)butyl]phenyl]acetyl]-3-fluoro-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 213208-23-2 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-[4-[bis(1-methylethyl)amino]butyl]phenyl]acetyl]-3-fluoro-5,10-dihydro- (9CI) (CA INDEX NAME)



RN 213208-24-3 CAPLUS
 CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-[4-[bis(2-methylpropyl)amino]butyl]phenyl]acetyl]-3-fluoro-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 213208-25-4 CAPLUS
 CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 2-chloro-5-[[4-[3-(ethylamino)propyl]phenyl]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 213208-26-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-[4-(ethylamino)butyl]phenyl]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 213208-33-4 CAPLUS

CN Pentanamide, N-[3-[4-[2-(2-chloro-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-5-yl)-2-oxoethyl]phenyl]propyl]-N-ethyl-2,2-dimethyl- (9CI) (CA INDEX NAME)



RN 213208-39-0 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 2-amino-5-[[4-[4-[bis(2-methylpropyl)amino]butyl]phenyl]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)



(i-Bu)₂N-(CH₂)₄

RN 213208-40-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 4-amino-5-[[4-[4-[bis(2-methylpropyl)amino]butyl]phenyl]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)




(i-Bu)₂N-(CH₂)₄

IT 213208-32-3P 213208-34-5P 213208-35-6P
213208-36-7P 213208-37-8P 213208-38-9P
213208-41-4P 213208-42-5P 213208-43-6P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of dibenzodiazepinone and pyridobenzodiazepinone derivs.)


RN 213208-32-3 CAPLUS

CN Pentanamide, N-[3-[4-[2-(10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-5-yl)-2-oxoethyl]phenyl]propyl]-N-ethyl-2,2-dimethyl- (9CI) (CA INDEX NAME)




RN 213208-34-5 CAPLUS

CN Pentanamide, N-[4-[4-[2-(10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-5-yl)-2-oxoethyl]phenyl]butyl]-N-ethyl-2,2-dimethyl- (9CI) (CA INDEX NAME)




RN 213208-35-6 CAPLUS

CN Pentanamide, N-[4-[4-[2-(2-chloro-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-5-yl)-2-oxoethyl]phenyl]butyl]-N-ethyl-2,2-dimethyl- (9CI) (CA INDEX NAME)




RN 213208-36-7 CAPLUS

CN Butanamide, N-[4-[4-[2-(10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-5-yl)-2-oxoethyl]phenyl]butyl]-N-(2-methylpropyl)- (9CI) (CA INDEX NAME)




RN 213208-37-8 CAPLUS

CN Propanamide, N-[4-[4-[2-(10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-5-yl)-2-oxoethyl]phenyl]butyl]-2-methyl-N-(2-methylpropyl)- (9CI) (CA INDEX NAME)




RN 213208-38-9 CAPLUS

CN Butanamide, N-[4-[4-[2-(10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-5-yl)-2-oxoethyl]phenyl]butyl]-3-methyl-N-(2-methylpropyl)- (9CI) (CA INDEX NAME)




RN 213208-41-4 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-[4-[bis(2-methylpropyl)amino]butyl]phenyl]acetyl]-5,10-dihydro-2-iodo- (9CI) (CA INDEX NAME)



RN 213208-42-5 CAPLUS
 CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-[4-[bis(2-methylpropyl)amino]butyl]phenyl]acetyl]-5,10-dihydro-4-iodo- (9CI) (CA INDEX NAME)




RN 213208-43-6 CAPLUS
 CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-[4-[bis(2-methylpropyl)amino]butyl]phenyl]acetyl]-5,10-dihydro-10-iodo- (9CI) (CA INDEX NAME)



RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT


L25 ANSWER 22 OF 104 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1998:380616 CAPLUS Full-text
 DN 129:117709
 TI Comparison of the in vitro and in vivo profiles of tolterodine with those of subtype-selective muscarinic receptor antagonists
 AU Gillberg, Per-Goran; Sundquist, Staffan; Nilvebrant, Lisbeth
 CS Department of Pharmacology, Pharmacia and Upjohn, Uppsala, SE-752 81, Swed.
 SO European Journal of Pharmacology (1998), 349(2/3), 285-292
 CODEN: EJPHAZ; ISSN: 0014-2999
 PB Elsevier Science B.V.
 DT Journal
 LA English
 AB Tolterodine [(R)-N,N-diisopropyl-3-(2-hydroxy-5-methylphenyl)-3-phenylpropanamine] is a new potent and competitive muscarinic receptor antagonist developed for the treatment of urinary urge incontinence and other symptoms of overactive bladder. In vivo, tolterodine exhibits functional selectivity for the urinary bladder over salivary glands, a profile that cannot be explained in terms of selectivity for a single muscarinic receptor subtype. The aim of this study was to compare the in vitro and in vivo antimuscarinic profiles of tolterodine with those of muscarinic receptor antagonists with distinct receptor subtype-selectivity profiles: darifenacin [(S)-2-(1-[2-(2,3-dihydrobenzofuran-5-yl)ethyl]-3-pyrrolidinyl)-2,2-diphenylacetamide; selective for muscarinic M3 receptors]; UH-AH 37 (6-chloro-5,10-dihydro-5-[(1-methyl-4-piperidinyl)acetyl]-11H-dibenzo-[b,e][1,4]diazepine-11-one; low affinity for muscarinic M2 receptors); and AQ-RA 741 (11-[(4-[4-(diethylamino)butyl]-1-piperidinyl)acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine-6-one; high affinity for muscarinic M2 receptors). The in vitro profiles of these compds. were in agreement with previous reports; darifenacin and UH-AH 37 demonstrated selectivity for muscarinic M3/m3 over M2/m2 receptors, while the converse was observed for AQ-RA 741. In vivo, AQ-RA 741 was more potent (1.4-2.7-fold) in inhibiting urinary bladder contraction than salivation in the anesthetized cat (i.e., a profile similar to that of tolterodine [2.5-3.3-fold]), while darifenacin and UH-AH 37 showed the reverse selectivity profile (0.6-0.8 and 0.4-0.5-fold, resp.). The results confirm that it is possible to sep. the antimuscarinic effects on urinary bladder and salivary glands in vivo. The data on UH-AH 37 and darifenacin support the view that a selectivity for muscarinic M3/m3 over M2/m2 receptors may result in a more pronounced effect on salivation than on bladder contraction. The data on AQ-RA 741 may indicate that muscarinic M2/m2 receptors may have a role in bladder contraction.
 IT 120382-14-1, UH-AH 37
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (comparison of the in vitro and in vivo profiles of tolterodine with those of subtype-selective muscarinic receptor antagonists)
 RN 120382-14-1 CAPLUS
 CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 6-chloro-5,10-dihydro-5-[(1-methyl-4-piperidinyl)acetyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RE.CNT 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


GI



```
(preparation, muscarinic receptor antagonist activity, and structure
activity relationship of phenylacetyl pyridobenzodiazepinones and
```

dibenzodiazepinones)
 RN 185801-57-4 CAPLUS
 CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[[3-nitro-4-[3-(1-piperidinyl)propoxy]phenyl]acetyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




IT 185801-55-2P 185801-60-9P 185801-62-1P
 185801-64-3P 185801-68-7P 185801-71-2P
 185801-77-8P 185801-80-3P 185801-84-7P
 185802-41-9P 185802-49-7P 203071-53-8P
 203071-54-9P 203071-55-0P 203071-56-1P
 203071-57-2P 203071-58-3P 203071-59-4P
 203071-60-7P 203071-61-8P 203071-62-9P
 203071-63-0P 203071-64-1P 203071-65-2P
 203071-66-3P 203071-67-4P 203071-68-5P
 203071-69-6P 203071-70-9P 203071-71-0P
 203071-74-3P 203071-75-4P 203071-76-5P
 203071-77-6P 203071-78-7P 203071-79-8P
 203071-80-1P 203071-81-2P 203071-84-5P
 203071-85-6P 203071-86-7P 203071-87-8P
 203071-89-0P 203071-90-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation, muscarinic receptor antagonist activity, and structure activity relationship of phenylacetyl pyridobenzodiazepinones and dibenzodiazepinones)


RN 185801-55-2 CAPLUS
 CN Propanamide, 3-(diethylamino)-N-[4-[2-(10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-5-yl)-2-oxoethyl]phenyl]- (9CI) (CA INDEX NAME)



RN 185801-60-9 CAPLUS

CN Acetamide, N-[5-[2-(10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-5-yl)-2-oxoethyl]-2-[3-(1-piperidinyl)propoxy]phenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A





RN 185801-62-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[[4-[3-(1-piperidinyl)propoxy]phenyl]acetyl]- (9CI) (CA INDEX NAME)




RN 185801-64-3 CAPLUS.
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-[3-[ethyl[[4-(4-ethyl-1-piperazinyl)phenyl]methyl]amino]propoxy]phenyl]acetyl]-5,10-dihydro- (9CI)
(CA INDEX NAME)



RN 185801-68-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-[3-(cyclohexylethylamino)propoxy]phenyl]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 185801-71-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-[3-[ethyl (phenylmethyl) amino]propoxy]phenyl]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 185801-77-8 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[3-[3-(diethylamino)propoxy]phenyl]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)



RN 185801-80-3 CAPLUS
 CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-[2-(diethylamino)ethoxy]phenyl]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 185801-84-7 CAPLUS
 CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-[3-(diethylamino)propoxy]phenyl]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)



RN 185802-41-9 CAPLUS
 CN Propanamide, N-[5-[2-(10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-5-yl)-2-oxoethyl]-2-[3-(1-piperidinyl)propoxy]phenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 185802-49-7 CAPLUS

CN Carbamic acid, [5-[2-(10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-5-yl)-2-oxoethyl]-2-[3-(1-piperidinyl)propoxy]phenyl]-, methyl ester (9CI)
(CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 203071-53-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[2-[3-(diethylamino)propoxy]phenyl]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 203071-54-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-[3-(diethylamino)propoxy]phenyl]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 203071-55-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-[4-(diethylamino)butoxy]phenyl]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)



RN 203071-56-1 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-[5-(diethylamino)pentyl]oxy]phenyl]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)



Et₂N—(CH₂)₅—O

RN 203071-57-2 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-[[6-(diethylamino)hexyl]oxy]phenyl]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)



Et₂N—(CH₂)₆—O

RN 203071-58-3 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-[3-(dimethylamino)propoxy]phenyl]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)



Me₂N—(CH₂)₃—O

RN 203071-59-4 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-[3-bis(1-methylethyl)amino]propoxy]phenyl]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)



(i-Pr)₂N- (CH₂)₃-O

RN 203071-60-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-[3-bis(2-methylpropyl)amino]propoxy]phenyl]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)




(i-Bu)₂N- (CH₂)₃-O

RN 203071-61-8 CAPLUS



CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[[4-[3-(1-pyrrolidinyl)propoxy]phenyl]acetyl]- (9CI) (CA INDEX NAME)

PAGE 1-A






RN 203071-62-9 CAPLUS
 CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-[3-(hexahydro-1H-azepin-1-yl)propoxy]phenyl]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 203071-63-0 CAPLUS
 CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-[3-(hexahydro-1(2H)-azocinyl)propoxy]phenyl]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A





RN 203071-64-1 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[[4-[3-(4-morpholinyl)propoxy]phenyl]acetyl]- (9CI) (CA INDEX NAME)

PAGE 1-A






RN 203071-65-2 CAPLUS
 CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[[4-[3-(4-methyl-1-piperazinyl)propoxy]phenyl]acetyl]- (9CI) (CA INDEX NAME)




RN 203071-66-3 CAPLUS
 CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[[4-[3-(4-methyl-1-piperidinyl)propoxy]phenyl]acetyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 203071-67-4 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-[3-(3,5-dimethyl-1-piperidinyl)propoxy]phenyl]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 203071-68-5 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-[3-(2,6-dimethyl-1-piperidinyl)propoxy]phenyl]acetyl]-5,10-dihydro-, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.




RN 203071-69-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[[4-[3-(4-phenyl-1-piperidinyl)propoxy]phenyl]acetyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 203071-70-9 CAPLUS
 CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[[4-[3-[4-(phenylmethyl)-1-piperidinyl]propoxy]phenyl]acetyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 203071-71-0 CAPLUS
 CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[[4-[3-[4-(phenylmethoxy)-1-piperidinyl]propoxy]phenyl]acetyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 203071-74-3 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[3-acetyl-4-[3-(1-piperidinyl)propoxy]phenyl]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 203071-75-4 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[[3-(1-oxopropyl)-4-[3-(1-piperidinyl)propoxy]phenyl]acetyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 203071-76-5 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[3-fluoro-4-[3-(1-piperidinyl)propoxy]phenyl]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 203071-77-6 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[3-chloro-4-[3-(1-piperidinyl)propoxy]phenyl]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 203071-78-7 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[3-bromo-4-[3-(1-piperidinyl)propoxy]phenyl]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 203071-79-8 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[[3-methoxy-4-[3-(1-piperidinyl)propoxy]phenyl]acetyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 203071-80-1 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[3-ethyl-4-[3-(1-piperidinyl)propoxy]phenyl]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 203071-81-2 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[[4-[3-(1-piperidinyl)propoxy]-3-propylphenyl]acetyl]- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 203071-84-5 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[[3-[(methylsulfonyl)amino]-4-[3-(1-piperidinyl)propoxy]phenyl]acetyl]- (9CI) (CA INDEX NAME)



RN 203071-85-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[[4-[[3-(1-piperidinyl)propyl]amino]phenyl]acetyl]- (9CI) (CA INDEX NAME)




PAGE 2-A




RN 203071-86-7 CAPLUS
CN 1-Piperidinepropanamide, N-[4-[2-(10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-5-yl)-2-oxoethyl]phenyl]- (9CI) (CA INDEX NAME)



PAGE 1-A




PAGE 2-A




RN 203071-87-8 CAPLUS
CN 1-Pyrrolidinepropanamide, N-[4-[2-(10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-5-yl)-2-oxoethyl]phenyl]- (9CI) (CA INDEX NAME)



RN 203071-89-0 CAPLUS
 CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[[4-[[3-(1-piperidinyl)propyl]sulfinyl]phenyl]acetyl]- (9CI) (CA INDEX NAME)



RN 203071-90-3 CAPLUS
 CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[[4-[[3-(1-piperidinyl)propyl]sulfonyl]phenyl]acetyl]- (9CI) (CA INDEX NAME)




IT 5814-41-5

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation, muscarinic receptor antagonist activity, and structure activity relationship of phenylacetyl pyridobenzodiazepinones and dibenzodiazepinones)

RN 5814-41-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro- (7CI, 8CI, 9CI) (CA INDEX NAME)



IT 185801-59-6P 185802-60-2P 185802-63-5P

185802-65-7P 185803-03-6P 185803-05-8P


185803-49-0P 185803-50-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation, muscarinic receptor antagonist activity, and structure activity relationship of phenylacetyl pyridobenzodiazepinones and dibenzodiazepinones)


RN 185801-59-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[3-amino-4-[3-(1-piperidinyl)propoxy]phenyl]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 185802-60-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[(4-nitrophenyl)acetyl]- (9CI) (CA INDEX NAME)




RN 185802-63-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[(4-aminophenyl)acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 185802-65-7 CAPLUS

CN Propanamide, 3-chloro-N-[4-[2-(10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-5-yl)-2-oxoethyl]phenyl]- (9CI) (CA INDEX NAME)




RN 185803-03-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-(3-bromopropoxy)phenyl]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 185803-05-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-(3-chloropropoxy)phenyl]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 185803-49-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-[(3-bromopropyl)thio]phenyl]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)



RN 185803-50-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-[(3-chloropropyl)thio]phenyl]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)



IT 185802-38-4P 203071-88-9P


RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation, muscarinic receptor antagonist activity, and structure activity relationship of phenylacetyl pyridobenzodiazepinones and dibenzodiazepinones)

RN 185802-38-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[3-(formylamino)-4-[3-(1-piperidinyl)propoxy]phenyl]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 203071-88-9 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[[4-[[3-(1-piperidinyl)propyl]thio]phenyl]acetyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RE.CNT 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 24 OF 104 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1997:730155 CAPLUS Full-text
 DN 128:30255
 TI New 5-aminoacyl-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-ones with antiarrhythmic activity
 AU Poppe, H.; Kaverina, N. V.; Lyskovzev, V. V.; Egerland, U.; Sauer, W.; Lichoscherstow, A.; Ruger, Carla; Skoldinow, A.
 CS Corporate Research Development, Arzneimittelwerk Dresden G.m.b.H., Radebeul, D-01445, Germany
 SO Pharmazie (1997), 52(11), 821-830
 CODEN: PHARAT; ISSN: 0031-7144
 PB Govi-Verlag Pharmazeutischer Verlag
 DT Journal
 LA English
 AB A series of new 5-substituted tricyclic 5,10-dihydro-11H-dibenzo[b,e][1,4]-diazepin-11-ones was identified as potential antiarrhythmic agents against bradyarrhythmias. The in vitro and in vivo interactions of the compds. with muscarinic receptors and the antiarrhythmic activity were examined. In receptor binding studies some derivs. showed a high affinity to the cardiac M2 receptor (K_i 10 nmol/L), an equal or smaller affinity to cortical M1 receptor and a lower affinity to the glandular M3 binding site. Functional expts. showed the derivs. as competitive antagonists with high affinity to the cardiac and smaller affinity to the intestinal muscarinic receptor. In vivo expts. correspond with the M2 selectivity. First the vagal or agonist-induced bradycardia was inhibited in rats and guinea pigs while the McNA-343 induced increase of blood pressure, methacholine-induced bronchi and bladder constriction as well as the salivation were inhibited only at higher doses. In conscious cats the tachycardia was examined in comparison with pupillomotoricity. The effect duration and the therapeutical range were determined in comparison to the M2 selective blocking agent AF-DX116. The antiarrhythmic activity was examined compared to quinidine sulfate in $CaCl_2$ -arrhythmia of rats, in atrial fibrillation and atrial flutter in dogs and in elec. induced atrial fibrillation under vagal stimulation in cats. In the atrial arrhythmias the derivs. are clearly longer effective than quinidine sulfate. The antiischemic activity was examined in the 2-stages coronary ligation in dogs. The long-running regularization of ectopies (about 2 h after i.v. injection) occurred without decrease of the heart rate, an effect particularly convenient to therapy of bradycardic dysrhythmias.
 IT 134000-77-4 134019-10-6 145950-54-5
 145950-55-6 199797-02-9 199797-06-3
 199797-17-6
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (aminoacyl dibenzodiazepinones with antiarrhythmic activity)
 RN 134000-77-4 CAPLUS
 CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-chloro-5-[6-(cyclohexylamino)-1-oxohexyl]-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 134019-10-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-chloro-5,10-dihydro-5-[6-(4-methyl-1-piperazinyl)-1-oxohexyl]- (9CI) (CA INDEX NAME)




RN 145950-54-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-chloro-5,10-dihydro-5-[1-oxo-6-[(1-phenylethyl)amino]hexyl]- (9CI) (CA INDEX NAME)




RN 145950-55-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-chloro-5-[6-(cyclopropylamino)-1-oxohexyl]-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 199797-02-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-chloro-5,10-dihydro-5-[4-(4-morpholinyl)-1-oxobutyl]- (9CI) (CA INDEX NAME)




RN 199797-06-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[6-(4-morpholinyl)-1-oxohexyl]- (9CI) (CA INDEX NAME)




RN 199797-17-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-chloro-5-[[[3-[(2,6-

O=C1NC(=O)c2ccccc2N1Cc3cc(Cl)ccc3CNC4CCCC4Nc5cc(Cl)c(Cl)cc5CN(Cc1ccccc1)CCCCCNC(=O)c2c3ccccc3n(c2)c4ccc(Cl)cc4


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-chloro-5-[6-(cyclopropylamino)-1-oxohexyl]-5,10-dihydro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 183850-02-4 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-chloro-5-[6-(cyclohexylamino)-1-oxohexyl]-5,10-dihydro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 199797-40-5 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-chloro-5,10-dihydro-5-[4-(4-morpholinyl)-1-oxobutyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 199797-42-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[6-(4-morpholinyl)-1-oxohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L25 ANSWER 25 OF 104 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1997:285637 CAPLUS Full-text

DN 126:343544

TI Synthesis and evaluation of halogenated dibenzodiazepines as muscarinic receptor ligands

AU Kassiou, Michael; Read, Roger W.; Shi, Xue-Qin

CS Radiopharmaceuticals Division, ANSTO, Menai, NSW 2234, Australia

SO Bioorganic & Medicinal Chemistry Letters (1997), 7(7), 799-804

CODEN: BMCLE8; ISSN: 0960-894X

PB Elsevier

DT Journal

LA English


AB Syntheses of four novel amide analogs of the muscarinic M2 receptor antagonists, DIBA and BIBN 140, are described from a common intermediate. Pharmacol. evaluation through in vitro assays reveals high muscarinic receptor affinity in each of the compds., but variable subtype selectivity, primarily M2 but in one case M3.

IT 189938-90-7P 189938-91-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent) (preparation and muscarinic receptor binding of dibenzodiazepines)


RN 189938-90-7 CAPLUS

CN Carbamic acid, [4-[1-[2-(10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-5-yl)-2-oxoethyl]-4-piperidinyl]butyl]ethyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 189938-91-8 CAPLUS

CN Carbamic acid, [4-[1-[2-(10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-5-yl)-2-oxoethyl]-4-piperidinyl]butyl]-, ethyl ester (9CI) (CA INDEX NAME)




IT 189938-92-9P 189938-93-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and muscarinic receptor binding of dibenzodiazepines)


RN 189938-92-9 CAPLUS

CN Benzamide, N-[4-[1-[2-(10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-5-yl)-2-oxoethyl]-4-piperidinyl]butyl]-N-ethyl-3-iodo- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 189938-93-0 CAPLUS

CN Benzamide, N-[4-[1-[2-(10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-5-yl)-2-oxoethyl]-4-piperidinyl]butyl]-N-ethyl-4-fluoro- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RE.CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 26 OF 104 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1997:145240 CAPLUS Full-text

DN 126:157525

TI Tricyclic inhibitors of protein farnesyltransferase

IN Bolton, Gary Louis; Doherty, Annette Marian; Kaltenbronn, James Stanley; Quin, John, III; Scholten, Jeffrey D.; Sebolt-Leopold, Judith; Zinnes, Harold

PA Warner-Lambert Company, USA; Bolton, Gary Louis; Doherty, Annette Marian; Kaltenbronn, James Stanley; Quin, John, III; Scholten, Jeffrey D.; Sebolt-Leopold, Judith; Zinnes, Harold

SO PCT Int. Appl., 82 pp.



CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 9700252	A1	19970103	WO 1996-US8528	19960604
	W: AU, BG, CA, CN, CZ, EE, GE, HU, IL, JP, KR, LT, LV, MX, NO, NZ, PL, RO, SG, SI, SK, UA, US, UZ, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	AU 9660342	A1	19970115	AU 1996-60342	19960604
	US 5919780	A	19990706	US 1997-981505	19971211
PRAI	US 1995-913P	P	19950616		
	WO 1996-US8528	W	19960604		
OS	MARPAT 126:157525				
GI					



AB Title compds. I [wherein X = N or CR₉; Y = NR₁₀, CH₂, O, S, SO, SO₂, C:O, or CH(OH); R = H or alkyl; R₁ = heteroaryl; n = 1-5; R₂-R₁₀ = H or various substituents] are useful as inhibitors of protein farnesyltransferase (PFT), and thus for the treatment of proliferative diseases including cancer, restenosis and psoriasis, and as antiviral agents. For example, condensation of 8-chloro-5,10-dihydrodibenzo[b,e][1,4]diazepine-11-one with 3-(aminomethyl)pyridine in refluxing EtOCH₂CH₂OH gave 80% title compound II. Eighteen I were prepared and tested for PFT inhibiting and anticancer activity. In two in vitro bioassays, II had IC₅₀ values of 3.7 and 5.0 μ M against PFT.


IT **167892-64-0P**, 8-(Benzyloxy)-5,10-dihydrodibenzo[b,e][1,4]diazepin-11-one

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of tricyclic inhibitors of protein farnesyltransferase)


RN 167892-64-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-(phenylmethoxy)-(9CI) (CA INDEX NAME)



L25 ANSWER 27 OF 104 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1997:85185 CAPLUS Full-text
 DN 126:104108
 TI Preparation of fused benzodiazepinone derivatives for the treatment of heart diseases
 IN Watanabe, Toshihiro; Kakefuda, Akio; Tanaka, Akihiro
 PA Yamanouchi Pharmaceutical Co., Ltd., Japan
 SO PCT Int. Appl., 67 pp.
 CODEN: PIXXD2
 DT Patent
 LA Japanese
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9638422	A1	19961205	WO 1996-JP1462	19960530
	W: AL, AM, AU, AZ, BB, BG, BR, BY, CA, CN, CZ, EE, GE, HU, IS, JP, KE, KG, KR, KZ, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9658447	A1	19961218	AU 1996-58447	19960530
	CN 1180350	A	19980429	CN 1996-193058	19960530
PRAI	JP 1995-133609	A	19950531		
	WO 1996-JP1462	W	19960530		
OS	MARPAT 126:104108				
GI					




AB Fused benzodiazepinone derivs. represented by general formula I [X represents CH or N; Y represents oxygen, NR₄, S(O)_n or NR₅CO, wherein R₄ and R₅ are the same or different and each represents hydrogen or lower alkyl; and n is an integer of from 0 to 2; A represents lower alkylene; R₁ and R₂ are the same or different and each represents hydrogen, lower alkyl, cycloalkyl, optionally substituted aryl or optionally substituted aralkyl, or R₁ and R₂ together with the nitrogen atom to which they are bonded may form a 4- to 9-membered nitrogen-containing saturated heterocycle optionally further containing one of oxygen, sulfur and nitrogen atoms and optionally having substituent(s); and R₃ represents hydrogen, optionally substituted lower alkyl, hydroxy, lower alkoxy, nitro, halogeno, lower acyl or optionally substituted amino] are prepared I have medicinal effects, in particular, preventive or therapeutic effects on heart diseases in which muscarinic M₂ receptors participate. I show high affinity for the muscarinic M₂ receptors.

IT 185801-55-2P 185801-56-3P 185801-57-4P
 185801-58-5P 185801-59-6P 185801-60-9P
 185801-61-0P 185801-62-1P 185801-63-2P
 185801-64-3P 185801-65-4P 185801-66-5P
 185801-67-6P 185801-69-8P 185801-70-1P
 185801-72-3P 185801-74-5P 185801-75-6P
 185801-76-7P 185801-77-8P 185801-78-9P
 185801-79-0P 185801-80-3P 185801-81-4P
 185801-82-5P 185801-83-6P 185801-84-7P
 185801-85-8P 185801-86-9P 185801-87-0P
 185801-88-1P 185801-89-2P 185801-90-5P
 185801-91-6P 185801-93-8P 185801-95-0P
 185801-98-3P 185802-00-0P 185802-02-2P
 185802-08-8P 185802-09-9P 185802-11-3P
 185802-13-5P 185802-16-8P 185802-19-1P
 185802-21-5P 185802-24-8P 185802-27-1P
 185802-29-3P 185802-33-9P 185802-35-1P
 185802-38-4P 185802-41-9P 185802-49-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of fused benzodiazepinone derivs. for the treatment of heart diseases)


RN 185801-55-2 CAPLUS

CN Propanamide, 3-(diethylamino)-N-[4-[2-(10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-5-yl)-2-oxoethyl]phenyl]- (9CI) (CA INDEX NAME)



RN 185801-56-3 CAPLUS


CN Propanamide, 3-(diethylamino)-N-[4-[2-(10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-5-yl)-2-oxoethyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



RN 185801-57-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[[3-nitro-4-[3-(1-piperidinyl)propoxy]phenyl]acetyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 185801-58-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[[3-nitro-4-[3-(1-piperidinyl)propoxy]phenyl]acetyl]-, monohydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● HCl

RN 185801-59-6 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[3-amino-4-[3-(1-piperidinyl)propoxy]phenyl]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)



RN 185801-60-9 CAPLUS
 CN Acetamide, N-[5-[2-(10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-5-yl)-2-oxoethyl]-2-amino-3-(3-(1-piperidinyl)propoxy)phenyl]- (9CI) (CA INDEX NAME)




PAGE 2-A




RN 185801-61-0 CAPLUS
CN Acetamide, N-[5-[2-(10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-5-yl)-2-oxoethyl]-2-[3-(1-piperidinyl)propoxy]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



● HCl

RN 185801-62-1 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[[4-[3-(1-piperidinyl)propoxy]phenyl]acetyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 185801-63-2 CAPLUS
CN 1-Piperidinepropanamide, N-[4-[2-(10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-5-yl)-2-oxoethyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● HCl


RN 185801-64-3 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-[3-[ethyl[[4-(4-ethyl-1-piperazinyl)phenyl]methyl]amino]propoxy]phenyl]acetyl]-5,10-dihydro- (9CI)
(CA INDEX NAME)

PAGE 1-A





RN 185801-65-4 CAPLUS
 CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[3-ethyl-4-[3-(1-piperidinyl)propoxy]phenyl]acetyl]-5,10-dihydro-, monohydrochloride (9CI)
 (CA INDEX NAME)




● HCl


RN 185801-66-5 CAPLUS
 CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-[3-(2,6-dimethyl-1-piperidinyl)propoxy]phenyl]acetyl]-5,10-dihydro-, monohydrochloride (9CI)

(CA INDEX NAME)

PAGE 1-A




PAGE 2-A



● HCl

RN 185801-67-6 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-[3-[bis(1-methylethyl)amino]propoxy]phenyl]acetyl]-5,10-dihydro-, monohydrochloride (9CI) (CA INDEX NAME)



(i-Pr)₂N—(CH₂)₃—O


● HCl

RN 185801-69-8 CAPLUS
 CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-[3-(cyclohexylethylamino)propoxy]phenyl]acetyl]-5,10-dihydro-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 185801-68-7
 CMF C32 H37 N3 O3

PAGE 1-A






CM 2

CRN 110-17-8


CMF C4 H4 O4

Double bond geometry as shown.



RN 185801-70-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-[3-(diethylamino)propoxy]phenyl]acetyl]-5,10-dihydro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 185801-72-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-[3-[ethyl(phenylmethyl)amino]propoxy]phenyl]acetyl]-5,10-dihydro-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 185801-71-2

CMF C33 H33 N3 O3



CM 2


CRN 144-62-7
CMF C2 H2 O4



RN 185801-74-5 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[3-[3-[ethyl(phenylmethyl)amino]propoxy]phenyl]acetyl]-5,10-dihydro-, (2E)-2-butenedioate (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 185801-73-4
CMF C33 H33 N3 O3




CM 2

CRN 110-17-8

CMF C4 H4 O4


Double bond geometry as shown.




RN 185801-75-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[[4-[3-(1-piperidinyl)propoxy]phenyl]acetyl]-, monohydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



● HCl


RN 185801-76-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[2-[3-(diethylamino)propoxy]phenyl]acetyl]-5,10-dihydro-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 185801-77-8 CAPLUS
 CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[3-[3-(diethylamino)propoxy]phenyl]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 185801-78-9 CAPLUS
 CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[3-[2-(diethylamino)ethoxy]phenyl]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 185801-79-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[2-[2-(diethylamino)ethoxy]phenyl]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 185801-80-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-[2-(diethylamino)ethoxy]phenyl]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 185801-81-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-[3-(diethylamino)propoxy]-3-nitrophenyl]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)



RN 185801-82-5 CAPLUS
 CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[[4-[3-(1-pyrrolidinyl)propoxy]phenyl]acetyl]-, monohydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




● HCl


RN 185801-83-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-[3-(hexahydro-1H-azepin-1-yl)propoxy]phenyl]acetyl]-5,10-dihydro-, monohydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



● HCl

RN 185801-84-7 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-[3-(dipropylamino)propoxy]phenyl]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)




(n-Pr)₂N- (CH₂)₃-O

RN 185801-85-8 CAPLUS
 CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[[4-[3-(4-phenyl-1-piperidinyl)propoxy]phenyl]acetyl]-, monohydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A



● HCl



RN 185801-86-9 CAPLUS
 CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[[4-[3-[4-(phenylmethyl)-1-piperidinyl]propoxy]phenyl]acetyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 185801-87-0 CAPLUS



CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[[4-[3-(4-phenoxy-1-piperidiny)propoxy]phenyl]acetyl]-, monohydrochloride (9CI) (CA INDEX NAME)





● HCl

RN 185801-88-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[[4-[3-[4-(phenylamino)-1-piperidiny]propoxy]phenyl]acetyl]- (9CI) (CA INDEX NAME)



RN 185801-89-2 CAPLUS
 CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[[4-[3-[4-(phenylmethoxy)-1-piperidinyl]propoxy]phenyl]acetyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl


RN 185801-90-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[[4-[3-(4-methyl-1-piperidiny)propoxy]phenyl]acetyl]-, monohydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● HCl

RN 185801-91-6 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-[3-(3,5-dimethyl-1-piperidinyl)propoxy]phenyl]acetyl]-5,10-dihydro-, monohydrochloride (9CI)
(CA INDEX NAME)

PAGE 1-A





PAGE 2-A



● HCl



RN 185801-93-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[[4-[3-(4-morpholinyl)propoxy]phenyl]acetyl]-, monohydrochloride (9CI) (CA INDEX NAME)





● HCl

RN 185801-95-0 CAPLUS
 CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[3-acetyl-4-[3-(1-piperidinyl)propoxy]phenyl]acetyl]-5,10-dihydro-, monohydrochloride (9CI)
 (CA INDEX NAME)



● HCl


RN 185801-98-3 CAPLUS
 CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[3-bromo-4-[3-(1-piperidinyl)propoxy]phenyl]acetyl]-5,10-dihydro-, monohydrochloride (9CI)
 (CA INDEX NAME)



● HCl

RN 185802-00-0 CAPLUS
 CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[[3-methoxy-4-[3-(1-piperidinyl)propoxy]phenyl]acetyl]-, monohydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




● HCl

RN 185802-02-2 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[3-chloro-4-[3-(1-piperidinyl)propoxy]phenyl]acetyl]-5,10-dihydro-, monohydrochloride (9CI)
(CA INDEX NAME)



● HCl


RN 185802-08-8 CAPLUS
 CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-[3-(dimethylamino)propoxy]phenyl]acetyl]-5,10-dihydro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 185802-09-9 CAPLUS
 CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[[3-(1-oxopropyl)-4-[3-(1-piperidinyl)propoxy]phenyl]acetyl]-, monohydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● HCl

RN 185802-11-3 CAPLUS
 CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[[4-[3-(1-piperidinyl)propoxy]-3-propylphenyl]acetyl]-, monohydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




● HCl

RN 185802-13-5 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[[4-[3-(4-methyl-1-piperazinyl)propoxy]phenyl]acetyl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 185802-16-8 CAPLUS
 CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-[3-[bis(2-methylpropyl)amino]propoxy]phenyl]acetyl]-5,10-dihydro-, monohydrochloride (9CI) (CA INDEX NAME)




(i-Bu)₂N—(CH₂)₃—O

● HCl


RN 185802-19-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[3-fluoro-4-[3-(1-piperidinyl)propoxy]phenyl]acetyl]-5,10-dihydro-, monohydrochloride (9CI)
(CA INDEX NAME)

PAGE 1-A




PAGE 2-A



● HCl

RN 185802-21-5 CAPLUS
 CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[[4-[[3-(1-piperidinyl)propyl]thio]phenyl]acetyl]-, monohydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



● HCl


RN 185802-24-8 CAPLUS
 CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[[4-[[3-(1-piperidinyl)propyl]sulfinyl]phenyl]acetyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 185802-27-1 CAPLUS
 CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[[4-[[3-(1-piperidinyl)propyl]sulfonyl]phenyl]acetyl]-, monohydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



● HCl

RN 185802-29-3 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[3-amino-4-[3-(diethylamino)propoxy]phenyl]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)



RN 185802-33-9 CAPLUS

CN Acetamide, N-[2-[3-(diethylamino)propoxy]-5-[2-(10,11-dihydro-11-oxo-5H-


dibenzo[b,e][1,4]diazepin-5-yl)-2-oxoethyl]phenyl]- (9CI) (CA INDEX NAME)




RN 185802-35-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[[3-[(methylsulfonyl)amino]-4-[3-(1-piperidinyl)propoxy]phenyl]acetyl]-, monohydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



● HCl

RN 185802-38-4 CAPLUS
 CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[3-(formylamino)-4-[3-(1-piperidinyl)propoxy]phenyl]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)


PAGE 1'-A




PAGE 2-A



RN 185802-41-9 CAPLUS
 CN Propanamide, N-[5-[2-(10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-5-yl)-2-oxoethyl]-2-[3-(1-piperidinyl)propoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 185802-49-7 CAPLUS
 CN Carbamic acid, [5-[2-(10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-5-yl)-2-oxoethyl]-2-[3-(1-piperidinyl)propoxy]phenyl]-, methyl ester (9CI)
 (CA INDEX NAME)






IT 5814-41-5

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of fused benzodiazepinone derivs. for the treatment of heart diseases)

RN 5814-41-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro- (7CI, 8CI, 9CI) (CA INDEX NAME)




IT 185802-60-2P 185802-63-5P 185802-65-7P
 185802-68-0P 185802-69-1P 185802-70-4P
 185802-97-5P 185802-98-6P 185802-99-7P
 185803-01-4P 185803-03-6P 185803-05-8P
 185803-07-0P 185803-09-2P 185803-11-6P
 185803-14-9P 185803-16-1P 185803-18-3P
 185803-19-4P 185803-21-8P 185803-23-0P
 185803-25-2P 185803-27-4P 185803-29-6P
 185803-36-5P 185803-37-6P 185803-45-6P
 185803-46-7P 185803-47-8P 185803-48-9P
 185803-49-0P 185803-50-3P 185803-51-4P
 185803-52-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of fused benzodiazepinone derivs. for the treatment of heart diseases)


RN 185802-60-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[(4-nitrophenyl)acetyl]- (9CI) (CA INDEX NAME)




RN 185802-63-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[(4-aminophenyl)acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 185802-65-7 CAPLUS

CN Propanamide, 3-chloro-N-[4-[2-(10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-5-yl)-2-oxoethyl]phenyl]- (9CI) (CA INDEX NAME)




RN 185802-68-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-[(3-bromopropyl)sulfinyl]phenyl]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 185802-69-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-[(3-chloropropyl)sulfinyl]phenyl]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 185802-70-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-[(3-chloropropyl)sulfonyl]phenyl]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 185802-97-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-(3-bromopropoxy)-3-nitrophenyl]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 185802-98-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-(3-chloropropoxy)-3-nitrophenyl]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 185802-99-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-(3-bromopropoxy)-3-ethylphenyl]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 185803-01-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-(3-chloropropoxy)-3-ethylphenyl]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 185803-03-6 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-(3-bromopropoxy)phenyl]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)



RN 185803-05-8 CAPLUS
 CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-(3-chloropropoxy)phenyl]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 185803-07-0 CAPLUS
 CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[3-(2-bromoethoxy)phenyl]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 185803-09-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[3-(2-chloroethoxy)phenyl]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 185803-11-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[2-(3-bromopropoxy)phenyl]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 185803-14-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[2-(3-chloropropoxy)phenyl]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 185803-16-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[3-(3-bromopropoxy)phenyl]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 185803-18-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[3-(3-chloropropoxy)phenyl]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 185803-19-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[2-(2-bromoethoxy)phenyl]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 185803-21-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[2-(2-chloroethoxy)phenyl]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 185803-23-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-(2-bromoethoxy)phenyl]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 185803-25-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-(2-chloroethoxy)phenyl]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 185803-27-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[3-acetyl-4-(3-bromopropoxy)phenyl]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 185803-29-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[3-acetyl-4-(3-chloropropoxy)phenyl]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 185803-36-5 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[3-bromo-4-(3-bromopropoxy)phenyl]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)



RN 185803-37-6 CAPLUS
 CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[3-bromo-4-(3-chloropropoxy)phenyl]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 185803-45-6 CAPLUS
 CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-(3-bromopropoxy)-3-(1-oxopropyl)phenyl]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 185803-46-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-(3-chloropropoxy)-3-(1-oxopropyl)phenyl]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 185803-47-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-(3-bromopropoxy)-3-propylphenyl]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 185803-48-9 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-(3-chloropropoxy)-3-propylphenyl]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)



RN 185803-49-0 CAPLUS
 CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-[(3-bromopropyl)thio]phenyl]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 185803-50-3 CAPLUS
 CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-[(3-chloropropyl)thio]phenyl]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 185803-51-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-(3-bromopropoxy)-3-fluorophenyl]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)



RN 185803-52-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-(3-chloropropoxy)-3-fluorophenyl]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)



L25 ANSWER 28 OF 104 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1996:601363 CAPLUS Full-text

DN 126:851

TI Interaction of dialkylaminoacyl derivatives of phenothiazine, dibenzazepine, and dibenzodiazepine with opiate receptors

AU Brusova, E. G.; Likhoshesterov, A. M.; Gritsenko, A. N.

CS Laboratoriya Farmakologii i Krovoobrashcheniya, NII Farmakologii, Moscow, 125315, Russia

SO Eksperimental'naya i Klinicheskaya Farmakologiya (1996), 59(2), 20-23

CODEN: EKFAE9; ISSN: 0869-2092

PB Meditsina

DT Journal

LA Russian

AB Specific binding of dialkylaminoacyl (DAC) derivs. of phenothiazine, dibenzazepine, and dibenzodiazepine to opiate receptors (OR) of μ - and δ -subtypes was studied. Some of the compds. studied exhibited moderate affinity to μ -OR in μ M range. Binding to δ -OR was less pronounced. Dibenzodiazepine derivative AL-234 was the most potent compound with respect to OR of both μ - and δ -subtypes (IC₅₀ values were 11 and 60 μ M, resp.). The ability of DAC-derivs. for specific binding to OR might play a decisive role in the realization of their antinociceptive and antiarrhythmic properties.


IT 183850-02-4

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(interaction of dialkylaminoacyl derivs. of phenothiazine, dibenzazepine, and dibenzodiazepine with opiate receptors)

RN 183850-02-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-chloro-5-[6-(cyclohexylamino)-1-oxohexyl]-5,10-dihydro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L25 ANSWER 29 OF 104 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1996:466922 CAPLUS Full-text

DN 125:114723

TI Preparation of benzodiazepinone derivatives as muscarine M2 receptor antagonists

IN Watanabe, Toshihiro; Kakefuda, Akio; Kinoyama, Isao; Yanagisawa, Isao

PA Yamanouchi Pharmaceutical Co., Ltd., Japan

SO PCT Int. Appl., 101 pp.


CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9613488	A1	19960509	WO 1995-JP2217	19951030
	W: AL, AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KE, KG, KR, KZ, LK, LR, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, TJ, TM, TT, UA, US, UZ, VN				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9537544	A1	19960523	AU 1995-37544	19951030
PRAI	JP 1994-266609	A	19941031		
	JP 1995-71869	A	19950329		
	WO 1995-JP2217	W	19951030		
OS	MARPAT 125:114723				
GI					



AB Benzodiazepinone derivs. I [X = N, CH₂; Z = alkylene; R₁ = H, alkyl, cycloalkyl; R₂ = H, alkyl, cycloalkyl, aryl, aralkyl; R₃ = (un)substituted heteroaryl; n = 1-5] and their salts, having a selective muscarine M2 receptor antagonism and being useful as a preventive or remedy for various diseases wherein muscarine M2 receptors participate, such as sick sinus syndrome including sinus bradycardia, sinus arrest and bradycardia-tachycardia including atrioventricular block and vagal bradycardia, and nervous syncope (carotid sinus anaphylaxis), were prepared I (X = N, Z = p-phenylene, R₁ = R₂ = Et, R₃ = 4-ethyl-1-piperazinyl, n = 2) was prepared and showed selective muscarine M2 receptor antagonist activity in rats.

IT 179328-43-9P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);

BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of benzodiazepinone derivs. as muscarine M2 receptor
 antagonists)


RN 179328-43-9 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-5-butanamide, N-ethyl-N-[2-[[[4-(4-ethyl-1-piperazinyl)phenyl]methyl]methylamino]ethyl]-10,11-dihydro- γ ,11-dioxo- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




IT 5814-41-5

RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of benzodiazepinone derivs. as muscarine M2 receptor
 antagonists)

RN 5814-41-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro- (7CI, 8CI, 9CI) (CA INDEX NAME)



IT 179328-40-6P 179328-41-7P 179328-42-8P
 179328-44-0P


RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological
 study); PREP (Preparation); USES (Uses)

(preparation of benzodiazepinone derivs. as muscarine M2 receptor antagonists)


RN 179328-40-6 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-5-butanamide, N-ethyl-N-[2-[ethyl[[4-[4-(1-methylethyl)-1-piperazinyl]phenyl]methyl]amino]ethyl]-10,11-dihydro-
γ,11-dioxo- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A





RN 179328-41-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-5-butanamide, N-ethyl-10,11-dihydro-N-[2-[methyl[[4-[4-(1-methylethyl)-1-piperazinyl]phenyl]methyl]amino]ethyl]-
γ,11-dioxo- (9CI) (CA INDEX NAME)




RN 179328-42-8 CAPLUS
 CN 5H-Dibenzo[b,e][1,4]diazepine-5-butanamide, N-ethyl-N-[2-[ethyl[[4-(4-morpholinyl)phenyl]methyl]amino]ethyl]-10,11-dihydro-γ,11-dioxo-
 (9CI) (CA INDEX NAME)




RN 179328-44-0 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-5-butanamide, N-ethyl-10,11-dihydro-N-[2-[methyl(phenylmethyl)amino]ethyl]-γ,11-dioxo- (9CI) (CA INDEX NAME)



L25 ANSWER 30 OF 104 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1996:338740 CAPLUS Full-text
 DN 125:48374
 TI Discovery of a new class of centrally active M1 selective muscarinic antagonists related to pirenzepine
 AU Van Hijfte, Luc; Zerr, Veronique; Richards, Mary H.; Moser, Paul; Hibert, Marcel F.; van Giersbergen, Paul L. M.
 CS Marion Merrell, Strasbourg Res. Cent., Strasbourg, 67080, Fr.
 SO Medicinal Chemistry Research (1996), 6(3), 190-196
 CODEN: MCREEB; ISSN: 1054-2523
 PB Birkhaeuser
 DT Journal
 LA English
 GI



AB A series of lipophilic analogs of the antimuscarinic ligand pirenzepine (I) were prepared and assessed for their antimuscarinic activity in a radioligand binding assay on the five muscarinic subtypes expressed in CHO or A9L cells. It was found that biaryl piperazine acetamides are m1 vs. m2 selective muscarinic receptor antagonists which display central activity.

IT **178269-72-2P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(discovery of a new class of centrally active M1 selective muscarinic antagonists related to pirenzepine)


RN 178269-72-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[(4-methyl-1-piperazinyl)acetyl]-, (2Z)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 108295-86-9

CMF C20 H22 N4 O2




CM 2

CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.




IT **5814-41-5P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(discovery of a new class of centrally active M1 selective muscarinic antagonists related to pirenzepine)

RN 5814-41-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro- (7CI, 8CI, 9CI) (CA INDEX NAME)




IT **108295-86-9P**

RL: SPN (Synthetic preparation); PREP (Preparation)

(discovery of a new class of centrally active M1 selective muscarinic antagonists related to pirenzepine)

RN 108295-86-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[(4-methyl-1-piperazinyl)acetyl]- (9CI) (CA INDEX NAME)



L25 ANSWER 31 OF 104 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1996:126534 CAPLUS Full-text

DN 124:193925

TI Pirenzepine blunts the pulmonary parenchymal response to inhaled methacholine

AU Sly, Peter D.; Willet, Karen E.; Kano, Sohei; Lanteri, Celia J.; Wale, Janet

CS Div. Clin. Sci., Inst. Child Health Res., Perth, Australia

SO Pulmonary Pharmacology (1995), 8(2/3), 123-9

CODEN: PUPHEX; ISSN: 0952-0600

PB Academic

DT Journal

LA English

AB To determine the role of M1 muscarinic receptors in the response of the pulmonary parenchyma to inhaled methacholine (MCh), mongrel, out-bred puppies, 8-10 wk of age, were challenged following pretreatment with either saline (control), UH-AH37 (a combined M1-M3 receptor blocker), or pirenzepine (a relatively selective M1 receptor blocker). In addition, fox hound-beagle puppies, born and raised in a clean animal house, were studied. Relatively selective doses of pirenzepine produced a dose-dependent shift to the right of the parenchymal dose-response curves to MCh, with no effect on the airway dose-response curve. The fox hound-beagle puppies showed less parenchymal response, but equivalent airway response, to MCh compared with the mongrel puppies. High doses of pirenzepine (10,000 µg/kg) and UH-AH37 (3 mg/kg) markedly inhibited both the parenchymal and airway responses to MCh. The data demonstrate that: (1) while both the airway and pulmonary parenchyma respond to inhaled MCh, the mechanisms by which they respond differ; (2) stimulation of M1 subtype muscarinic receptors is responsible, at least partly, for the parenchymal response; and (3) exptl. conditions, such as the breed and housing conditions of animals, may have major influences on the parenchymal response to inhalational challenge tests.


IT 120382-14-1, UH-AH37

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)

(pulmonary parenchymal response to inhaled methacholine response to)


RN 120382-14-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 6-chloro-5,10-dihydro-5-[(1-methyl-4-piperidiny)acetyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L25 ANSWER 32 OF 104 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1996:6906 CAPLUS Full-text
 DN 124:194697
 TI Characterization of in vivo brain muscarinic acetylcholine receptor
 subtype selectivity by competition studies against (R,S)-[125I]IQNB.
 [Erratum to document cited in CA123:189112]
 AU Gitler, M. S.; Boulay, S. F.; Sood, V. K.; McPherson, D. W.; Knap, F. F.
 (Russ) Jr.; Zeeberg, B. R.; Reba, R. C.
 CS Med. Cent., Geo. Washington Univ., Washington, DC, 20037, USA
 SO Brain Research (1995), 704(1), 151
 CODEN: BRREAP; ISSN: 0006-8993
 PB Elsevier
 DT Journal
 LA English
 AB The errors were not reflected in the abstract or the index entries.
 IT **166983-78-4**
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological
 study, unclassified); BIOL (Biological study)
 (brain muscarinic receptor subtype selectivity characterization by
 competition studies against (R,S)-[125I]IQNB (Erratum))
 RN 166983-78-4 CAPLUS
 CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[4-[4-[bis(2-
 methylpropyl)amino]butyl]phenyl]-5,10-dihydro- (9CI) (CA INDEX NAME)



L25 ANSWER 33 OF 104 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1995:810571 CAPLUS Full-text

DN 123:227691

TI Preparation of aminocarboxamide antiarrhythmics

IN Sauer, Wolfgang; Schindler, Rudolf; Rueger, Carla; Poppe, Hildegard; Marx, Degenhard; Bartsch, Reni; Kaverina, Natalja; Lichoserstov, Arkadij; Seredenin, Sergej; et al.

PA Arzneimittelwerk Dresden G.m.b.H., Germany

SO Ger. Offen., 24 pp.

CODEN: GWXXBX


DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 4344648	A1	19950629	DE 1993-4344648	19931224
	CA 2179810	AA	19950706	CA 1993-2179810	19931224
	WO 9518099	A1	19950706	WO 1994-DE1343	19941112
	W: CA, CN, CZ, FI, HU, JP, NO, PL, RU, UA, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP	736005	A1	19961009	EP 1995-900625	19941112
	R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, NL, SE				
RU	2134683	C1	19990820	RU 1996-115017	19941112.
PRAI	DE 1993-4344648	A	19931224		
	WO 1994-DE1343	W	19941112		
OS	MARPAT 123:227691				
GI					

Q=



AB The title compds. R1(R2)NCO(CH2)nN(R3)(CH2)mN(R4)R5 [I; R1, R2 = H, (un)branched alkyl, cycloalkyl, (un)substituted Ph; R3 = COR7, (un)substituted SO2Ph, pyridylcarbonyl, Q; R4, R5 = (un)branched alkyl, cycloalkyl, (un)substituted Ph; m = 2-4; n = 1-5; NR1R2 and NR4R5 may be a piperidinyl, pyrrolidinyl, morpholinyl, etc.], useful as antiarrhythmics, are prepared Thus, 4-cyano-N-(dicyclohexylcarbamoylemethyl)-N-(2-diethylaminoethyl)benzamide oxalate, m.p. 173-181°, prepared from 4-cyanobenzoyl chloride, demonstrated antiarrhythmic activity.


IT 168089-83-6P 168089-84-7P 168089-93-8P

168089-94-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of aminocarboxamide antiarrhythmics)


RN 168089-83-6 CAPLUS

CN Benzamide, N-[2-(8-chloro-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-5-yl)-2-oxoethyl]-N-[3-(diethylamino)propyl]-4-[(methylsulfonyl)amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 168089-84-7 CAPLUS
 CN Benzamide, N-[6-(8-chloro-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-5-yl)-6-oxohexyl]-N-[3-(diethylamino)propyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 168089-93-8 CAPLUS
 CN Benzamide, N-[2-(8-chloro-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-5-yl)-2-oxoethyl]-N-[3-(diethylamino)propyl]-4-

[(methylsulfonyl)amino]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

||

RN 168089-94-9 CAPLUS

CN Benzamide, N-[6-(8-chloro-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-5-yl)-6-oxohexyl]-N-[3-(diethylamino)propyl]-
(9CI) (CA INDEX NAME)



L25 ANSWER 34 OF 104 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1995:781752 CAPLUS Full-text

DN 123:189112

TI Characterization of in vivo brain muscarinic acetylcholine receptor subtype selectivity by competition studies against (R,S)-[125I]IQNB

AU Gitler, Miriam S.; Boulay, Sheila F.; Sood, Virendar K.; McPherson, Dan W.; Knapp, F. F., Jr.; Zeeberg, Barry R.; Reba, Richard C.

CS Med. Cent., George Washington Univ., Washington, DC, 20037, USA

SO Brain Research (1995), 687(1,2), 71-8

CODEN: BRREAP; ISSN: 0006-8993

PB Elsevier

DT Journal

LA English

AB The authors studied the in vivo rat brain muscarinic acetylcholine receptor (mAChR) m2 subtype selectivities of 3 quinuclidine derivs.: (R)-3-quinuclidinyl benzilate (QNB), E(+,+)-1-azabicyclo[2.2.2]oct-3-yl α -hydroxy- α -(1-iodo-1-propen-3-yl)- α -phenylacetate (E-(+,-)-IQNP), and E(+,-)-1-azabicyclo[2.2.2]oct-3-yl α -hydroxy- α -(1-iodo-1-propen-3-yl)- α -phenylacetate (E-(+,-)-IQNP), and 2 tricyclic ring compds.: 5-[4-[4-(diisobutylamino)butyl]-1-phenyl]-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepin-11-one (DIBD), and 11-[4-[4-(diisobutylamino)butyl-1-phenyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one (PBID), by correlating the regional inhibition of (R,S)-[125I]IQNB with the regional composition of the m1-m4 subtypes. Subtle effects are demonstrated after reduction of the between-animal variability by normalization to corpus striatum. Substantial in vivo m2 selectivity is exhibited by QNB and DIBD, modest in vivo m2 selectivity is exhibited by E(+,+)AQNP, and little or no in vivo m2 selectivity is exhibited by PBID and E-(+,-)-IQNP. Surprisingly, the in vivo m2 selectivity is not correlated with the in vitro m2 selectivity. For example, QNB, which appears to be the most strongly in vivo m2-selective compound, exhibits negligible in vitro m2 selectivity. These examples indicate that a strategy which includes only preliminary in vitro screening may very well preclude the discovery of a novel compound which would prove useful in vivo.


IT 166983-78-4

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)

(brain muscarinic receptor subtype selectivity characterization by competition studies against (R,S)-[125I]IQNB)

RN 166983-78-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[4-[4-[bis(2-methylpropyl)amino]butyl]phenyl]-5,10-dihydro- (9CI) (CA INDEX NAME)




L25 ANSWER 35 OF 104 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1995:661142 CAPLUS Full-text
 DN 123:198838
 TI Dibenzodiazepine endothelin antagonists
 IN Murugesan, Natesan
 PA Bristol-Myers Squibb Company, USA
 SO U.S., 12 pp.
 CODEN: USXXAM

DT Patent
 LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5420123	A	19950530	US 1992-993562	19921221
PRAI	US 1992-993562		19921221		
OS	MARPAT 123:198838				
GI					



AB Dibenzodiazepines I wherein: one of R1 and R2 is Y2CO2H and the other is R; R is (a) hydrogen, (b) alkyl, (c) alkenyl, (d) alkynyl, (e) cycloalkyl, (f) cycloalkenyl, (g) aryl, (h) cycloalkylalkyl, (i) cycloalkenylalkyl, or (j) aralkyl; R3 is aryl or heteroaryl; X1 and X2 are each independently (a) hydrogen, (b) halo or haloalkyl, (c) hydroxy, (d) alkoxy, (e) cyano, (f) nitro, or (g) amino, alkylamino, or dialkylamino; Y1 is (a) a single bond, (b) alkylene, (c) alkenylene, (d) alkynylene, (e) Z1OZ2, (f) Z1C(O)Z2, (g) Z1OC(O)Z2, (h) Z1C(O)OZ2, (i) Z1N(Z3)Z2, (j) Z1C(O)N(H)Z2, (k) Z1N(H)C(O)Z2, (l) Z1C(S)Z2, or (m) Z1SZ2; Y2 is (a) alkylene, (b) alkenylene, (c) alkynylene, (d) Z1OZ2 (wherein Z2 is other than a single bond), (e) Z1C(O)Z2, (f) Z1OC(O)Z2, (g) Z1C(O)OZ2 (wherein Z2 is other than a single bond), (h) Z2C(O)N(H)Z2 (wherein Z2 is other than a single bond), (i) Z1N(H)C(O)Z2, (j) Z1C(S)Z2, or (k) Z1SZ2 (wherein Z2 is other than a single bond); Z1 and Z2 are each independently a single bond, alkylene, alkenylene, or alkynylene; and Z3 is hydrogen, lower alkyl, alkanoyl, aroyl, or aralkanoyl, are disclosed as endothelin antagonists (no data). Thus, e.g., alkylation of 4-bromo-3-nitrophenol with 1-(bromomethyl)naphthalene afforded 2-bromo-5-(1-naphthalenylmethoxy)nitrobenzene (92%); aminolysis of the latter with anthranilic acid afforded 2-nitro-4-(1-naphthalenylmethoxy)diphenylamine-2'-carboxylic acid (95%); reduction to the 2-amino compound (88%) followed by cyclodehydration afforded 5,11-dihydro-8-(1-naphthalenylmethoxy)-11-oxo-10H-dibenzo[b,e]-1,4-diazepine (48%); alkylation of the latter with Me bromoacetate (69%) followed by saponification afforded title compound 5,11-dihydro-8-(1-naphthalenylmethoxy)-11-oxo-10H-dibenzo[b,e]-1,4-diazepine-10-acetic acid (I; X1 = R1 = X2 = H; R2 = CH2CO2H, Y1R3 = 1-naphthalenylmethoxy, 77% yield for saponification step).


IT 163627-40-5P 167892-59-3P 167892-64-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (dibenzodiazepine endothelin antagonists)

RN 163627-40-5 CAPLUS


CN 1H-Isoindole-1,3(2H)-dione, 2-(10,11-dihydro-11-oxo-5H-

dibenzo[b,e][1,4]diazepin-8-yl)- (9CI) (CA INDEX NAME)




RN 167892-59-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-(1-naphthalenylmethoxy)- (9CI) (CA INDEX NAME)



RN 167892-64-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-(phenylmethoxy)- (9CI) (CA INDEX NAME)



L25 ANSWER 36 OF 104 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1995:570871 CAPLUS Full-text

DN 122:314588

TI Preparation of sulfonamide and sulfonic ester derivatives each having tricyclic heterocyclic ring as antitumor agents

IN Yoshino, Hiroshi; Ueda, Norihiro; Niijima, Jun; Haneda, Toru; Kotake, Yoshihiko; Yoshimatsu, Kentaro; Watanabe, Tatsuo; Nagasu, Takeshi; Tsukahara, Naoko; et al.

PA Eisai Co., Ltd., Japan

SO PCT Int. Appl., 84 pp.

CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	WO 9503279	A1	19950202	WO 1994-JP1231	19940726
	W: CA, FI, NO, RU, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA 2144854	AA	19950202	CA 1994-2144854	19940726
	EP 679641	A1	19951102	EP 1994-921819	19940726
	EP 679641	B1	20021002		
	R: AT, BE, CH, DE, ES, FR, GB, IT, LI, NL, SE				
	JP 08081441	A2	19960326	JP 1994-174643	19940726
	AT 225334	E	20021015	AT 1994-921819	19940726
	NO 9501108	A	19950523	NO 1995-1108	19950323
	US 5834462	A	19981110	US 1995-397254	19950323
	FI 9501416	A	19950517	FI 1995-1416	19950324
	US 5854274	A	19981229	US 1996-760738	19961205
	US 5846969	A	19981208	US 1997-873033	19970611
PRAI	JP 1993-202466	A	19930726		
	JP 1994-158870	A	19940711		
	WO 1994-JP1231	W	19940726		
	US 1995-397254	A3	19950323		
	US 1996-760738	A3	19961205		

OS MARPAT 122:314588

GI For diagram(s), see printed CA Issue.


AB N-heterocyclylarylsulfonamide and heterocyclyl arylsulfonate derivs. each having a tricyclic hetero ring, represented by general formula G-SO₂-L-M [G = a 5- or 6-membered aromatic ring; L = O or NR₁, wherein R₁ = H or lower alkyl; M = a tricyclic structure selected from the members Q - Q₅, wherein rings A and B represent each a 5 or 6-membered unsatd. ring; X = NR₂ (wherein R₂ = H or lower alkyl) or NHCO; Y = O, S(O)_n, CR₃R₄, CO, NR₅, CHR₆CHR₇, CR₈:R₉, NR₁₀CO, N:CR₁₁, OCHR₁₂, S(O)_nCH₁₃, or NR₁₄CHR₁₅; Z = N or CR₁₆, wherein n represents 0, 1 or 2; R₃- R₁₃, R₁₅, R₁₆ = H or lower alkyl; R₁₄ = H, lower alkyl, or lower acyl] are prepared Thus, 107 mg 1-amino-10H-phenothiazine was dissolved in pyridine and a solution of 115 mg 4-methoxybenzenesulfonyl chloride in THF was added followed by stirring the mixture overnight at room temperature to give, after silica gel chromatog., a title compound (I) (115 mg)... I and phenothiazin-3-one derivative (II) showed IC₅₀ of 0.11 and 0.016 µg/mL against KB cells (human nasal cavity cancer). A total of 49 I were prepared

IT 163307-88-8P 163308-03-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-heterocyclylarylsulfonamide as antitumor agent)


RN 163307-88-8 CAPLUS

CN Benzenesulfonamide, N-(10,11-dihydro-11-oxodibenz[b,f][1,4]oxazepin-9-yl)-4-methoxy- (9CI) (CA INDEX NAME)




RN 163308-03-0 CAPLUS

CN Benzenesulfonamide, N-(2-fluoro-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-6-yl)-4-methoxy- (9CI) (CA INDEX NAME)



L25 ANSWER 37 OF 104 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1995:479538 CAPLUS Full-text
 DN 123:275233
 TI Novel potent and m2-selective antimuscarinic compounds which penetrate the blood-brain barrier
 AU Cohen, V. I.; Jin, B.; Gitler, M. S.; de la Cruz, R. A.; Boulay, S. F.; Sood, V. K.; Zeeberg, B. R.; Reba, R. C.
 CS Section Radiopharmaceutical Chem., George Washington Univ. Med. Cent., Washington, DC, 20037, USA
 SO European Journal of Medicinal Chemistry (1995), 30(1), 61-9
 CODEN: EJMCA5; ISSN: 0223-5234
 PB Elsevier
 DT Journal
 LA English
 GI




AB A series of 5-[[[(dialkylamino)alkyl]-1-phenyl]acetyl]-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepin-11-ones (I; R1 = Me, Et, Pr, iso-Pr, Bu, iso-Bu; R2 = Me, Et, Pr, iso-Pr, Bu, iso-Bu, vinyl) were prepared as potential m2-selective ligands. The binding affinities and selectivities of these compds. for the muscarinic cholinergic receptor subtypes were determined. The best m2-selective antimuscarinic agent studied was I (R1 = iso-Bu, R2 = iso-Bu), which caused a significant reduction in (R,R)-3-quinuclidinyl-[125I]-4-iodobenzilate ((R,R)-[125I]-4IQNB) binding in brain regions known to contain a high percentage of m2-receptors. Thus DIBD penetrates the blood-brain barrier and exhibits in vivo selectivity for the m2 subtype. In contrast, neither DIBA, AF-DX 116, nor AQ-RA 741 caused a significant m2-selective reduction in (R,R)-[125I]-4IQNB binding in the brain regions studied.

IT 5814-41-5

RL: RCT (Reactant); RACT (Reactant or reagent)
 (in preparation of substituted dibenzodiazepinones as m2-selective antimuscarinic agents and penetration of blood-brain barrier)

RN 5814-41-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro- (7CI, 8CI, 9CI) (CA INDEX NAME)




IT 163400-01-9P 163400-02-0P 163400-03-1P
 163400-04-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (in preparation of substituted dibenzodiazepinones as m2-selective antimuscarinic agents and penetration of blood-brain barrier)


RN 163400-01-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-(2-bromoethyl)phenyl]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 163400-02-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-(3-bromopropyl)phenyl]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 163400-03-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-(4-bromobutyl)phenyl]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)



RN 163400-04-2 CAPLUS
 CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-(5-bromopentyl)phenyl]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)




IT 156586-94-6P 163399-88-0P 163399-89-1P
 163399-90-4P 163399-91-5P 163399-92-6P
 163399-93-7P 163399-94-8P 163399-95-9P
 163399-96-0P 163399-97-1P 163399-98-2P
 163399-99-3P 163400-00-8P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation of substituted dibenzodiazepinones as m2-selective antimuscarinic agents and penetration of blood-brain barrier)

RN 156586-94-6 CAPLUS
 CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-[4-[bis(2-methylpropyl)amino]butyl]phenyl]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 163399-88-0 CAPLUS
 CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-[2-(diethylamino)ethyl]phenyl]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 163399-89-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-[3-[bis(2-methylpropyl)amino]propyl]phenyl]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 163399-90-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-[4-(dimethylamino)butyl]phenyl]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 163399-91-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-[4-(diethylamino)butyl]phenyl]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 163399-92-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-[4-(dipropylamino)butyl]phenyl]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 163399-93-7 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-[4-[bis(1-methylethyl)amino]butyl]phenyl]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)



RN 163399-94-8 CAPLUS
 CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-[4-(dibutylamino)butyl]phenyl]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 163399-95-9 CAPLUS
 CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[[4-[4-(methylpropylamino)butyl]phenyl]acetyl]- (9CI) (CA INDEX NAME)




RN 163399-96-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[[4-[4-(methyl-2-propenylamino)butyl]phenyl]acetyl]- (9CI) (CA INDEX NAME)




RN 163399-97-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[[4-[4-(methyl-2-propynylamino)butyl]phenyl]acetyl]- (9CI) (CA INDEX NAME)




RN 163399-98-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-[4-[bis(3-methylbutyl)amino]butyl]phenyl]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 163399-99-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-[5-(diethylamino)pentyl]phenyl]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 163400-00-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-[5-[bis(2-methylpropyl)amino]pentyl]phenyl]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)



L25 ANSWER 38 OF 104 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1995:395483 CAPLUS Full-text
 DN 123:9425
 TI Design and synthesis of nonpeptidyl endothelin receptor antagonists based on the structure of a cyclic pentapeptide
 AU Murugesan, Natesan; Gu, Zhengxiang; Lee, Ving; Webb, Maria L.; Liu, Eddie C.-K.; Hermsmeier, Mark; Hunt, John T.
 CS Bristol-Myers Squibb Pharmaceutical Res. Inst., Princeton, NJ, 08543-4000, USA
 SO Bioorganic & Medicinal Chemistry Letters (1995), 5(3), 253-8
 CODEN: BMCLE8; ISSN: 0960-894X
 PB Elsevier
 DT Journal
 LA English
 OS CASREACT 123:9425
 GI



AB A series of dibenzodiazepine-10-acetic acid derivs., e.g., I (R = H, Z = OCH2, R1 = 1-naphthyl; R = Pr, Z = OCH2, NHCO, NHCH2, R1 = 1-naphthyl), were synthesized as prototypes to mimic the structural features of the cyclopentapeptide endothelin antagonist BQ-123. Some of the analogs showed moderate affinity for both the ETA and ETB receptors.


IT **163627-37-0P 163627-40-5P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(synthesis of dibenzodiazepineacetic acid derivs. based on structure of cyclic pentapeptide as endothelin receptor antagonists)


RN 163627-37-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-7-(1-naphthalenylmethoxy)- (9CI) (CA INDEX NAME)




RN 163627-40-5 CAPLUS

CN 1H-Isoindole-1,3(2H)-dione, 2-(10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl)- (9CI) (CA INDEX NAME)



L25 ANSWER 39 OF 104 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1995:247779 CAPLUS Full-text
DN 122:23712
TI Selectivity profile of some recent muscarinic antagonists in bovine and guinea pig trachea and heart
AU Roffel, A. F.; Hamstra, J. J.; Elzinga, C. R. S.; Zaagsma, J.
CS Dep. Med. Chem. Mol. Pharmacol., Univ. Groningen, Groningen, NL-9713 AW, Neth.
SO Archives Internationales de Pharmacodynamie et de Therapie (1994), 328(1), 82-98
CODEN: AIPTAK; ISSN: 0003-9780
PB Heymans Institute of Pharmacology
DT Journal
LA English
AB The functional affinities of some recently developed sub-type-selective muscarinic antagonists towards bovine tracheal smooth muscle muscarinic M3 receptors were established and compared to binding affinities for bovine cardiac M2 and functional affinities for guinea-pig tracheal smooth muscle M3 receptors; functional affinities towards bovine or guinea-pig cardiac M2 receptors were determined when the M2/M3 selectivity in bovine tissues deviated from reported guinea-pig data. It was found that the M2-selective antagonist AQ-RA 741 showed similar high affinities in bovine and guinea-pig heart (8.27-8.41); the affinity in bovine trachea, however, was almost 10-fold higher than in guinea-pig trachea (7.51-6.63). The M3-selective antagonist DAC 5945 displayed functional affinities that were similarly high in bovine and guinea-pig trachea (8.16-8.24) and approx. a 100-fold lower in bovine and guinea-pig heart (6.15-6.36); with this compound, the binding affinity in bovine cardiac membranes (6.92) was clearly higher than the functional affinity, as has meanwhile also been reported for the guinea-pig. With the M3-selective muscarinic antagonists p-fluorohexahydrosiladifenidol and UH-AH 371, affinities towards bovine tracheal muscarinic M3 receptors were 0.3 log units higher than in guinea-pig trachea (7.36-7.09 and 8.43-8.13, resp.), and, in case of p-fluorohexahydrosiladifenidol, both were lower than previously reported for the guinea-pig ileum (typically 7.8). In some instances, especially AQ-RA 741 in bovine trachea and p-fluorohexahydrosiladifenidol in bovine and guinea-pig trachea, the M3 receptor affinities found here correlated better to the reported M1 than to the M3 receptor affinities. It is concluded that small but occasionally clear species and tissue differences exist with regard to the affinities of muscarinic receptor antagonists for smooth muscle M3 receptors, and it is suggested that this may be due to small, but potentially important differences in their amino acid sequences.
IT 140130-54-7, UH-AH 371
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(selectivity profile of muscarinic antagonists in bovine and guinea pig trachea and heart and species difference)
RN 140130-54-7 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 6-chloro-5,10-dihydro-5-[(1-methyl-4-piperidinyl)acetyl]-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (9CI) (CA INDEX NAME)
CM 1
CRN 87646-93-3
CMF C21 H22 Cl N3 O2




CM 2

CRN 87-69-4

CMF C4 H6 O6

Absolute stereochemistry.



L25 ANSWER 40 OF 104 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1994:700869 CAPLUS Full-text

DN 121:300869

TI Synthesis of some dibenzodiazepinone derivatives as potent and m2-selective antimuscarinic compounds

AU Cohen, Victor I.; Jin, Biyun; Gitler, Miriam S.; de la Cruz, Rosanna A.; Rzeszotarski, Wacław J.; Zeeberg, Barry R.; Baumgold, Jesse

CS Medical Cent., George Washington Univ., Washington, DC, 20037, USA


SO Journal of Heterocyclic Chemistry (1994), 31(4), 787-91

CODEN: JHTCAD; ISSN: 0022-152X

DT Journal

LA English

GI



AB Dibenzodiazepinones I [Z = 1,4-cyclohexanediyl, R12N = Et2N or Z = (CH2)n (n = 4, 5), R1, R2 = alkyl] were synthesized as potential m2-selective ligands. Their affinity and selectivity for the muscarinic cholinergic receptor m-AChR subtypes were determined. Replacing a nitrogen with CH in the piperidine ring of I (Z = piperidine moiety, R1, R2 = alkyl) significantly altered the affinity and selectivity to the muscarinic receptor subtypes.

IT 159300-67-1P 159300-68-2P 159300-69-3P

159300-70-6P 159300-71-7P 159300-72-8P


159300-73-9P 159300-74-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(synthesis of dibenzodiazepinone derivs. as potent and m2-selective antimuscarinic compds.)


RN 159300-67-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-[4-(dimethylamino)butyl]cyclohexyl]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 159300-68-2 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-[4-(diethylamino)butyl]cyclohexyl]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)



RN 159300-69-3 CAPLUS
 CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-[4-(dipropylamino)butyl]cyclohexyl]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 159300-70-6 CAPLUS
 CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-[4-(dibutylamino)butyl]cyclohexyl]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 159300-71-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-[4-[bis(2-methylpropyl)amino]butyl]cyclohexyl]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 159300-72-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[[4-[4-(methylpropylamino)butyl]cyclohexyl]acetyl]- (9CI) (CA INDEX NAME)




RN 159300-73-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[[4-[4-(methyl-2-propenylamino)butyl]cyclohexyl]acetyl]- (9CI) (CA INDEX NAME)



RN 159300-74-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[[4-[4-(methyl-2-propynylamino)butyl]cyclohexyl]acetyl]- (9CI) (CA INDEX NAME)




IT 5814-41-5

RL: RCT (Reactant); RACT (Reactant or reagent)

(synthesis of dibenzodiazepinone derivs. as potent and m2-selective antimuscarinic compds.)

RN 5814-41-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro- (7CI, 8CI, 9CI) (CA INDEX NAME)




IT 159300-77-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)

(synthesis of dibenzodiazepinone derivs. as potent and m2-selective
antimuscarinic compds.)

RN 159300-77-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-(4-
chlorobutyl)cyclohexyl]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)



L25 ANSWER 41 OF 104 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1994:290525 CAPLUS Full-text

DN 120:290525

TI Pharmacological profile of selective muscarinic receptor antagonists on guinea pig ileal smooth muscle

AU Doods, Henri N.; Entzeroth, Michael; Ziegler, Harald; Mayer, Norbert; Holzer, Peter

CS Dr. Karl Thomae GmbH, Biberach, 88397, Germany

SO European Journal of Pharmacology (1994), 253(3), 275-81

CODEN: EJPHAZ; ISSN: 0014-2999

DT Journal

LA English

AB The present study examined the effects of a series of tricyclic muscarinic receptor antagonists on muscarinic receptors present in the guinea-pig ileum, both in vitro and in vivo. The selectivity profiles of these antagonists and that of atropine were determined by their affinity for cortical muscarinic M1, cardiac M2 and submandibular M3 receptors and for m4 receptors expressed in CHO cells. The compds. pirenzepine, UH-AH 37, AQ-RA 391 and AQ-RA 618 possessed high affinity (pKi 7.94-8.22) for muscarinic M1 receptors. Pirenzepine exhibited the most pronounced muscarinic M1 selectivity. AF-DX 384 and AQ-RA 741 possessed an approx. 10-fold higher affinity for the cardiac muscarinic M2 receptor than AF-DX 116. However, both compds. also exhibited high affinity for muscarinic m4 receptors. High affinity for muscarinic M3 and m4 receptors was observed for UH-AH 37, AQ-RA 391 and AQ-RA 681. The antagonists were then tested for their interaction with the muscarinic receptors which are responsible for the methacholine-induced contraction of longitudinal muscle in vitro, circular muscle in vivo and muscarinic receptors which mediate the distension-evoked ascending reflex contraction of circular muscle in vitro. Compds. showing high affinity for muscarinic M3 receptors (e.g. AQ-RA 618) were the most potent antagonists in the functional expts. Comparison of the binding displacement data with the functional results indicates that the effects of methacholine on the longitudinal and circular muscle of the guinea-pig ileum were predominantly mediated by muscarinic M3-type receptors. In contrast, the correlation between muscarinic M2 receptor affinity and antagonism of muscarinic receptors in the ileum was very weak.


IT 87588-81-6, AQ-RA 391 120382-14-1, UH-AH 37

RL: BIOL (Biological study)

(muscarinic receptors binding of, in ileal smooth muscle cells)


RN 87588-81-6 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-5-carboxamide, 10,11-dihydro-N-(1-methyl-4-piperidinyl)-11-oxo- (9CI) (CA INDEX NAME)



RN 120382-14-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 6-chloro-5,10-dihydro-5-[(1-methyl-4-piperidinyl)acetyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L25 ANSWER 42 OF 104 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1993:486375 CAPLUS Full-text

DN 119:86375

TI Structural basis of the subtype selectivity of muscarinic antagonists: A study with chimeric m2/m5 muscarinic receptors

AU Wess, Jurgen; Gdula, David; Brann, Mark R.

CS Lab. Mol. Biol., Natl. Inst. Neurol. Disorders and Stroke, Bethesda, MD, 20892, USA

SO Molecular Pharmacology (1992), 41(2), 369-74

CODEN: MOPMA3; ISSN: 0026-895X

DT Journal

LA English


AB The 5 muscarinic receptors (m1-m5), although structurally closely related, can be distinguished pharmacol. by the use of subtype-selective ligands. Various tricyclic muscarinic antagonists, including the AF-DX derivative AQ-RA 741 and the alkaloid himbacine, for example, have been shown to display up to 200-fold higher affinities for m2 and m4 than for m5 receptors. On the other hand, antagonists such as sila-hexocyclium and the pirenzepine derivative UH-AH 37 exhibit lower affinities for m2 than for m5 and all other muscarinic receptors. To identify receptor epitopes that contribute to the subtype selectivities of these antagonists, the authors prepared a series of chimeric m2/m5 muscarinic receptors in which regions of the m5 receptor were systematically replaced with the homologous regions of the m2 receptor. AQ-RA 741, himbacine, and sila-hexocyclium bound to the various chimeric receptors, expressed in COS-7 cells, with affinity profiles indicative of multiple receptor domains contributing to the subtype selectivities of these antagonists. On the other hand, the higher affinity of UH-AH 37 for m5 than for m2 receptors appears to be largely dependent on a short stretch of 31 amino acids comprising most of transmembrane region VI and the third extracellular loop, a region that does not contribute to the subtype selectivity of AQ-RA 741 and himbacine. The data indicate that different receptor epitopes are involved in conferring subtype selectivity on structurally different muscarinic antagonists.

IT 120382-14-1

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(muscarinic receptor subtype binding by, receptor structure in determination of)

RN 120382-14-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 6-chloro-5,10-dihydro-5-[(1-methyl-4-piperidinyl)acetyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L25 ANSWER 43 OF 104 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1993:124572 CAPLUS Full-text

DN 118:124572

TI Preparation of 5-aminoacyl-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-ones as antiarrhythmics and anticholinergics

IN Rueger, Carla; Sauer, Wolfgang; Poppe, Hodegard

PA Arzneimittelwerk Dresden G.m.b.H., Germany

SO Ger. Offen., 9 pp.


CODEN: GWXXBX

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 4117123	A1	19921126	DE 1991-4117123	19910525
	EP 515796	A1	19921202	EP 1992-105394	19920328
	R: AT, BE, CH, DE, ES, FR, GB, IT, LI, NL, SE				
PRAI	DE 1991-4117123	A	19910525		
OS	MARPAT 118:124572				
GI					




AB Title compds. [I; R1 = H, Cl; R2 = H, Me; R3, R4 = H, alkyl, (substituted) cycloalkyl, cycloalkylmethyl, phenylalkyl; R3R4N = morpholino, N-methylpiperazino; n = 3-6; with provisos] were prepared Thus, 5-(6-chlorohexanoyl)-5,10-dihydro-10-methyl-11H-dibenzo[b,e][1,4]diazepin-11-one was refluxed with Et2NH in DMF to give 26% I.HCl (R1 = H, R2 = Me, R3 = R4 = Et, n = 5). The latter inhibited CaCl2-induced arrhythmia in rats with ED50 = 0.033 mg/kg and showed LD50 = 78 mg/kg in rats.

IT 145950-54-5P 145950-55-6P 146117-47-7P
146117-50-2P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as antiarrhythmic and anticholinergic)


RN 145950-54-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-chloro-5,10-dihydro-5-[1-oxo-6-[(1-phenylethyl)amino]hexyl]- (9CI) (CA INDEX NAME)




RN 145950-55-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-chloro-5-[6-(cyclopropylamino)-1-oxohexyl]-5,10-dihydro- (9CI) (CA INDEX NAME)



RN 146117-47-7 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-chloro-5,10-dihydro-5-[1-oxo-6-[(1-phenylethyl)amino]hexyl]-, monohydrobromide (9CI) (CA INDEX NAME)



● HBr


RN 146117-50-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-chloro-5-[6-(cyclopropylamino)-1-oxohexyl]-5,10-dihydro-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl


L25 ANSWER 44 OF 104 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1993:101916 CAPLUS Full-text
 DN 118:101916
 TI Synthesis and structure-activity relationship of some 5-
 [[[(dialkylamino)alkyl]-1-piperidinyl]acetyl]-10,11-dihydro-5H-
 dibenzo[b,e][1,4]diazepin-11-ones as M2-selective antimuscarinics
 AU Cohen, Victor I.; Baumgold, Jesse; Jin, Biyun; De la Cruz, Rosanna;
 Rzeszotarski, Wacław J.; Reba, Richard C.
 CS Med. Cent., George Washington Univ., Washington, DC, 20037, USA
 SO Journal of Medicinal Chemistry (1993), 36(1), 162-5
 CODEN: JMCMAR; ISSN: 0022-2623
 DT Journal
 LA English
 GI




AB A series of 5-[[[(dialkylamino)alkyl]-1-piperidinyl]acetyl]-10,11-dihydro- 5H-
 dibenzo[b,e][1,4]diazepin-11-ones I (R = alkyl, n = 2, 4) were prepared from
 the dibenzodiazepinone II and aminoalkylpiperidines as potential M2-selective
 ligands. The compds. were evaluated for their affinity and selectivity for
 the muscarinic cholinergic receptor. The best M2-selective antimuscarinic
 agent studied is 5-[[4-[4-(diethylamino)butyl]- 1-piperidinyl]acetyl]-10,11-
 dihydro-5H-dibenzo[b,e][1,4]diazepin-11-one, which is approx. 10 times more
 potent at M2 receptors than previously known compds. such as 11-[[4-[4-
 (dimethylamino)butyl]-1- piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-
 b][1,4]benzodiazepin-6-one (AQ-RA 741).
 IT 142860-99-9P 145932-59-8P 145932-60-1P
 145932-61-2P 145932-62-3P 145932-63-4P
 145932-64-5P 145932-65-6P 145932-66-7P
 145932-67-8P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 .(preparation and M2-selective antimuscarinic activity of)
 RN 142860-99-9 CAPLUS
 CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-[4-(diethylamino)butyl]-1-
 piperidinyl]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)



RN 145932-59-8 CAPLUS
 CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[2-[2-(dipropylamino)ethyl]-1-piperidinyl]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 145932-60-1 CAPLUS
 CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[2-[2-(dibutylamino)ethyl]-1-piperidinyl]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 145932-61-2 CAPLUS
 CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[2-[2-[bis(2-

methylpropyl) amino]ethyl]-1-piperidinyl]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 145932-62-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-[2-(dimethylamino)ethyl]-1-piperidinyl]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 145932-63-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-[2-(diethylamino)ethyl]-1-piperidinyl]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 145932-64-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-[2-(dipropylamino)ethyl]-1-piperidinyl]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 145932-65-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-[2-(dibutylamino)ethyl]-1-piperidinyl]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 145932-66-7 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-[2-[bis(2-methylpropyl)amino]ethyl]-1-piperidinyl]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)



RN 145932-67-8 CAPLUS
 CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-[4-(dimethylamino)butyl]-1-piperidinyl]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)



IT **5814-41-5**
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (reaction of, with chloroacetyl chloride)
 RN 5814-41-5 CAPLUS
 CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro- (7CI, 8CI, 9CI) (CA INDEX NAME)



L25 ANSWER 45 OF 104 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1993:80956 CAPLUS Full-text
 DN 118:80956
 TI Preparation of(piperidinylacetyl)heterocyclobenzodiazepinones as
 muscarinic M2 receptor antagonists useful as CNS agents
 IN Eberlein, Wolfgang; Mihm, Gerhard; Engel, Wolfhard; Rudolf, Klaus; Doods,
 Henri; Ziegler, Harald; Entzeroth, Michael
 PA Thomae, Dr. Karl, G.m.b.H., Germany
 SO Eur. Pat. Appl., 29 pp.
 CODEN: EPXXDW
 DT Patent
 LA German
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 508370	A1	19921014	EP 1992-105989	19920407
	EP 508370	B1	19960703		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, PT, SE				
	DE 4112014	A1	19921015	DE 1991-4112014	19910412
	AT 140004	E	19960715	AT 1992-105989	19920407
	ES 2090396	T3	19961016	ES 1992-105989	19920407
	CA 2065800	AA	19921013	CA 1992-2065800	19920410
	NO 9201447	A	19921013	NO 1992-1447	19920410
	NO 180303	B	19961216		
	NO 180303	C	19970326		
	AU 9214814	A1	19921015	AU 1992-14814	19920410
	AU 653802	B2	19941013		
	HU 61301	A2	19921228	HU 1992-1247	19920410
	JP 05097845	A2	19930420	JP 1992-89174	19920410
	ZA 9202617	A	19931011	ZA 1992-2617	19920410
	IL 101560	A1	19960331	IL 1992-101560	19920410
	PL 169745	B1	19960830	PL 1992-294184	19920410
	FI 97470	B	19960913	FI 1992-1589	19920410
	FI 97470	C	19961227		
	RU 2081870	C1	19970620	RU 1992-5011249	19920410
	CZ 283399	B6	19980415	CZ 1992-1111	19920413
	SK 279466	B6	19981104	SK 1992-1111	19920413
	US 5641772	A	19970624	US 1995-421108	19950413
	US 5610155	A	19970311	US 1995-457061	19950601
PRAI	DE 1991-4112014	A	19910412		
	US 1992-865575	B1	19920409		
	US 1993-134332	B1	19931012		
	US 1994-287574	B1	19940809		
	US 1995-421108	A3	19950413		
OS	MARPAT 118:80956				
GI					

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. [I; X = CH, N; l = 1-3; m = 1,2; n = 1-4; R1 = H, alkyl; R2 = H, alkyl, alkenyl, (alkyl)cycloalkyl, adamantyl, (Me-, MeO-, halo-substituted) Ph, phenylalkyl; R3, R4 = H, halo, Me, Et, MeO, EtO; R5 = H, Cl, Me; R6 = H, alkyl; R7 = H, halo, alkyl; Q = Q1-Q4], were prepared Thus, MeCH2CMe2COCl in THF was added to a mixture of Et3N and 5,11-dihydro-11-[[4-[3-(ethylamino)propyl]-1-piperidinyl]acetyl]6H- pyrido[2,3-b][1,4]benzodiazepin-6-one in THF and the mixture was stirred 1 h at 50° to give 46.2% title compound II. I bound to mouse muscarinic receptor preps. with Ki = 150-1000


nM for M1 (cortex) receptors and $K_i = 15-100$ nM for M2 (heart) receptors, with M1/M2 selectivities of 10-35. Drug formulations containing II were prepared

IT **145301-79-7P**

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as muscarinic M2 antagonist)

RN 145301-79-7 CAPLUS

CN Pentanamide, N-[3-[1-[2-(10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-5-yl)-2-oxoethyl]-4-piperidinyl]propyl]-N-ethyl-2,2-dimethyl- (9CI) (CA INDEX NAME)




IT **145301-97-9**


RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, in preparation of muscarinic M2 receptor antagonist)

RN 145301-97-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-[3-(ethylamino)propyl]-1-piperidinyl]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)



L25 ANSWER 46 OF 104 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1992:483330 CAPLUS Full-text
 DN 117:83330
 TI A novel M2-selective muscarinic antagonist: binding characteristics and autoradiographic distribution in rat brain
 AU Gitler, Miriam S.; Reba, Richard C.; Cohen, Victor I.; Rzeszutarski, Wacław J.; Baumgold, Jesse
 CS Med. Cent., George Washington Univ., Washington, DC, 20037, USA
 SO Brain Research (1992), 582(2), 253-60
 CODEN: BRREAP; ISSN: 0006-8993
 DT Journal
 LA English
 GI




AB Although several M2-selective muscarinic antagonists have been described, they are not particularly potent. Thus, the development of potent M2-selective compds. remains an important goal. The authors now report that a bio-isoster of AQ-RA 741 is both one order of magnitude more potent and slightly more selective than previously described compds. DIBA (I), a di-benzo derivative of AQ-RA 741, in which the pyridine of the tricycle is replaced with a benzene ring, had K_i values of 4, 0.3, 11 and 2 nM at M₁ through M₄ receptors, resp. These values were determined in competition studies with [³H]N-methylscopolamine ([³H]NMS) in membranes from transfected A9 L cells (M₁ and M₃), rat heart (M₂) and NG108-15 cells (M₄). AQ-RA 741 had K_i values of 34, 4, 86 and 15 nM at each of these receptors. The autoradiog. distribution of I binding sites was determined by competition studies of [³H]NMS in rat brain. At low concentration, I reduced [³H]NMS binding most significantly from superior colliculi, thalamus, hypothalamus, pontine nucleus, and interpeduncular nucleus, and not appreciably from caudate nucleus, cerebral cortical regions, or hippocampus, consistent with its binding to m2 receptors. These data indicate that I is the most potent, M2-selective muscarinic antagonist yet described. I should therefore become a useful probe in future studies of muscarinic function.

IT 142860-99-9, DIBA


RL: BIOL (Biological study) (as M2 muscarinic antagonist, binding and distribution of, in brain regions)

RN 142860-99-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-[4-(diethylamino)butyl]-1-piperidinyl]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)




L25 ANSWER 47 OF 104 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1992:463629 CAPLUS Full-text
DN 117:63629
TI A muscarinic receptor different from the M1, M2, M3 and M4 subtypes
mediates the contraction of the rabbit iris sphincter.
AU Bogner, I. T.; Altes, U.; Beinhauer, C.; Kessler, I.; Fuder, H.
CS Pharmakol. Inst., Univ. Mainz, Mainz, W-6500, Germany
SO Naunyn-Schmiedeberg's Archives of Pharmacology (1992), 345(6), 611-18
CODEN: NSAPCC; ISSN: 0028-1298
DT Journal
LA English
AB In order to analyze the subtype of muscarinic receptors involved in the
methacholine-induced contraction of the rabbit iris sphincter the equilibrium
dissociation consts. (KB) of various antagonists were determined in the
sphincter muscle. The values were compared with those observed at M1 (rabbit
vas deferens), M2 (heteroreceptors in rat iris) and M3 receptors (guinea-pig
ileum), or at the muscarinic receptors in the guinea-pig uterus. The
methacholine-induced contraction of the uterus from immature guinea-pigs was
competitively antagonized by pirenzepine (6.64, -log KB), 4-DAMP (8.39),
hexahydrodifenidol (HHD; 7.00 for the (R)- and 5.40 for the (S)-enantiomer),
p-fluoro-hexahydrosiladifenidol (p-F-HHSiD; 6.25) and valethamate bromide
(8.04). The affinity of the antagonists is consistent with the presence of an
M2 receptor. The -log KB values of the antagonists in the rabbit iris
sphincter (6.43, p-F-HHSiD; 6.22, AQ-RA 741; 7.23 and 5.34, (R)- and (S)-
trihexyphenidyl) were lower than, or within the lowest range of, ests. in the
other exptl. models, irresp. of the subtype selectivity of the antagonist.
This excludes the presence of an M1, M2, M3 or M4 receptor in this smooth
muscle. The affinity of UH-AH 37 in the iris was intermediate between that
for M1 or M3, and M2 receptors. The low affinity of AQ-RA 741 and the low
enantiomeric ratio of trihexyphenidyl (THP) in the iris (77.6) would be
compatible with a presumed M5 receptor. Valethamate bromide and clozapine did
not differentiate between M1, M2 and M3 receptors in the present functional
studies; the pA2 values at the M1-M3 sites (8.46-8.57 and 7.26-7.58, resp.)
were about 10 and 100 times higher, resp., than the ests. in the iris
sphincter. In absolute terms, however, the -log KB values of the THP-
enantiomers, UH-AH 37 and clozapine in the iris sphincter were 0.8-2 log units
lower than previous data on cloned M5 receptors suggesting receptor properties
different from the presumed M5 receptor. In conclusion, the muscarinic
receptors in the rabbit iris sphincter may represent a novel type differing
from M1-M4 receptors.
IT 120382-14-1, UH-AH 37
RL: BIOL (Biological study)
(iris sphincter contraction induction by methacholine inhibition by,
muscarinic receptor subtype in relation to)
RN 120382-14-1 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 6-chloro-5,10-dihydro-5-[(1-methyl-4-
piperidinyl)acetyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl


L25 ANSWER 48 OF 104 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1992:194275 CAPLUS Full-text
 DN 116:194275
 TI Reaction of tetrafluorodibenz[b,f][1,4]oxazepin-11(10H)-ones with
 nucleophiles
 AU Konstantinova, A. V.; Yakovleva, O. D.; Gerasimova, T. N.
 CS Novosib. Inst. Org. Khim., Novosibirsk, 630090, USSR
 SO Khimiya Geterotsiklicheskikh Soedinenii (1991), (9), 1259-61
 CODEN: KGSSAQ; ISSN: 0453-8234
 DT Journal
 LA Russian
 GI



AB The nucleophilic substitution reactions of the title compound I (R = R2 = F; R1 = H) with NaOMe/MeOH or piperidine gave I (R2 = OMe or piperidino). In excess piperidine a 1,3-dipiperidino derivative was formed. I (R = R2 = H; R1 = F) did not react with NaOMe/MeOH or piperidine.
 IT **140406-58-2P 140406-59-3P**
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 140406-58-2 CAPLUS
 CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 1,2,4-trifluoro-3-(1-piperidinyl)-
 (9CI) (CA INDEX NAME)



RN 140406-59-3 CAPLUS
 CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2,4-difluoro-1,3-di-1-piperidinyl-
 (9CI) (CA INDEX NAME)



L25 ANSWER 49 OF 104 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1992:187501 CAPLUS Full-text

DN 116:187501

TI Affinity profiles of pizotifen, ketotifen and other tricyclic antimuscarinics at muscarinic receptor subtypes M1, M2 and M3

AU Eltze, Manfred; Mutschler, Ernst; Lambrecht, Guenter

CS Dep. Pharmacol., Byk Gulden Pharm., Konstanz, D-7550, Germany

SO European Journal of Pharmacology (1992), 211(3), 283-93

CODEN: EJPHAZ; ISSN: 0014-2999

DT Journal

LA English

AB The affinity of pizotifen, ketotifen and other tricyclic antimuscarinic drugs for different muscarinic receptor subtypes was investigated in vitro in functional expts. with field-stimulated vas deferens of the rabbit (M1 and M2 receptors) and with ileum and trachea of the guinea pig (M3 receptors). All compds. were competitive antagonists in the three tissues. Like the close analog cyproheptadine ($pA_2 = 7.99-8.08$), pizotifen ($pA_2 = 7.23-7.81$) and ketotifen ($pA_2 = 6.34-6.99$) were devoid of selectivity for the receptor subtypes studied. Thiazinamium, although exhibiting high affinity for muscarinic receptors ($pA_2 = 7.83-8.51$), was nonselective. In contrast, the novel pirenzepine analog nuvenzepine was selective for M1 receptors ($pA_2 = 6.63-7.74$). The lack of selectivity of cyproheptadine, pizotifen, and ketotifen is reflected in the chemical structures of these drugs. All three antagonists are composed of a very similar tricyclic ring system linked to a 1-methyl-4-piperidylene ring. The finding that thiazinamium, pizotifen, and cyproheptadine were potent muscarinic antagonists and possessed nonselective affinity characteristics may have therapeutic implications.


IT 120382-14-1, UH-AH 37

RL: BIOL (Biological study)

(muscarinic receptor subtypes affinity for)

RN 120382-14-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 6-chloro-5,10-dihydro-5-[(1-methyl-4-piperidinyl)acetyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L25 ANSWER 50 OF 104 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1992:166820 CAPLUS Full-text

DN 116:166820

TI Identification of multiple muscarinic binding site subtypes in cat and human cerebral vasculature

AU Dauphin, Francois; Hamel, Edith

CS Lab. Cerebrovasc. Res., Montreal Neurol. Inst., Montreal, QC, Can.

SO Journal of Pharmacology and Experimental Therapeutics (1992), 260(2), 660-7

CODEN: JPETAB; ISSN: 0022-3565

DT Journal

LA English

AB The binding characteristics of the nonselective muscarinic antagonist [3H]N-methylscopolamine ([3H]NMS) have been studied in membrane fractions of cat and human cerebral blood vessels. A computer-fitting method was used to analyze the data obtained from association/dissociation, saturation and competition expts. Specific binding of [3H]NMS to membrane preps. from cat and human pia-arachnoid vessels was found to be saturable (resp. Bmax values of 98 and 67 fmol/mg protein) and of high affinity (KD values of 165 and 125 pM, resp.). Competition studies, in the presence of various well-characterized M1, M2 or M3 putative muscarinic antagonists, performed against the binding of [3H]NMS, revealed the heterogeneity of muscarinic binding sites in these vascular tissues. A population of M1 sites was clearly identified in both human and cat pial vessel membranes and accounted for approx. 40 (human) and 20% (cat) of the total population of cerebrovascular muscarinic binding sites labeled with [3H]NMS. Such observation was further supported by saturation studies of [3H]NMS binding performed under M1 blocking conditions (75 nM pirenzepine). Competition and saturation (in the presence of M2 antagonists) studies suggested the presence of M2 sites (approx. 35% of total sites) in cat pial vessels. However, under the same conditions, no M2 binding sites could be detected in human cerebrovascular membranes. A small population of M3 sites (approx. 20%) was found in both human and cat cerebrovascular membranes. These results clearly emphasize the multiplicity of cerebrovascular muscarinic receptors and support recent pharmacol. identification of M1 contractile and M3 dilatatory receptors in cat cerebral arteries. Furthermore, the results also suggest that a proportion of muscarinic binding sites, with a pharmacol. different from that of M1, M2 and M3 sites, is present in cerebrovascular membranes from both human and cat.

IT 140130-54-7, UH-AH 371

RL: BIOL (Biological study)

(methylscopolamine binding by muscarinic receptor subtypes response to, in cerebral vasculature of cat and human)


RN 140130-54-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 6-chloro-5,10-dihydro-5-[(1-methyl-4-piperidiny)l)acetyl]-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 87646-93-3


CMF C21 H22 C1 N3 O2



CM 2

CRN 87-69-4
CMF C4 H6 O6

Absolute stereochemistry.



L25 ANSWER 51 OF 104 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1991:632302 CAPLUS Full-text

DN 115:232302

TI Preparation of 5-[(N-phenethyl-N-methylamino)acyl]-10,11-dihydrodibenzo[b,e][1,4]diazepin-11-ones and related compounds as muscarinic receptor antagonists

IN Alker, David; Cross, Peter Edward

PA Pfizer Ltd., UK; Pfizer Inc.

SO PCT Int. Appl., 42 pp.



CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9110654	A1	19910725	WO 1990-EP2044	19901128
	W: CA, FI, JP, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE				
	CA 2069931	AA	19910707	CA 1990-2069931	19901128
	CA 2069931	C	19970826		
	EP 508995	A1	19921021	EP 1991-900776	19901128
	EP 508995	B1	19940216		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	JP 05501711	T2	19930402	JP 1991-501208	19901128
	AT 101599	E	19940315	AT 1991-900776	19901128
	JP 06092376	B4	19941116	JP 1990-501208	19901128
	ES 2062755	T3	19941216	ES 1991-900776	19901128
	FI 9202346	A	19920522	FI 1992-2346	19920522
	US 5418229	A	19950523	US 1994-251037	19940531
PRAI	GB 1990-302	A	19900106		
	EP 1991-900776	A	19901128		
	WO 1990-EP2044	W	19901128		
	US 1992-877166	B1	19920629		
OS	MARPAT 115:232302				
GI					



AB Title compds. I [X = N, CR4; R4 = H, halo, Cl-4 alkyl; R1, R2 = H, Cl-4 alkyl; Y = bond, O, S; m = 1-4; n = 2, 3; R3 = naphthyl, pyridyl, pyrazinyl, thienyl,

(substituted) Ph, etc.], which are muscarinic receptor antagonists useful for the treatment of irritable bowel syndrome (no data), were prepared Thus, a mixture of 5-(3-methylaminopropionyl)-10,11- dihydrodibenzo[b,e][1,4]diazepin-11-one, 4-methylphenethyl bromide, and NaHCO₃ in MeCN was refluxed 16 h to give title compound II in 21% yield.


IT 137068-94-1P 137068-95-2P 137068-96-3P
137068-97-4P 137068-99-6P 137069-00-2P
137069-01-3P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as muscarinic antagonist)


RN 137068-94-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[3-[methyl[2-(4-methylphenyl)ethyl]amino]-1-oxopropyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 137068-95-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[3-[methyl[2-(4-methylphenyl)ethyl]amino]-1-oxopropyl]- (9CI) (CA INDEX NAME)




RN 137068-96-3 CAPLUS
 CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[3-[[2-(4-chlorophenyl)ethyl]methylamino]-1-oxopropyl]-5,10-dihydro- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 137068-97-4 CAPLUS
 CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[3-[[2-(4-methoxyphenyl)ethyl]methylamino]-1-oxopropyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 137068-99-6 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[4-[[2-(4-methoxyphenyl)ethyl]methylamino]-1-oxobutyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 137069-00-2 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[4-[[2-(4-chlorophenyl)ethyl]methylamino]-1-oxobutyl]-5,10-dihydro- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A



RN 137069-01-3 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[4-[[2-(2,3-dihydro-5-benzofuranyl)ethyl]methylamino]-1-oxobutyl]-5,10-dihydro- (9CI) (CA INDEX NAME)




IT **5814-41-5**

RL: RCT (Reactant); RACT (Reactant or reagent)

(reaction of, in preparation of muscarinic antagonists)

RN 5814-41-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro- (7CI, 8CI, 9CI) (CA INDEX NAME)



L25 ANSWER 52 OF 104 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1991:559188 CAPLUS Full-text
 DN 115:159188
 TI Preparation of (diazaspiroalkylcarbonyl)diazepinones as spasmolytics
 IN Engel, Wolfhard; Eberlein, Wolfgang; Trummlitz, Guenter; Mihm, Gerhard;
 Doods, Henri; Mayer, Norbert; De Jonge, Adriaan
 PA Thomae, Dr. Karl, G.m.b.H., Germany
 SO Eur. Pat. Appl., 62 pp.
 CODEN: EPXXDW

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 417631	A2	19910320	EP 1990-117078	19900905
	EP 417631	A3	19911211		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	DE 3930262	A1	19910321	DE 1989-3930262	19890911
	CA 2025005	AA	19910312	CA 1990-2025005	19900910
	NO 9003941	A	19910312	NO 1990-3941	19900910
	HU 55393	A2	19910528	HU 1990-5852	19900910
	HU 206882	B	19930128		
	DD 299308	A5	19920409	DD 1990-343932	19900910
	IL 95622	A1	19940412	IL 1990-95622	19900910
	AU 9062352	A1	19910314	AU 1990-62352	19900911
	AU 626452	B2	19920730		
	JP 03209382	A2	19910912	JP 1990-241064	19900911
	ZA 9007199	A	19920527	ZA 1990-7199	19900911
	PL 165197	B1	19941130	PL 1990-286835	19900911
	RU 2017740	C1	19940815	RU 1992-5011116	19920318
PRAI	DE 1989-3930262	A	19890911		

OS MARPAT 115:159188

GI For diagram(s), see printed CA Issue.

AB The title compds. [I; B = bivalent residue Q-Q3; R = (un)substituted C1-4 alkyl; R1,R2 = H, F, Cl, Br, C1-4 alkyl; R3 = H, Cl, Me; R4 = H, C1-4 alkyl; R5 = R4, halo; m, n, o, p = 1, 2; m + n + o + p ≤ 6], their isomers and physiol. compatible salts, useful for the treatment of cholinergic spasms, gastrointestinal disorders, cystitis, relative incontinence, bronchial asthma, bronchitis, and cardiac ischemia, were prepared, e.g., by amidation of 11-(chlorocarbonyl)pyridobenzodiazepinone with diazaspiroalkanes. Thus, reduction of 4,4-bis(ethoxycarbonyl)-1-methyl-2-pyrrolidinone (preparation in 91% yield from triethyl 1,1,2-ethanetricarboxylate and 1,3,5-trimethylhexahydro-1,3,5-triazine in the presence of CF3CO2H given) by LiAlH4 gave 71.4% 3,3-bis-(hydroxymethyl)-1-methylpyrrolidine. This was brominated (94%) by 63% HBr, the di-Br derivative cyclocondensed with p-MeC6H4SO2NH2, and the resulting (61%) diazaspiro[3,4]octane derivative detosylated (34%) by NaAlH2(OCH2CH2OMe)2 in PhMe. Amidation of the appropriate 11-(chlorocarbonyl)pyridobenzodiazepinone by the product 6-methyl-2,6-diazaspiro[3,4]octane of at 50° in the presence of Na2CO3 in MeCN gave 26% title compound 5,11-dihydro-11-[[6-methyl-2,6-diazaspiro[3,4]oct-2-yl]carbonyl]-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one. The latter suppressed methacholine-induced contraction of guinea pig ileum and heart atrium at 3.39 + 10⁻⁷ and 7.24 + 10⁻⁸ mol/L, resp., vs. 1.23 + 10⁻⁷ and 1.94 + 10⁻⁷ mol/L, resp., for pirenzepine, with a heart-vs.-ileum selectivity of 4.7 (0.63 for pirenzepine).


IT 136349-31-0P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of, as spasmolytic)


RN 136349-31-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[(7-methyl-2,7-

diazaspiro[4.4]non-2-yl)carbonyl]- (9CI) (CA INDEX NAME)




L25 ANSWER 53 OF 104 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1991:506809 CAPLUS Full-text
 DN 115:106809
 TI Characterization of prejunctional muscarinic autoreceptors in the guinea pig trachea
 AU Kilbinger, H.; Schneider, R.; Siefken, H.; Wolf, D.; D'Agostino, G.
 CS Pharmakol. Inst., Univ. Mainz, Mainz, D-6500, Germany
 SO British Journal of Pharmacology (1991), 103(3), 1757-63
 CODEN: BJPCBM; ISSN: 0007-1188
 DT Journal
 LA English
 AB The effects of ten muscarinic antagonists on elec. evoked [3H]acetylcholine release and muscle contraction were compared in epithelium-free preps. of the guinea pig trachea preincubated with [3H]choline. The M3-selective antagonists UH-AH 37, 4-diphenylacetoxy-N- piperidine methobromide, and p-fluorohexahydrosiladiphenidol were more potent in reducing the contractile response than in facilitating the evoked [3H]acetylcholine release. Hexahydrosiladiphenidol did not discriminate between pre- and postjunctional effects. The rank order of the postjunctional potencies of the ten antagonists as well as the postjunctional pA2 values obtained for hexahydrosiladiphenidol (7.95) and AQ-RA 741 (7.08) identified the muscular receptor as the M3 subtype. The M2-selective antagonists methoctramine, AF-DX 116, and AQ-RA 741 were more potent in facilitating the evoked [3H]acetylcholine release than in inhibiting the contractile response. The increase in release by low concns. of methoctramine, AF-DX 116, and AQ-RA 741 was paralleled by an enhancement of the stimulation-evoked contractions. Comparison of the pre- and postjunctional potencies of the M1-, M2-, and M3-selective antagonists suggests that autoinhibition of acetylcholine release is mediated via an M2-like receptor which differs from the cardiac type M2 receptor in its relatively high affinity for hexahydrosiladiphenidol.
 IT **120382-14-1**, UH-AH-37
 RL: BIOL (Biological study)
 (tracheal contractility and acetylcholine release response to, muscarinic receptor subtypes in)
 RN 120382-14-1 CAPLUS
 CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 6-chloro-5,10-dihydro-5-[(1-methyl-4-piperidinyl)acetyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L25 ANSWER 54 OF 104 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1991:471659 CAPLUS Full-text
 DN 115:71659
 TI Preparation of anellated diazabicycloalkyldiazepinones as drugs
 IN Rudolf, Klaus; Engel, Wolfhard; Eberlein, Wolfgang; Trummelitz, Guenter;
 Mihm, Gerhard; Doods, Henri; Mayer, Norbert
 PA Thomae, Dr. Karl, G.m.b.H., Germany
 SO Ger. Offen., 22 pp.
 CODEN: GWXXBX
 DT Patent
 LA German
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 3930266	A1	19910314	DE 1989-3930266	19890911
	EP 417630	A2	19910320	EP 1990-117077	19900905
	EP 417630	A3	19911211		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	CA 2025006	AA	19910312	CA 1990-2025006	19900910
	NO 9003939	A	19910312	NO 1990-3939	19900910
	HU 55392	A2	19910528	HU 1990-5851	19900910
	HU 208137	B	19930830		
	JP 03167192	A2	19910719	JP 1990-239788	19900910
	DD 299307	A5	19920409	DD 1990-343926	19900910
	ZA 9007170	A	19920527	ZA 1990-7170	19900910
	IL 95621	A1	19940624	IL 1990-95621	19900910
	AU 9062353	A1	19910314	AU 1990-62353	19900911
	AU 626453	B2	19920730		
	US 5179090	A	19930112	US 1991-779203	19911018
PRAI	DE 1989-3930266	A	19890911		
	US 1990-580893	B1	19900911		
OS	MARPAT 115:71659				
GI					



AB Title compds. [I; X = CH, N; R = (substituted) alkyl; B = Q1-Q4; R4, R5 = H, F, Cl, Br, alkyl; R6 = H, Cl, Me; R7 = H, alkyl; R8 = R7, halo; m, n, o, p =


0-3, with restrictions; A1-A4 = H; A1A2 or A3A4 = CH₂CH₂], were prepared
 Thus, 11-chlorocarbonyl-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one
 and L-2-methyl-2,6-diazabicyclo[3.3.0]octane [preparation from L-2-benzyl-2,6-
 diazabicyclo[3.3.0]octane given] were refluxed 3 h in MeCN to give L-5,11-
 dihydro-11-[[6-methyl-2,6- diazabicyclo[3.3.0]oct-2-yl]carbonyl]-6H-
 pyrido[2,3-b][1,4]benzodiazepin-6- one. In guinea pigs the latter antagonized
 acetylcholine-induced bronchoconstriction with -log ED₅₀ = 7.31, vs.
 bradycardia antagonism with -log ED₅₀ = 5.98 mol.kg⁻¹ i.v. Numerous
 formulations were prepared containing D-6,11-dihydro-11-[[6-methyl-2,6-
 diazabicyclo[3.3.0]oct-3-yl]carbonyl]-5H- pyrido[2,3-b][1,5]-benzodiazepin-5-
 one.

IT **135063-25-1P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological
 study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
 BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of, as drug)

RN 135063-25-1 CAPLUS

CN 4,7-Imino-1H-isoindole, 2-[(10,11-dihydro-11-oxo-5H-
 dibenzo[b,e][1,4]diazepin-5-yl)carbonyl]octahydro-8-methyl- (9CI) (CA
 INDEX NAME)



L25 ANSWER 55 OF 104 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1991:415614 CAPLUS Full-text

DN 115:15614

TI Condensed diazepinones as central nervous system drugs

IN Engel, Wolfhard; Mayer, Norbert; Doods, Henri; Eberlein, Wolfgang; Mihm, Gerhard; Rudolf, Klaus

PA Thomae, Dr. Karl, G.m.b.H., Germany

SO Ger. Offen., 20 pp.

CODEN: GWXXBX

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 3919076	A1	19901213	DE 1989-3919076	19890610
	EP 402734	A2	19901219	EP 1990-110574	19900605
	EP 402734	A3	19920318		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	CA 2018582	AA	19901210	CA 1990-2018582	19900608
	AU 9056936	A1	19901213	AU 1990-56936	19900608
	AU 629355	B2	19921001		
	HU 54301	A2	19910228	HU 1990-3776	19900608
	HU 210567	B	19950529		
	JP 03063222	A2	19910319	JP 1990-151445	19900608
	ZA 9004429	A	19920226	ZA 1990-4429	19900608
PRAI	DE 1989-3919076	A	19890610		

OS MARPAT 115:15614

AB Condensed diazepinones (Markush given), such as 11-[[2-
[(diethylamino)methyl]-1-piperidiny]acetyl]-5,11-dihydro-6H-pyrido[2,3-
b][1,4]benzodiazepin-6-one or 4,9-dihydro-3-methyl-4-[[4-[3-(1-
piperidiny]propyl)-1-piperidiny]acetyl]-10H-thieno[3,4-
b][1,5]benzodiazepin-10-one are drugs for the treatment of central nervous
system diseases (parkinsonism, Alzheimer disease, etc.) and for stimulation of
the cerebral blood flow (no data). Formulaton examples are given.


IT **127173-46-0 134426-42-9 134426-43-0**

RL: BIOL (Biological study)

(central nervous system diseases treatment by)


RN 127173-46-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[[2-(hexahydro-1-methyl-1H-azepin-
2-yl)ethyl]methylamino]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 134426-42-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[[3-[3-(1-piperidinyl)propyl]-1-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 134426-43-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[4-[3-[(dimethylamino)methyl]-4-morpholinyl]-1-oxobutyl]-5,10-dihydro- (9CI) (CA INDEX NAME)



L25 ANSWER 56 OF 104 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1991:247322 CAPLUS Full-text

DN 114:247322

TI Preparation of 5-(ω -aminoacyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]-
diazepin-11-ones as antiarrhythmics

IN Rueger, Carla; Sauer, Wolfgang; Lohmann, Dieter; Poppe, Hildegard;
Bartsch, Reni; Likhoshesterov, A. M.; Kaverina, N. V.; Skoldinov, A. P.;
Grigor'eva, E. K.; et al.

PA Arzneimittelwerk Dresden G.m.b.H. I. G., Germany

SO Eur. Pat. Appl., 25 pp.


CODEN: EPXXDW

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 411567	A1	19910206	EP 1990-114687	19900731
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, NL, SE				
	DD 293582	A5	19910905	DD 1989-331279	19890731
	JP 03291273	A2	19911220	JP 1990-202331	19900730
	US 5264432	A	19931123	US 1992-971671	19921104
PRAI	DD 1989-331279	A	19890731		
	US 1990-559309	B1	19900730		
OS	MARPAT 114:247322				
GI					




AB Title compds. [I; R1 = H, Cl; R2, R3 = H, (cyclo)alkyl; R2R3N = morpholino, N-methylpiperazino; n = 3-6], were prepared Thus, 5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one was refluxed 5 h with bromocaproyl chloride to give 65.6% 5-(6-bromocaproyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one. The latter in DMF at 2° was treated with Me2NH in DMF and the mixture was kept 30 min at 40° to give 61% title compound I (R1 = H, R2 = R3 = Me, n = 5). I inhibited CaCl2-induced arrhythmia in rats with ED50 = 0.044-0.44 mg/kg.

IT **5814-41-5**

RL: RCT (Reactant); RACT (Reactant or reagent)
(acylation of, in preparation of antiarrhythmic)

RN 5814-41-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro- (7CI, 8CI, 9CI) (CA INDEX NAME)




IT 134000-70-7P 134000-76-3P 134000-77-4P

134019-09-3P 134019-10-6P 134019-11-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as antiarrhythmic)


RN 134000-70-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-chloro-5,10-dihydro-5-[6-(4-morpholinyl)-1-oxohexyl]- (9CI) (CA INDEX NAME)



RN 134000-76-3 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[6-(cyclohexylamino)-1-oxohexyl]-5,10-dihydro- (9CI) (CA INDEX NAME)



RN 134000-77-4 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-chloro-5-[6-(cyclohexylamino)-1-

oxohexyl]-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 134019-09-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-chloro-5,10-dihydro-5-[7-(4-morpholinyl)-1-oxohexyl]- (9CI) (CA INDEX NAME)




RN 134019-10-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-chloro-5,10-dihydro-5-[6-(4-methyl-1-piperazinyl)-1-oxohexyl]- (9CI) (CA INDEX NAME)




RN 134019-11-7 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[6-(4-methyl-1-piperazinyl)-1-oxohexyl]- (9CI) (CA INDEX NAME)



L25 ANSWER 57 OF 104 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1991:101958 CAPLUS Full-text
 DN 114:101958
 TI New derivatives of 5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-ones with
 anticholinergic activity
 AU Rueger, Carla; Roehnert, H.; Lohmann, D.
 CS Geschaefsbereich Forsch. Entwickl., Arzneimittelwerk Dresden G.m.b.H.,
 Radebeul, DDR-8122, Ger. Dem. Rep.
 SO Pharmazie (1990), 45(8), 555-9
 CODEN: PHARAT; ISSN: 0031-7144
 DT Journal
 LA German
 OS CASREACT 114:101958
 GI



AB Condensation of 4,2-R(O₂N)C₆H₃Cl (R = H, Cl) with 2-H₂NC₆H₄CO₂H gave 2-[4,2-R(O₂N)C₆H₃NH]C₆H₄CO₂H (same R). The reduction of the latter gave 2-[4,2-R(H₂N)C₆H₃NH]C₆H₄CO₂H which upon cyclocondensation gave 5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one and its 8-chloro derivative. The latter products were acylated or methylated and acylated to give 5-acyl-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-ones I (R = H, Cl; R₁ = H, Me; R₂ = Cl, CH₂Cl, etc.); the I thus obtained were aminated to give II [R = H, Cl; R₁ = H, Me; R₂ = N(CH₂CH₂OH)₂, NMe(CH₂CH₂OH), etc.] (II). The ulcer-inhibiting activity of II was postulated; II (R = Cl; R₁ = H; R₂ = N(CH₂CH₂H)).HCl, i.e. AWD 26-06, is selected for clin. evaluation (no data). II thus prepared differ from other tricyclic psychopharmaceuticals in their lipid solubility and hence have no effect as central nervous system agents.
 IT **5814-41-5P**
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and acylation or alkylation of)
 RN 5814-41-5 CAPLUS
 CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro- (7CI, 8CI, 9CI) (CA INDEX NAME)



IT 98374-61-9P 98374-62-0P 98374-65-3P
 98374-66-4P 98374-70-0P 98374-78-8P
 98374-85-7P 98374-86-8P 98374-88-0P


98399-77-0P 98399-79-2P 98399-80-5P

132164-81-9P 132164-82-0P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)


RN 98374-61-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-chloro-5-[[4-(2-furanylcarbonyl)-1-piperazinyl]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)



RN 98374-62-0 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-chloro-5-[[4-(2-furanylcarbonyl)-1-piperazinyl]acetyl]-5,10-dihydro-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 98374-65-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-(2-furanylcarbonyl)-1-piperazinyl]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 98374-66-4 CAPLUS
 CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-(2-furanylcarbonyl)-1-(piperazinyl)acetyl]-5,10-dihydro-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 98374-70-0 CAPLUS
 CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-chloro-5,10-dihydro-5-[[[2-(4-morpholinyl)-2-oxoethyl]amino]acetyl]-, monohydrochloride (9CI) (CA INDEX NAME)




RN 98374-78-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-chloro-5-[2-[4-(2-furanylcarbonyl)-1-piperazinyl]-1-oxopropyl]-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 98374-85-7 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-chloro-5,10-dihydro-5-[[methyl[2-(4-morpholinyl)-2-oxoethyl]amino]acetyl]- (9CI) (CA INDEX NAME)



RN 98374-86-8 CAPLUS
 CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-chloro-5,10-dihydro-5-[[methyl[2-(4-morpholinyl)-2-oxoethyl]amino]acetyl]-, monohydrochloride (9CI) (CA INDEX NAME)




RN 98374-88-0 CAPLUS
 CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[(4-acetyl-1-piperazinyl)acetyl]-8-chloro-5,10-dihydro-, monohydrochloride (9CI) (CA INDEX NAME)




RN 98399-77-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-chloro-5-[2-[4-(2-furanylcarbonyl)-1-piperazinyl]-1-oxopropyl]-5,10-dihydro-, monohydrochloride (9CI) (CA INDEX NAME)




RN 98399-79-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[[methyl[2-(4-morpholinyl)-2-oxoethyl]amino]acetyl]- (9CI) (CA INDEX NAME)



RN 98399-80-5 CAPLUS



CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[[methyl[2-(4-morpholinyl)-2-oxoethyl]amino]acetyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 132164-81-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-chloro-5,10-dihydro-5-[[4-(3,4,5-trimethylbenzoyl)-1-piperazinyl]acetyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl


RN 132164-82-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-chloro-5,10-dihydro-5-[[4-(3,4,5-trimethylbenzoyl)-1-piperazinyl]acetyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



L25 ANSWER 58 OF 104 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1991:75666 CAPLUS Full-text

DN 114:75666

TI Selectivity profile of the novel muscarinic antagonist UH-AH 37 determined by the use of cloned receptors and isolated tissue preparations

AU Wess, Hans Jürgen; Lambrecht, G.; Mutschler, E.; Brann, M. R.; Doerje, F.

CS Lab. Mol. Biol., Natl. Inst. Neurol. Disord. Stroke, Bethesda, MD, 20892, USA

SO British Journal of Pharmacology (1991), 102(1), 246-50

CODEN: BJPCBM; ISSN: 0007-1188

DT Journal

LA English

AB Functional in vitro expts. were carried out to determine the antimuscarinic potencies of the pirenzepine derivative UH-AH 37 at M1 muscarinic receptors of rabbit vas deferens, M2 receptors of rat left atria, and M3 receptors of rat ileum. Furthermore, N-[3H]-methylnscopolamine competition binding expts. were performed to obtain its affinities for the 5 cloned human muscarinic receptors (m1-m5) stably expressed in CHO-K1 cells. Pirenzepine served as a reference drug throughout all expts. In all preps. used, UH-AH 37 interacted with muscarinic receptors in a fashion characteristic of a simple competitive antagonist. In the functional studies, UH-AH 37, like pirenzepine, showed high affinity for M1 (pA2 8.49) and low affinity for M2 muscarinic receptors (pA2 6.63). In contrast to pirenzepine, UH-AH 37 also displayed high affinity for M3 receptors (pA2 8.04). In agreement with its functional profile, UH-AH 37 bound with highest affinity to m1 (pKi 8.74) and with lowest affinity to m2 receptors (pKi 7.35). Moreover, it showed a 7-fold higher affinity for m3 (pKi 8.19) than for m2 receptors, whereas pirenzepine bound to both receptors with low affinities. The binding affinity of UH-AH 37 for m4 and m5 receptors (pKi 8.32 for both receptors) was only ca. 2.5-fold lower than that for m1 receptors, while the corresponding affinity differences were 6- and 13-fold in case of pirenzepine. The receptor selectivity profile of UH-AH 37 differs clearly from that of its parent compound, pirenzepine, in both functional and radioligand binding studies, the major characteristics being its pronounced M2 (m2)/M3 (m3) selectivity. Thus, UH-AH 37 represents a useful tool for the further pharmacol. characterization of muscarinic receptor subtypes.


IT 120382-14-1, UH-AH 37

RL: BIOL (Biological study)

(muscarinic receptor characterization by)

RN 120382-14-1 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 6-chloro-5,10-dihydro-5-[(1-methyl-4-piperidinyl)acetyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L25 ANSWER 59 OF 104 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1990:440739 CAPLUS Full-text
 DN 113:40739
 TI Preparation of 11-[[(pyrrolidinylalkyl) amino]alkanoyl]pyrido[2,3-
 6][1,4]benzodiazepin-6-ones and analogs as antiarrhythmic and spasmolytic
 agents
 IN Mihm, Gerhard; Eberlein, Wolfgang; Engel, Wolfhard; Trummelitz, Guenter;
 Mayer, Norbert; De Jonge, Adriaan; Doods, Henri
 PA Thomae, Dr. Karl, G.m.b.H., Fed. Rep. Ger.
 SO Ger. Offen., 18 pp.
 CODEN: GWXXBX
 DT Patent
 LA German
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 3820346	A1	19891221	DE 1988-3820346	19880615
	SU 1678209	A3	19910915	SU 1989-4614119	19890524
	EP 346745	A1	19891220	EP 1989-110264	19890607
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	NO 8902432	A	19891218	NO 1989-2432	19890613
	NO 168477	B	19911118		
	NO 168477	C	19920226		
	DD 284016	A5	19901031	DD 1989-329535	19890613
	ZA 8904461	A	19910227	ZA 1989-4461	19890613
	IL 90590	A1	19930221	IL 1989-90590	19890613
	DK 8902911	A	19891216	DK 1989-2911	19890614
	FI 8902897	A	19891216	FI 1989-2897	19890614
	JP 02040381	A2	19900209	JP 1989-152047	19890614
	HU 50472	A2	19900228	HU 1989-3089	19890614
	HU 201759	B	19901228		
	AU 8936446	A1	19891221	AU 1989-36446	19890615
	AU 612493	B2	19910711		
	US 5002943	A	19910326	US 1989-366828	19890615
PRAI	DE 1988-3820346	A	19880615		
OS	MARPAT 113:40739				
GI					




AB The title compds. [I; A1, A2 = (CH₂)₁₋₄; G = 2,3-pyridylenediyl, arylenediyl, Q1-Q4; R1, R2 = H, (hydroxy)alkyl, cycloalkyl; R3 = H, Cl, alkyl; R4 = H, Me; R5, R6 = H, F, Cl, Br, alkyl; R7 = H, Cl, Me; R8 = H, alkyl; R9 = H, halo, alkyl; R10 = H, Me; X = CH, N; X ≠ N when G = 2,3-pyridylenediyl] were prepared. Thus, chloroacetylpyridobenzodiazepinone II (R = COCH₂Cl) was stirred 8 h with MeNHCH₂CH₂Q (Q = N-methyl-2-pyrrolidinyl) in DMF to give II (R = COCH₂NMeCH₂CH₂Q).HCl which had -logED₅₀ = 7.91 mg/kg i.v. against elec. stimulated bradycardia in rats.

IT 127826-80-6P 127826-86-2P 127826-88-4P
127826-89-5P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of and, as antiarrhythmic and spasmolytic agent)


RN 127826-80-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[[[2-(1-methyl-2-pyrrolidinyl)ethyl]amino]acetyl]-, dihydrochloride (9CI) (CA INDEX NAME)




RN 127826-86-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[3-[[2-(1-methyl-2-pyrrolidinyl)ethyl]amino]-1-oxopropyl]- (9CI) (CA INDEX NAME)



RN 127826-88-4 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[[methyl[2-(1-methyl-2-pyrrolidinyl)ethyl]amino]acetyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 127826-89-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[ethyl[2-(1-methyl-2-pyrrolidinyl)ethyl]amino]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)



L25 ANSWER 60 OF 104 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1990:406382 CAPLUS Full-text
 DN 113:6382
 TI Preparation and formulation of pyrido-fused diazepinones and analogs as
 central nervous system (CNS) agents
 IN Engel, Wolfhard; Eberlein, Wolfgang; Mihm, Gerhard; Trummelitz, Guenter;
 Mayer, Norbert; De Jonge, Adriaan
 PA Thomae, Dr. Karl, G.m.b.H., Fed. Rep. Ger.
 SO Ger. Offen., 29 pp.
 CODEN: GWXXBX
 DT Patent
 LA German
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 3818299	A1	19891207	DE 1988-3818299	19880530
	SU 1731057	A3	19920430	SU 1989-4614115	19890515
	EP 344543	A2	19891206	EP 1989-109040	19890519
	EP 344543	A3	19900822		
	EP 344543	B1	19920722		
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	AT 78479	E	19920815	AT 1989-109040	19890519
	FI 8902596	A	19891201	FI 1989-2596	19890529
	NO 8902152	A	19891201	NO 1989-2152	19890529
	NO 169539	B	19920330		
	NO 169539	C	19920708		
	HU 50343	A2	19900129	HU 1989-2717	19890529
	HU 203887	B	19911028		
	JP 02028163	A2	19900130	JP 1989-135700	19890529
	DD 283822	A5	19901024	DD 1989-329002	19890529
	ZA 8904048	A	19910227	ZA 1989-4048	19890529
	AU 8935850	A1	19891130	AU 1989-35850	19890530
	AU 617814	B2	19911205		
	US 5006522	A	19910409	US 1989-358740	19890530
PRAI	DE 1988-3818299	A	19880530		
	EP 1989-109040	A	19890519		
OS	CASREACT 113:6382; MARPAT 113:6382				
GI					



AB The title compds. [I; R1 = C1-4 alkyl, R2 = (un)substituted C1-7 alkyl, C3-7 cycloalkyl(methyl); NR1R2 = 4- to 7-membered (un)substituted monocyclic heterocyclic ring; R3 = H, Cl, C1-4 alkyl; R4 = H, Me; X = Q-Q4; X1, X2 = CH;

R5, R6 = H, F, Cl, Br, Cl-4 alkyl; R7 = H, Cl, Me; R8 = H, Cl-4 alkyl; R9 = H, halo, Cl-4 alkyl; R10 = H, Me; X1, X2 = N when X = Q, Q2, Q4] and their physiol. compatible salts, were prepared as cholinergic and muscarinic neurotransmitter antagonists and antiemetics, useful for treatment of CNS-related ailments, Alzheimer and Parkinson's disease, bradyarrhythmia, bradycardia, migraine, etc. A suspension of 5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one in dioxane was lithiated by BuLi at room temperature, heated at 70-75° with 1-bromo-6-(1-piperidinyl)hexane, and the whole was stirred 4 h at 80° to give 19% 5,11-dihydro-11-[6-(1-piperidinyl)hexyl]-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one (II). II in vitro selectively antagonized 3H-N-methylscopolamine in rat heart, cortex, and submandibular tissue preps. with IC50 values of 0.6, 4, and 10 nM resp., vs. 2, 4, and 4 nM for atropine, resp. Tablets, dragees, suppositories, and drops containing II were formulated.


IT 127537-26-2P

RL: SPN (Synthetic preparation); FORM (Formation, nonpreparative); PREP (Preparation)

(formation of, in preparation of neurotransmitter antagonist)

RN 127537-26-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[6-[4-[2-(1,3-dioxolan-2-yl)ethyl]-1-piperazinyl]hexyl]-5,10-dihydro- (9CI) (CA INDEX NAME)




IT 127537-04-6P 127537-24-0P 127537-25-1P

127537-28-4P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as neurotransmitter antagonist)

RN 127537-04-6 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[6-(hexahydro-1H-azepin-1-yl)hexyl]-5,10-dihydro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 127537-24-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[6-(1-piperidinyl)hexyl]- (9CI) (CA INDEX NAME)



RN 127537-25-1 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[6-(4-methyl-1-piperazinyl)hexyl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 127537-28-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[6-(1-pyrrolidinyl)hexyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


IT 5814-41-5

RL: RCT (Reactant); RACT (Reactant or reagent)

(reaction of, in preparation of neurotransmitter antagonist)


RN 5814-41-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro- (7CI, 8CI, 9CI) (CA INDEX NAME)



L25 ANSWER 61 OF 104 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1990:235347 CAPLUS Full-text
 DN 112:235347
 TI Preparation of 11-[[(heterocyclylalkyl)amino]alkanoyl]pyrido[2,3-
 b][1,4]benzodiazepin-6-ones and analogs as antiarrhythmic and spasmolytic
 agents
 IN Mihm, Gerhard; Eberlein, Wolfgang; Engel, Wolfhard; Trummelitz, Guenter;
 Mayer, Norbert; Doods, Henri; De Jonge, Adriaan
 PA Thomae, Dr. Karl, G.m.b.H., Fed. Rep. Ger.
 SO Ger. Offen., 18 pp.
 CODEN: GWXXBX
 DT Patent
 LA German
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 3820345	A1	19891221	DE 1988-3820345	19880615
	EP 346744	A1	19891220	EP 1989-110262	19890607
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	DD 284015	A5	19901031	DD 1989-329534	19890613
	ZA 8904459	A	19910227	ZA 1989-4459	19890613
	IL 90591	A1	19920818	IL 1989-90591	19890613
	DK 8902910	A	19891216	DK 1989-2910	19890614
	FI 8902896	A	19891216	FI 1989-2896	19890614
	NO 8902469	A	19891218	NO 1989-2469	19890614
	NO 168586	B	19911202		
	NO 168586	C	19920311		
	JP 02040371	A2	19900209	JP 1989-152048	19890614
	HU 50471	A2	19900228	HU 1989-3087	19890614
	HU 201758	B	19901228		
	AU 8936448	A1	19891221	AU 1989-36448	19890615
	AU 612495	B2	19910711		
PRAI	DE 1988-3820345	A	19880615		
OS	MARPAT 112:235347				
GI					




AB The title compds. [I; A1, A2 = C1-4 alkylene; G = divalent (hetero)aryl groups Q1-Q4; R1 = H, alkyl, cycloalkyl, cycloalkylalkyl; R2 = alkyl, cycloalkyl; R3, R4 = H, F, Cl, Br, alkyl; R5 = H, Cl, Me; R6, R7 = H, alkyl; R7 may addnl. = halo; X = CH, CCl, N; G = Q4 when X ≠ N; Z = O, C1-3 alkylene] were prepared. Thus, chloroacetylpyridobenzodiazepinone II (R = COCH2Cl) was stirred 0.5 h with 1-methyl-2-[2-(methylamino)ethyl]piperidine in DMF containing Et3N to give 37% II (R = COCH2NMeCH2CH2Q; Q = 1-methyl-2-piperidyl) which had -log IC50 of 7.48 mol/kg i.v. against elec. stimulated bradycardia in rats.

IT **127173-42-6P 127173-46-0P**

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as antiarrhythmic and spasmolytic agent)


RN 127173-42-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[[methyl[3-(1-methyl-2-piperidinyl)propyl]amino]acetyl]- (9CI) (CA INDEX NAME)



RN 127173-46-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[[2-(hexahydro-1-methyl-1H-azepin-2-yl)ethyl]methylamino]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)



L25 ANSWER 62 OF 104 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1990:171736 CAPLUS Full-text

DN 112:171736

TI Presynaptic effects of atropine

AU Alberts, Peteris

CS Div. Exp. Med., Swed. Def. Res. Establ., Umea, S-901 82, Swed.

SO Proc. Int. Symp. Prot. Chem. Warf. Agents, 3rd (1989), Issue PB89-225379, 203-10 Publisher: Swed. Def. Res. Establ., Umea, Swed.

CODEN: 56SIAH

DT Conference

LA English

AB The presynaptic effect of atropine was compared with that of (-)-hyoscyamine on the elec. evoked secretion of 3H-acetylcholine in the guinea-pig ileum myenteric plexus. Furthermore, the effect of piranzepine, and the racemate and isomers of a muscarinic antagonist related to pirenzepine (UH-AH 37), lacking an asym. carbon, but yielding chiral isomers due to steric restriction, were also tested. Finally, the effect of a classical partial agonist/antagonist, pilocarpine, compared to the effect of the classical muscarinic antagonist atropine. Pilocarpine enhanced the 3H-acetylcholine secretion to a lower level than the full antagonists.


IT 87646-93-3, (+)-UH-AH 37 108303-17-9, (-)-UH-AH 37
108324-50-1, (+)-UH-AH 37

RL: BIOL (Biological study)

(presynaptic muscarinic neurotransmission response to, stereospecificity in)


RN 87646-93-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 6-chloro-5,10-dihydro-5-[(1-methyl-4-piperidinyl)acetyl]- (9CI) (CA INDEX NAME)




RN 108303-17-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 6-chloro-5,10-dihydro-5-[(1-methyl-4-piperidinyl)acetyl]-, (-)- (9CI) (CA INDEX NAME)



RN 108324-50-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 6-chloro-5,10-dihydro-5-[(1-methyl-4-piperidiny)acetyl]-, (+)- (9CI) (CA INDEX NAME)



L25 ANSWER 63 OF 104 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1990:132473 CAPLUS Full-text

DN 112:132473

TI Treatment of ischemic heart diseases with dibenzodiazepinone derivatives

IN Trach, Volker; Eberlein, Wolfgang; Engel, Wolfhard; Mihm, Gerhard; Mayer, Norbert; Doods, Henri; Trummelitz, Guenter

PA Thomae, Dr. Karl, G.m.b.H., Fed. Rep. Ger.

SO Ger. Offen., 4 pp.

CODEN: GWXXBX

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 3738980	A1	19890524	DE 1987-3738980	19871117
	EP 316690	A2	19890524	EP 1988-118471	19881105
	EP 316690	A3	19901010		
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
	DK 8806390	A	19890518	DK 1988-6390	19881116
	JP 01160920	A2	19890623	JP 1988-289905	19881116
	HU 48465	A2	19890628	HU 1988-5934	19881116
	HU 199292	B	19900228		
	AU 8825641	A1	19890518	AU 1988-25641	19881117
PRAI	DE 1987-3738980	A	19871117		


AB 6-Chloro-5,10-dihydro-5-[(1-methyl-4-piperidinyl)acetyl]-11H-dibenzo[b,e][1,4]diazepin-11-one (I), (+)-I and I salts are drugs for the treatment of ischemic heart diseases, especially angina pectoris. Contrary to atropine, I derivs. are highly selective for muscarine receptors in the smooth coronary muscle. Expts. on the isolated rat heart indicated that I antagonizes the effect of carbachol (10⁻⁶ - 10⁻²M) on the coronary flow and heart beat. A tablet comprised (+)-I 5, lactose 152, starch 65, and Mg stearate 2 mg.

IT 87646-93-3 108324-50-1 125850-29-5

RL: BIOL (Biological study)
(ischemic heart disease treatment by)


RN 87646-93-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 6-chloro-5,10-dihydro-5-[(1-methyl-4-piperidinyl)acetyl]- (9CI) (CA INDEX NAME)




RN 108324-50-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 6-chloro-5,10-dihydro-5-[(1-methyl-4-piperidinyl)acetyl]-, (+)- (9CI) (CA INDEX NAME)



RN 125850-29-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 6-chloro-5,10-dihydro-5-[(1-methyl-4-piperidinyl)acetyl]-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

L25 ANSWER 64 OF 104 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1989:632774 CAPLUS Full-text

DN 111:232774

TI Preparation of tricyclic lactams and analogs as muscarinic antagonists

IN Turconi, Marco; Donetti, Arturo; Cereda, Enzo; Quintero, Myrna Gil;
Schiavi, Giovanni Battista; Micheletti, Rosamaria

PA Istituto De Angeli S.p.A., Italy

SO Eur. Pat. Appl., 46 pp.

CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 309422	A2	19890329	EP 1988-830374	19880919
	EP 309422	A3	19900110		
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	DD 282689	A5	19900919	DD 1988-319831	19880915
	DK 8805226	A	19890322	DK 1988-5226	19880920
	FI 8804305	A	19890322	FI 1988-4305	19880920
	NO 8804174	A	19890322	NO 1988-4174	19880920
	JP 01132567	A2	19890525	JP 1988-236178	19880920
	AU 8822380	A1	19890323	AU 1988-22380	19880921
PRAI	IT 1987-21978	A	19870921		

OS MARPAT 111:232774

GI For diagram(s), see printed CA Issue.

AB Title compds. I [R = H, halo; X = N, CH; W = NHCO, CH:CH, (CH₂)₂, O, S; R₁ = H, C₁-4 alkyl; n = 0, 1; Y = S, CH; A = C, N; B = CH when A ≠ N, CO₂, CO, CH₂; m = 0-3; Z = NH, CO, CO₂, CH, bond; p, q = 0, 1; Q = (homo)piperazinyl, piperidinyl, tropyl, tetrahydropyrimidinyl, the above groups may be substituted by a C₁-4 alkyl or an amino; R = CR₂:NR₃; R₂ = H, C₁-4 alkyl, (C₁-4 alkyl- or Ph-substituted) amino; R₃ = C₁-8 alkyl, H (provided that the bond of QR is a C-C bond or AB = C:CH); R₂R₃ = atoms to form a 5-membered ring] are prepared for treatment of motility disorders of the gastrointestinal or urogenital tract and peptic ulcer disorders. A mixture of 5,10-dihydro-5-[2-piperazin-1-yl)acetyl]-11H-dibenzo[b,e][1,4]-diazepin-11-one and H₂NC(:NH)SMe.H₂SO₄ in EtOH was refluxed to give the 4-guanylpiperazinyl analog isolated as its 2 HCl salt. The latter salt showed a dissociation constant (K_D) of 6 nM for displacement of 3H-pirenzepine from cerebral cortex homogenate of rats. Tablets were formulated containing I 20, lactose 247, cornstarch 30, and Mg stearate 3 mg.


IT 122859-62-5P 122859-65-8P 122859-72-7P
122859-74-9P 122859-76-1P 122859-82-9P
122859-86-3P 122859-87-4P 122859-91-0P
122859-92-1P 122859-93-2P 122859-95-4P
122859-99-8P 122860-00-8P 122860-10-0P
122860-11-1P 122860-12-2P 122860-13-3P
122860-14-4P 122860-15-5P 122860-16-6P
122860-17-7P 122860-18-8P 122860-19-9P
122860-25-7P 122860-26-8P 122860-39-3P
122860-40-6P 122860-41-7P 122860-47-3P
122860-51-9P 122860-52-0P 122860-53-1P
122860-54-2P 122860-56-4P 122860-59-7P
122860-62-2P 122860-63-3P 122860-64-4P
122860-70-2P 122860-75-7P 122860-81-5P
122873-74-9P 122882-82-0P 122882-86-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and reaction of, in preparation of muscarinic antagonists)


RN 122859-62-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-(1-piperazinylacetyl)-
(9CI) (CA INDEX NAME)




RN 122859-65-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-4-methyl-5-(1-piperazinylacetyl)- (9CI) (CA INDEX NAME)




RN 122859-72-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 6-chloro-5,10-dihydro-5-(1-piperazinylacetyl)- (9CI) (CA INDEX NAME)




RN 122859-74-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[(hexahydro-1H-1,4-diazepin-1-yl)acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 122859-76-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[(2,6-dimethyl-1-piperazinyl)acetyl]- (9CI) (CA INDEX NAME)




RN 122859-82-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-(4-piperidinylacetyl)- (9CI) (CA INDEX NAME)




RN 122859-86-3 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[2-(10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-5-yl)-2-oxoethylidene]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 122859-87-4 CAPLUS

CN 1(2H)-Pyridinecarboxylic acid, 4-[2-(10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-5-yl)-2-oxoethyl]-3,6-dihydro-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 122859-91-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[[1-(phenylmethyl)-3-piperidinylidene]acetyl]- (9CI) (CA INDEX NAME)



RN 122859-92-1 CAPLUS


CN 8-Azabicyclo[3.2.1]octane-8-carboxylic acid, 3-[2-(10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-5-yl)-2-oxoethylidene]-, ethenyl ester (9CI) (CA INDEX NAME)



RN 122859-93-2 CAPLUS


CN 8-Azabicyclo[3.2.1]oct-2-ene-8-carboxylic acid, 3-[2-(10,11-dihydro-11-oxo-

5H-dibenzo[b,e][1,4]diazepin-5-yl)-2-oxoethyl]-, ethenyl ester (9CI) (CA INDEX NAME)




RN 122859-95-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-(3-piperidinylacetyl)- (9CI) (CA INDEX NAME)




RN 122859-99-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-(8-azabicyclo[3.2.1]oct-3-ylacetyl)-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 122860-00-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-(8-azabicyclo[3.2.1]oct-2-en-3-ylacetyl)-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 122860-10-0 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-5-carboxamide, 10,11-dihydro-11-oxo-N-4-piperidinyl- (9CI) (CA INDEX NAME)




RN 122860-11-1 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[(10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-5-yl)carbonyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 122860-12-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-(1-piperazinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 122860-13-3 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-5-carboxamide, 10,11-dihydro-11-oxo-N-3-piperidinyl- (9CI) (CA INDEX NAME)




RN 122860-14-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-5-carboxamide, 10,11-dihydro-11-oxo-N-3-pyridinyl- (9CI) (CA INDEX NAME)



RN 122860-15-5 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-5-carboxamide, 10,11-dihydro-11-oxo-N-3-pyridinyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 122860-16-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-(4-piperidinylcarbonyl)- (9CI) (CA INDEX NAME)



RN 122860-17-7 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-(4-pyridinylcarbonyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 122860-18-8 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-(3-pyridinylcarbonyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 122860-19-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-(3-piperidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 122860-25-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[4-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)-1-oxobutyl]-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 122860-26-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 122860-39-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[[4-imino(nitroamino)methyl]-1-piperazinyl]acetyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 122860-40-6 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 6-chloro-5,10-dihydro-5-[[4-imino(nitroamino)methyl]-1-piperazinyl]acetyl]- (9CI) (CA INDEX NAME)




RN 122860-41-7 CAPLUS
 CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[[4-[imino(nitroamino)methyl]-1-piperazinyl]acetyl]- (9CI) (CA INDEX NAME)



RN 122860-47-3 CAPLUS
 CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[hexahydro-4-[imino(nitroamino)methyl]-1H-1,4-diazepin-1-yl]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 122860-51-9 CAPLUS
 CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[[1-[imino(nitroamino)methyl]-3-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 122860-52-0 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-5-carboxamide, 10,11-dihydro-N-[1-[imino(nitroamino)methyl]-3-piperidinyl]-11-oxo- (9CI) (CA INDEX NAME)




RN 122860-53-1 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-5-carboxamide, 10,11-dihydro-N-[1-[imino(nitroamino)methyl]-4-piperidinyl]-11-oxo- (9CI) (CA INDEX NAME)




RN 122860-54-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[[1-[imino(nitroamino)methyl]-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 122860-56-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[[1-[imino(nitroamino)methyl]-4-piperidinyl]acetyl]- (9CI) (CA INDEX NAME)




RN 122860-59-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[[1-[imino(nitroamino)methyl]-3-piperidinyl]acetyl]- (9CI) (CA INDEX NAME)




RN 122860-62-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[[4-[imino(nitroamino)methyl]-1-piperazinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 122860-63-3 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[[8-[imino(nitroamino)methyl]-8-azabicyclo[3.2.1]oct-3-yl]acetyl]- (9CI) (CA INDEX NAME)



RN 122860-64-4 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-5-carboxylic acid, 10,11-dihydro-11-oxo-, 8-[[8-[imino(nitroamino)methyl]-8-azabicyclo[3.2.1]oct-3-yl]acetyl]-

1-[imino(nitroamino)methyl]-3-piperidiny] ester (9CI) (CA INDEX NAME)




RN 122860-70-2 CAPLUS

CN Carbamic acid, [3-[[3-(10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-5-yl)-3-oxopropyl]amino]propyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 122860-75-7 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-5-carboxylic acid, 10,11-dihydro-11-oxo-, 2-methyl-5-pyrimidinyl ester (9CI) (CA INDEX NAME)



RN 122860-81-5 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-5-carboxamide, 10,11-dihydro-11-oxo-N-[1-

(phenylmethyl)-4-piperidiny]- (9CI) (CA INDEX NAME)




RN 122873-74-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-(8-azabicyclo[3.2.1]oct-3-ylideneacetyl)-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 122882-82-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[3-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)-1-oxopropyl]-5,10-dihydro- (9CI) (CA INDEX NAME)



RN 122882-86-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[3-[5,6-dihydro-2-(nitroamino)-1(4H)-pyrimidinyl]-1-oxopropyl]-5,10-dihydro- (9CI) (CA INDEX NAME)




IT 122858-73-5P 122858-74-6P 122858-75-7P
 122858-82-6P 122858-84-8P 122858-86-0P
 122858-88-2P 122858-89-3P 122858-91-7P
 122858-92-8P 122858-97-3P 122859-00-1P
 122859-02-3P 122859-04-5P 122859-10-3P
 122859-11-4P 122859-13-6P 122859-16-9P
 122859-17-0P 122859-18-1P 122859-21-6P
 122859-25-0P 122859-27-2P 122859-28-3P
 122859-31-8P 122859-32-9P 122859-34-1P
 122859-35-2P 122859-37-4P 122859-39-6P
 122859-41-0P 122859-43-2P 122859-44-3P
 122859-45-4P 122859-46-5P 122859-49-8P
 122859-56-7P 122882-72-8P 122882-74-0P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of, as muscarinic antagonist)

RN 122858-73-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-(aminoiminomethyl)-1-piperazinyl]acetyl]-5,10-dihydro-4-methyl-, dihydrochloride (9CI) (CA INDEX NAME)




●2 HCl

RN 122858-74-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-(aminoiminomethyl)-1-piperazinyl]acetyl]-6-chloro-5,10-dihydro-, dihydrochloride (9CI) (CA


INDEX NAME)



●2 HCl

RN 122858-75-7 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-(aminoiminomethyl)-1-piperazinyl]acetyl]-5,10-dihydro-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 122858-82-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-(aminoiminomethyl)hexahydro-1H-1,4-diazepin-1-yl]acetyl]-5,10-dihydro-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 122858-84-8 CAPLUS

CN Formic acid, compd. with 5-[[1-(aminoiminomethyl)-3-piperidinyl]carbonyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 122858-83-7


CMF C20 H21 N5 O2



CM 2

CRN 64-18-6

CMF C H2 O2




RN 122858-86-0 CAPLUS

CN Formic acid, compd. with N-[1-(aminoiminomethyl)-4-piperidinyl]-10,11-

dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepine-5-carboxamide (1:1) (9CI)
(CA INDEX NAME)


CM 1

CRN 122858-85-9
CMF C20 H22 N6 O2



CM 2


CRN 64-18-6
CMF C H2 O2



RN 122858-88-2 CAPLUS
CN Formic acid, compd. with N-[1-(aminoiminomethyl)-3-piperidiny]-10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepine-5-carboxamide (1:1) (9CI)
(CA INDEX NAME)

CM 1


CRN 122858-87-1
CMF C20 H22 N6 O2



CM 2


CRN 64-18-6

CMF C H2 O2



RN 122858-89-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[1-(aminoiminomethyl)-4-piperidiny]carbonyl]-5,10-dihydro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 122858-91-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-5-carboxylic acid, 10,11-dihydro-11-oxo-, 1-(aminoiminomethyl)-3-piperidiny ester, monoformate (9CI) (CA INDEX NAME)

CM 1

CRN 122858-90-6


CMF C20 H21 N5 O3



CM 2


CRN 64-18-6

CMF C H2 O2



RN 122858-92-8 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[1-(aminoiminomethyl)-4-piperidinyl]acetyl]-5,10-dihydro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 122858-97-3 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[1-(aminoiminomethyl)-3-piperidinyl]acetyl]-5,10-dihydro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 122859-00-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-(aminoiminomethyl)-1-piperazinyl]carbonyl]-5,10-dihydro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 122859-02-3 CAPLUS

CN Formic acid, compd. with 5-[[8-(aminoiminomethyl)-8-azabicyclo[3.2.1]oct-3-yl]acetyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 122859-01-2


CMF C23 H25 N5 O2



CM 2


CRN 64-18-6

CMF C H2 O2




RN 122859-04-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-(aminoiminomethyl)-2,6-dimethyl-1-piperazinyl]acetyl]-5,10-dihydro-, dihydrochloride (9CI) (CA INDEX NAME)



RN 122859-10-3 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[[4-[(methylimino)methyl]-1-piperazinyl]acetyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 122859-11-4 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[[1-[(1-methylethyl)imino]methyl]-4-piperidinyl]acetyl]-, monohydrochloride (9CI)
(CA INDEX NAME)



● HCl

RN 122859-13-6 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[[1-[(octylimino)methyl]-4-piperidinyl]acetyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 122859-16-9 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[[4-[[[(1-methylethyl)imino]methyl]-1-piperazinyl]acetyl]-, dihydrochloride (9CI)
(CA INDEX NAME)



●2 HCl

RN 122859-17-0 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-[[[(1,1-dimethylethyl)imino]methyl]-1-piperazinyl]acetyl]-5,10-dihydro-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 122859-18-1 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[[4-
[(octylimino)methyl]-1-piperazinyl]carbonyl]-, monohydrochloride (9CI)
(CA INDEX NAME)



● HCl


RN 122859-21-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[[4-(1-iminoethyl)-1-
piperazinyl]acetyl]-, dihydrochloride (9CI) (CA INDEX NAME)



RN 122859-25-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[[1-(1-iminoethyl)-4-piperidinyl]acetyl]-, monohydrochloride (9CI) (CA INDEX NAME)




RN 122859-27-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[[1-(1-iminoethyl)-3-piperidinyl]acetyl]-, compd. with 2,4,6-trinitrophenol (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 122859-26-1


CMF C22 H24 N4 O2



CM 2


CRN 88-89-1

CMF C6 H3 N3 O7



RN 122859-28-3 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[[1-(1-iminoethyl)-3-piperidinyl]carbonyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 122859-31-8 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[[4-[imino(methylamino)methyl]-1-piperazinyl]acetyl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 122859-32-9 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[[4-[(methyldimethylamino)methyl]-1-piperazinyl]acetyl]-, dihydrochloride (9CI)
(CA INDEX NAME)



●2 HCl

RN 122859-34-1 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[[4-[(methyldimethylamino)methyl]-1-piperazinyl]acetyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 122859-35-2 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-(4,5-dihydro-1H-imidazol-2-yl)-1-piperazinyl]acetyl]-5,10-dihydro-, monohydriodide (9CI) (CA INDEX NAME)



● HI

RN 122859-37-4 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[1-(4,5-dihydro-1H-imidazol-2-yl)-4-piperidinyl]acetyl]-5,10-dihydro-, monohydriodide (9CI) (CA INDEX NAME)



● HI

RN 122859-39-6 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-(aminoiminomethyl)-1-piperidinyl]acetyl]-5,10-dihydro-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl


RN 122859-41-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[[4-[imino(methylamino)methyl]-1-piperidinyl]acetyl]-, dihydrochloride (9CI) (CA INDEX NAME)




RN 122859-43-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[[3-[imino(methylamino)methyl]-1-piperidinyl]acetyl]-, dihydrochloride (9CI)
(CA INDEX NAME)




RN 122859-44-3 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-[[[(1,1-dimethylethyl)amino]iminomethyl]-1-piperidinyl]acetyl]-5,10-dihydro-, dihydrochloride (9CI) (CA INDEX NAME)



RN 122859-45-4 CAPLUS
 CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[[4-[imino(phenylamino)methyl]-1-piperidiny]acetyl]-, dihydrochloride (9CI)
 (CA INDEX NAME)




RN 122859-46-5 CAPLUS
 CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[3-(5,6-dihydro-1(4H)-pyrimidinyl)-1-oxopropyl]-5,10-dihydro-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 122859-49-8 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[3-(5,6-dihydro-2-methyl-1(4H)-pyrimidinyl)-1-oxopropyl]-5,10-dihydro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 122859-56-7 CAPLUS


CN 5H-Dibenzo[b,e][1,4]diazepine-5-carboxylic acid, 10,11-dihydro-11-oxo-, 1,4,5,6-tetrahydro-2-methyl-5-pyrimidinyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 122882-72-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[[4-[1-(methylimino)ethyl]-1-piperazinyl]acetyl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl


RN 122882-74-0 CAPLUS

CN Formic acid, compd. with 5-[3-(2-amino-5,6-dihydro-1(4H)-pyrimidinyl)-1-oxopropyl]-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 122882-73-9

CMF C20 H21 N5 O2



CM 2

CRN 64-18-6

CMF C H2 O2




IT **5814-41-5 122859-62-5**

RL: RCT (Reactant); RACT (Reactant or reagent)

(reaction of, in preparation of muscarinic antagonists)


RN 5814-41-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro- (7CI, 8CI, 9CI) (CA INDEX NAME)



RN 122859-62-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-(1-piperazinylacetyl)- (9CI) (CA INDEX NAME)



L25 ANSWER 65 OF 104 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1989:614512 CAPLUS Full-text

DN 111:214512

TI Preparation, testing, and formulation of annelated heterocyclylcarbonylbenzodiazepinone derivatives as antiarrhythmics and cardiotonics

IN Engel, Wolfhard; Trummlitz, Guenter; Eberlein, Wolfgang; Mihm, Gerhard; Mayer, Norbert; De Jonge, Adriaan; Rudolf, Klaus

PA Thomae, Dr. Karl, G.m.b.H., Fed. Rep. Ger.

SO Ger. Offen., 30 pp.

CODEN: GWXXBX

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 3726908	A1	19890223	DE 1987-3726908	19870813
	EP 306698	A1	19890315	EP 1988-112443	19880801
	EP 306698	B1	19920325		
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	AT 74133	E	19920415	AT 1988-112443	19880801
	US 4931436	A	19900605	US 1988-230406	19880809
	DD 282226	A5	19900905	DD 1988-318853	19880811
	DK 8804516	A	19890214	DK 1988-4516	19880812
	FI 8803745	A	19890214	FI 1988-3745	19880812
	NO 8803585	A	19890214	NO 1988-3585	19880812
	NO 167145	B	19910701		
	NO 167145	C	19911009		
	AU 8820912	A1	19890216	AU 1988-20912	19880812
	AU 608641	B2	19910411		
	JP 01066186	A2	19890313	JP 1988-201788	19880812
	HU 50793	A2	19900328	HU 1988-4348	19880812
	HU 201924	B	19910128		
	ZA 8805955	A	19900425	ZA 1988-5955	19880812
	IL 87433	A1	19911212	IL 1988-87433	19880812
PRAI	DE 1987-3726908	A	19870813		
	EP 1988-112443	A	19880801		

OS MARPAT 111:214512

GI For diagram(s), see printed CA Issue.

AB The title compds. [I; R1 = C1-4 alkyl, PhCH₂; R2 = (hydroxy-substituted) C1-7 alkyl, cycloalkyl, cycloalkylmethyl; R1R2 = atoms to complete a 4-7-membered ring; R3 = C1-4 alkyl, Cl, H; R4 = H, Me; A = (O-, S-, or imino-interrupted) C2-7 alkylene; B = atoms to form fused 2,3-pyridylene, (substituted) phenylene, pyrrolene, 3,4-thienylene, 4,5-imidazolene; dotted line = atoms to complete a 5-, 6-, or 7-membered ring; X1, X2 = CH, N; Z = bond, O, S, CH₂, CH₂CH₂], useful for treatment of bradycardia and bradyarrhythmia, were prepared 11-(Chlorocarbonyl)-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one in DMF was treated with 3-[3-(1-piperidinyl)propyl]piperidine in DMF to give 5,11-dihydro-11-[[3-[3-(1-piperidinyl)propyl]-1-piperidinyl]carbonyl]-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one (II). The latter in rats bound to heart atrial receptors with an ID₅₀ of 0.01 mg/kg, to heart ventricle receptors with an ID₅₀ of 0.005 mg/kg, and to bronchial receptors with an ID₅₀ of 0.06 mg/kg. Tablets were prepared containing II 5.0, lactose 148.0, potato starch 65.0, and Mg stearate 2.0 mg.

IT **122373-61-9P**


RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of, for treatment for bradycardia and bradyarrhythmia)

RN 122373-61-9 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[[3-[2-(1-

pyrrolidinyl)ethyl]-1-piperidinyl]carbonyl]-, monohydrochloride (9CI) (CA
INDEX NAME)




● HCl

L25 ANSWER 66 OF 104 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1989:186504 CAPLUS Full-text
 DN 110:186504
 TI UH-AH 37, an ileal-selective muscarinic antagonist that does not discriminate between M2 and M3 binding sites
 AU Doods, Henri N.; Mayer, Norbert
 CS Dep. Pharmacol., Dr. Karl Thomae G.m.b.H., Biberach, 7950/1, Fed. Rep. Ger.
 SO European Journal of Pharmacology (1989), 161(2-3), 215-18
 CODEN: EJPHAZ; ISSN: 0014-2999
 DT Journal
 LA English
 AB The novel antimuscarinic compound UH-AH 37 (6-chloro-5,10-dihydro-5-[(1-methyl-4-piperidyl)acetyl]-11H-dibenzo-[b,e][1,4]diazepine-11-one-HCl) showed a 14-fold higher affinity for ileal than for atrial muscarinic receptors. In receptor binding studies, UH-AH 37 showed no marked selectivity for either atrial, glandular, or ileal muscarinic binding sites. Moreover, it did not reveal binding heterogeneity in membranes from ileal smooth muscle. These results indicate that UH-AH 37 possesses a unique and novel selectivity profile.
 IT **120382-14-1**, UH-AH 37
 RL: BIOL (Biological study)
 (muscarinic receptor affinity for, in heart and intestine and submandibular gland)
 RN 120382-14-1 CAPLUS
 CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 6-chloro-5,10-dihydro-5-[(1-methyl-4-piperidyl)acetyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L25 ANSWER 67 OF 104 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1989:108137 CAPLUS Full-text
 DN 110:108137
 TI The relative potencies of cholinomimetics and muscarinic antagonists on the rat iris in vivo: effects of pH on potency of pirenzepine and telenzepine
 AU Hagan, J. J.; Van der Heijden, B.; Broekkamp, C. L. E.
 CS CNS Pharmacol. Lab., Organon Int. B. V., Oss, 5340 BH, Neth.
 SO Naunyn-Schmiedeberg's Archives of Pharmacology (1988), 338(5), 476-83
 CODEN: NSAPCC; ISSN: 0028-1298
 DT Journal
 LA English
 AB Topical administration of drugs to the cornea of anesthetized rats pretreated with clonidine provides a rapid and simple method for the detection of cholinomimetic activity, whether this is due to direct agonist activity, acetylcholinesterase inhibition or facilitation of transmitter release. In non-clonidine-treated rats antagonist effects are readily detected and both agonist and antagonist data tentatively suggest that contraction of the iris sphincter may be mediated through an M2 (ileal) receptor. Finally, the potency of pirenzepine and telenzepine were found to vary as a function of pH, an effect which appears to be mediated by facilitation of trans-corneal transport or diffusion and which may have important implications for understanding the mode of action of these drugs in anti-ulcer therapy.
 IT **87646-93-3**
 RL: BIOL (Biological study)
 (mydriasis from)
 RN 87646-93-3 CAPLUS
 CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 6-chloro-5,10-dihydro-5-[(1-methyl-4-piperidiny)acetyl]- (9CI) (CA INDEX NAME)



L25 ANSWER 68 OF 104 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1989:39029 CAPLUS Full-text
 DN 110:39029
 TI Condensed diazepinones, their preparation, pharmaceuticals containing
 them, and their use as vagal pacemakers
 IN Engel, Wolfhard; Eberlein, Wolfgang; Mihm, Gerhard; Trummelitz, Guenter;
 Mayer, Norbert; De Jonge, Adriaan
 PA Thomae, Dr. Karl, G.m.b.H., Fed. Rep. Ger.
 SO Ger. Offen., 44 pp.
 CODEN: GWXXBX
 DT Patent
 LA German
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 3643666	A1	19880630	DE 1986-3643666	19861220
	EP 273239	A1	19880706	EP 1987-118030	19871205
	EP 273239	B1	19910306		
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	AT 61367	E	19910315	AT 1987-118030	19871205
	DK 8706691	A	19880621	DK 1987-6691	19871218
	DK 170670	B1	19951127		
	FI 8705583	A	19880621	FI 1987-5583	19871218
	FI 86725	B	19920630		
	FI 86725	C	19921012		
	NO 8705318	A	19880621	NO 1987-5318	19871218
	NO 166645	B	19910513		
	NO 166645	C	19910821		
	AU 8782806	A1	19880623	AU 1987-82806	19871218
	AU 596479	B2	19900503		
	JP 63166882	A2	19880711	JP 1987-321183	19871218
	JP 2574348	B2	19970122		
	HU 46002	A2	19880928	HU 1987-5864	19871218
	HU 199468	B	19900228		
	ZA 8709492	A	19890830	ZA 1987-9492	19871218
	US 4873236	A	19891010	US 1987-136212	19871218
	DD 275243	A5	19900117	DD 1987-310750	19871218
	IL 84874	A1	19910816	IL 1987-84874	19871218
	CA 1320197	A1	19930713	CA 1987-554792	19871218
PRAI	DE 1986-3643666	A	19861220		
	EP 1987-118030	A	19871205		
OS	CASREACT 110:39029; MARPAT 110:39029				
GI					

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Condensed diazepinones I [Z1Z2 = Q, Q1, Q2, Q3, Q4; D = Q5, Q6, Q7, Q8, Q9;
 X1, X2 = :CH and when Z1Z2 = Q, Q2, Q4, both or only 1 of X1 and X2 = N; A1 =
 alkylene; A2 = alkylene, when in 3 position to N, also bond; Z = bond, O, S,
 CH2, CH2CH2; R = H, Me; R1 = alkyl; R2 = alkyl(un)substituted with OH or
 cycloalkyl or cycloalkylmethyl ring-(un)substituted with OH; NR1R2 =
 heterocyclyl with addnl. O or NMe in ring; R3 = alkyl, Cl, H; R4 = H, Me; R5,
 R6 = H, F, Cl, Br, alkyl; R7 = H, Cl, Me; R8 =: H, alkyl; R9 = H, halo, alkyl;
 R10 = H, Me; R12 = alkyl; when Z1Z2 = Q1 and R7 = H, R3 ≠ Cl Z ≠ S] and their
 diastereomers, enantiomers, and salts, having a favorable effect on heart
 frequency and, because of no gastric secretion and salination inhibitory and
 no mydriatric effects, suitable as vagal pacemakers for treating bradycardia


and bradyarrhythmias in human and veterinary medicine, were prepared by 3 methods. Some I also have a spasmolytic effect on peripheral organs, especially colon and bladder, and are cardioselective antimuscarinic agents. A mixture of aqueous NaHSO₃ and formalin was treated with 2-[(diethylamino)methyl]piperidine, then with aqueous NaCN to give 2-[2-[(diethylamino)methyl]-1-piperidinyl]acetonitrile which was hydrogenated over Raney Ni in NH₃(l) to give 2-[2-[(diethylamino)methyl]-1-piperidinyl]ethanamine (II). 5,11-Dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one in dioxane reacted with COCl₂ in PhMe to give the 11-COCl derivative which reacted with II in MeCN to give III. A tablet formulation comprised 5,11-dihydro-11-[[[2-[2-[(dipropylamino)methyl]-1-piperidinyl]ethyl]amino]carbonyl]-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one (IV)-MeSO₃H 5, lactose 148.0, starch 65.0, and Mg stearate 2.0 mg per tablet. The ED₅₀ for increasing heart rate 50 beats/min in concious dogs was 43 µg IV/kg i.v. and 300 µg IV/kg orally.

IT 118290-40-7P 118290-41-8P 118290-42-9P
118306-35-7P 118306-73-3P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as vagal pacemaker)


RN 118290-40-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-5-carboxamide, N-[2-[2-[(diethylamino)methyl]-1-piperidinyl]ethyl]-10,11-dihydro-11-oxo- (9CI)
(CA INDEX NAME)




RN 118290-41-8 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-5-carboxamide, N-[3-[2-[(diethylamino)methyl]-1-piperidinyl]propyl]-10,11-dihydro-11-oxo- (9CI)
(CA INDEX NAME)




RN 118290-42-9 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-5-carboxamide, N-[2-[2-[(dimethylamino)methyl]-1-piperidinyl]ethyl]-10,11-dihydro-11-oxo- (9CI)
(CA INDEX NAME)




RN 118306-35-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-5-carboxamide, N-[2-[2-[(diethylamino)methyl]-1-pyrrolidinyl]ethyl]-10,11-dihydro-11-oxo- (9CI)
(CA INDEX NAME)



RN 118306-73-3 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-5-carboxamide, N-[3-[2-[(dimethylamino)methyl]-1-piperidinyl]propyl]-10,11-dihydro-11-oxo- (9CI)
(CA INDEX NAME)



L25 ANSWER 69 OF 104 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1988:229484 CAPLUS Full-text

DN 108:229484

TI Silver halide color photographic material containing cyandye-forming coupler

IN Ono, Michio; Aoki, Kozo

PA Fuji Photo Film Co., Ltd., Japan

SO Eur. Pat. Appl., 96 pp.

CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	EP 244697	A2	19871111	EP 1987-105889	19870422
	EP 244697	A3	19881117		
	EP 244697	B1	19910828		
	R: DE, FR, GB, NL				
	JP 62257158	A2	19871109	JP 1986-100222	19860430
	JP 05045021	B4	19930708		
	US 4746602	A	19880524	US 1987-44270	19870430
PRAI	JP 1986-100222	A	19860430		

OS CASREACT 108:229484

GI For diagram(s), see printed CA Issue.


AB A Ag halide color photog. material, which forms a dye image excellent in fastness and color reproducibility and free from white background stains, is comprised of ≥ 1 Ag halide emulsion layer containing a cyan dye-forming coupler having the general formula I (R = an aliphatic group, an aromatic group, a substituted amino group, or a heterocyclic group; R1 = H or a group releasable upon coupling with the oxidation product of a color photog. developing agent; Y = an atomic group forming an at least 7-membered N-containing heterocyclic ring containing ≥ 1 -NHCO-group; any of R, R1, and Y may form a dimer or higher polymer). Thus, a solution of the coupler II and di-Bu phthalate in Et acetate was dispersed in an aqueous gelatin solution containing Na dodecylbenzenesulfonate, mixed with a red-sensitive Ag(Br,Cl) emulsion, coated on a polyethylene-laminated paper support, overcoated with a gelatin protective layer, exposed to light through a continuous wedge, and color processed to give a dye image which showed a d. reduction of 7% after heating at 100° in the dark for 6 days, 5% after heating at 60° and 70% relative humidity in the dark for 6 wk, or 8% after irradiating with a Xe lamp (100,000 lx) for 6 days and low yellowing of white background.

IT 114747-73-8


RL: TEM (Technical or engineered material use); USES (Uses)
(cyan photog. coupler, for stabilized dye image formation)

RN 114747-73-8 CAPLUS


CN Benzamide, N-(9-chloro-10,11-dihydro-6-hydroxy-11-oxodibenz[b,f][1,4]oxazepin-7-yl)-2-[(hexadecylsulfonyl)amino]- (9CI) (CA INDEX NAME)




L25 ANSWER 70 OF 104 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1988:221679 CAPLUS Full-text
 DN 108:221679
 TI Tricyclic compounds as selective antimuscarinics. 2. Structure-activity relationships of M1-selective antimuscarinics related to pirenzepine
 AU Eberlein, Wolfgang G.; Engel, Wolfhard W.; Trümmlitz, Guenter; Schmidt, Guenther; Hammer, Rudolf
 CS Dep. Chem. Res., Dr. Karl Thomae G.m.b.H., Biberach, D-7950/1, Fed. Rep. Ger.
 SO Journal of Medicinal Chemistry (1988), 31(6), 1169-74
 CODEN: JMCMAR; ISSN: 0022-2623
 DT Journal
 LA English
 OS CASREACT 108:221679
 GI



AB In order to gain some insight into those structural features that control M1 selectivity, a selected set of pirenzepine analogs I (R = aminoalkyl, aminoalkylamino, aminoalkoxy) were prepared. Binding studies were conducted in rat tissue homogenates from cerebral cortex (M1) and gastric fundus (M2). The ratio of ED50 values of I in the two different tissues was taken as a measure of M1 receptor selectivity. Several I, especially those with flexible side chains, i.e. high degree of freedom of rotation around single bonds, proved to be nonselective. Among semirigid compds. only those containing 6-membered ring systems showed significant M1 selectivity. Principles of structure-activity and structure-selectivity relationships are discussed.
 IT **108295-86-9**
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (antimuscarinic activity of)
 RN 108295-86-9 CAPLUS
 CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[(4-methyl-1-piperazinyl)acetyl]- (9CI) (CA INDEX NAME)



L25 ANSWER 71 OF 104 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1987:554311 CAPLUS Full-text
 DN 107:154311
 TI Tricyclic compounds as selective antimuscarinics. 1. Structural requirements for selectivity towards the muscarinic acetylcholine receptor in a series of pirenzepine and imipramine analogs
 AU Eberlein, Wolfgang G.; Trummelitz, Guenter; Engel, Wolfhard W.; Schmidt, Guenther; Pelzer, Helmut; Mayer, Norbert
 CS Dep. Chem. Res., Dr. Karl Thomae G.m.b.H., Biberach, D-7950/1, Fed. Rep. Ger.
 SO Journal of Medicinal Chemistry (1987), 30(8), 1378-82
 CODEN: JMCMAR; ISSN: 0022-2623
 DT Journal
 LA English
 OS CASREACT 107:154311
 GI




AB Analogs of pirenzepine (I) and imipramine (II) comprising 3 different tricycles and 3 different side chains were prepared and were determined to be nonselective antimuscarinics. Thus, tricyclic compds. III [X = CH, N; Z = NHCO; R = Me₂N(CH₂)₃] were prepared by N-alkylation of III (X, Z = same; R = H) with BuLi followed by addition of Me₂N(CH₂)₃Cl. Acylation of III (X = CH, N; Z = NHCO, CH₂CH₂; R = H) with Cl(CH₂)_nCOCl (n = 1, 2) formed chloroacyl derivs. IV (same X, Z). Reaction of IV with Me₂NH or N-methylpiperazine afforded tricyclic derivs. V (X = CH, N; Z = NHCO, CH₂CH₂; NR₁₂ = NMe₂, 4-methylpiperazinyl; n = 1, 2). Binding affinities of I, II, and selected analogs to the muscarinic receptors in homogenized rat-cortex tissue were determined. Results indicate that preferential binding by I towards the muscarinic receptor is brought about by the endocyclic amide group, by the positioning of the protonated N atom of the side chain, and to a minor extent by the exocyclic amide group. A model for selective binding of I to the muscarinic receptor was derived.

IT 108295-86-9P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation, antimuscarinic activity, and binding affinity of, for muscarinic acetylcholine receptors)

RN 108295-86-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[(4-methyl-1-piperazinyl)acetyl]- (9CI) (CA INDEX NAME)




IT **5814-41-5**

RL: RCT (Reactant); RACT (Reactant or reagent)
(N-acylation or -alkylation of)


RN 5814-41-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro- (7CI, 8CI, 9CI) (CA
INDEX NAME)



L25 ANSWER 72 OF 104 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1987:213986 CAPLUS Full-text
 DN 106:213986
 TI A chiral benzodiazepine derivative useful as an antiulcer agent
 IN Trummlitz, Guenter; Engel, Wolfhard; Eberlein, Wolfgang; Mihm, Gerhard;
 Giachetti, Antonio
 PA Thomae, Dr. Karl, G.m.b.H., Fed. Rep. Ger.
 SO Ger. Offen., 7 pp.
 CODEN: GWXXBX
 DT Patent
 LA German
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 3531682	A1	19870312	DE 1985-3531682	19850905
	US 4668674	A	19870526	US 1986-898153	19860819
	EP 214528	A2	19870318	EP 1986-111580	19860821
	EP 214528	A3	19870805		
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
	FI 8603549	A	19870306	FI 1986-3549	19860903
	DK 8604238	A	19870306	DK 1986-4238	19860904
	NO 8603539	A	19870306	NO 1986-3539	19860904
	AU 8662341	A1	19870312	AU 1986-62341	19860904
	AU 582271	B2	19890316		
	JP 62056478	A2	19870312	JP 1986-208831	19860904
	HU 42472	A2	19870728	HU 1986-3826	19860904
	HU 195499	B	19880530		
	DD 251976	A5	19871202	DD 1986-294151	19860904
	ES 2001290	A6	19880501	ES 1986-1622	19860904
	ZA 8606703	A	19880525	ZA 1986-6703	19860904
PRAI	DE 1985-3531682	A	19850905		
OS	CASREACT 106:213986				
GI					




AB (+)-6-Chloro-5,10-dihydro-5-[(1-methyl-4-piperidiny1)-acetyl]-11H-dibenzo[b,e][1,4]-11-diazepinone [(+)-I] was prepared as an antiulcer drug. (+)-Tartaric acid and racemic I were heated to boiling in EtOH. Cooling gave crystals of tartrate salt having a 90:10 ratio of (+)-I to its enantiomer. This material was recrystd. to give, after conversion to the free base, (+)-I of >98% enantiomeric purity. Tablets were prepared containing (+)-I 0.5, lactose 152.5, potato starch 65.0, and Mg stearate 2.0 mg. In rats (+)-I reduced stomach acid secretion with an ED50 of 0.18 mg/kg i.v.

IT **108319-10-4P**
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation and conversion of, to free base)

RN 108319-10-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 6-chloro-5,10-dihydro-5-[(1-methyl-4-piperidiny1)acetyl]-, (-)-, [S-(R*,R*)]-2,3-dihydroxybutanedioate (1:1) (9CI) (CA INDEX NAME)


CRN 108303-17-9
CMF C21 H22 Cl N3 O2



CM 2

CRN 147-71-7
CMF C4 H6 O6

Absolute stereochemistry.




IT 108303-17-9P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 108303-17-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 6-chloro-5,10-dihydro-5-[(1-methyl-4-piperidinyl)acetyl]-, (-)- (9CI) (CA INDEX NAME)



IT 108324-51-2P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as ulcer inhibitor)

RN 108324-51-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 6-chloro-5,10-dihydro-5-[(1-methyl-4-piperidinyl)acetyl]-, (+)-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (9CI)
(CA INDEX NAME)

CM 1


CRN 108324-50-1
CMF C21 H22 Cl N3 O2



CM 2

CRN 87-69-4
CMF C4 H6 O6

Absolute stereochemistry.




IT 87646-93-3

RL: PROC (Process)
(resolution of)


RN 87646-93-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 6-chloro-5,10-dihydro-5-[(1-methyl-4-piperidinyl)acetyl]- (9CI) (CA INDEX NAME)



L25 ANSWER 73 OF 104 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1987:156504 CAPLUS Full-text
 DN 106:156504
 TI 1,4-Pyrido[2,3-b][1,4]benzodiazepin-6-one derivatives
 PA Thomae, Dr. Karl, G.m.b.H., Fed. Rep. Ger.
 SO Jpn. Kokai Tokkyo Koho, 18 pp.
 CODEN: JKXXAF
 DT Patent
 LA Japanese
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 62004288	A2	19870110	JP 1986-150632	19860626
	DE 3523002	A1	19870102	DE 1985-3523002	19850627
	DE 3611097	A1	19871008	DE 1986-3611097	19860403
PRAI	DE 1985-3523002	A	19850627		
	DE 1986-3611097	A	19860403		
OS	CASREACT 106:156504				
GI					




AB The title compds. [I; R = NR₁R₂ [R₁, R₂ = H, alkyl, phenylalkyl, (hydroxy)cycloalkyl], Q (R₃ = H, hydroxyalkyl, branched alkyl, n = 0-2), 4-substituted 1-piperazinyl; Z = CHR₄, NR₄ (R₄ = H, alkyl), O], which showed antimuscarinic activity and anticonvulsant activity in the rectum and bladder, and antithrombotic activity, are prepared. A mixture of 5,11-dihydro-11-(1-oxo-4-pentynyl)-6H pyrido[2,3-b][1,4]benzodiazepin-6-one (preparation given), paraformaldehyde, and piperidine in dioxane in the presence of CuCl was refluxed to give I (Z = CH₂; R = piperidino), which increased the heart beats in a dog at ED₅₀ of 44 µg/kg i.v. at which neither desalivation or mydriasis was observed.

IT **112309-39-4P 112309-40-7P 112309-41-8P**
112309-42-9P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of, as muscarinic antagonist, antithrombotic, anticonvulsant, and blood platelet aggregation inhibitor)


RN 112309-39-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[2-methyl-6-(4-methyl-1-piperazinyl)-1-oxo-4-hexynyl]- (9CI) (CA INDEX NAME)




RN 112309-40-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[1-oxo-6-(1-piperidinyl)-4-hexynyl]- (9CI) (CA INDEX NAME)




RN 112309-41-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[6-(hexahydro-1H-azepin-1-yl)-1-oxo-4-hexynyl]-5,10-dihydro- (9CI) (CA INDEX NAME)



RN 112309-42-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[2-methyl-6-(4-methyl-1-piperaziny)-1-oxo-4-hexynyl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

L25 ANSWER 74 OF 104 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1986:129934 CAPLUS Full-text
 DN 104:129934
 TI Condensed diazepinones and their pharmaceutical use
 IN Engel, Wolfhard; Trummelitz, Guenter; Eberlein, Wolfgang; Mihm, Gerhard;
 Schmidt, Guenther; Hammer, Rudolf; Giachetti, Antonio
 PA Thomae, Dr. Karl, G.m.b.H., Fed. Rep. Ger.
 SO Ger. Offen., 99 pp.
 CODEN: GWXXBX

DT Patent
 LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 3409237	A1	19850919	DE 1984-3409237	19840314
	ZA 8501871	A	19861126	ZA 1985-1871	19850113
	EP 156191	A2	19851002	EP 1985-102387	19850304
	EP 156191	A3	19861230		
	EP 156191	B1	19890719		
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
	AT 44744	E	19890815	AT 1985-102387	19850304
	DD 235260	A5	19860430	DD 1985-274054	19850312
	IL 74573	A1	19880531	IL 1985-74573	19850312
	DK 8501149	A	19850915	DK 1985-1149	19850313
	DK 171023	B1	19960422		
	FI 8500991	A	19850915	FI 1985-991	19850313
	FI 81342	B	19900629		
	FI 81342	C	19901010		
	NO 8500992	A	19850916	NO 1985-992	19850313
	NO 161371	B	19890502		
	NO 161371	C	19890809		
	AU 8539815	A1	19850919	AU 1985-39815	19850313
	AU 571315	B2	19880414		
	JP 60215683	A2	19851029	JP 1985-50229	19850313
	JP 05068474	B4	19930929		
	HU 37611	A2	19860123	HU 1985-939	19850313
	HU 192272	B	19870528		
	ES 541212	A1	19860516	ES 1985-541212	19850313
	CA 1244016	A1	19881101	CA 1985-476368	19850313
	US 4550107	A	19851029	US 1985-711913	19850314
	ES 551276	A1	19861201	ES 1986-551276	19860127
	ES 551277	A1	19870116	ES 1986-551277	19860127
PRAI	DE 1984-3409237	A	19840314		
	EP 1985-102387	A	19850304		

OS CASREACT 104:129934

GI For diagram(s), see printed CA Issue.

AB Condensed, tricyclic, benzo- and pyridodiazepinones I [R1 = alkyl; R2 = (hydroxy)alkyl, (hydroxy)cycloalkyl; R1R2N = heterocyclyl; X = CH, N; X1 = atoms required to complete a C6H6, (un)substituted pyrrole, or thiophene ring; X2 = CH2, O, bond; Z = CH2, CH2CH2; Z1 = bond, Z] were prepared Thus, Et2N was alkylated with 2-(chloromethyl)pyridine to give 2-[(diethylamino)methyl]pyridine which was hydrogenated in AcOH over PtO2 to give (±)-2-[(diethylamino)methyl]piperidine. The latter was refluxed with 11-(chloroacetyl)-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one to give 84% piperidinylacetyl derivative (±)-II.


IT 100158-22-3P 100158-23-4P 100158-24-5P
 100158-25-6P 100158-26-7P 100158-27-8P
 100158-28-9P 100158-29-0P 100158-31-4P
 100158-48-3P 100158-49-4P 100158-50-7P
 100158-51-8P 100158-52-9P 100158-53-0P

100180-39-0P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as antibradycardia agent)


RN 100158-22-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 100158-23-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[3-[2-[(diethylamino)methyl]-1-piperidinyl]-1-oxopropyl]-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 100158-24-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[2-[2-(dimethylamino)ethyl]-1-piperidinyl]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 100158-25-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[2-[2-(diethylamino)ethyl]-1-piperidinyl]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 100158-26-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[[2-(1-ethylpyrrolidinyl)methyl]-1-piperidinyl]acetyl]- (9CI) (CA INDEX NAME)




RN 100158-27-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[[2-(4-morpholinylmethyl)-1-piperidinyl]acetyl]- (9CI) (CA INDEX NAME)




RN 100158-28-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[2-[(cyclohexylmethylamino)methyl]-1-piperidinyl]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 100158-29-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[[2-[(4-methyl-1-piperazinyl)methyl]-1-piperidinyl]acetyl]- (9CI) (CA INDEX NAME)




RN 100158-31-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[[2-[[[4-hydroxycyclohexyl)methylamino)methyl]-1-piperidinyl]acetyl]- (9CI) (CA INDEX NAME)



RN 100158-48-3 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[3-(dimethylamino)-1-piperidinyl]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 100158-49-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[[2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]acetyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 100158-50-7 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[3-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,10-dihydro-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 100158-51-8 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[3-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)



RN 100158-52-9 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[2-[(diethylamino)methyl]-1-pyrrolidinyl]acetyl]-5,10-dihydro-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 100158-53-0 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[[2-[(4-methyl-1-piperazinyl)methyl]-1-pyrrolidinyl]acetyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 100180-39-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[2-[(dimethylamino)methyl]-1-piperidinyl]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)



L25 ANSWER 75 OF 104 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1985:542024 CAPLUS Full-text

DN 103:142024

TI 5,10-Dihydro-11H-dibenzo[b,e][1,4]diazepin-11-ones substituted in the 5-position

IN Rueger, Carla; Roehnert, Helmut; Bahr, Fritz; Lohmann, Dieter; Hoffmann, Evelyn; Bartsch, Reni; Schumann, Steffen

PA VEB Arzneimittelwerk, Ger. Dem. Rep.

SO Eur. Pat. Appl., 37 pp.


CODEN: EPXXDW

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 139627	A1	19850502	EP 1984-890185	19841009
	EP 139627	B1	19910522		
	R: AT, CH, DE, FR, GB, LI				
	DD 236731	A1	19860618	DD 1983-255766	19831019
	DD 236731	B3	19921210		
	AT 63743	E	19910615	AT 1984-890185	19841009
	HU 37131	O	19851128	HU 1984-3852	19841015
	HU 192876	B	19870728		
	CS 247562	B1	19870115	CS 1984-7923	19841018
	JP 60172972	A2	19850906	JP 1984-220339	19841019
	JP 04040348	B4	19920702		
	SU 1364623	A1	19880107	SU 1984-3804098	19841019
PRAI	DD 1983-255766	A	19831019		
	EP 1984-890185	A	19841009		
OS	CASREACT 103:142024				
GI					




AB The title compds. I [R = H, Cl; R¹ = H, Me; R² = H, Me, HOCH₂CH₂; R³ = HOCH₂CH₂, (4-morpholinylcarbonyl)methyl, AcNHCH₂CH₂; R²R³ = 4-acyl-1-piperazinyl; Z = CH₂, CH₂CH₂, MeCH, bond] were prepared. Thus, 8-chloro-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one was acylated with ClCH₂COCl to give 66.3% 5-(chloroacetyl) derivative. This was refluxed in CHCl₃ with (HOCH₂CH₂)₂NH to give 43.7% I (R = Cl, R¹ = H, R² = R³ = HOCH₂CH₂, Z = CH₂) (II). In rats II inhibited ulcers caused by immobilization with an ED₅₀ of 6 mg/kg orally. Selected I are also mydriatics.

IT 5814-41-5

RL: RCT (Reactant); RACT (Reactant or reagent)
(acylation of)

RN 5814-41-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro- (7CI, 8CI, 9CI) (CA INDEX NAME)




IT 98374-61-9P 98374-62-0P 98374-65-3P

98374-66-4P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and antiulcer and mydriatic activity of)


RN 98374-61-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-chloro-5-[[4-(2-furanylcarbonyl)-1-piperazinyl]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)



RN 98374-62-0 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-chloro-5-[[4-(2-furanylcarbonyl)-1-piperazinyl]acetyl]-5,10-dihydro-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 98374-65-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-(2-furanylcarbonyl)-1-piperazinyl]acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 98374-66-4 CAPLUS
 CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[[4-(2-furanylcarbonyl)-1-piperazinyl]acetyl]-5,10-dihydro-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

IT 98374-69-7P 98374-70-0P 98374-71-1P
 98374-72-2P 98374-78-8P 98374-80-2P
 98374-85-7P 98374-86-8P 98374-87-9P
 98374-88-0P 98374-91-5P 98374-92-6P
 98399-77-0P 98399-79-2P 98399-80-5P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of, as mydriatic and antiulcer agent)
 RN 98374-69-7 CAPLUS
 CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-chloro-5,10-dihydro-5-[[[2-(4-morpholinyl)-2-oxoethyl]amino]acetyl]- (9CI) (CA INDEX NAME)



RN 98374-70-0 CAPLUS



CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-chloro-5,10-dihydro-5-[[[2-(4-morpholinyl)-2-oxoethyl]amino]acetyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl



RN 98374-71-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-chloro-5,10-dihydro-5-[[[4-(3,4,5-trimethoxybenzoyl)-1-piperazinyl]acetyl]- (9CI) (CA INDEX NAME)



RN 98374-72-2 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-chloro-5,10-dihydro-5-[[4-(3,4,5-trimethoxybenzoyl)-1-piperazinyl]acetyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 98374-78-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-chloro-5-[2-[4-(2-furanylcarbonyl)-1-piperazinyl]-1-oxopropyl]-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 98374-80-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-chloro-5,10-dihydro-5-(4-morpholinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 98374-85-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-chloro-5,10-dihydro-5-[[methyl[2-(4-morpholinyl)-2-oxoethyl]amino]acetyl]- (9CI) (CA INDEX NAME)




RN 98374-86-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-chloro-5,10-dihydro-5-[[methyl[2-(4-morpholinyl)-2-oxoethyl]amino]acetyl]-, monohydrochloride (9CI) (CA INDEX NAME)




RN 98374-87-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-chloro-5,10-dihydro-5-[[[3-(4-morpholinyl)propyl]amino]acetyl]-, monohydrochloride (9CI) (CA INDEX NAME)




RN 98374-88-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[(4-acetyl-1-piperazinyl)acetyl]-8-chloro-5,10-dihydro-, monohydrochloride (9CI) (CA INDEX NAME)




RN 98374-91-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-chloro-5,10-dihydro-5-[2-(4-methyl-1-piperazinyl)-1-oxopropyl]- (9CI) (CA INDEX NAME)




RN 98374-92-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-chloro-5,10-dihydro-5-[2-(4-methyl-1-piperazinyl)-1-oxopropyl]-, monohydrochloride (9CI) (CA INDEX NAME)




RN 98399-77-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-chloro-5-[2-[4-(2-furanylcarbonyl)-1-piperazinyl]-1-oxopropyl]-5,10-dihydro-, monohydrochloride (9CI) (CA INDEX NAME)




RN 98399-79-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[[methyl[2-(4-morpholinyl)-2-oxoethyl]amino]acetyl]- (9CI) (CA INDEX NAME)



RN 98399-80-5 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[[methyl[2-(4-morpholinyl)-2-oxoethyl]amino]acetyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


L25 ANSWER 76 OF 104 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1985:220855 CAPLUS Full-text
 DN 102:220855
 TI Dibenzo[1,4]diazepinone, pyrido[1,4]benzodiazepinone, and
 pyrido[1,5]benzodiazepinone derivatives and their pharmacological
 activities
 IN Giani, Roberto; Parini, Ettore; Tonon, Giancarlo
 PA Dompe Farmaceutici S.p.A., Italy
 SO Eur. Pat. Appl., 32 pp.
 CODEN: EPXXDW
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 125607	A2	19841121	EP 1984-105156	19840507
	EP 125607	A3	19850807		
	EP 125607	B1	19881026		
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
	AT 38227	E	19881115	AT 1984-105156	19840507
	US 4556653	A	19851203	US 1984-609100	19840509
	JP 60016976	A2	19850128	JP 1984-98462	19840516
	JP 03014313	B4	19910226		
	JP 01199971	A2	19890811	JP 1988-328777	19840516
PRAI	IT 1983-21134	A	19830517		
	EP 1984-105156	A	19840507		
GI					




AB The title compds. I [X = N, CH; A = NH, B = CO, CS or A = CO, CS, B = NH; R = CO(CHR₁)_nM (R₁ = C1-4 alkyl, n = 0, 1, 2, M = substituted tetrahydropyrrolidinyl, piperazinyl, alkylamino, piperidino], having antisecretory, anticholinergic, and antimuscarinic activity, were prepared Thus, refluxing 11-(2-chloropropionyl)-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one with piperidine in C₆H₆ for 20 h gave 30% I [X = N, A = NH, B = CO, R = COCHR₁Me (R₁ = piperidino)], which showed 10.3% inhibition of gastric juice secretion in rats at 6.25 mg/kg p.o. compared to 7.9% for pirenzepine.

IT **96449-07-9P 96449-08-0P 96449-09-1P**
96449-10-4P 96449-11-5P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 96449-07-9 CAPLUS
 CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[(2-methyl-1-pyrrolidinyl)acetyl]- (9CI) (CA INDEX NAME)




RN 96449-08-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[3-(2-methyl-1-pyrrolidinyl)-1-oxopropyl]- (9CI) (CA INDEX NAME)




RN 96449-09-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[3-(4-methyl-1-piperazinyl)-1-oxopropyl]- (9CI) (CA INDEX NAME)




RN 96449-10-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[3-(cyclohexylmethylamino)-1-oxopropyl]-5,10-dihydro- (9CI) (CA INDEX NAME)



RN 96449-11-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[(3,3-dimethyl-1-piperidiny)acetyl]-5,10-dihydro- (9CI) (CA INDEX NAME)



L25 ANSWER 77 OF 104 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1985:203959 CAPLUS Full-text

DN 102:203959

TI Quaternary salts of dibenzo[1,4]diazepinone, pyrido[1,4]benzodiazepinone, and pyrido[1,5]benzodiazepinone derivatives and their pharmacological activity

IN Giani, Roberto; Parini, Ettore; Tonon, Giancarlo

PA Dompe Farmaceutici S.p.A., Italy

SO Eur. Pat. Appl., 27 pp.

CODEN: EPXXDW


DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 126366	A2	19841128	EP 1984-105155	19840507
	EP 126366	A3	19850724		
	EP 126366	B1	19881214		
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
	AT 39252	E	19881215	AT 1984-105155	19840507
	US 4594190	A	19860610	US 1984-609102	19840509
	JP 60016977	A2	19850128	JP 1984-98463	19840516
	JP 01193225	A2	19890803	JP 1988-307664	19840516
PRAI	IT 1983-21135	A	19830517		
	EP 1984-105155	A	19840507		

GI




AB The title compds. I [X = N, CH; A = NH, B = CO, CS or A = CO, CS, B = NH; R = CO(CHR₁)_nM (R₁ = C1-4 alkyl, n = 1, 2, M = R₂R₃R₄N⁺ (R₂, R₃, R₄ = aliphatic, nitrogen heterocyclyl, substituted piperazinyl), useful as antiulcer, antisecretory, spasmolytic, and antimuscarinic agents, were prepared Thus, 11-(2-chloroacetyl)-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one and N,N1-dimethylpiperazine in MeCN were refluxed 2 h to give 42.9% I [X = N, A = NH, B = CO, R = COCH₂R₁ (R₁ = 1,4-dimethylpiperazinyl chloride), which was methylated by MeI to give 33% the dimethiodide. The latter showed 10.3% inhibition of gastric juice secretion in rats at 6.25 mg/kg compared to 7.9% for pirenzepine.

IT **96437-22-8P 96437-92-2P**

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 96437-22-8 CAPLUS


CN Pyrrolidinium, 1-[3-(10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-5-yl)-3-oxopropyl]-1,2-dimethyl-, iodide (9CI) (CA INDEX NAME)



● I⁻

RN 96437-92-2 CAPLUS

CN Pyrrolidinium, 1-[2-(10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-5-yl)-2-oxoethyl]-1,2-dimethyl-, iodide (9CI) (CA INDEX NAME)




● I⁻

L25 ANSWER 78 OF 104 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1984:407218 CAPLUS Full-text
 DN 101:7218
 TI Pyridoindolobenzodiazepine tranquilizers
 IN Rajagopalan, Parthasarathi
 PA du Pont de Nemours, E. I., and Co. , USA
 SO U.S., 15 pp.
 CODEN: USXXAM


DT Patent
 LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 4438120	A	19840320	US 1982-441376	19821112
PRAI	US 1982-441376		19821112		
OS	CASREACT 101:7218				
GI					



I



III


AB Pyridoindolobenzodiazepines I [R = H, (un)substituted alkyl; R1, R2, R4, R5 = H, CF3, Me, Et, halo; R3 = H, alkyl; X = H2, O, S] and their trans-4a,14a dihydro derivs. (II) were prepared Thus, the dibenzodiazepinone III (R6 = H) was nitrosated to give III (R6 = NO) which was treated with Zn-HOAc and 4-piperidone to give I (R = R1 = R3 = R4 = R5 = H, R2 = Cl; X = O; IV). IV was acetylated to give I (R = Ac, R1 = R3 = R4 = R5 = H, R2 = Cl, X = O; IV) which was reduced by B2H6 in THF, then refluxed with 6N HCl to give II.2HCl (R = Et, R1 = R3 = R4 = R5 = H, R2 = Cl, X = H2; V). In the conditioned avoidance response test with mice, the ED50 for IV and V were 29 and 0.3 mg/kg orally, resp.

IT 5814-41-5

RL: RCT (Reactant); RACT (Reactant or reagent)
 (nitrosation of)

RN 5814-41-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro- (7CI, 8CI, 9CI) (CA INDEX NAME)




IT 90353-36-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation and borane reduction of)

RN 90353-36-9 CAPLUS

CN Pyrido[4',3':2,3]indolo[1,7-ab][1,4]benzodiazepin-9(8H)-one,
3-(cyclopropylcarbonyl)-1,2,3,4-tetrahydro-6-(trifluoromethyl)- (9CI) (CA
INDEX NAME)




IT 90353-38-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation and reduction of, by borane)

RN 90353-38-1 CAPLUS

CN Pyrido[4',3':2,3]indolo[1,7-ab][1,4]benzodiazepin-9(8H)-one,
11-chloro-1,2,3,4-tetrahydro-3-(phenylacetyl)- (9CI) (CA INDEX NAME)




IT 90340-37-7P 90340-52-6P 90340-54-8P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and tranquilizer activity of)


RN 90340-37-7 CAPLUS

CN Pyrido[4',3':2,3]indolo[1,7-ab][1,4]benzodiazepin-9(8H)-one,
6-chloro-1,2,3,4-tetrahydro-11-methyl-3-(2-phenylethyl)- (9CI) (CA INDEX
NAME)




RN 90340-52-6 CAPLUS

CN Pyrido[4',3':2,3]indolo[1,7-ab][1,4]benzodiazepin-9(8H)-one,
3-(cyclohexylmethyl)-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)



RN 90340-54-8 CAPLUS

CN Pyrido[4',3':2,3]indolo[1,7-ab][1,4]benzodiazepin-9(8H)-one,
6-chloro-3-[4-(4-fluorophenyl)-4-oxobutyl]-1,2,3,4-tetrahydro- (9CI) (CA
INDEX NAME)




IT 90353-37-0P 90353-39-2P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)


RN 90353-37-0 CAPLUS

CN Pyrido[4',3':2,3]indolo[1,7-ab][1,4]benzodiazepin-9(8H)-one,
6-chloro-3-(cyclohexylcarbonyl)-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)



RN 90353-39-2 CAPLUS

CN Pyrido[4',3':2,3]indolo[1,7-ab][1,4]benzodiazepin-9(8H)-one,
3-benzoyl-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)




IT 90353-83-6 90353-92-7 90353-94-9

RL: RCT (Reactant); RACT (Reactant or reagent)
(reduction of, by borane)


RN 90353-83-6 CAPLUS

CN Pyrido[4',3':2,3]indolo[1,7-ab][1,4]benzodiazepin-9(8H)-one,
6-chloro-3-(cyclohexylmethyl)-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)




RN 90353-92-7 CAPLUS

CN Pyrido[4',3':2,3]indolo[1,7-ab][1,4]benzodiazepin-9(8H)-one,
11-chloro-3-(cyclopropylcarbonyl)-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)




RN 90353-94-9 CAPLUS

CN Pyrido[4',3':2,3]indolo[1,7-ab][1,4]benzodiazepin-9(8H)-one,
6-chloro-1,2,3,4-tetrahydro-11-methyl-3-(phenylacetyl)- (9CI) (CA INDEX NAME)



L25 ANSWER 79 OF 104 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1984:209889 CAPLUS Full-text
 DN 100:209889
 TI Dibenzoxazepine derivatives
 PA Chugai Pharmaceutical Co., Ltd., Japan
 SO Jpn. Kokai Tokkyo Koho, 4 pp.
 CODEN: JKXXAF
 DT Patent
 LA Japanese
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 58225074	A2	19831227	JP 1982-108516	19820625
	JP 03059068	B4	19910909		
PRAI	JP 1982-108516		19820625		
OS	CASREACT 100:209889				
GI					




AB Ten anti-ulcer (no data) dibenzoxazepine derivs. I [R1 = H, halo, alkoxy, alkyl; n = 1, 2; NR2R3 = NH(CH2)mNR4R5 (R4, R5 = alkyl; NR4R5 may form a heterocyclic ring; m = 2, 3), 4-methyl(homo)piperazino] and their HCl salts were prepared by reaction of II with R2R3NH. Thus, refluxing 3.4 g II (R1 = 2- and 4-Me2CH, n = 2) with 10 mL SOCl2 in C6H6 3 h gave the chloride, which (in CHCl3) was added to a mixture of 3 g N-methylpiperazine and 15 mL 10% aqueous NaOH with ice cooling and the whole stirred 1 h with ice cooling and 2 h at room temperature to give 85.4% I (R1 = 2- and 4-Me2CH, n = 2, NR2R3 = 4-methylpiperazino).

IT 90174-02-0P 90174-03-1P 90174-07-5P
 90174-08-6P 90174-09-7P 90174-10-0P
 90174-11-1P 90174-12-2P 90174-13-3P
 90174-17-7P 90174-18-8P 90174-19-9P
 90174-20-2P 90174-21-3P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)


RN 90174-02-0 CAPLUS

CN Piperazine, 1-[[[10,11-dihydro-2,4-bis(1-methylethyl)-11-oxodibenz[b,f][1,4]oxazepin-8-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 90174-03-1 CAPLUS

CN Piperazine, 1-[(10,11-dihydro-11-oxodibenz[b,f][1,4]oxazepin-8-yl)carbonyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 90174-07-5 CAPLUS

CN Piperazine, 1-[(10,11-dihydro-3-methyl-11-oxodibenz[b,f][1,4]oxazepin-8-yl)carbonyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 90174-08-6 CAPLUS

CN Piperazine, 1-[(10,11-dihydro-4-methoxy-11-oxodibenz[b,f][1,4]oxazepin-8-yl)carbonyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 90174-09-7 CAPLUS


CN 1H-1,4-Diazepine, 1-[[10,11-dihydro-2,4-bis(1-methylethyl)-11-oxodibenz[b,f][1,4]oxazepin-8-yl]carbonyl]hexahydro-4-methyl- (9CI) (CA INDEX NAME)




RN 90174-10-0 CAPLUS
 CN Dibenzo[b,f][1,4]oxazepine-8-carboxamide, 10,11-dihydro-2,4-bis(1-methylethyl)-11-oxo-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 90174-11-1 CAPLUS
 CN Dibenzo[b,f][1,4]oxazepine-8-carboxamide, 10,11-dihydro-2,4-bis(1-methylethyl)-N-[2-(4-morpholinyl)ethyl]-11-oxo- (9CI) (CA INDEX NAME)




RN 90174-12-2 CAPLUS
 CN Piperazine, 1-[(10,11-dihydro-2,4-bis(1-methylethyl)-11-oxodibenzo[b,f][1,4]oxazepin-8-yl)carbonyl]-4-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 90174-13-3 CAPLUS
 CN Piperazine, 1-[(10,11-dihydro-11-oxodibenzo[b,f][1,4]oxazepin-8-yl)carbonyl]-4-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 90174-17-7 CAPLUS


CN Piperazine, 1-[(10,11-dihydro-3-methyl-11-oxodibenz[b,f][1,4]oxazepin-8-yl)carbonyl]-4-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 90174-18-8 CAPLUS


CN Piperazine, 1-[(10,11-dihydro-4-methoxy-11-oxodibenz[b,f][1,4]oxazepin-8-yl)carbonyl]-4-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 90174-19-9 CAPLUS


CN 1H-1,4-Diazepine, 1-[[10,11-dihydro-2,4-bis(1-methylethyl)-11-oxodibenz[b,f][1,4]oxazepin-8-yl]carbonyl]hexahydro-4-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 90174-20-2 CAPLUS


CN Dibenzo[b,f][1,4]oxazepine-8-carboxamide, 10,11-dihydro-2,4-bis(1-methylethyl)-11-oxo-N-[2-(1-pyrrolidinyl)ethyl]-, monohydrochloride (9CI)
(CA INDEX NAME)



● HCl

RN 90174-21-3 CAPLUS

CN Dibenzo[b,f][1,4]oxazepine-8-carboxamide, 10,11-dihydro-2,4-bis(1-methylethyl)-N-[2-(4-morpholinyl)ethyl]-11-oxo-, monohydrochloride (9CI)
(CA INDEX NAME)



● HCl


L25 ANSWER 80 OF 104 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1983:595010 CAPLUS Full-text
 DN 99:195010
 TI Pyridobenzodiazepinones and pharmaceutical compositions containing them
 IN Eberlein, Wolfgang; Trummelitz, Guenter; Schmidt, Guenther; Engel,
 Wolfhard; Hammer, Rudolf; Del Soldato, Piero
 PA Thomae, Dr. Karl, G.m.b.H., Fed. Rep. Ger.
 SO Ger. Offen., 38 pp.
 CODEN: GWXXBX

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 3204403	A1	19830811	DE 1982-3204403	19820209
	EP 85899	A2	19830817	EP 1983-100730	19830127
	EP 85899	A3	19840307		
	EP 85899	B1	19861029		
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
	AT 23160	E	19861115	AT 1983-100730	19830127
	US 4424226	A	19840103	US 1983-462377	19830131
	AU 8311232	A1	19830818	AU 1983-11232	19830208
	AU 556922	B2	19861127		
	JP 58148884	A2	19830905	JP 1983-19522	19830208
	JP 03073551	B4	19911122		
	ES 519606	A1	19840301	ES 1983-519606	19830208
	ZA 8300858	A	19841031	ZA 1983-858	19830208
PRAI	DE 1982-3204403	A	19820209		
	EP 1983-100730	A	19830127		
OS	CASREACT 99:195010				
GI					




AB Pharmacol. active I (R = heterocyclyl, heterocyclylmethyl) were prepared Thus, 1-methyl-1,2,5,6-tetrahydro-4-pyridineacetic acid was treated with NaH to give the Na salt, which was treated with 5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one and POCl₃ to give 27% I [R = (1-methyl-1,2,5,6-tetrahydro-4-pyridinyl)methyl] (II). II is a muscarinic neurotransmitter antagonist with IC₅₀ of 50 nmol/L in rat cortex. II is also an inhibitor of gastric ulcers and of saliva secretion and is a mydriatic.

IT **87752-55-4P**

RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation and pharmacol. of)


RN 87752-55-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-5-acetic acid, 10,11-dihydro-11-oxo-,
 1,2,3,6-tetrahydro-1-methyl-4-pyridinyl ester (9CI) (CA INDEX NAME)




L25 ANSWER 81 OF 104 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1983:575815 CAPLUS Full-text
 DN 99:175815
 TI Substituted dibenzodiazepinones and drugs containing them
 IN Engel, Wolfhard; Trummlitz, Guenter; Schmidt, Guenther; Eberlein,
 Wolfgang; Hammer, Rudolf; Del Soldato, Piero
 PA Thomae, Dr. Karl, G.m.b.H., Fed. Rep. Ger.
 SO Ger. Offen., 33 pp.
 CODEN: GWXXBX
 DT Patent
 LA German
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 3204158	A1	19830811	DE 1982-3204158	19820206
	EP 86980	A1	19830831	EP 1983-100676	19830126
	EP 86980	B1	19860102		
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
	AT 17246	E	19860115	AT 1983-100676	19830126
	US 4443452	A	19840417	US 1983-462378	19830131
	JP 58146574	A2	19830901	JP 1983-16869	19830203
	JP 04014112	B4	19920311		
	AU 8311122	A1	19830811	AU 1983-11122	19830204
	AU 557100	B2	19861204		
	ES 519528	A1	19840301	ES 1983-519528	19830204
	ZA 8300773	A	19841031	ZA 1983-773	19830204
	ES 526521	A1	19840616	ES 1983-526521	19831017
	ES 526522	A1	19840616	ES 1983-526522	19831017
PRAI	DE 1982-3204158	A	19820206		
	EP 1983-100676	A	19830126		
OS	CASREACT 99:175815				
GI					



AB Pharmacol. active I [R = (un)substituted heterocyclyl; Z = O, NH, NMe] were prepared Thus, 4-amino-1-methylpiperidine was acylated with 10,11-dihydro-5H-dibenzo[b,e][1,4]diazepine-5-carbonyl chloride to give 56% I (R = 1-methyl-4-piperidiny, Z = NH) (II). II is a muscarinic neurotransmitter antagonist with IC₅₀ of 13 nmol/L in rat cortex. I are also inhibitors of gastric ulcers and of saliva secretion and are mydriatics.

IT **5814-41-5**
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (acylation of)
 RN 5814-41-5 CAPLUS
 CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro- (7CI, 8CI, 9CI) (CA INDEX NAME)




IT 87571-84-4P 87571-85-5P 87588-81-6P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and pharmacol. of)


RN 87571-84-4 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-5-carboxamide, 10,11-dihydro-N-(4-methyl-1-piperazinyl)-11-oxo- (9CI) (CA INDEX NAME)




RN 87571-85-5 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-5-carboxylic acid, 10,11-dihydro-11-oxo-, 1-methyl-4-piperidinyl ester (9CI) (CA INDEX NAME)



RN 87588-81-6 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-5-carboxamide, 10,11-dihydro-N-(1-methyl-4-piperidinyl)-11-oxo- (9CI) (CA INDEX NAME)




IT 87571-83-3P 87571-87-7P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 87571-83-3 CAPLUS



CN 5H-Dibenzo[b,e][1,4]diazepine-5-carboxamide, 10,11-dihydro-N-methyl-N-(1-methyl-4-piperidinyl)-11-oxo- (9CI) (CA INDEX NAME)



RN 87571-87-7 CAPLUS

CN 5H-Dibenzo[b,e][1,4]diazepine-5-carboxamide, 10,11-dihydro-N-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-11-oxo-, endo- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L25 ANSWER 82 OF 104 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1983:575813 CAPLUS Full-text

DN 99:175813

TI Substituted dibenzodiazepinones and pharmaceutical compositions containing them

IN Trummelitz, Guenter; Engel, Wolfhard; Eberlein, Wolfgang; Schmidt, Guenther; Hammer, Rudolf; Del Soldato, Piero

PA Thomae, Dr. Karl, G.m.b.H., Fed. Rep. Ger.

SO Ger. Offen., 43 pp.


CODEN: GWXXBX

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 3204157	A1	19830811	DE 1982-3204157	19820206
	EP 85892	A1	19830817	EP 1983-100677	19830126
	EP 85892	B1	19851218		
	R: AT, BE, CH, DE, FR, IT, LI, LU, NL, SE				
	AT 17002	E	19860115	AT 1983-100677	19830126
	US 4447434	A	19840508	US 1983-462149	19830131
	FI 8300337	A	19830807	FI 1983-337	19830201
	FI 75818	B	19880429		
	FI 75818	C	19880808		
	DK 8300489	A	19830807	DK 1983-489	19830204
	NO 8300386	A	19830808	NO 1983-386	19830204
	NO 158623	B	19880704		
	NO 158623	C	19881012		
	AU 8311123	A1	19830811	AU 1983-11123	19830204
	AU 557463	B2	19861224		
	JP 58146581	A2	19830901	JP 1983-17291	19830204
	JP 03016953	B4	19910306		
	GB 2115411	A1	19830907	GB 1983-3102	19830204
	GB 2115411	B2	19850731		
	DD 207200	A5	19840222	DD 1983-247724	19830204
	ES 519531	A1	19840301	ES 1983-519531	19830204
	HU 31120	O	19840428	HU 1983-396	19830204
	HU 190708	B	19861028		
	ZA 8300774	A	19841031	ZA 1983-774	19830204
	CA 1189507	A1	19850625	CA 1983-420920	19830204
	IL 67836	A1	19860131	IL 1983-67836	19830204
	CS 241138	B2	19860313	CS 1983-784	19830204
	PL 138523	B1	19860930	PL 1983-240437	19830204
	SU 1301314	A3	19870330	SU 1983-3550248	19830204
	ES 526726	A1	19841116	ES 1983-526726	19831025
	ES 526727	A1	19841116	ES 1983-526727	19831025
	ES 526728	A1	19841116	ES 1983-526728	19831025
	ES 526729	A1	19841116	ES 1983-526729	19831025
PRAI	DE 1982-3204157	A	19820206		
	EP 1983-100677	A	19830126		
OS	CASREACT 99:175813				
GI					



I


AB Title compds. I (R = H, Cl; R1 = substituted heterocyclyl, heterocyclylmethyl) were prepared Thus, 6-chloro-5,10-dihydro-11H- dibenzo[b,e][1,4]diazepin-11-one was treated with 1-methyl-4- piperidineacetyl chloride-HCl to give 32% I (R = Cl, R1 = 1-methyl-4-piperidinylmethyl) (II). II is a muscarinic neurotransmitter antagonist with IC50 of 28 nmol/L in mouse cortex. In mice, I are also mydriatics and inhibitors of saliva secretion and of gastric ulcers.

IT **5814-41-5**

RL: RCT (Reactant); RACT (Reactant or reagent)
(acylation of)

RN 5814-41-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro- (7CI, 8CI, 9CI) (CA INDEX NAME)





IT **87646-90-0P 87646-93-3P 87646-96-6P**

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and pharmacol. of)

RN 87646-90-0 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)acetyl]-, endo- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 87646-93-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 6-chloro-5,10-dihydro-5-[(1-methyl-4-piperidinyl)acetyl]- (9CI) (CA INDEX NAME)



RN 87646-96-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[(1,2,3,6-tetrahydro-1-methyl-4-pyridinyl)carbonyl]- (9CI) (CA INDEX NAME)




IT 87646-98-8P 87647-01-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reduction of)

RN 87646-98-8 CAPLUS


CN Pyridinium, 4-[(10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-5-yl)carbonyl]-1-methyl-, iodide (9CI) (CA INDEX NAME)



● I⁻

RN 87647-01-6 CAPLUS

CN Pyridinium, 4-[(10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-5-yl)carbonyl]-1,2,6-trimethyl-, iodide (9CI) (CA INDEX NAME)




● I⁻

IT 87646-97-7P 87646-99-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (preparation and N-methylation of)


RN 87646-97-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-(4-pyridinylcarbonyl)- (9CI) (CA INDEX NAME)



RN 87646-99-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[(2,6-dimethyl-4-pyridinyl)carbonyl]-5,10-dihydro- (9CI) (CA INDEX NAME)




IT 87646-84-2P 87646-89-7P 87646-92-2P
87647-02-7P 87647-03-8P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)


RN 87646-84-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[(1,2,3,6-tetrahydro-1-methyl-4-pyridinyl)acetyl]- (9CI) (CA INDEX NAME)




RN 87646-89-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[(1-methyl-4-piperidinylidene)acetyl]- (9CI) (CA INDEX NAME)




RN 87646-92-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[(1-methyl-4-piperidinyl)acetyl]- (9CI) (CA INDEX NAME)




RN 87647-02-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[(1,2,3,6-tetrahydro-1,2,6-trimethyl-4-pyridinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 87647-03-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[(3-methyl-4-pyridinyl)carbonyl]- (9CI) (CA INDEX NAME)



L25 ANSWER 83 OF 104 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1982:423828 CAPLUS Full-text
 DN 97:23828
 TI 5-Substituted 5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-ones and
 medicaments containing them
 IN Schmidt, Guenther; Bergamaschi, Mario
 PA Thomae, Dr. Karl, G.m.b.H., Fed. Rep. Ger.
 SO Eur. Pat. Appl., 34 pp.
 CODEN: EPXXDW
 DT Patent
 LA German
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 44989	A1	19820203	EP 1981-105421	19810711
	EP 44989	B1	19830525		
	R: AT, BE, CH, DE, FR, IT, LU, NL, SE				
	DE 3028001	A1	19820218	DE 1980-3028001	19800724
	AT 3548	E	19830615	AT 1981-105421	19810711
	US 4377576	A	19830322	US 1981-282501	19810713
	DD 202023	A5	19830824	DD 1981-231897	19810717
	JP 57056470	A2	19820405	JP 1981-113421	19810720
	DK 8103264	A	19820125	DK 1981-3264	19810722
	FI 8102321	A	19820125	FI 1981-2321	19810723
	FI 67697	B	19850131		
	FI 67697	C	19850510		
	NO 8102529	A	19820125	NO 1981-2529	19810723
	AU 8173370	A1	19820128	AU 1981-73370	19810723
	AU 543677	B2	19850426		
	GB 2081264	A	19820217	GB 1981-22782	19810723
	GB 2081264	B2	19840125		
	ES 504206	A1	19821116	ES 1981-504206	19810723
	ZA 8105043	A	19830330	ZA 1981-5043	19810723
	CA 1154763	A1	19831004	CA 1981-382372	19810723
	HU 28455	O	19831228	HU 1981-2160	19810723
	HU 187340	B	19851228		
PRAI	DE 1980-3028001	A	19800724		
	EP 1981-105421	A	19810711		
OS	CASREACT 97:23828				
GI					



AB Dibenzodiazepinones I (R1 = H, Me, Et; R2, R3 = H, Cl; R4 = 1-pyrrolidinyl, piperidino, 2-methyl-, 2-ethyl-, 2,6-dimethylpiperidino, morpholino) and their physiol. tolerable salts, useful in inhibiting gastric secretion and gastric ulcers, were prepared Acylating 5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one with Cl(CH2)2COCl in dioxane gave I (R1-R3 = H, R4 = Cl) which N-alkylated pyrrolidine in refluxing Me2CHOH in 45 min to give I (R2-R3 = H, R4


= 1-pyrrolidinyl) (II). The ED50 for gastric secretion inhibition for II.HCl was 0.20 mg/kg (duodenum) in rats vs. 8.15 for the 5-(1-pyrrolidinylacetyl) analog.

IT 82097-66-3P 82097-70-9P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and antisecretory and antiulcer activity of)

RN 82097-66-3 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[1-oxo-3-(1-pyrrolidinyl)propyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 82097-70-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[1-oxo-3-(1-piperidiny)propyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

IT 82096-30-8P 82096-31-9P 82096-32-0P

82096-34-2P 82096-36-4P 82096-39-7P


82096-47-7P 82097-68-5P 82097-71-0P

82097-72-1P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)


RN 82096-30-8 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 2-chloro-5,10-dihydro-5-[3-(2-methyl-1-piperidiny)-1-oxopropyl]- (9CI) (CA INDEX NAME)




RN 82096-31-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-chloro-5,10-dihydro-5-[3-(2-methyl-1-piperidiny)-1-oxopropyl]- (9CI) (CA INDEX NAME)




RN 82096-32-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[3-(2-ethyl-1-piperidiny)-1-oxopropyl]-5,10-dihydro- (9CI) (CA INDEX NAME)




RN 82096-34-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[3-(4-morpholinyl)-1-oxopropyl]- (9CI) (CA INDEX NAME)




RN 82096-36-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[1-oxo-3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)




RN 82096-39-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[3-(2-methyl-1-piperidinyl)-1-oxopropyl]- (9CI) (CA INDEX NAME)




RN 82096-47-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[1-oxo-3-(1-piperidinyl)propyl]- (9CI) (CA INDEX NAME)




RN 82097-68-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 2-chloro-5,10-dihydro-5-[1-oxo-3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)



RN 82097-71-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 2-chloro-5,10-dihydro-5-[1-oxo-3-(1-piperidinyl)propyl]- (9CI) (CA INDEX NAME)




RN 82097-72-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[3-(2-methyl-1-piperidinyl)-1-oxopropyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 82096-39-7

CMF C22 H25 N3 O2




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.




IT **5814-41-5**

RL: RCT (Reactant); RACT (Reactant or reagent)
(N-acylation of, by acid halides)

RN 5814-41-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro- (7CI, 8CI, 9CI) (CA
INDEX NAME)



L25 ANSWER 84 OF 104 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1980:447088 CAPLUS Full-text

DN 93:47088

TI Synthesis of aryl β -D-glucopyranosides and aryl β -D-glucopyranosiduronic acids

AU Brewster, Keith; Harrison, John M.; Inch, Thomas D.

CS Chem. Def. Establ., Porton Down, SP4 0JQ, UK

SO Tetrahedron Letters (1979), (52), 5051-4

CODEN: TELEAY; ISSN: 0040-4039

DT Journal

LA English

AB Aryl 2,3,4,6-tetra-O-benzyl- β -D-glucopyranosides were prepared (30-68%) by stereospecific aryloxylation of 2,3,4,6-tetra-O-benzyl- α -D-glucopyranosyl bromide (I) with phenols (aqueous NaOH or KOH, CH₂Cl₂, PhCH₂N+Et₃ Cl⁻ phase transfer catalyst, room temperature, 8-60 h). E.g., 68% Ph 2,3,4,6-tetra-O-benzyl- β -D-glucopyranoside was obtained from I and PhOH. Ph, 4-methoxyphenyl, and 2-tolyl 2,3,4,6-tetra-O-benzyl- β -D-glucopyranoside were converted to the corresponding aryl β -D-glucopyranosiduronic acids by sequential catalytic debenzylation (H, Pd-C) catalytic oxidation (Pt, O, 85-90°, pH 8-10), benzylation, and hydrogenolysis (Pd-C, EtOH).

IT **74256-85-2P 74279-34-8P**


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and catalytic debenzylation of)

RN 74256-85-2 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 4-[[2,3,4,6-tetrakis-O-(phenylmethyl)- β -D-glucopyranosyl]oxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 74279-34-8 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 7-[[2,3,4,6-tetrakis-O-(phenylmethyl)- β -D-glucopyranosyl]oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 74256-87-4P 74256-88-5P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 74256-87-4 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 4-(β-D-glucopyranosyloxy)-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 74256-88-5 CAPLUS

CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 7-(β-D-glucopyranosyloxy)-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.




L25 ANSWER 85 OF 104 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1979:40180 CAPLUS Full-text
 DN 90:40180
 TI Synthesis of 8-substituted-10,11-dihydro-11-oxo-5H-
 dibenzo[b,e][1,4]diazepines: Part II
 AU Grover, Raman; Joshi, B. C.
 CS Chem. Lab., Univ. Rajasthan, Jaipur, India
 SO Journal of the Indian Chemical Society (1978), 55(2), 154-5
 CODEN: JICSAH; ISSN: 0019-4522
 DT Journal
 LA English
 OS CASREACT 90:40180
 GI



AB Diazotization of 8-amino-10,11-dihydro-11-oxo-5H- dibenzo[b,d][1,4]diazepine
 [3604-56-6] and coupling with RH, i.e., phenol [108-95-2], resorcinol [108-
 46-3], α -naphthol [90-15-3], β -naphthol [135-19-3], 1-hydroxy-2-naphthoic
 acid [86-48-6], or 3-hydroxy-2-naphthoic acid [92-70-6], gave monoazo dyes
 of general structure I. The structures of these dyes were established by
 elemental anal. and spectral studies; λ_{max} ranged from 412 to 475 nm (DMF).
 Color reactions of I in acid and alkaline media are also discussed.
 IT **68838-06-2P 68838-07-3P 68838-08-4P**
68838-09-5P 68838-10-8P 68838-11-9P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation, spectra and color reactions of)
 RN 68838-06-2 CAPLUS
 CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-[(4-
 hydroxyphenyl)azo]- (9CI) (CA INDEX NAME)




RN 68838-07-3 CAPLUS
 CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-[(2,4-dihydroxyphenyl)azo]-5,10-
 dihydro- (9CI) (CA INDEX NAME)




RN 68838-08-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-[(4-hydroxy-1-naphthalenyl)azo]- (9CI) (CA INDEX NAME)




RN 68838-09-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-8-[(2-hydroxy-1-naphthalenyl)azo]- (9CI) (CA INDEX NAME)




RN 68838-10-8 CAPLUS

CN 2-Naphthalenecarboxylic acid, 4-[(10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl)azo]-1-hydroxy- (9CI) (CA INDEX NAME)




RN 68838-11-9 CAPLUS


CN 2-Naphthalenecarboxylic acid, 4-[(10,11-dihydro-11-oxo-5H-dibenzo[b,e][1,4]diazepin-8-yl)azo]-3-hydroxy- (9CI) (CA INDEX NAME)




L25 ANSWER 86 OF 104 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1976:421313 CAPLUS Full-text
 DN 85:21313
 TI Photo- and radiochemical studies, Part 31. Photosynthesis of
 5-phenyl-5,10-dihydrodibenzo[b,e][1,4]diazepin-11-one from
 1,2-diphenylindazolone
 AU Reisch, Johannes; Kapoor, Sushil K.
 CS Inst. Pharm. Chem., Westfael. Wilhelms-Univ., Muenster, Fed. Rep. Ger.
 SO Archiv der Pharmazie (Weinheim, Germany) (1976), 309(4), 316-19
 CODEN: ARPMAS; ISSN: 0365-6233
 DT Journal
 LA German
 OS CASREACT 85:21313
 GI




AB The dibenzodiazepinone I was formed together with acridone and azobenzene in
 the photolysis of 1,2-diphenylindazolone (II). The structure of I was
 confirmed by synthesis from 2-O₂NC₆H₄I and 2-PhNHC₆H₄CO₂H to give 2-
 O₂NC₆H₄NPhC₆H₄CO₂H-2, reducing to 2-H₂NC₆H₄NPhC₆H₄CO₂H-2, and cyclizing. II
 was prepared by treating 2-ClC₆H₄COCl with PhNHNHPh and cyclizing 2-
 ClC₆H₄CONPhNHPh.
 IT **59497-24-4P**
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 59497-24-4 CAPLUS
 CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-phenyl- (9CI) (CA
 INDEX NAME)




L25 ANSWER 87 OF 104 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1975:118772 CAPLUS Full-text
 DN 82:118772
 TI Structure-activity relations in the Sintamil series
 AU Nagarajan, K.; David, J.; Grewal, R. S.; Govindachari, T. R.
 CS CIBA Res. Cent., Bombay, India
 SO Indian Journal of Experimental Biology (1974), 12(3), 217-24
 CODEN: IJEBA6; ISSN: 0019-5189
 DT Journal
 LA English
 GI For diagram(s), see printed CA Issue.
 AB 10-Aminoalkyl-2-nitrodibenz[b,f][1,4]oxazepines exhibited antidepressant activity. Among these, Sintamil (I) [16398-39-3] was the most active. The effects of substituting the dimethylamino group in I by acyclic and cyclic bases as well as shortening the side chain to a C2 chain were discussed. Analogs with other substituents in ring C and position isomers of I, in which the nitro group was moved to other positions, were studied. In connection with the sedative and antinociceptive activities of 2-aminodibenz[b,f][1,4]oxazepin-11(10H)-one [23474-66-0], a number of analogs in this series and in the pyridodibenzoxazepine and pyridobenzoxazine series were evaluated. Potent central nervous depressants were encountered in the class of 11-aminodibenzoxazepines and dibenzthiazepines; moderate depressant activity was exhibited by a group of 11-(aminoalkyloxy)- and 11-(aminoalkylmercapto)dibenzoxazepines and thiazepines, and a 11-(dimethylaminomethyl) derivative. Imidazo, pyrimido, triazolo, and tetrazolodibenzoxazepines having common structural features were evaluated.
 IT **54252-90-3**
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (antidepressant activity of)
 RN 54252-90-3 CAPLUS
 CN 4-Morpholineacetamide, N-(10,11-dihydro-11-oxodibenz[b,f][1,4]oxazepin-2-yl)- (9CI) (CA INDEX NAME)




L25 ANSWER 88 OF 104 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1975:4223 CAPLUS Full-text
 DN 82:4223
 TI Condensed heterotricycles. Amino and aminoalkyldibenz[b,f][1,4]oxazepin-11(10H)-ones
 AU Nagarajan, K.; Venkateswarlu, A.; Kulkarni, C. L.; Goud, A. Nagana; Shah, R. K.
 CS Res. Cent., CIBA, Bombay, India
 SO Indian Journal of Chemistry (1974), 12(3), 236-46
 CODEN: IJOCAP; ISSN: 0019-5103
 DT Journal
 LA English
 OS CASREACT 82:4223
 GI For diagram(s), see printed CA Issue.
 AB Treatment of 2-nitrodibenz[b,f][1,4]-oxazepin-11(10H)-one (I, R = NO₂, R₁ - R₅ = H) (II) with dimethylaminopropyl chloride in aqueous acetone-alkali gave I [R = NO₂, R₁-R₄ = H, R₅ (CH₂)₃NMe₂] characterized as the hydrochloride, Sintamil. Other analogs e.g., I (R = H, NO₂; R₁ = H, NO₂; R₂ = H, NO₂, MeO; R₃ = H, MeO, Me, Ac; R₄ = H, NO₂; R₅ = aminoalkyl), were also prepared III undergoes ring cleavage with NaOMe to 2,5-MeO(O₂N)C₆H₃CON-[(CH₂)₃NMe₂]C₆H₄OH-2 which is converted into its Me ether. II undergoes similar ring cleavage with NaOMe, dimethylamine, and NaOH to form IV (R = MeO, NMe₂, and OH). The last reagent brings about, in addition a Smiles-type rearrangement leading to the formation of 2,4-HO₂C(O₂N)C₆H₃NHC₆H₄OH-2. Treatment of the 8-nitrodibenzoxazepinone with dimethylaminopropyl chloride in DMF and sodamide yields in addition to the expected N-(CH₂)₃NMe₂ derivative, the ring cleavage product 2-HO-C₆H₄CON[(CH₂)₃NMe₂]C₆H₃(NMe₂)₂NO₂-2.5. Nitration expts. on dibenzoxazepinones without a substituent on the lactam N or with a dimethylaminopropyl group are described. Many nitro derivs. are reduced to amines.
 IT **54252-90-3P**
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 54252-90-3 CAPLUS
 CN 4-Morpholineacetamide, N-(10,11-dihydro-11-oxodibenz[b,f][1,4]oxazepin-2-yl)- (9CI) (CA INDEX NAME)



L25 ANSWER 89 OF 104 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1974:552199 CAPLUS Full-text
 DN 81:152199
 TI Condensed heterotricycles. Synthesis of dibenz[b,f][1,4]oxazepines, dibenz[b,f][1,4]thiazepines, and dibenz[b,e][1,4]diazepines by cyclization of 2-halo-2'-hydroxy(mercapto or amino)benzanilides
 AU Nagarajan, K.; Venkateswarlu, A.; Kulkarni, C. L.; Shah, R. K.
 CS Res. Cent., CIBA, Bombay, India
 SO Indian Journal of Chemistry (1974), 12(3), 227-35
 CODEN: IJOCAP; ISSN: 0019-5103
 DT Journal
 LA English
 GI For diagram(s), see printed CA Issue.
 AB The action of hot aqueous alkali on 2-chloro-5-nitrobenzamides on o-aminophenols I (R, R2, R3 = H, R1 = H, Me, Cl, MeO) affords high yields of 2-nitrodibenz[b,f][1,4]oxazepin-11(10H)-ones II. Pyrolysis of the sodium salts of amides III (R, R1, R2, R3, R4, R5, R6 = H, Ac, NO2, Cl) gives the analogous tricyclic lactams IV. The synthesis has been extended to aminoalkyldibenzoxazepinones, such as the antidepressant Sintamil N-(CH2)3NMe2 derivative of IV (R-R3, R5 = H, R4 = NO2).HCl and the R4 = Cl analog. 2-Nitrodibenzoxazepine is obtained from the Schiff base and converted to a quaternary salt and the dihydro derivs. N-(2-Chloro-5-nitrobenzoyl)-o-aminothiophenol fails to undergo cyclization to a dibenzothiazepinone, since it readily passes over to a benzothiazole. However, 2-chloro and 2,5-dichlorobenzoyl derivs. of o-aminothiophenol can be converted to the expected tricycles VII. Among the o-phenylenediamine derivs. tried, the N-(2-chloro-5-nitrobenzoyl)-N'-(p-tolylsulfonyl) compound gives the dibenzodiazepine VIII, while pyrolysis of 2-amino-2'-carbomethoxy-4'-nitrodiphenylamine leads to IX.
 IT **20169-49-7P**
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 20169-49-7 CAPLUS
 CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[(4-methylphenyl)sulfonyl]-2-nitro- (9CI) (CA INDEX NAME)



L25 ANSWER 90 OF 104 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1974:536120 CAPLUS Full-text
 DN 81:136120
 TI Condensed heterotricycles. Potential metabolites of
 dibenz[b,f][1,4]oxazepine antidepressant, Sintamil
 AU Nagarajan, K.; Maller, R. K.; Anjaneyulu, B.; Goud, A. Nagana;
 Venkateswarlu, A.
 CS Res. Cent. , CIBA, Bombay, India
 SO Indian Journal of Chemistry (1974), 12(3), 270-4
 CODEN: IJOCAP; ISSN: 0019-5103
 DT Journal
 LA English
 GI For diagram(s), see printed CA Issue.
 AB The demethyl derivative [I, R = (CH₂)₃NHMe, R₁ = H] (II) of Sintamil [I, R =
 (CH₂)₃NMe₂, R₁ = H] (III) was prepared by alkylation of I (R, R₁ = H) (IV)
 with Cl(CH₂)₃NMeCHO followed by acid hydrolysis, by treating III with BrCN
 followed by hot HCl hydrolysis, or by refluxing III with ClCO₂Et in toluene to
 give a urethane which was treated with HBr in HOAc. IV was added to CH₂: CHCN
 and converted to the ester I (R = CH₂CH₂CO₂Me, R₁ = H), which was also
 obtained by base catalyzed addition of IV to CH₂:CHCO₂Me. Treatment of 2,5-
 Cl(O₂N)C₆H₃COCl with 3,4-HO(H₂N)C₆H₃OCH₂Ph gave an amide, which was cyclized
 in aqueous alkali to give I (R = H, R₁ = OCH₂Ph), alkylated with Cl
 (CH₂)₃NMe₂, and debenzylated in hot HCl to yield I [R = (CH₂)₃NMe₂, R₁ = OH].
 IT **54026-42-5P**
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 54026-42-5 CAPLUS
 CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 2-nitro-7-(phenylmethoxy)- (9CI)
 (CA INDEX NAME)



L25 ANSWER 91 OF 104 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1974:520710 CAPLUS Full-text
 DN 81:120710
 TI Antiulcerous 2-chloro-5,10-dihydro-5-(1-pyrrolidinylacetyl)-11H-dibenzo[b,e][1,4]diazepin-11-one
 IN Schmidt, Guenther; Machleidt, Hans; Leitold, Matyas; Engelhorn, Robert
 PA Thomae, Dr. Karl, G.m.b.H.
 SO Ger. Offen., 9 pp. Division of Ger. Offen. 2,022,790 (CA 74; 100123p).
 CODEN: GWXXBX

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 2065570	A1	19740704	DE 1970-2065570	19700509
	DE 2065570	B2	19760520		
	DE 2065570	C3	19770127		
PRAI	DE 1970-2065570	A	19700509		

GI For diagram(s), see printed CA Issue.


AB The dibenzodiazepinone I (R = 1-pyrrolidinyl) (II) was prepared in 50% yield by refluxing I (R = Cl) and pyrrolidine in dioxane. II had antiulcerous activity when tested orally in the rat, stomach secretion-inhibiting activity when tested intraduodenally or i.p. in the rat, and spasmolytic activity when tested in the isolated guinea pig colon.

IT **29174-20-7P**


RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)

RN 29174-20-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 2-chloro-5,10-dihydro-5-(1-pyrrolidinylacetyl)- (8CI, 9CI) (CA INDEX NAME)



L25 ANSWER 92 OF 104 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1973:466327 CAPLUS Full-text
 DN 79:66327
 TI Synthesis of 4,4-diphenyl-7-oxodibenzodihydro-1,4-diazepinium salts
 AU Nesmeyanov, A. N.; Tolstaya, T. P.; Grib, A. V.; Casanova, Jose A.
 CS Inst. Elementoorg. Soedin., Moscow, USSR
 SO Izvestiya Akademii Nauk SSSR, Seriya Khimicheskaya (1973), (5), 1096-101
 CODEN: IASKA6; ISSN: 0002-3353
 DT Journal
 LA Russian
 GI For diagram(s), see printed CA Issue.
 AB Ph2NC6H4NH2-o (I) reacted with o-O2NC6H4COCl (II) in Et3N/dioxane to give 100% of the N-aryl derivative (III) which was reduced with FeSO4 in neutral aqueous NH4OH to give the o-aminobenzoyl analog (IV), while reduction in ammoniacal FeSO4 gave a solid lacking a free NH2 group. IV and HCl in Me2CO was treated with NaNO2 to yield 100% 6-oxo-1-[o-(diphenylamino)phenyl]benzo[4.5]-1,2,3-triazine. I and II in Et3N gave o-Ph2NC6H4N(COC6H4NO2-o)2. III and AcCl gave the N-Ac derivative, which was reduced over Raney Ni to the o-aminobenzoyl analog, and then diazotized and heated to give V. I and tosyl chloride gave the N-tosyl derivative, which gave the N-aryl derivative with II, and was reduced by SnCl2 to the o-aminobenzoyl analog, then diazotized and heated to give V. Treatment of V with 85% H3PO4 in aqueous PROH gave, after prolonged heating and reaction with HI, 4,4-diphenyl-7-oxodibenzodihydro-1,4-diazepinium iodide, whose structure was confirmed by reactions with Ag2O, aqueous NaOH and nitrosylsulfuric acid.
 IT **42343-91-9P**
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 42343-91-9 CAPLUS
 CN 5H-Dibenzo[b,e][1,4]diazepinium, 10,11-dihydro-11-oxo-5,5-diphenyl-, iodide (9CI) (CA INDEX NAME)



● I⁻

L25 ANSWER 93 OF 104 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1971:100124 CAPLUS Full-text
 DN 74:100124
 TI 5-(Piperidinoacetyl)-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepin-11-ones
 IN Schmidt, Guenther; Machleidt, Hans; Engelhorn, Robert; Leitold, Matyas
 PA Thomae, Dr. Karl, G.m.b.H.
 SO Ger. Offen., 20 pp. Addn. to Ger. Offen. 1,795,176
 CODEN: GWXXBX
 DT Patent
 LA German
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 1931487	A	19710107	DE 1969-1931487	19690620
	DE 1931487	B2	19750417		
	DE 1931487	C3	19751218		
	DE 1795176	A	19720203	DE 1967-1795176	19680820
	FI 49509	B	19750401	FI 1969-2162	19690722
	RO 56187	P	19750615	RO 1969-60620	19690724
	US 3634408	A	19720111	US 1969-848356	19690807
	ES 370395	A1	19710416	ES 1969-370395	19690811
	SU 512704	D	19760430	SU 1969-1357008	19690812
	CH 510685	A	19710731	CH 1969-510685	19690813
	AT 292709	B	19710910	AT 1969-7959	19690819
	NO 125386	B	19720904	NO 1969-3363	19690819
	PL 69663	P	19730831	PL 1969-135429	19690819
	DK 135043	B	19770228	DK 1969-4431	19690819
	DK 135043	C	19770822		
	BE 737747	A	19700220	BE 1969-737747	19690820
	NL 6912653	A	19700224	NL 1969-12653	19690820
	FR 2016008	A5	19700430	FR 1969-28589	19690820
	FR 2016008	B1	19731221		
	GB 1236112	A	19710623	GB 1969-1236112	19690820
	BR 6911744	A0	19730118	BR 1969-211744	19690820
	SE 367199	B	19740520	SE 1969-11570	19690820
	CS 163730	P	19751107	CS 1969-5774	19690820
PRAI	DE 1967-1795176	A	19680820		
	DE 1969-1931487	A	19690620		

GI For diagram(s), see printed CA Issue.


AB The antiulcerous title compds. (I), which inhibit the secretion of gastric juice, were prepared Thus, refluxing 5-chloroacetyl-10,11-dihydro- 11H-dibenzo[b,e][1,4]diazepin-11-one and 2-methylpiperidine in C6H6 18 hr gave 45% I (R = Me, R1 = R2 = R3 = R4 = R5 = R6 = H). Similarly prepared were I (R-R6 given): H, Me, H, H, H, H, H; H, H, Me, H, H, H, H; Et, H, H, H, H, H, H; Et, H, H, H, H, Me, H; H, H, MeO, H, H, H, H; Me, H, H, H, Cl, H, H; Et, H, H, H, Cl, H, H; Me, H, H, H, Cl, Et, H; Et, H, H, H, H Et, H; H, H, Pr, H, H, H, H; Me, H, H, H, H, Et, H; Me, H, H, H, H, H, Cl; Me, H, H, Me, H, H, H.

IT 29174-37-6P 29174-38-7P 29174-40-1P
 29174-41-2P 29174-43-4P 29174-44-5P
 29174-45-6P 29174-48-9P 29174-51-4P
 31261-91-3P 31348-41-1P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)


RN 29174-37-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[(2-methylpiperidino)acetyl]- (8CI) (CA INDEX NAME)




RN 29174-38-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[(3-methylpiperidino)acetyl]- (8CI) (CA INDEX NAME)



RN 29174-40-1 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[(4-methylpiperidino)acetyl]- (8CI) (CA INDEX NAME)



RN 29174-41-2 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[(2-ethylpiperidino)acetyl]-5,10-

dihydro- (8CI) (CA INDEX NAME)




RN 29174-43-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[(4-methoxypiperidino)acetyl]- (8CI) (CA INDEX NAME)




RN 29174-44-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 2-chloro-5,10-dihydro-5-[(2-methylpiperidino)acetyl]- (8CI) (CA INDEX NAME)




RN 29174-45-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 2-chloro-5-[(2-ethylpiperidino)acetyl]-5,10-dihydro- (8CI) (CA INDEX NAME)



RN 29174-48-9 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[(4-propylpiperidino)acetyl]-, monohydrochloride (8CI) (CA INDEX NAME)



● HCl


RN 29174-51-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-chloro-5,10-dihydro-5-[(2-methylpiperidino)acetyl]- (8CI) (CA INDEX NAME)



RN 31261-91-3 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[(3-methylpiperidino)acetyl]-, hydrochloride (8CI) (CA INDEX NAME)



●x HCl

RN 31348-41-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[(2,6-dimethylpiperidino)acetyl]-5,10-dihydro-, monohydrochloride (8CI) (CA INDEX NAME)



● HCl

L25 ANSWER 94 OF 104 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1971:100123 CAPLUS Full-text

DN 74:100123

TI Ulcer- and secretion-inhibiting 5-(aminoacetyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-ones

IN Schmidt, Guenther; Machleidt, Hans; Leitold, Matays; Engelhorn, Robert
PA Thomae, Dr. Karl, G.m.b.H.

SO Ger. Offen., 10 pp. Addn. to Ger. Offen. 1,795,176

CODEN: GWXXBX

DT Patent

LA German

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	DE 2022790	A	19710211	DE 1970-2022790	19700509
	DE 2022790	B2	19760708		
	DE 2022790	C3	19770707		
	FI 49509	B	19750401	FI 1969-2162	19690722
	FR 2016008	A5	19700430	FR 1969-28589	19690820
	FR 2016008	B1	19731221		
PRAI	FI 1969-2162	A	19690722		
	DE 1967-1795176	A	19680820		
	DE 1969-1931487	A	19690620		

GI For diagram(s), see printed CA Issue.


AB The title compds. (I) and their physiol. compatible salts, the activities of which were tested in rats and guinea-pigs, were prepared by refluxing the 5-chloroacetyl derivative and the cyclic amine in a solvent. Prepared were I bis(hydrogenfumarate) (R = Me, X = H, n = 1) and I (R = H, X = Cl, n = 0) of LD50 3400 and >1500 mg/kg, resp., in mice on oral administration. Formulations containing I are reported.

IT **29174-20-7P**

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 29174-20-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 2-chloro-5,10-dihydro-5-(1-pyrrolidinylacetyl)- (8CI, 9CI) (CA INDEX NAME)



L25 ANSWER 95 OF 104 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1970:520695 CAPLUS Full-text

DN 73:120695

TI 5,10-Dihydro-11H-dibenzo[b,e] [1,4]diazepine-11-ones substituted in 5-position, and their ulcer-inhibiting activity

IN Schmidt, Guenther; Engelhorn, Robert; Leitold, Matyas; Machleidt, Hans

PA Thomae, Dr. Karl, G.m.b.H.

SO S. African, 49 pp.

CODEN: SFXAB

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	ZA 6905930		19700312		
	DE 1795176			DE	
	FR 2016008			FR	
	GB 1236112			GB	
	US 3634408		19720000	US	
PRAI	DE		19680820		
	DE		19690620		


AB I (R = H, 2-Cl, 8-Cl; R1 = H, Me; X = pyrrolidino, piperidino, morpholino, 4-substituted 1-piperazinyl, etc.) ulcer- and secretion-inhibiting compds., are prepared from II. Thus, 10 g 5-(chloroacetyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]-diazepin-11-one and 10 ml N-methylpiperazine gave I (R = R1 = H; X = 4-methyl-1-piperazinyl). Forty-seven preps. are given.

IT 29174-10-5P 29174-11-6P 29174-12-7P
29174-13-8P 29174-14-9P 29174-15-0P
29174-16-1P 29174-20-7P 29174-23-0P
29174-26-3P 29174-34-3P 29174-37-6P
29174-38-7P 29174-39-8P 29174-40-1P
29174-41-2P 29174-43-4P 29174-44-5P
29174-45-6P 29174-48-9P 29174-51-4P
29181-43-9P 29183-80-0P 29183-81-1P
29183-82-2P 29183-83-3P 31348-41-1P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 29174-10-5 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[(4-benzyl-1-piperazinyl)acetyl]-
5,10-dihydro-, dihydrochloride (8CI) (CA INDEX NAME)



●2 HCl

RN 29174-11-6 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-(1-piperazinylacetyl)-, dihydrochloride (8CI) (CA INDEX NAME)



●2 HCl

RN 29174-12-7 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[[4-(2-hydroxyethyl)-1-piperazinyl]acetyl]-, dihydrochloride (8CI) (CA INDEX NAME)



●2 HCl

RN 29174-13-8 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[[4-(o-methylbenzyl)-1-piperazinyl]acetyl]-, dihydrochloride (8CI) (CA INDEX NAME)



●2 HCl


RN 29174-14-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-(piperidinoacetyl)-
(8CI) (CA INDEX NAME)




RN 29174-15-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-(morpholinoacetyl)-
(8CI) (CA INDEX NAME)




RN 29174-16-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-(1-pyrrolidinylacetyl)- (8CI) (CA INDEX NAME)




RN 29174-20-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 2-chloro-5,10-dihydro-5-(1-pyrrolidinylacetyl)- (8CI, 9CI) (CA INDEX NAME)




RN 29174-23-0 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 2-chloro-5,10-dihydro-5-(1-piperidinoacetyl)- (8CI) (CA INDEX NAME)




RN 29174-26-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 2-chloro-5,10-dihydro-5-(morpholinoacetyl)- (8CI) (CA INDEX NAME)




RN 29174-34-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[(4-ethyl-1-piperazinyl)acetyl]-5,10-dihydro-, dihydrochloride (8CI) (CA INDEX NAME)




RN 29174-37-6 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[(2-methylpiperidino)acetyl]- (8CI) (CA INDEX NAME)




RN 29174-38-7 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[(3-methylpiperidino)acetyl]- (8CI) (CA INDEX NAME)



RN 29174-39-8 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[(3-methylpiperidino)acetyl]-, monohydrochloride (8CI) (CA INDEX NAME)



● HCl


RN 29174-40-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[(4-methylpiperidino)acetyl]- (8CI) (CA INDEX NAME)




RN 29174-41-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[(2-ethylpiperidino)acetyl]-5,10-dihydro- (8CI) (CA INDEX NAME)




RN 29174-43-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[(4-methoxypiperidino)acetyl]- (8CI) (CA INDEX NAME)




RN 29174-44-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 2-chloro-5,10-dihydro-5-[(2-methylpiperidino)acetyl]- (8CI) (CA INDEX NAME)



RN 29174-45-6 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 2-chloro-5-[(2-ethylpiperidino)acetyl]-5,10-dihydro- (8CI) (CA INDEX NAME)



RN 29174-48-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[(4-


propylpiperidino)acetyl]-, monohydrochloride (8CI) (CA INDEX NAME)



● HCl

RN 29174-51-4 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-chloro-5,10-dihydro-5-[(2-methylpiperidino)acetyl]- (8CI) (CA INDEX NAME)




RN 29181-43-9 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[(hexahydro-1H-azepin-1-yl)acetyl]-5,10-dihydro-, fumarate (1:1) (8CI) (CA INDEX NAME)

CM 1

CRN 47476-46-0

CMF C21 H23 N3 O2




CM 2

CRN 110-17-8


CMF C4 H4 O4

Double bond geometry as shown.



RN 29183-80-0 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[(4-methyl-1-piperazinyl)acetyl]-, dihydrochloride (8CI) (CA INDEX NAME)



●2 HCl

RN 29183-81-1 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 2-chloro-5,10-dihydro-5-[(4-methyl-1-piperazinyl)acetyl]-, dihydrochloride (8CI) (CA INDEX NAME)



● 2 HCl

RN 29183-82-2 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 3-chloro-5,10-dihydro-5-[(4-methyl-1-piperazinyl)acetyl]-, dihydrochloride (8CI) (CA INDEX NAME)



● 2 HCl


RN 29183-83-3 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 8-chloro-5,10-dihydro-5-[(4-methyl-1-piperazinyl)acetyl]- (8CI) (CA INDEX NAME)




RN 31348-41-1 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-[(2,6-dimethylpiperidino)acetyl]-5,10-dihydro-, monohydrochloride (8CI) (CA INDEX NAME)




● HCl


L25 ANSWER 97 OF 104 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1968:506685 CAPLUS Full-text
 DN 69:106685
 TI New synthesis of dibenz[b,f][1,4]oxazepine, dibenzo[b,f][1,4]thiazepine, and dibenzo[b,e][1,4]diazepine derivatives
 AU Nagarajan, K.; Kulkarni, C. L.; Venkateswarlu, A.
 CS CIBA Res. Centre, Goregaon, India
 SO Indian Journal of Chemistry (1968), 6(4), 225-6
 CODEN: IJOCAP; ISSN: 0019-5103
 DT Journal
 LA English
 AB Beckmann rearrangement of xanthone oxime (Graebe and Roder, 1899) in ether using PCl₅ catalyst afforded 50% 10,11-dihydro-11-oxodibenz[b,f][1,4]oxazepine (I), m. 210-12°, identical with a sample obtained by thermal lactamization of 2-amino-2'-carbethoxydiphenyl ether (CA 61:8326d). Similarly, thioxanthone oxime, m. 192-3°, gave on rearrangement 52% 10,11-dihydro-11-oxodibenz[b,f][1,4]thiazepine, m. 261-2°, identical with a sample prepared by the alternative procedure. I was also prepared by refluxing N-(2-chlorobenzoyl)-2-hydroxyaniline (II), m. 188-90°, as its dry Na salt in HCONMe₂ 72 hrs. Ano. of analogs with other substituents in the nuclei were similarly synthesized. As expected, activation of the Cl atom by electron-withdrawing groups suitably situated in the aroyl part of II facilitated ring closure. An extension to N-(γ-dimethylaminopropyl)-N-(2,5-dichlorobenzoyl)-2-hydroxyaniline, m. 176-9°, offered an efficient alternative synthesis of 80% 2-chloro-10,11-dihydro-10-(γ-dimethylaminopropyl)-11-oxodibenz[b,f][1,4]oxazepine (III) of psychotropic interest (CA 62: 16283a). III was characterized as the HCl salt, m. 191-3°, identical with an authentic sample (CA 62: 16283a). N-(2-Chlorobenzoyl)-o-phenylenediamine as its N-p-tolylsulfonyl derivative could not be cyclized. However, N-(2-chloro-5-nitrobenzoyl)-N'-(p-tolylsulfonyl)-o-phenylenediamine, m. 161-3°, could be similarly treated to afford 60% 10,11-dihydro-2-nitro-11-oxo-5-(p-tolylsulfonyl)dibenzo[b,e][1,4]diazepine, m. 252-5°.
 IT **20169-49-7P**
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 20169-49-7 CAPLUS
 CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[(4-methylphenyl)sulfonyl]-2-nitro- (9CI) (CA INDEX NAME)



L25 ANSWER 98 OF 104 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1967:473117 CAPLUS Full-text
DN 67:73117
TI Antiinflammatory dialkylaminoalkylureas
AU Coyne, William E.; Cusic, John W.
CS G. D. Searle and Co., Chicago, IL, USA
SO Journal of Medicinal Chemistry (1967), 10(4), 541-6
CODEN: JMCMAR; ISSN: 0022-2623
DT Journal
LA English
AB A series of dialkylaminoalkylureas were synthesized from various tricyclic amines and tested for their antiinflammatory activity
IT **16813-64-2P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 16813-64-2 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5-(p-chlorobenzoyl)-5,10-dihydro-(8CI) (CA INDEX NAME)



L25 ANSWER 99 OF 104 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1967:402582 CAPLUS Full-text
 DN 67:2582
 TI Oximes of 2- and 4-phenylxanthenes and their Beckmann rearrangement
 AU Troshchenko, A. T.; Lobanova, T. P.
 CS Novosibirsk. Inst. Org. Khim., Novosibirsk, USSR
 SO Zhurnal Organicheskoi Khimii (1967), 3(3), 501-3
 CODEN: ZORKAE; ISSN: 0514-7492
 DT Journal
 LA Russian
 GI For diagram(s), see printed CA Issue.
 AB A mixture of 5 g. 4-phenylxanthone (I), 18 g. $\text{NH}_2\text{OH}\cdot\text{HCl}$, and 50 ml. anhydrous pyridine was boiled 25 hrs. Pyridine was partially evaporated and the product crystallized from MeOH and C_6H_6 to yield 85% 4-phenylxanthone oxime (II), m. $159-60^\circ$, which heated with dilute HCl gave I, m. $143-5^\circ$. In the same way 2-phenylxanthone oxime (III), m. $131-2^\circ$ (benzene), was prepared in 86% yield. Heating 0.1 g. II in 5 g. polyphosphoric acid 1 hr. at $150-60^\circ$, followed by precipitation with water and recrystn. gave 60% yield of 2-(2-aminophenoxy)biphenyl-3-carboxylic acid lactam, m. $174-6^\circ$ (alc.), which on ammonolysis with alc. NH_4OH solution in a sealed tube at $210-30^\circ$ 14 hrs. gave 80% yield of o-aminophenol, m. $173-4^\circ$, and 81% yield of 2-amino-3-phenylbenzoic acid (IV), m. $209-12^\circ$ (alc.). Last reaction proved anti-configuration of II. Diazotization of IV followed by heating with 60% H_2SO_4 gave 2-hydroxy-3-phenylbenzoic acid, m. $178-9^\circ$. Heating II in polyphosphoric acid gave only II and no Beckmann rearrangement product.
 IT **16190-72-0P**
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 16190-72-0 CAPLUS
 CN Dibenz[b,f][1,4]oxazepin-11(10H)-one, 4-phenyl- (8CI) (CA INDEX NAME)



AN 1966:19327 CAPLUS Full-text

DN 64:19327

OREF 64:3539d-g

TI Metabolism of noveril; 14C-labeling and synthesis of the metabolites

AU Hunziker, F.; Schindler, O.

CS Dr. A. Wanter A.-G., Bern, Switz.

SO Helvetica Chimica Acta (1965), 48(7), 1590-7

CODEN: HCACAV; ISSN: 0018-019X

DT Journal


LA German

AB 5-Methyl-10 β -dimethylaminoethyl-10,11-dihydro-11-oxo-5H-dibenzo [b,e]-1,4-diazepine hydrochloride (Noveril) was labeled by condensation of 5-methyl-10,11-dihydro-11-oxo-5H-dibenzo [b,e]-1,4-diazepine and β -dimethylaminoethyl chloride which was prepared from β -hydroxyethyl dimethylamine hydrobromide labeled in the ethyl C atoms for the purpose of metabolic study. The demethyl compds., 5-methyl-10 β -methylaminoethyl-10,11-dihydro-11-oxo-5H-dibenzo [b,e]-1,4-diazepine and 10 β -methylaminoethyl-10,11-dihydro-11-oxo-5H-dibenzo [b,e]-1,4-diazepine, were obtained by hydrogenolysis of the N-benzyl-N-methyl derivs., 5-methyl-10 β -N-benzyl-N-methylamino-10,11-dihydro-11-oxo-5H-dibenzo [b,e]-1,4-diazepine-HCl and 10-(β -N-benzyl-N-methylaminoethyl)-10,11-dihydro-11-oxo-5H-dibenzo [b,e]-1,4-diazepine-HCl. The primary amines, 5-methyl-10 β -aminoethyl-10,11-dihydro-11-oxo-5H-dibenzo [b,e]-1,4-diazepine and 10 β -aminoethyl-10,11-dihydro-11-oxo-5H-dibenzo [b,e]-1,4-diazepine, were obtained by hydrogenation of the cyanomethyl compds. 5-methyl-10-cyanomethyl-10,11-dihydro-11-oxo-5H-dibenzo [b,e]-1,4-diazepine and 10-cyanomethyl-10,11-dihydro-11-oxo-5H-dibenzo [b,e]-1,4-diazepine. 5-Methyl-10 β -aminoethyl-10,11-dihydro-11-oxo-5H-dibenzo [b,e]-1,4-diazepine was also produced by Hofmann degradation of the acid amide, 5-methyl-10 β -carbamoyl ethyl-10,11-dihydro-11-oxo-5H-dibenzo [b,e]-1,4-diazepine. 8-Methyl-1,2-dihydroimidazo [2,1-g]-8H-dibenzo [b,e]-1,4-diazepine and 1,2-dihydroimidazo [2,1-g]8H-dibenzo [b,e]-1,4-diazepine were formed by dehydration of 5-methyl-10 β -aminoethyl-10,11-dihydro-11-oxo-5H-dibenzo [b,e]-1,4-diazepine, and 10 β -aminoethyl-10,11-dihydro-11-oxo-5H-dibenzo [b,e]-1,4-diazepine, resp. Contrary to the literature the monobromination product obtained from m-nitrophenol was 4-bromo-3-nitrophenol and not 2-bromo-3-nitrophenol. 5-Methyl-8-hydroxy-10-(dimethylaminoethyl)-10,11-dihydro-11-oxo-5H-dibenzo [b,e]-1,4-diazepine was obtained from 2-bromo-5-benzyloxynitrobenzene via the intermediates.

IT 4576-35-6, 11H-Dibenzo [b,e] [1,4] diazepin-11-one,
8-(benzyloxy)-5,10-dihydro-5-methyl-
(preparation of)

RN 4576-35-6 CAPLUS

CN 11H-Dibenzo [b,e] [1,4] diazepin-11-one, 8-(benzyloxy)-5,10-dihydro-5-methyl-
(7CI, 8CI) (CA INDEX NAME)



AN 1964:425478 CAPLUS Full-text

DN 61:25478

OREF 61:4380e-h

TI 5-(Basic substituted)-10,11-dihydro-11-oxo-5H-dibenzo-[b,e][1,4]-diazepine derivatives (I)

PA Dr. A. Wander A.-G.

SO 6 pp.

DT Patent

LA Unavailable


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	GB 959995		19640603	GB	
	CH 380144			CH	
	US 3150125		1964	US	
PRAI	CH		19590922		

AB The title compds. are prepared by cyclization of the appropriate o-amino-o'-carboxydiphenylamines. Hence, 23.3 g. N- [β- (dimethylamino)ethyl]-2-nitrodiphenylamine-2'-ethyl carboxylate was catalytically hydrogenated and the resulting 2-amino compound dissolved in 500 cc. xylene. After 4 hrs. the xylene was distilled and the residue dried, boiled with 200 cc. N AcOH, and made alkaline with NH₃ to give 9.7 g. 5-[β-(dimethylamino)ethyl]-10,11-dihydro-11-oxo-5H-dibenzo [b,e][1,4]diazepine (I), m. 195-6°. Similarly prepared are the following derivs. of I (% yield and m.p. given): 7-chloro, 54, 197-8°; 8-chloro, 44, 180-4°; 8-methyl, 40, 165-7°; 8-methoxy, 56, 157-9°; 3-chloro, 38, 194°; 8-chloro-10-methyl, 57, - (b0.01 179°); 8-methoxy-10-methyl, 62, 115-18°; 8,10-dimethyl, 56, 71-4°; 7-methoxy, 68, 203-5°; 7-methylthio, 63, 185-7°; 7-chloro-10-methyl, 59, - (hydrochloride m. 216-19°). Further derivs. of I were prepared (substituents): 5-[γ-(dimethylamino)propyl], 59, 141-4°; 5-[γ-(dimethylamino)propyl]-7-chloro, 56, - [hydrochloride m. 244-5° (decomposition)]; 5-[γ-(dimethylamino)propyl]-8-chloro, 42, 184-7°; 5-[γ-(dimethylamino)propyl]-10-benzyl, 47, b0.03 230°; 5-(β-piperidinoethyl), 75, 184-6°; 5-(γ-piperidinopropyl), 58, 141-3°; 5-(β-morpholinoethyl), 66, 218-19°; 5-[β-(N'- methylpiperazino)ethyl], 60, 159-61°; 5-(pyrrolidinoethyl)-7-chloro- 10-methyl, 67, - (hydrochloride m. 221-6°). These compds. are useful as parasymphatholytics, antihistaminics, spasmolytics, tranquilizers, and psychic energizers.

IT **5814-41-5**, 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-(derivs.)

RN 5814-41-5 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro- (7CI, 8CI, 9CI) (CA INDEX NAME)




IT **94312-00-2**, 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-(2-morpholinoethyl)- **94758-64-2**, 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[2-(4-methyl-1-piperazinyl)ethyl]- **96167-07-6**, 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-(3-piperidinopropyl)-

(preparation of)


RN 94312-00-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-(2-morpholinoethyl)-
(7CI) (CA INDEX NAME)




RN 94758-64-2 CAPLUS

CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-[2-(4-methyl-1-piperazinyl)ethyl]- (7CI) (CA INDEX NAME)




RN 96167-07-6 CAPLUS


CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-(3-piperidinopropyl)-
(7CI) (CA INDEX NAME)




L25 ANSWER 102 OF 104 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1964:408626 CAPLUS Full-text
 DN 61:8626
 OREF 61:1380g-h,1381a
 TI Use of the genealogical coefficients method for calculating molecular terms
 AU Kaplan, I. G.
 CS L. Karpov Inst. Phys. Chem., Moscow
 SO Lietuvos Fiz. Rinkiny, Lietuvos TSR Mokslu Akad., Lietuvos TSR Aukstosios Mokyklos (1963), 3(1-2), 227-33
 DT Journal
 LA Russian
 AB The results obtained earlier (Zh. Eksperim. i Teor. Fiz. 41, 560-8, 790-9(1961)) were extended to the case of a field with arbitrary symmetry, when there is no vector bond with respect to the angular moments. The coordinate wave function for a system of n particles, in the Heitler-London approximation, is constructed with the aid of Young's operator. Linear combinations of such functions, which belong to the nonreducible representation of the mol. point group symmetry, are found from the projection operators of the point group. Expansion of the wave function in terms of the product of the (n - 2) particle wave functions and the function of the remaining 2 particles makes it possible to express the matrix elements of the operator, G, in terms of the 2-particle matrix elements and the genealogical coefficient. Methods of calculating these coeffs. are given and the tabulation of such values for all possible symmetries of the particle system with n = 3-6 are reported.
 IT **96166-63-1**, 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-(2-piperidinoethyl)-(preparation of)
 RN 96166-63-1 CAPLUS
 CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-(2-piperidinoethyl)-(7CI) (CA INDEX NAME)




L25 ANSWER 103 OF 104 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1964:408625 CAPLUS Full-text
DN 61:8625
OREF 61:1380g
TI Experiments on energy bands in solids
AU Lax, Benjamin
CS Massachusetts Inst. of Technol., Lexington
SO AGARDograph (1963), No. 62, 247-79
CODEN: AGAGAS; ISSN: 0365-2467
DT Journal
LA Unavailable
AB A review with 112 references.
IT **96166-63-1**, 11H-Dibenzo[b,e][1,4]diazepin-11-one,
5,10-dihydro-5-(2-piperidinoethyl)-
(preparation of)
RN 96166-63-1 CAPLUS
CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-(2-piperidinoethyl)-
(7CI) (CA INDEX NAME)



L25 ANSWER 104 OF 104 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1964:408624 CAPLUS Full-text
 DN 61:8624
 OREF 61:1380f-g
 TI Tetrahedral NiCl₄²⁻ in molten salts. Complete spin-allowed spectrum of 3d orbital transitions
 AU Boston, Charles R.; Smith, G. Pedro
 CS Oak Ridge Natl. Lab., Oak Ridge, TN
 SO Journal of the American Chemical Society (1964), 85(7), 1006-7
 CODEN: JACSAT; ISSN: 0002-7863
 DT Journal
 LA Unavailable
 AB The complete spin-allowed spectrum of 3d orbital transitions for NiCl₄²⁻ in solution in molten CsCl and KCl at 680° were measured. Measurements included the 3T₁(F) → 3T₂(F) transition near 4000 cm.⁻¹ which furnished addnl. information for the identification of the tetrahedral Ni(II) complex in molten salts.
 IT **96166-63-1**, 11H-Dibenzo[b,e][1,4]diazepin-11-one,
 5,10-dihydro-5-(2-piperidinoethyl)-
 (preparation of)
 RN 96166-63-1 CAPLUS
 CN 11H-Dibenzo[b,e][1,4]diazepin-11-one, 5,10-dihydro-5-(2-piperidinoethyl)-
 (7CI) (CA INDEX NAME)



=> d l1; d d l6; d his; log y
L1 HAS NO ANSWERS
L1 STR



G1 C,N
G2 O,N

Structure attributes must be viewed using STN Express query preparation.

(FILE 'HOME' ENTERED AT 14:18:52 ON 12 AUG 2005)

FILE 'REGISTRY' ENTERED AT 14:19:07 ON 12 AUG 2005
DEL PLATZEK/A
ACT A10785120/A

L1 STR
L2 3101 SEA FILE=REGISTRY SSS FUL L1

FILE 'CAPLUS' ENTERED AT 14:20:01 ON 12 AUG 2005
L3 698 S L2
L4 ANALYZE L3 1- RN HIT : 2629 TERMS

FILE 'REGISTRY' ENTERED AT 14:22:20 ON 12 AUG 2005
L5 1 S 4498-32-2/RN
SET NOTICE 1 DISPLAY
SET NOTICE LOGIN DISPLAY

FILE 'STNGUIDE' ENTERED AT 14:23:23 ON 12 AUG 2005

FILE 'REGISTRY' ENTERED AT 14:23:29 ON 12 AUG 2005
L6 STRUCTURE UPLOADED
L7 QUE L6
L8 50 S L7 SAM SUB=L2
L9 2034 S L7 FUL SUB=L2
L10 1067 S L2 NOT L9

FILE 'CAPLUS' ENTERED AT 14:25:06 ON 12 AUG 2005
L11 457 S L10
L12 0 S L9 NOT L2

FILE 'REGISTRY' ENTERED AT 14:25:33 ON 12 AUG 2005
L13 0 S L9 NOT L2

FILE 'CAPLUS' ENTERED AT 14:26:13 ON 12 AUG 2005
L14 323 S L9
L15 ANALYZE L14 1- RN : 13041 TERMS
L16 ANALYZE L14 1- RN HIT : 1748 TERMS

FILE 'REGISTRY' ENTERED AT 14:27:39 ON 12 AUG 2005
L17 1 S 5814-41-5/RN

SET NOTICE 1 DISPLAY
SET NOTICE LOGIN DISPLAY

FILE 'STNGUIDE' ENTERED AT 14:28:03 ON 12 AUG 2005

L18 FILE 'REGISTRY' ENTERED AT 14:28:21 ON 12 AUG 2005
613 S L9 AND NRS=1
L19 1421 S L9 NOT L18

L20 FILE 'CAPLUS' ENTERED AT 14:29:29 ON 12 AUG 2005
104 S L19
L21 72 S L17
L22 22 S L20 AND L21

FILE 'STNGUIDE' ENTERED AT 14:32:21 ON 12 AUG 2005

FILE 'STNGUIDE' ENTERED AT 14:32:41 ON 12 AUG 2005

FILE 'REGISTRY' ENTERED AT 14:32:43 ON 12 AUG 2005

L23 FILE 'CAPLUS' ENTERED AT 14:33:12 ON 12 AUG 2005
ANALYZE L20 1- RN HIT : 1189 TERMS

L24 FILE 'REGISTRY' ENTERED AT 14:34:07 ON 12 AUG 2005
1 S 120382-14-1/RN
SET NOTICE 1 DISPLAY
SET NOTICE LOGIN DISPLAY

FILE 'CAPLUS' ENTERED AT 14:35:38 ON 12 AUG 2005

L25 FILE 'CAPLUS' ENTERED AT 14:36:10 ON 12 AUG 2005
104 S L20 OR L22

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	517.81	621.63
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-75.92	-75.92

STN INTERNATIONAL LOGOFF AT 14:41:45 ON 12 AUG 2005